



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, C07K 14/47, 16/18, C12Q 1/68</b>		<b>A2</b>	(11) International Publication Number: <b>WO 99/25825</b>
			(43) International Publication Date: 27 May 1999 (27.05.99)
(21) International Application Number: <b>PCT/IB98/01862</b>			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 13 November 1998 (13.11.98)			
(30) Priority Data: 60/066,677 13 November 1997 (13.11.97) US 60/069,957 17 December 1997 (17.12.97) US 60/074,121 9 February 1998 (09.02.98) US 60/081,563 13 April 1998 (13.04.98) US 60/096,116 10 August 1998 (10.08.98) US 60/099,273 4 September 1998 (04.09.98) US			
(71) Applicant (for all designated States except US): GENSET [FR/FR]; 24, rue Royale, F-75008 Paris (FR).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BOUGUELERET, Lydie [FR/FR]; 108, avenue Victor Hugo, F-92170 Vanves (FR). DUCLERT, Aymeric [FR/FR]; 6 Ter, rue Victorine, F-94100 Saint-Maur (FR). DUMAS MILNE EDWARDS, Jean-Baptiste [FR/FR]; 8, rue Grégoire de Tours, F-75006 Paris (FR).			
(74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regimbeau, 26, avenue Kléber, F-75116 Paris (FR).			<b>Published</b> Without international search report and to be republished upon receipt of that report.
(54) Title: EXTENDED cDNAs FOR SECRETED PROTEINS			
(57) Abstract <p>The sequences of extended cDNAs encoding secreted proteins are disclosed. The extended cDNAs can be used to express secreted proteins or portions thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The extended cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The extended cDNAs may also be used to design expression vectors and secretion vectors.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## EXTENDED cDNAs FOR SECRETED PROTEINS

Background of the Invention

The estimated 50,000-100,000 genes scattered along the human chromosomes offer tremendous  
5 promise for the understanding, diagnosis, and treatment of human diseases. In addition, probes capable of specifically hybridizing to loci distributed throughout the human genome find applications in the construction of high resolution chromosome maps and in the identification of individuals.

In the past, the characterization of even a single human gene was a painstaking process, requiring  
years of effort. Recent developments in the areas of cloning vectors, DNA sequencing, and computer  
10 technology have merged to greatly accelerate the rate at which human genes can be isolated, sequenced, mapped, and characterized. Cloning vectors such as yeast artificial chromosomes (YACs) and bacterial artificial chromosomes (BACs) are able to accept DNA inserts ranging from 300 to 1000 kilobases (kb) or 100-400 kb in length respectively, thereby facilitating the manipulation and ordering of DNA sequences distributed over great distances on the human chromosomes. Automated DNA sequencing machines permit  
15 the rapid sequencing of human genes. Bioinformatics software enables the comparison of nucleic acid and protein sequences, thereby assisting in the characterization of human gene products.

Currently, two different approaches are being pursued for identifying and characterizing the genes distributed along the human genome. In one approach, large fragments of genomic DNA are isolated, cloned, and sequenced. Potential open reading frames in these genomic sequences are identified using bio-  
20 informatics software. However, this approach entails sequencing large stretches of human DNA which do not encode proteins in order to find the protein encoding sequences scattered throughout the genome. In addition to requiring extensive sequencing, the bio-informatics software may mischaracterize the genomic sequences obtained. Thus, the software may produce false positives in which non-coding DNA is mischaracterized as coding DNA or false negatives in which coding DNA is mislabeled as non-coding  
25 DNA.

An alternative approach takes a more direct route to identifying and characterizing human genes. In this approach, complementary DNAs (cDNAs) are synthesized from isolated messenger RNAs (mRNAs) which encode human proteins. Using this approach, sequencing is only performed on DNA which is derived from protein coding portions of the genome. Often, only short stretches of the cDNAs are  
30 sequenced to obtain sequences called expressed sequence tags (ESTs). The ESTs may then be used to isolate or purify extended cDNAs which include sequences adjacent to the EST sequences. The extended cDNAs may contain all of the sequence of the EST which was used to obtain them or only a portion of the sequence of the EST which was used to obtain them. In addition, the extended cDNAs may contain the full coding sequence of the gene from which the EST was derived or, alternatively, the extended cDNAs may  
35 include portions of the coding sequence of the gene from which the EST was derived. It will be appreciated that there may be several extended cDNAs which include the EST sequence as a result of alternate splicing or the activity of alternative promoters.

In the past, the short EST sequences which could be used to isolate or purify extended cDNAs were often obtained from oligo-dT primed cDNA libraries. Accordingly, they mainly corresponded to the 3' untranslated region of the mRNA. In part, the prevalence of EST sequences derived from the 3' end of the mRNA is a result of the fact that typical techniques for obtaining cDNAs are not well suited for isolating cDNA sequences derived from the 5' ends of mRNAs. (Adams et al., *Nature* 377:174, 1996, Hillier et al., *Genome Res.* 6:807-828, 1996).

In addition, in those reported instances where longer cDNA sequences have been obtained, the reported sequences typically correspond to coding sequences and do not include the full 5' untranslated region of the mRNA from which the cDNA is derived. Such incomplete sequences may not include the first exon of the mRNA, particularly in situations where the first exon is short. Furthermore, they may not include some exons, often short ones, which are located upstream of splicing sites. Thus, there is a need to obtain sequences derived from the 5' ends of mRNAs which can be used to obtain extended cDNAs which may include the 5' sequences contained in the 5' ESTs.

While many sequences derived from human chromosomes have practical applications, approaches based on the identification and characterization of those chromosomal sequences which encode a protein product are particularly relevant to diagnostic and therapeutic uses. Of the 50,000-100,000 protein coding genes, those genes encoding proteins which are secreted from the cell in which they are synthesized, as well as the secreted proteins themselves, are particularly valuable as potential therapeutic agents. Such proteins are often involved in cell to cell communication and may be responsible for producing a clinically relevant response in their target cells.

In fact, several secretory proteins, including tissue plasminogen activator, G-CSF, GM-CSF, erythropoietin, human growth hormone, insulin, interferon- $\alpha$ , interferon- $\beta$ , interferon- $\gamma$ , and interleukin-2, are currently in clinical use. These proteins are used to treat a wide range of conditions, including acute myocardial infarction, acute ischemic stroke, anemia, diabetes, growth hormone deficiency, hepatitis, kidney carcinoma, chemotherapy induced neutropenia and multiple sclerosis. For these reasons, extended cDNAs encoding secreted proteins or portions thereof represent a particularly valuable source of therapeutic agents. Thus, there is a need for the identification and characterization of secreted proteins and the nucleic acids encoding them.

In addition to being therapeutically useful themselves, secretory proteins include short peptides, called signal peptides, at their amino termini which direct their secretion. These signal peptides are encoded by the signal sequences located at the 5' ends of the coding sequences of genes encoding secreted proteins. Because these signal peptides will direct the extracellular secretion of any protein to which they are operably linked, the signal sequences may be exploited to direct the efficient secretion of any protein by operably linking the signal sequences to a gene encoding the protein for which secretion is desired. This may prove beneficial in gene therapy strategies in which it is desired to deliver a particular gene product to cells other than the cell in which it is produced. Signal sequences encoding signal peptides also find

application in simplifying protein purification techniques. In such applications, the extracellular secretion of the desired protein greatly facilitates purification by reducing the number of undesired proteins from which the desired protein must be selected. Thus, there exists a need to identify and characterize the 5' portions of the genes for secretory proteins which encode signal peptides.

Public information on the number of human genes for which the promoters and upstream regulatory regions have been identified and characterized is quite limited. In part, this may be due to the difficulty of isolating such regulatory sequences. Upstream regulatory sequences such as transcription factor binding sites are typically too short to be utilized as probes for isolating promoters from human genomic libraries. Recently, some approaches have been developed to isolate human promoters. One of them consists of making a CpG island library (Cross, S.H. et al., Purification of CpG Islands using a Methylated DNA Binding Column, *Nature Genetics* 6: 236-244 (1994)). The second consists of isolating human genomic DNA sequences containing Spel binding sites by the use of Spel binding protein. (Mortlock et al., *Genome Res.* 6:327-335, 1996). Both of these approaches have their limits due to a lack of specificity or of comprehensiveness.

5' ESTs and extended cDNAs obtainable therefrom may be used to efficiently identify and isolate upstream regulatory regions which control the location, developmental stage, rate, and quantity of protein synthesis, as well as the stability of the mRNA. Theil et al., *BioFactors* 4:87-93 (1993). Once identified and characterized, these regulatory regions may be utilized in gene therapy or protein purification schemes to obtain the desired amount and locations of protein synthesis or to inhibit, reduce, or prevent the synthesis of undesirable gene products.

In addition, ESTs containing the 5' ends of secretory protein genes or extended cDNAs which include sequences adjacent to the sequences of the ESTs may include sequences useful as probes for chromosome mapping and the identification of individuals. Thus, there is a need to identify and characterize the sequences upstream of the 5' coding sequences of genes encoding secretory proteins.

### Summary of the Invention

The present invention relates to purified, isolated, or recombinant extended cDNAs which encode secreted proteins or fragments thereof. Preferably, the purified, isolated or recombinant cDNAs contain the entire open reading frame of their corresponding mRNAs, including a start codon and a stop codon. For example, the extended cDNAs may include nucleic acids encoding the signal peptide as well as the mature protein. Alternatively, the extended cDNAs may contain a fragment of the open reading frame. In some embodiments, the fragment may encode only the sequence of the mature protein. Alternatively, the fragment may encode only a portion of the mature protein. A further aspect of the present invention is a nucleic acid which encodes the signal peptide of a secreted protein.

The present extended cDNAs were obtained using ESTs which include sequences derived from the authentic 5' ends of their corresponding mRNAs. As used herein the terms "EST" or "5' EST" refer to the

short cDNAs which were used to obtain the extended cDNAs of the present invention. As used herein, the term "extended cDNA" refers to the cDNAs which include sequences adjacent to the 5' EST used to obtain them. The extended cDNAs may contain all or a portion of the sequence of the EST which was used to obtain them. The term "corresponding mRNA" refers to the mRNA which was the template for the cDNA synthesis which produced the 5' EST. As used herein, the term "purified" does not require absolute purity; rather, it is intended as a relative definition. Individual extended cDNA clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The extended cDNA clones are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The conversion of mRNA into a cDNA library involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection. Thus, creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in an approximately  $10^4$ - $10^6$  fold purification of the native message. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

As used herein, the term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide present in a living animal is not isolated, but the same polynucleotide, separated from some or all of the coexisting materials in the natural system, is isolated.

As used herein, the term "recombinant" means that the extended cDNA is adjacent to "backbone" nucleic acid to which it is not adjacent in its natural environment. Additionally, to be "enriched" the extended cDNAs will represent 5% or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules. Backbone molecules according to the present invention include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic acids used to maintain or manipulate a nucleic acid insert of interest. Preferably, the enriched extended cDNAs represent 15% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. More preferably, the enriched extended cDNAs represent 50% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. In a highly preferred embodiment, the enriched extended cDNAs represent 90% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. "Stringent", "moderate," and "low" hybridization conditions are as defined in Example 29.

Unless otherwise indicated, a "complementary" sequence is fully complementary. Thus, extended cDNAs encoding secreted polypeptides or fragments thereof which are present in cDNA libraries in which one or more extended cDNAs encoding secreted polypeptides or fragments thereof make up 5% or more of the number of nucleic acid inserts in the backbone molecules are "enriched recombinant extended cDNAs"

as defined herein. Likewise, extended cDNAs encoding secreted polypeptides or fragments thereof which are in a population of plasmids in which one or more extended cDNAs of the present invention have been inserted such that they represent 5% or more of the number of inserts in the plasmid backbone are "enriched recombinant extended cDNAs" as defined herein. However, extended cDNAs encoding secreted polypeptides or fragments thereof which are in cDNA libraries in which the extended cDNAs encoding secreted polypeptides or fragments thereof constitute less than 5% of the number of nucleic acid inserts in the population of backbone molecules, such as libraries in which backbone molecules having a cDNA insert encoding a secreted polypeptide are extremely rare, are not "enriched recombinant extended cDNAs."

In particular, the present invention relates to extended cDNAs which were derived from genes encoding secreted proteins. As used herein, a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal peptides in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g. soluble proteins), or partially (e.g. receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

Extended cDNAs encoding secreted proteins may include nucleic acid sequences, called signal sequences, which encode signal peptides which direct the extracellular secretion of the proteins encoded by the extended cDNAs. Generally, the signal peptides are located at the amino termini of secreted proteins.

Secreted proteins are translated by ribosomes associated with the "rough" endoplasmic reticulum. Generally, secreted proteins are co-translationally transferred to the membrane of the endoplasmic reticulum. Association of the ribosome with the endoplasmic reticulum during translation of secreted proteins is mediated by the signal peptide. The signal peptide is typically cleaved following its co-translational entry into the endoplasmic reticulum. After delivery to the endoplasmic reticulum, secreted proteins may proceed through the Golgi apparatus. In the Golgi apparatus, the proteins may undergo post-translational modification before entering secretory vesicles which transport them across the cell membrane.

The extended cDNAs of the present invention have several important applications. For example, they may be used to express the entire secreted protein which they encode. Alternatively, they may be used to express portions of the secreted protein. The portions may comprise the signal peptides encoded by the extended cDNAs or the mature proteins encoded by the extended cDNAs (i.e. the proteins generated when the signal peptide is cleaved off). The portions may also comprise polypeptides having at least 10 consecutive amino acids encoded by the extended cDNAs. Alternatively, the portions may comprise at least 15 consecutive amino acids encoded by the extended cDNAs. In some embodiments, the portions may comprise at least 25 consecutive amino acids encoded by the extended cDNAs. In other embodiments, the portions may comprise at least 40 amino acids encoded by the extended cDNAs.

Antibodies which specifically recognize the entire secreted proteins encoded by the extended cDNAs or fragments thereof having at least 10 consecutive amino acids, at least 15 consecutive amino

acids, at least 25 consecutive amino acids, or at least 40 consecutive amino acids may also be obtained as described below. Antibodies which specifically recognize the mature protein generated when the signal peptide is cleaved may also be obtained as described below. Similarly, antibodies which specifically recognize the signal peptides encoded by the extended cDNAs may also be obtained.

5 In some embodiments, the extended cDNAs include the signal sequence. In other embodiments, the extended cDNAs may include the full coding sequence for the mature protein (i.e. the protein generated when the signal polypeptide is cleaved off). In addition, the extended cDNAs may include regulatory regions upstream of the translation start site or downstream of the stop codon which control the amount, location, or developmental stage of gene expression. As discussed above, secreted proteins are  
10 therapeutically important. Thus, the proteins expressed from the cDNAs may be useful in treating or controlling a variety of human conditions. The extended cDNAs may also be used to obtain the corresponding genomic DNA. The term "corresponding genomic DNA" refers to the genomic DNA which encodes mRNA which includes the sequence of one of the strands of the extended cDNA in which thymidine residues in the sequence of the extended cDNA are replaced by uracil residues in the mRNA.

15 The extended cDNAs or genomic DNAs obtained therefrom may be used in forensic procedures to identify individuals or in diagnostic procedures to identify individuals having genetic diseases resulting from abnormal expression of the genes corresponding to the extended cDNAs. In addition, the present invention is useful for constructing a high resolution map of the human chromosomes.

The present invention also relates to secretion vectors capable of directing the secretion of a protein  
20 of interest. Such vectors may be used in gene therapy strategies in which it is desired to produce a gene product in one cell which is to be delivered to another location in the body. Secretion vectors may also facilitate the purification of desired proteins.

The present invention also relates to expression vectors capable of directing the expression of an inserted gene in a desired spatial or temporal manner or at a desired level. Such vectors may include  
25 sequences upstream of the extended cDNAs such as promoters or upstream regulatory sequences.

In addition, the present invention may also be used for gene therapy to control or treat genetic diseases. Signal peptides may also be fused to heterologous proteins to direct their extracellular secretion.

One embodiment of the present invention is a purified or isolated nucleic acid comprising the sequence of one of SEQ ID NOs: 134-180 or a sequence complementary thereto. In one aspect of this  
30 embodiment, the nucleic acid is recombinant.

Another embodiment of the present invention is a purified or isolated nucleic acid comprising at least 10 consecutive bases of the sequence of one of SEQ ID NOs: 134-180 or one of the sequences complementary thereto. In one aspect of this embodiment, the nucleic acid comprises at least 15, 25, 30, 40, 50, 75, or 100 consecutive bases of one of the sequences of SEQ ID NOs: 134-180 or one of the sequences  
35 complementary thereto. The nucleic acid may be a recombinant nucleic acid.

Another embodiment of the present invention is a purified or isolated nucleic acid of at least 15



bases capable of hybridizing under stringent conditions to the sequence of one of SEQ ID NOs: 134-180 or a sequence complementary to one of the sequences of SEQ ID NOs: 134-180. In one aspect of this embodiment, the nucleic acid is recombinant.

Another embodiment of the present invention is a purified or isolated nucleic acid comprising the  
5 full coding sequences of one of SEQ ID NOs: 134-180, wherein the full coding sequence optionally comprises the sequence encoding signal peptide as well as the sequence encoding mature protein. In one aspect of this embodiment, the nucleic acid is recombinant.

A further embodiment of the present invention is a purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 134-180 which encode a mature protein. In one aspect of this  
10 embodiment, the nucleic acid is recombinant.

Yet another embodiment of the present invention is a purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 134-180 which encode the signal peptide. In one aspect of this embodiment, the nucleic acid is recombinant.

Another embodiment of the present invention is a purified or isolated nucleic acid encoding a  
15 polypeptide having the sequence of one of the sequences of SEQ ID NOs: 181-227.

Another embodiment of the present invention is a purified or isolated nucleic acid encoding a polypeptide having the sequence of a mature protein included in one of the sequences of SEQ ID NOs: 181-227.

Another embodiment of the present invention is a purified or isolated nucleic acid encoding a  
20 polypeptide having the sequence of a signal peptide included in one of the sequences of SEQ ID NOs: 181-227.

Yet another embodiment of the present invention is a purified or isolated protein comprising the sequence of one of SEQ ID NOs: 181-227.

Another embodiment of the present invention is a purified or isolated polypeptide comprising at  
25 least 10 consecutive amino acids of one of the sequences of SEQ ID NOs: 181-227. In one aspect of this embodiment, the purified or isolated polypeptide comprises at least 15, 20, 25, 35, 50, 75, 100, 150 or 200 consecutive amino acids of one of the sequences of SEQ ID NOs: 181-227. In still another aspect, the purified or isolated polypeptide comprises at least 25 consecutive amino acids of one of the sequences of SEQ ID NOs: 181-227.

Another embodiment of the present invention is an isolated or purified polypeptide comprising a  
30 signal peptide of one of the polypeptides of SEQ ID NOs: 181-227.

Yet another embodiment of the present invention is an isolated or purified polypeptide comprising a mature protein of one of the polypeptides of SEQ ID NOs: 181-227.

A further embodiment of the present invention is a method of making a protein comprising one of  
35 the sequences of SEQ ID NO: 181-227, comprising the steps of obtaining a cDNA comprising one of the sequences of sequence of SEQ ID NO: 134-180, inserting the cDNA in an expression vector such that the

cDNA is operably linked to a promoter, and introducing the expression vector into a host cell whereby the host cell produces the protein encoded by said cDNA. In one aspect of this embodiment, the method further comprises the step of isolating the protein.

Another embodiment of the present invention is a protein obtainable by the method described in the preceding paragraph.

Another embodiment of the present invention is a method of making a protein comprising the amino acid sequence of the mature protein contained in one of the sequences of SEQ ID NO: 181-227, comprising the steps of obtaining a cDNA comprising one of the nucleotides sequence of sequence of SEQ ID NO: 134-180 which encode for the mature protein, inserting the cDNA in an expression vector such that the cDNA is operably linked to a promoter, and introducing the expression vector into a host cell whereby the host cell produces the mature protein encoded by the cDNA. In one aspect of this embodiment, the method further comprises the step of isolating the protein.

Another embodiment of the present invention is a mature protein obtainable by the method described in the preceding paragraph.

Another embodiment of the present invention is a host cell containing the purified or isolated nucleic acids comprising the sequence of one of SEQ ID NOs: 134-180 or a sequence complementary thereto described herein.

Another embodiment of the present invention is a host cell containing the purified or isolated nucleic acids comprising the full coding sequences of one of SEQ ID NOs: 134-180, wherein the full coding sequence comprises the sequence encoding signal peptide and the sequence encoding mature protein described herein.

Another embodiment of the present invention is a host cell containing the purified or isolated nucleic acids comprising the nucleotides of one of SEQ ID NOs: 134-180 which encode a mature protein which are described herein.

Another embodiment of the present invention is a host cell containing the purified or isolated nucleic acids comprising the nucleotides of one of SEQ ID NOs: 134-180 which encode the signal peptide which are described herein.

Another embodiment of the present invention is a purified or isolated antibody capable of specifically binding to a protein having the sequence of one of SEQ ID NOs: 181-227. In one aspect of this embodiment, the antibody is capable of binding to a polypeptide comprising at least 10 consecutive amino acids of the sequence of one of SEQ ID NOs: 181-227.

Another embodiment of the present invention is an array of cDNAs or fragments thereof of at least 15 nucleotides in length which includes at least one of the sequences of SEQ ID NOs: 134-180, or one of the sequences complementary to the sequences of SEQ ID NOs: 134-180, or a fragment thereof of at least 15 consecutive nucleotides. In one aspect of this embodiment, the array includes at least two of the sequences of SEQ ID NOs: 134-180, the sequences complementary to the sequences of SEQ ID NOs: 134-

180, or fragments thereof of at least 15 consecutive nucleotides. In another aspect of this embodiment, the array includes at least five of the sequences of SEQ ID NOs: 134-180, the sequences complementary to the sequences of SEQ ID NOs: 134-180, or fragments thereof of at least 15 consecutive nucleotides.

A further embodiment of the invention encompasses purified polynucleotides comprising an  
5 insert from a clone deposited in ATCC accession No. 98619 or a fragment thereof comprising a contiguous span of at least 8, 10, 12, 15, 20, 25, 40, 60, 100, or 200 nucleotides of said insert. An additional embodiment of the invention encompasses purified polypeptides which comprise, consist of, or consist essentially of an amino acid sequence encoded by the insert from a clone deposited in ATCC accession No. 98619, as well as polypeptides which comprise a fragment of said amino acid sequence  
10 consisting of a signal peptide, a mature protein, or a contiguous span of at least 5, 8, 10, 12, 15, 20, 25, 40, 60, 100, or 200 amino acids encoded by said insert.

An additional embodiment of the invention encompasses purified polypeptides which comprise a contiguous span of at least 5, 8, 10, 12, 15, 20, 25, 40, 60, 100, or 200 amino acids of SEQ ID NOs: 185, 186, 191, 192, 200, 201, 213, 214, 215, or 227, wherein said contiguous span comprises at least one of the  
15 amino acid positions which was not shown to be identical to a public sequence in any of Figures 9 to 16. Also encompassed by the invention are purified polynucleotides encoding said polypeptides.

#### **Brief Description of the Drawings**

Figure 1 is a summary of a procedure for obtaining cDNAs which have been selected to include the 5' ends of the mRNAs from which they are derived.

20 Figure 2 is an analysis of the 43 amino terminal amino acids of all human SwissProt proteins to determine the frequency of false positives and false negatives using the techniques for signal peptide identification described herein.

Figure 3 shows the distribution of von Heijne scores for 5' ESTs in each of the categories described herein and the probability that these 5' ESTs encode a signal peptide.

25 Figure 4 shows the distribution of 5' ESTs in each category and the number of 5' ESTs in each category having a given minimum von Heijne's score.

Figure 5 shows the tissues from which the mRNAs corresponding to the 5' ESTs in each of the categories described herein were obtained.

Figure 6 is a map of pED6dpc2. PED6dpc2 is derived from pED6dpc1 by insertion of a new  
30 polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. PED vectors are described in Kaufman et al. (1991), NAR 19: 4485-4490.

Figure 7 provides a schematic description of the promoters isolated and the way they are assembled with the corresponding 5' tags.

Figure 8 describes the transcription factor binding sites present in each of these promoters.

35 Figure 9 depicts an amino acid alignment between SEQ ID NO: 214 and murine SH3BGRL (AF042081). Identities are shown by (:) and conservative substitutions by (.). Cell attachment motif (RGD) is in bold type and the proline rich region is underlined.

Figure 10 depicts a multiple amino acid alignment between SEQ ID NOs: 185 and 215, and murine MEK binding partner (AF082526). Positions conserved in all three proteins are indicated by (\*).

Figure 11 depicts an amino acid alignment between SEQ ID NO: 186 and murine claudin-2 (AF072128). Identities are shown by (:) and conservative substitutions by (.).

5 Figure 12 depicts an amino acid alignment between SEQ ID NO: 213 and GMF- $\gamma$  (AB001993). In the alignment present the translation starts at position 2 of SEQ ID NO: 166. The actual start methionine of SEQ ID NO: 213 appears to be at position 13. Identities are shown by (:) and conservative substitutions by (.).

10 Figure 13 depicts an amino acid alignment between SEQ ID NO: 191 and Derwent Protein Sequence Database Accession NO: W36955. Identities are shown by (:) and conservative substitutions by (.).

15 Figure 14 depicts an amino acid alignment between SEQ ID NO: 200 and human Ring zinc finger protein (AF037204). Amino acids defining an EGF-like domain are highlighted. The region defining an almost perfect Ring Finger domain is boxed. Identities are shown by (:) and conservative substitutions by (.).

Figure 15 depicts an amino acid alignment between SEQ ID NO: 192 and Y15286. Identities are shown by (:) and conservative substitutions by (.).

20 Figure 16 depicts a multiple amino acid alignment between SEQ ID NOs: 201 and 227, and human stomatin (x85116). Positions conserved in all three proteins are indicated by (\*). The amino acid sequences in SEQ ID NOs: 201 and 227 differ in their N-terminal sequences: segment 1-76 (SEQ ID NO: 201) and segment 1-26 (SEQ ID NO: 227). The remainder of these 2 proteins are 99.5% identical. The band 7 protein family signature is boxed. The microbody C-terminal targeting signal appears in bold type.

### Detailed Description of the Preferred Embodiment

#### 25 I. Obtaining 5' ESTs

The present extended cDNAs were obtained using 5' ESTs which were isolated as described below.

#### A. Chemical Methods for Obtaining mRNAs having Intact 5' Ends

In order to obtain the 5' ESTs used to obtain the extended cDNAs of the present invention, mRNAs having intact 5' ends must be obtained. Currently, there are two approaches for obtaining such mRNAs.

30 One of these approaches is a chemical modification method involving derivatization of the 5' ends of the mRNAs and selection of the derivatized mRNAs. The 5' ends of eukaryotic mRNAs possess a structure referred to as a "cap" which comprises a guanosine methylated at the 7 position. The cap is joined to the first transcribed base of the mRNA by a 5', 5'-triphosphate bond. In some instances, the 5' guanosine is methylated in both the 2 and 7 positions. Rarely, the 5' guanosine is trimethylated at the 2, 7 and 7  
35 positions. In the chemical method for obtaining mRNAs having intact 5' ends, the 5' cap is specifically derivatized and coupled to a reactive group on an immobilizing substrate. This specific derivatization is

based on the fact that only the ribose linked to the methylated guanosine at the 5' end of the mRNA and the ribose linked to the base at the 3' terminus of the mRNA, possess 2', 3'-cis diols. Optionally, where the 3' terminal ribose has a 2', 3'-cis diol, the 2', 3'-cis diol at the 3' end may be chemically modified, substituted, converted, or eliminated, leaving only the ribose linked to the methylated guanosine at the 5' end of the mRNA with a 2', 3'-cis diol. A variety of techniques are available for eliminating the 2', 3'-cis diol on the 3' terminal ribose. For example, controlled alkaline hydrolysis may be used to generate mRNA fragments in which the 3' terminal ribose is a 3'-phosphate, 2'-phosphate or (2', 3')-cyclophosphate. Thereafter, the fragment which includes the original 3' ribose may be eliminated from the mixture through chromatography on an oligo-dT column. Alternatively, a base which lacks the 2', 3'-cis diol may be added to the 3' end of the mRNA using an RNA ligase such as T4 RNA ligase. Example 1 below describes a method for ligation of pCp to the 3' end of messenger RNA.

### EXAMPLE 1

#### Ligation of the Nucleoside Diphosphate pCp to the 3' End of Messenger RNA.

1 µg of RNA was incubated in a final reaction medium of 10 µl in the presence of 5 U of T<sub>4</sub> phage RNA ligase in the buffer provided by the manufacturer (Gibco - BRL), 40 U of the RNase inhibitor RNasin (Promega) and, 2 µl of <sup>32</sup>pCp (Amersham #PB 10208). The incubation was performed at 37°C for 2 hours or overnight at 7-8°C.

Following modification or elimination of the 2', 3'-cis diol at the 3' ribose, the 2', 3'-cis diol present at the 5' end of the mRNA may be oxidized using reagents such as NaBH<sub>4</sub>, NaBH<sub>3</sub>CN, or sodium periodate, thereby converting the 2', 3'-cis diol to a dialdehyde. Example 2 describes the oxidation of the 2', 3'-cis diol at the 5' end of the mRNA with sodium periodate.

### EXAMPLE 2

#### Oxidation of 2', 3'-cis diol at the 5' End of the mRNA

0.1 OD unit of either a capped oligoribonucleotide of 47 nucleotides (including the cap) or an uncapped oligoribonucleotide of 46 nucleotides were treated as follows. The oligoribonucleotides were produced by in vitro transcription using the transcription kit "AmpliScribe T7" (Epicentre Technologies). As indicated below, the DNA template for the RNA transcript contained a single cytosine. To synthesize the uncapped RNA, all four NTPs were included in the in vitro transcription reaction. To obtain the capped RNA, GTP was replaced by an analogue of the cap, m<sup>7</sup>G(5')ppp(5')G. This compound, recognized by polymerase, was incorporated into the 5' end of the nascent transcript during the step of initiation of transcription but was not capable of incorporation during the extension step. Consequently, the resulting RNA contained a cap at its 5' end. The sequences of the oligoribonucleotides produced by the in vitro transcription reaction were:

+Cap:

5' m<sup>7</sup>GpppGCAUCCUACUCCCAUCCAAUCCACCCUAACUCCUCCCAUCUCCAC-3' (SEQ ID NO: 1)

-Cap:

5'-pppGCAUCCUACUCCCAUCCAAUCCACCCUAACUCCUCCCAUCUCCAC-3' (SEQ ID NO: 2)


The oligoribonucleotides were dissolved in 9  $\mu$ l of acetate buffer (0.1 M sodium acetate, pH 5.2) and 3  $\mu$ l of freshly prepared 0.1 M sodium periodate solution. The mixture was incubated for 1 hour in the dark at 4°C or room temperature. Thereafter, the reaction was stopped by adding 4  $\mu$ l of 10% ethylene glycol. The product was ethanol precipitated, resuspended in 10  $\mu$ l or more of water or appropriate buffer and dialyzed against water.

The resulting aldehyde groups may then be coupled to molecules having a reactive amine group, such as hydrazine, carbazide, thiocarbazide or semicarbazide groups, in order to facilitate enrichment of the 5' ends of the mRNAs. Molecules having reactive amine groups which are suitable for use in selecting mRNAs having intact 5' ends include avidin, proteins, antibodies, vitamins, ligands capable of specifically binding to receptor molecules, or oligonucleotides. Example 3 below describes the coupling of the resulting dialdehyde to biotin.

### EXAMPLE 3

#### Coupling of the Dialdehyde with Biotin

The oxidation product obtained in Example 2 was dissolved in 50  $\mu$ l of sodium acetate at a pH of between 5 and 5.2 and 50  $\mu$ l of freshly prepared 0.02 M solution of biotin hydrazide in a methoxyethanol/water mixture (1:1) of formula:



In the compound used in these experiments, n=5, and the solid black dots represent oxygen. However, it will be appreciated that other commercially available hydrazides may also be used, such as molecules of the formula above in which n varies from 0 to 5.

The mixture was then incubated for 2 hours at 37°C. Following the incubation, the mixture was precipitated with ethanol and dialyzed against distilled water.

Example 4 demonstrates the specificity of the biotinylation reaction.

## EXAMPLE 4

Specificity of Biotinylation

The specificity of the biotinylation for capped mRNAs was evaluated by gel electrophoresis of the following samples:

5 Sample 1. The 46 nucleotide uncapped in vitro transcript prepared as in Example 2 and labeled with  $^{32}$ pCp as described in Example 1.

Sample 2. The 46 nucleotide uncapped in vitro transcript prepared as in Example 2, labeled with  $^{32}$ pCp as described in Example 1, treated with the oxidation reaction of Example 2, and subjected to the biotinylation conditions of Example 3.

10 Sample 3. The 47 nucleotide capped in vitro transcript prepared as in Example 2 and labeled with  $^{32}$ pCp as described in Example 1.

Sample 4. The 47 nucleotide capped in vitro transcript prepared as in Example 2, labeled with  $^{32}$ pCp as described in Example 1, treated with the oxidation reaction of Example 2, and subjected to the biotinylation conditions of Example 3.

15 Samples 1 and 2 had identical migration rates, demonstrating that the uncapped RNAs were not oxidized and biotinylated. Sample 3 migrated more slowly than Samples 1 and 2, while Sample 4 exhibited the slowest migration. The difference in migration of the RNAs in Samples 3 and 4 demonstrates that the capped RNAs were specifically biotinylated.

In some cases, mRNAs having intact 5' ends may be enriched by binding the molecule containing a  
20 reactive amine group to a suitable solid phase substrate such as the inside of the vessel containing the mRNAs, magnetic beads, chromatography matrices, or nylon or nitrocellulose membranes. For example, where the molecule having a reactive amine group is biotin, the solid phase substrate may be coupled to avidin or streptavidin. Alternatively, where the molecule having the reactive amine group is an antibody or receptor ligand, the solid phase substrate may be coupled to the cognate antigen or receptor. Finally, where  
25 the molecule having a reactive amine group comprises an oligonucleotide, the solid phase substrate may comprise a complementary oligonucleotide.

The mRNAs having intact 5' ends may be released from the solid phase following the enrichment procedure. For example, where the dialdehyde is coupled to biotin hydrazide and the solid phase comprises streptavidin, the mRNAs may be released from the solid phase by simply heating to 95 degrees Celsius in  
30 2% SDS. In some methods, the molecule having a reactive amine group may also be cleaved from the mRNAs having intact 5' ends following enrichment. Example 5 describes the capture of biotinylated mRNAs with streptavidin coated beads and the release of the biotinylated mRNAs from the beads following enrichment.

**EXAMPLE 5****Capture and Release of Biotinylated mRNAs Using Streptavidin Coated Beads**

The streptavidin-coated magnetic beads were prepared according to the manufacturer's instructions (CPG Inc., USA). The biotinylated mRNAs were added to a hybridization buffer (1.5 M NaCl, pH 5 - 6).

5 After incubating for 30 minutes, the unbound and nonbiotinylated material was removed. The beads were washed several times in water with 1% SDS. The beads obtained were incubated for 15 minutes at 95°C in water containing 2% SDS.

Example 6 demonstrates the efficiency with which biotinylated mRNAs were recovered from the streptavidin coated beads.

10

**EXAMPLE 6****Efficiency of Recovery of Biotinylated mRNAs**

The efficiency of the recovery procedure was evaluated as follows. RNAs were labeled with  $^{32}$ PpCp, oxidized, biotinylated and bound to streptavidin coated beads as described above. Subsequently, the bound  
15 RNAs were incubated for 5, 15 or 30 minutes at 95°C in the presence of 2% SDS.

The products of the reaction were analyzed by electrophoresis on 12% polyacrylamide gels under denaturing conditions (7 M urea). The gels were subjected to autoradiography. During this manipulation, the hydrazone bonds were not reduced.

Increasing amounts of nucleic acids were recovered as incubation times in 2% SDS increased,  
20 demonstrating that biotinylated mRNAs were efficiently recovered.

In an alternative method for obtaining mRNAs having intact 5' ends, an oligonucleotide which has been derivatized to contain a reactive amine group is specifically coupled to mRNAs having an intact cap. Preferably, the 3' end of the mRNA is blocked prior to the step in which the aldehyde groups are joined to the derivatized oligonucleotide, as described above, so as to prevent the derivatized oligonucleotide from  
25 being joined to the 3' end of the mRNA. For example, pCp may be attached to the 3' end of the mRNA using T4 RNA ligase. However, as discussed above, blocking the 3' end of the mRNA is an optional step. Derivatized oligonucleotides may be prepared as described below in Example 7.

**EXAMPLE 7**

30

**Derivatization of the Oligonucleotide**

An oligonucleotide phosphorylated at its 3' end was converted to a 3' hydrazide in 3' by treatment with an aqueous solution of hydrazine or of dihydrazide of the formula  $H_2N(R)NH_2$  at about 1 to 3 M, and at pH 4.5, in the presence of a carbodiimide type agent soluble in water such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide at a final concentration of 0.3 M at a temperature of 8°C overnight.

35 The derivatized oligonucleotide was then separated from the other agents and products using a standard technique for isolating oligonucleotides.



As discussed above, the mRNAs to be enriched may be treated to eliminate the 3' OH groups which may be present thereon. This may be accomplished by enzymatic ligation of sequences lacking a 3' OH, such as pCp, as described above in Example 1. Alternatively, the 3' OH groups may be eliminated by alkaline hydrolysis as described in Example 8 below.

5

#### EXAMPLE 8

##### Alkaline Hydrolysis of mRNA

The mRNAs may be treated with alkaline hydrolysis as follows. In a total volume of 100 $\mu$ l of 0.1N sodium hydroxide, 1.5 $\mu$ g mRNA is incubated for 40 to 60 minutes at 4°C. The solution is neutralized with acetic acid and precipitated with ethanol.

10

Following the optional elimination of the 3' OH groups, the diol groups at the 5' ends of the mRNAs are oxidized as described below in Example 9.

#### EXAMPLE 9

##### Oxidation of Diols

15

Up to 1 OD unit of RNA was dissolved in 9  $\mu$ l of buffer (0.1 M sodium acetate, pH 6-7 or water) and 3  $\mu$ l of freshly prepared 0.1 M sodium periodate solution. The reaction was incubated for 1 h in the dark at 4°C or room temperature. Following the incubation, the reaction was stopped by adding 4  $\mu$ l of 10% ethylene glycol. Thereafter the mixture was incubated at room temperature for 15 minutes. After ethanol precipitation, the product was resuspended in 10 $\mu$ l or more of water or appropriate buffer and dialyzed against water.

20

Following oxidation of the diol groups at the 5' ends of the mRNAs, the derivatized oligonucleotide was joined to the resulting aldehydes as described in Example 10.

25

#### EXAMPLE 10

##### Reaction of Aldehydes with Derivatized Oligonucleotides

The oxidized mRNA was dissolved in an acidic medium such as 50  $\mu$ l of sodium acetate pH 4-6. 50  $\mu$ l of a solution of the derivatized oligonucleotide was added such that an mRNA:derivatized oligonucleotide ratio of 1:20 was obtained and mixture was reduced with a borohydride. The mixture was allowed to incubate for 2 h at 37°C or overnight (14 h) at 10°C. The mixture was ethanol precipitated, resuspended in 10 $\mu$ l or more of water or appropriate buffer and dialyzed against distilled water. If desired, the resulting product may be analyzed using acrylamide gel electrophoresis, HPLC analysis, or other conventional techniques.

30

Following the attachment of the derivatized oligonucleotide to the mRNAs, a reverse transcription reaction may be performed as described in Example 11 below.

35

## EXAMPLE 11

Reverse Transcription of mRNAs

An oligodeoxyribonucleotide was derivatized as follows. 3 OD units of an oligodeoxyribonucleotide of sequence ATCAAGAATTCGCACGAGACCATTA (SEQ ID NO:3) having 5'-OH and 3'-P ends were dissolved in 70  $\mu$ l of a 1.5 M hydroxybenzotriazole solution, pH 5.3, prepared in dimethylformamide/water (75:25) containing 2  $\mu$ g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The mixture was incubated for 2 h 30 min at 22°C. The mixture was then precipitated twice in LiClO<sub>4</sub>/acetone. The pellet was resuspended in 200  $\mu$ l of 0.25 M hydrazine and incubated at 8°C from 3 to 14 h. Following the hydrazine reaction, the mixture was precipitated twice in LiClO<sub>4</sub>/acetone.

The messenger RNAs to be reverse transcribed were extracted from blocks of placenta having sides of 2 cm which had been stored at -80°C. The mRNA was extracted using conventional acidic phenol techniques. Oligo-dT chromatography was used to purify the mRNAs. The integrity of the mRNAs was checked by Northern-blotting.

The diol groups on 7  $\mu$ g of the placental mRNAs were oxidized as described above in Example 9. The derivatized oligonucleotide was joined to the mRNAs as described in Example 10 above except that the precipitation step was replaced by an exclusion chromatography step to remove derivatized oligodeoxyribonucleotides which were not joined to mRNAs. Exclusion chromatography was performed as follows:

10 ml of AcA34 (BioSeptra#230151) gel were equilibrated in 50 ml of a solution of 10 mM Tris pH 8.0, 300 mM NaCl, 1 mM EDTA, and 0.05% SDS. The mixture was allowed to sediment. The supernatant was eliminated and the gel was resuspended in 50 ml of buffer. This procedure was repeated 2 or 3 times.

A glass bead (diameter 3 mm) was introduced into a 2 ml disposable pipette (length 25 cm). The pipette was filled with the gel suspension until the height of the gel stabilized at 1 cm from the top of the pipette. The column was then equilibrated with 20 ml of equilibration buffer (10 mM Tris HCl pH 7.4, 20 mM NaCl).

10  $\mu$ l of the mRNA which had been reacted with the derivatized oligonucleotide were mixed in 39  $\mu$ l of 10 mM urea and 2  $\mu$ l of blue-glycerol buffer, which had been prepared by dissolving 5 mg of bromophenol blue in 60% glycerol (v/v), and passing the mixture through a filter with a filter of diameter 0.45  $\mu$ m.

The column was loaded. As soon as the sample had penetrated, equilibration buffer was added. 100  $\mu$ l fractions were collected. Derivatized oligonucleotide which had not been attached to mRNA appeared in fraction 16 and later fractions. Fractions 3 to 15 were combined and precipitated with ethanol.

The mRNAs which had been reacted with the derivatized oligonucleotide were spotted on a nylon membrane and hybridized to a radioactive probe using conventional techniques. The radioactive probe used in these hybridizations was an oligodeoxyribonucleotide of sequence TAATGGTCTCGTGCGAATTCTTGAT (SEQ ID NO:4) which was anticomplementary to the derivatized

oligonucleotide and was labeled at its 5' end with  $^{32}\text{P}$ . 1/10th of the mRNAs which had been reacted with the derivatized oligonucleotide was spotted in two spots on the membrane and the membrane was visualized by autoradiography after hybridization of the probe. A signal was observed, indicating that the derivatized oligonucleotide had been joined to the mRNA.

5 The remaining 9/10 of the mRNAs which had been reacted with the derivatized oligonucleotide was reverse transcribed as follows. A reverse transcription reaction was carried out with reverse transcriptase following the manufacturer's instructions. To prime the reaction, 50 pmol of nonamers with random sequence were used.

A portion of the resulting cDNA was spotted on a positively charged nylon membrane using  
10 conventional methods. The cDNAs were spotted on the membrane after the cDNA:RNA heteroduplexes had been subjected to an alkaline hydrolysis in order to eliminate the RNAs. An oligonucleotide having a sequence identical to that of the derivatized oligonucleotide was labeled at its 5' end with  $^{32}\text{P}$  and hybridized to the cDNA blots using conventional techniques. Single-stranded cDNAs resulting from the reverse transcription reaction were spotted on the membrane. As controls, the blot contained 1 pmol, 100 fmol, 50  
15 fmol, 10 fmol and 1 fmol respectively of a control oligodeoxyribonucleotide of sequence identical to that of the derivatized oligonucleotide. The signal observed in the spots containing the cDNA indicated that approximately 15 fmol of the derivatized oligonucleotide had been reverse transcribed.

These results demonstrate that the reverse transcription can be performed through the cap and, in particular, that reverse transcriptase crosses the 5'-P-P-P-5' bond of the cap of eukaryotic messenger RNAs.

20 The single stranded cDNAs obtained after the above first strand synthesis were used as template for PCR reactions. Two types of reactions were carried out. First, specific amplification of the mRNAs for the alpha globin, dehydrogenase, pp15 and elongation factor E4 were carried out using the following pairs of oligodeoxyribonucleotide primers.

alpha-globin

25 GLO-S: CCG ACA AGA CCA ACG TCA AGG CCG C (SEQ ID NO:5)

GLO-As: TCA CCA GCA GGC AGT GGC TTA GGA G 3' (SEQ ID NO:6)

dehydrogenase

3 DH-S: AGT GAT TCC TGC TAC TTT GGA TGG C (SEQ ID NO:7)

3 DH-As: GCT TGG TCT TGT TCT GGA GTT TAG A (SEQ ID NO:8)

30 pp15

PP15-S: TCC AGA ATG GGA GAC AAG CCA ATT T (SEQ ID NO:9)

PP15-As: AGG GAG GAG GAA ACA GCG TGA GTC C (SEQ ID NO:10)

Elongation factor E4

EFA1-S: ATG GGA AAG GAA AAG ACT CAT ATC A (SEQ ID NO:11)

35 EF1A-As: AGC AGC AAC AAT CAG GAC AGC ACA G (SEQ ID NO:12)

Non-specific amplifications were also carried out with the antisense (\_As)

oligodeoxyribonucleotides of the pairs described above and a primer chosen from the sequence of the derivatized oligodeoxyribonucleotide (ATCAAGAATTTCGCACGAGACCATTA) (SEQ ID NO:13).

A 1.5% agarose gel containing the following samples corresponding to the PCR products of reverse transcription was stained with ethidium bromide. (1/20th of the products of reverse transcription were used for each PCR reaction).

Sample 1: The products of a PCR reaction using the globin primers of SEQ ID NOs 5 and 6 in the presence of cDNA.

Sample 2: The products of a PCR reaction using the globin primers of SEQ ID NOs 5 and 6 in the absence of added cDNA.

Sample 3: The products of a PCR reaction using the dehydrogenase primers of SEQ ID NOs 7 and 8 in the presence of cDNA.

Sample 4: The products of a PCR reaction using the dehydrogenase primers of SEQ ID NOs 7 and 8 in the absence of added cDNA.

Sample 5: The products of a PCR reaction using the pp15 primers of SEQ ID NOs 9 and 10 in the presence of cDNA.

Sample 6: The products of a PCR reaction using the pp15 primers of SEQ ID NOs 9 and 10 in the absence of added cDNA.

Sample 7: The products of a PCR reaction using the EIE4 primers of SEQ ID NOs 11 and 12 in the presence of added cDNA.

Sample 8: The products of a PCR reaction using the EIE4 primers of SEQ ID NOs 11 and 12 in the absence of added cDNA.

In Samples 1, 3, 5 and 7, a band of the size expected for the PCR product was observed, indicating the presence of the corresponding sequence in the cDNA population.

PCR reactions were also carried out with the antisense oligonucleotides of the globin and dehydrogenase primers (SEQ ID NOs 6 and 8) and an oligonucleotide whose sequence corresponds to that of the derivatized oligonucleotide. The presence of PCR products of the expected size in the samples corresponding to samples 1 and 3 above indicated that the derivatized oligonucleotide had been incorporated.

The above examples summarize the chemical procedure for enriching mRNAs for those having intact 5' ends. Further detail regarding the chemical approaches for obtaining mRNAs having intact 5' ends are disclosed in International Application No. WO96/34981, published November 7, 1996.

Strategies based on the above chemical modifications to the 5' cap structure may be utilized to generate cDNAs which have been selected to include the 5' ends of the mRNAs from which they are derived. In one version of such procedures, the 5' ends of the mRNAs are modified as described above. Thereafter, a reverse transcription reaction is conducted to extend a primer complementary to the mRNA to the 5' end of the mRNA. Single stranded RNAs are eliminated to obtain a population of cDNA/mRNA

heteroduplexes in which the mRNA includes an intact 5' end. The resulting heteroduplexes may be captured on a solid phase coated with a molecule capable of interacting with the molecule used to derivatize the 5' end of the mRNA. Thereafter, the strands of the heteroduplexes are separated to recover single stranded first cDNA strands which include the 5' end of the mRNA. Second strand cDNA synthesis may then proceed using conventional techniques. For example, the procedures disclosed in WO 96/34981 or in Carninci, P. et al. High-Efficiency Full-Length cDNA Cloning by Biotinylated CAP Trapper. *Genomics* 37:327-336 (1996), may be employed to select cDNAs which include the sequence derived from the 5' end of the coding sequence of the mRNA.

Following ligation of the oligonucleotide tag to the 5' cap of the mRNA, a reverse transcription reaction is conducted to extend a primer complementary to the mRNA to the 5' end of the mRNA. Following elimination of the RNA component of the resulting heteroduplex using standard techniques, second strand cDNA synthesis is conducted with a primer complementary to the oligonucleotide tag.

Figure 1 summarizes the above procedures for obtaining cDNAs which have been selected to include the 5' ends of the mRNAs from which they are derived.

#### B. Enzymatic Methods for Obtaining mRNAs having Intact 5' Ends

Other techniques for selecting cDNAs extending to the 5' end of the mRNA from which they are derived are fully enzymatic. Some versions of these techniques are disclosed in Dumas Milne-Edwards J.B. (Doctoral Thesis of Paris VI University, Le clonage des ADNc complets: difficultes et perspectives nouvelles. Apports pour l'etude de la regulation de l'expression de la tryptophane hydroxylase de rat, 20 Dec. 1993), EP0 625572 and Kato et al. Construction of a Human Full-Length cDNA Bank. *Gene* 150:243-250 (1994).

Briefly, in such approaches, isolated mRNA is treated with alkaline phosphatase to remove the phosphate groups present on the 5' ends of uncapped incomplete mRNAs. Following this procedure, the cap present on full length mRNAs is enzymatically removed with a decapping enzyme such as T4 polynucleotide kinase or tobacco acid pyrophosphatase. An oligonucleotide, which may be either a DNA oligonucleotide or a DNA-RNA hybrid oligonucleotide having RNA at its 3' end, is then ligated to the phosphate present at the 5' end of the decapped mRNA using T4 RNA ligase. The oligonucleotide may include a restriction site to facilitate cloning of the cDNAs following their synthesis. Example 12 below describes one enzymatic method based on the doctoral thesis of Dumas.

### EXAMPLE 12

#### Enzymatic Approach for Obtaining 5' ESTs

Twenty micrograms of PolyA+ RNA were dephosphorylated using Calf Intestinal Phosphatase (Biolabs). After a phenol chloroform extraction, the cap structure of mRNA was hydrolyzed using the Tobacco Acid Pyrophosphatase (purified as described by Shinshi et al., *Biochemistry* 15: 2185-2190, 1976) and a hemi 5'DNA/RNA-3' oligonucleotide having an unphosphorylated 5' end, a stretch of adenosine

ribophosphate at the 3' end, and an EcoRI site near the 5' end was ligated to the 5'P ends of mRNA using the T4 RNA ligase (Biolabs). Oligonucleotides suitable for use in this procedure are preferably 30-50 bases in length. Oligonucleotides having an unphosphorylated 5' end may be synthesized by adding a fluorochrome at the 5' end. The inclusion of a stretch of adenosine ribophosphates at the 3' end of the oligonucleotide increases ligation efficiency. It will be appreciated that the oligonucleotide may contain cloning sites other than EcoRI.

Following ligation of the oligonucleotide to the phosphate present at the 5' end of the decapped mRNA, first and second strand cDNA synthesis may be carried out using conventional methods or those specified in EP0 625,572 and Kato et al. Construction of a Human Full-Length cDNA Bank. *Gene* 150:243-250 (1994), and Dunyas Milne-Edwards, *supra*. The resulting cDNA may then be ligated into vectors such as those disclosed in Kato et al. Construction of a Human Full-Length cDNA Bank. *Gene* 150:243-250 (1994) or other nucleic acid vectors known to those skilled in the art using techniques such as those described in Sambrook et al., *Molecular Cloning: A Laboratory Manual* 2d Ed., Cold Spring Harbor Laboratory Press (1989).

## II. Characterization of 5' ESTs

The above chemical and enzymatic approaches for enriching mRNAs having intact 5' ends were employed to obtain 5' ESTs. First, mRNAs were prepared as described in Example 13 below.

### EXAMPLE 13

#### Preparation of mRNA

Total human RNAs or PolyA+ RNAs derived from 29 different tissues were respectively purchased from LABIMO and CLONTECH and used to generate 44 cDNA libraries as described below. The purchased RNA had been isolated from cells or tissues using acid guanidium thiocyanate-phenol-chloroform extraction (Chomczynski, P and Sacchi, N., *Analytical Biochemistry* 162:156-159, 1987). PolyA+ RNA was isolated from total RNA (LABIMO) by two passes of oligodT chromatography, as described by Aviv and Leder (Aviv, H. and Leder, P., *Proc. Natl. Acad. Sci. USA* 69:1408-1412, 1972) in order to eliminate ribosomal RNA.

The quality and the integrity of the poly A+ were checked. Northern blots hybridized with a globin probe were used to confirm that the mRNAs were not degraded. Contamination of the PolyA+ mRNAs by ribosomal sequences was checked using RNAs blots and a probe derived from the sequence of the 28S RNA. Preparations of mRNAs with less than 5% of ribosomal RNAs were used in library construction. To avoid constructing libraries with RNAs contaminated by exogenous sequences (prokaryotic or fungal), the presence of bacterial 16S ribosomal sequences or of two highly expressed mRNAs was examined using PCR.

Following preparation of the mRNAs, the above described chemical and/or the enzymatic procedures for enriching mRNAs having intact 5' ends discussed above were employed to obtain 5' ESTs

from various tissues. In both approaches an oligonucleotide tag was attached to the cap at the 5' ends of the mRNAs. The oligonucleotide tag had an EcoRI site therein to facilitate later cloning procedures.

Following attachment of the oligonucleotide tag to the mRNA by either the chemical or enzymatic methods, the integrity of the mRNA was examined by performing a Northern blot with 200-500ng of mRNA using a probe complementary to the oligonucleotide tag.

#### EXAMPLE 14

##### cDNA Synthesis Using mRNA Templates Having Intact 5' Ends

For the mRNAs joined to oligonucleotide tags using both the chemical and enzymatic methods, first strand cDNA synthesis was performed with reverse transcriptase using random nonamers as primers. In order to protect internal EcoRI sites in the cDNA from digestion at later steps in the procedure, methylated dCTP was used for first strand synthesis. After removal of RNA by an alkaline hydrolysis, the first strand of cDNA was precipitated using isopropanol in order to eliminate residual primers.

For both the chemical and the enzymatic methods, synthesis of the second strand of the cDNA is conducted as follows. After removal of RNA by alkaline hydrolysis, the first strand of cDNA is precipitated using isopropanol in order to eliminate residual primers. The second strand of the cDNA was synthesized with Klenow using a primer corresponding to the 5' end of the ligated oligonucleotide described in Example 12. Preferably, the primer is 20-25 bases in length. Methylated dCTP was also used for second strand synthesis in order to protect internal EcoRI sites in the cDNA from digestion during the cloning process.

Following cDNA synthesis, the cDNAs were cloned into pBlueScript as described in Example 15 below.

#### EXAMPLE 15

##### Insertion of cDNAs into BlueScript

Following second strand synthesis, the ends of the cDNA were blunted with T4 DNA polymerase (Biolabs) and the cDNA was digested with EcoRI. Since methylated dCTP was used during cDNA synthesis, the EcoRI site present in the tag was the only site which was hemi-methylated. Consequently, only the EcoRI site in the oligonucleotide tag was susceptible to EcoRI digestion. The cDNA was then size fractionated using exclusion chromatography (AcA, Biosepra). Fractions corresponding to cDNAs of more than 150 bp were pooled and ethanol precipitated. The cDNA was directionally cloned into the SmaI and EcoRI ends of the phagemid pBlueScript vector (Stratagene). The ligation mixture was electroporated into bacteria and propagated under appropriate antibiotic selection.

Clones containing the oligonucleotide tag attached were selected as described in Example 16 below.

## EXAMPLE 16

Selection of Clones Having the Oligonucleotide Tag Attached Thereto

The plasmid DNAs containing 5' EST libraries made as described above were purified (Qiagen). A positive selection of the tagged clones was performed as follows. Briefly, in this selection procedure, the plasmid DNA was converted to single stranded DNA using gene II endonuclease of the phage F1 in combination with an exonuclease (Chang *et al.*, *Gene* 127:95-8, (1993)) such as exonuclease III or T7 gene 6 exonuclease. The resulting single stranded DNA was then purified using paramagnetic beads as described by Fry *et al.*, *Biotechniques*, 13: 124-131 (1992). In this procedure, the single stranded DNA was hybridized with a biotinylated oligonucleotide having a sequence corresponding to the 3' end of the oligonucleotide described in Example 13. Preferably, the primer has a length of 20-25 bases. Clones including a sequence complementary to the biotinylated oligonucleotide were captured by incubation with streptavidin coated magnetic beads followed by magnetic selection. After capture of the positive clones, the plasmid DNA was released from the magnetic beads and converted into double stranded DNA using a DNA polymerase such as the ThermoSequenase obtained from Amersham Pharmacia Biotech. Alternatively, protocols such as the Gene Trapper kit (Gibco BRL) may be used. The double stranded DNA was then electroporated into bacteria. The percentage of positive clones having the 5' tag oligonucleotide was estimated to typically rank between 90 and 98% using dot blot analysis.

Following electroporation, the libraries were ordered in 384-microtiter plates (MTP). A copy of the MTP was stored for future needs. Then the libraries were transferred into 96 MTP and sequenced as described below.

## EXAMPLE 17

Sequencing of Inserts in Selected Clones

Plasmid inserts were first amplified by PCR on PE 9600 thermocyclers (Perkin-Elmer), using standard SETA-A and SETA-B primers (Genset SA), AmpliTaqGold (Perkin-Elmer), dNTPs (Boehringer), buffer and cycling conditions as recommended by the Perkin-Elmer Corporation.

PCR products were then sequenced using automatic ABI Prism 377 sequencers (Perkin Elmer, Applied Biosystems Division, Foster City, CA). Sequencing reactions were performed using PE 9600 thermocyclers (Perkin Elmer) with standard dye-primer chemistry and ThermoSequenase (Amersham Life Science). The primers used were either T7 or 21M13 (available from Genset SA) as appropriate. The primers were labeled with the JOE, FAM, ROX and TAMRA dyes. The dNTPs and ddNTPs used in the sequencing reactions were purchased from Boehringer. Sequencing buffer, reagent concentrations and cycling conditions were as recommended by Amersham.

Following the sequencing reaction, the samples were precipitated with EtOH, resuspended in formamide loading buffer, and loaded on a standard 4% acrylamide gel. Electrophoresis was performed for 2.5 hours at 3000V on an ABI 377 sequencer, and the sequence data were collected and analyzed using the



ABI Prism DNA Sequencing Analysis Software, version 2.1.2.

The sequence data from the 44 cDNA libraries made as described above were transferred to a proprietary database, where quality control and validation steps were performed. A proprietary base-caller ("Trace"), working using a Unix system automatically flagged suspect peaks, taking into account the shape of the peaks, the inter-peak resolution, and the noise level. The proprietary base-caller also performed an automatic trimming. Any stretch of 25 or fewer bases having more than 4 suspect peaks was considered unreliable and was discarded. Sequences corresponding to cloning vector or ligation oligonucleotides were automatically removed from the EST sequences. However, the resulting EST sequences may contain 1 to 5 bases belonging to the above mentioned sequences at their 5' end. If needed, these can easily be removed on a case by case basis.

Thereafter, the sequences were transferred to the proprietary NETGENE™ Database for further analysis as described below.

Following sequencing as described above, the sequences of the 5' ESTs were entered in a proprietary database called NETGENE™ for storage and manipulation. It will be appreciated by those skilled in the art that the data could be stored and manipulated on any medium which can be read and accessed by a computer. Computer readable media include magnetically readable media, optically readable media, or electronically readable media. For example, the computer readable media may be a hard disc, a floppy disc, a magnetic tape, CD-ROM, RAM, or ROM as well as other types of other media known to those skilled in the art.

In addition, the sequence data may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, the sequence data may be stored as text in a word processing file, such as Microsoft WORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE.

The computer readable media on which the sequence information is stored may be in a personal computer, a network, a server or other computer systems known to those skilled in the art. The computer or other system preferably includes the storage media described above, and a processor for accessing and manipulating the sequence data.

Once the sequence data has been stored it may be manipulated and searched to locate those stored sequences which contain a desired nucleic acid sequence or which encode a protein having a particular functional domain. For example, the stored sequence information may be compared to other known sequences to identify homologies, motifs implicated in biological function, or structural motifs.

Programs which may be used to search or compare the stored sequences include the MacPattern (EMBL), BLAST, and BLAST2 program series (NCBI), basic local alignment search tool programs for nucleotide (BLASTN) and peptide (BLASTX) comparisons (Altschul et al, *J. Mol. Biol.* 215: 403 (1990)) and FASTA (Pearson and Lipman, *Proc. Natl. Acad. Sci. USA*, 85: 2444 (1988)). The BLAST programs then extend the alignments on the basis of defined match and mismatch criteria.

Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets. signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

Before searching the cDNAs in the NETGENE™ database for sequence motifs of interest, cDNAs derived from mRNAs which were not of interest were identified and eliminated from further consideration as described in Example 18 below.

### EXAMPLE 18

#### Elimination of Undesired Sequences from Further Consideration

5' ESTs in the NETGENE™ database which were derived from undesired sequences such as transfer RNAs, ribosomal RNAs, mitochondrial RNAs, procaryotic RNAs, fungal RNAs, Alu sequences, L1 sequences, or repeat sequences were identified using the FASTA and BLASTN programs with the parameters listed in Table I.

To eliminate 5' ESTs encoding tRNAs from further consideration, the 5' EST sequences were compared to the sequences of 1190 known tRNAs obtained from EMBL release 38, of which 100 were human. The comparison was performed using FASTA on both strands of the 5' ESTs. Sequences having more than 80% homology over more than 60 nucleotides were identified as tRNA. Of the 144,341 sequences screened, 26 were identified as tRNAs and eliminated from further consideration.

To eliminate 5' ESTs encoding rRNAs from further consideration, the 5' EST sequences were compared to the sequences of 2497 known rRNAs obtained from EMBL release 38, of which 73 were human. The comparison was performed using BLASTN on both strands of the 5' ESTs with the parameter S=108. Sequences having more than 80% homology over stretches longer than 40 nucleotides were identified as rRNAs. Of the 144,341 sequences screened, 3,312 were identified as rRNAs and eliminated from further consideration.

To eliminate 5' ESTs encoding mRNAs from further consideration, the 5' EST sequences were compared to the sequences of the two known mitochondrial genomes for which the entire genomic sequences are available and all sequences transcribed from these mitochondrial genomes including tRNAs, rRNAs, and mRNAs for a total of 38 sequences. The comparison was performed using BLASTN on both strands of the 5' ESTs with the parameter S=108. Sequences having more than 80% homology over stretches longer than 40 nucleotides were identified as mRNAs. Of the 144,341 sequences screened, 6,110 were identified as mRNAs and eliminated from further consideration.

Sequences which might have resulted from exogenous contaminants were eliminated from further consideration by comparing the 5' EST sequences to release 46 of the EMBL bacterial and fungal divisions using BLASTN with the parameter S=144. All sequences having more than 90% homology over at least 40

nucleotides were identified as exogenous contaminants. Of the 42 cDNA libraries examined, the average percentages of procaryotic and fungal sequences contained therein were 0.2% and 0.5% respectively. Among these sequences, only one could be identified as a sequence specific to fungi. The others were either fungal or procaryotic sequences having homologies with vertebrate sequences or including repeat sequences which had not been masked during the electronic comparison.

In addition, the 5' ESTs were compared to 6093 Alu sequences and 1115 L1 sequences to mask 5' ESTs containing such repeat sequences from further consideration. 5' ESTs including THE and MER repeats, SSTR sequences or satellite, micro-satellite, or telomeric repeats were also eliminated from further consideration. On average, 11.5% of the sequences in the libraries contained repeat sequences. Of this 11.5%, 7% contained Alu repeats, 3.3% contained L1 repeats and the remaining 1.2% were derived from the other types of repetitive sequences which were screened. These percentages are consistent with those found in cDNA libraries prepared by other groups. For example, the cDNA libraries of Adams et al. contained between 0% and 7.4% Alu repeats depending on the source of the RNA which was used to prepare the cDNA library (Adams et al., *Nature* 377:174, 1996).

The sequences of those 5' ESTs remaining after the elimination of undesirable sequences were compared with the sequences of known human mRNAs to determine the accuracy of the sequencing procedures described above.

#### EXAMPLE 19

##### Measurement of Sequencing Accuracy by Comparison to Known Sequences

To further determine the accuracy of the sequencing procedure described above, the sequences of 5' ESTs derived from known sequences were identified and compared to the known sequences. First, a FASTA analysis with overhangs shorter than 5 bp on both ends was conducted on the 5' ESTs to identify those matching an entry in the public human mRNA database. The 6655 5' ESTs which matched a known human mRNA were then realigned with their cognate mRNA and dynamic programming was used to include substitutions, insertions, and deletions in the list of "errors" which would be recognized. Errors occurring in the last 10 bases of the 5' EST sequences were ignored to avoid the inclusion of spurious cloning sites in the analysis of sequencing accuracy.

This analysis revealed that the sequences incorporated in the NETGENE™ database had an accuracy of more than 99.5%.

To determine the efficiency with which the above selection procedures select cDNAs which include the 5' ends of their corresponding mRNAs, the following analysis was performed.

#### EXAMPLE 20

##### Determination of Efficiency of 5' EST Selection

To determine the efficiency at which the above selection procedures isolated 5' ESTs which

included sequences close to the 5' end of the mRNAs from which they were derived, the sequences of the ends of the 5' ESTs which were derived from the elongation factor 1 subunit  $\alpha$  and ferritin heavy chain genes were compared to the known cDNA sequences for these genes. Since the transcription start sites for the elongation factor 1 subunit  $\alpha$  and ferritin heavy chain are well characterized, they may be used to determine the percentage of 5' ESTs derived from these genes which included the authentic transcription start sites.

For both genes, more than 95% of the cDNAs included sequences close to or upstream of the 5' end of the corresponding mRNAs.

To extend the analysis of the reliability of the procedures for isolating 5' ESTs from ESTs in the NETGENE™ database, a similar analysis was conducted using a database composed of human mRNA sequences extracted from GenBank database release 97 for comparison. For those 5' ESTs derived from mRNAs included in the GeneBank database, more than 85% had their 5' ends close to the 5' ends of the known sequence. As some of the mRNA sequences available in the GenBank database are deduced from genomic sequences, a 5' end matching with these sequences will be counted as an internal match. Thus, the method used here underestimates the yield of ESTs including the authentic 5' ends of their corresponding mRNAs.

The EST libraries made above included multiple 5' ESTs derived from the same mRNA. The sequences of such 5' ESTs were compared to one another and the longest 5' ESTs for each mRNA were identified. Overlapping cDNAs were assembled into continuous sequences (contigs). The resulting continuous sequences were then compared to public databases to gauge their similarity to known sequences, as described in Example 21 below.

## EXAMPLE 21

### Clustering of the 5' ESTs and Calculation of Novelty Indices for cDNA Libraries

For each sequenced EST library, the sequences were clustered by the 5' end. Each sequence in the library was compared to the others with BLASTN2 (direct strand, parameters S=107). ESTs with High Scoring Segment Pairs (HSPs) at least 25 bp long, having 95% identical bases and beginning closer than 10 bp from each EST 5' end were grouped. The longest sequence found in the cluster was used as representative of the cluster. A global clustering between libraries was then performed leading to the definition of super-contigs.

To assess the yield of new sequences within the EST libraries, a novelty rate (NR) was defined as:  $NR = 100 \times (\text{Number of new unique sequences found in the library} / \text{Total number of sequences from the library})$ . Typically, novelty rating range between 10% and 41% depending on the tissue from which the EST library was obtained. For most of the libraries, the random sequencing of 5' EST libraries was pursued until the novelty rate reached 20%.

Following characterization as described above, the collection of 5' ESTs in NETGENE™ was

screened to identify those 5' ESTs bearing potential signal sequences as described in Example 22 below.

## EXAMPLE 22

### Identification of Potential Signal Sequences in 5' ESTs

5 The 5' ESTs in the NETGENE™ database were screened to identify those having an uninterrupted open reading frame (ORF) longer than 45 nucleotides beginning with an ATG codon and extending to the end of the EST. Approximately half of the cDNA sequences in NETGENE™ contained such an ORF. The ORFs of these 5' ESTs were searched to identify potential signal motifs using slight modifications of the procedures disclosed in Von Heijne, G. A New Method for Predicting Signal Sequence Cleavage Sites. 10 *Nucleic Acids Res.* 14:4683-4690 (1986). Those 5' EST sequences encoding a 15 amino acid long stretch with a score of at least 3.5 in the Von Heijne signal peptide identification matrix were considered to possess a signal sequence. Those 5' ESTs which matched a known human mRNA or EST sequence and had a 5' end more than 20 nucleotides downstream of the known 5' end were excluded from further analysis. The remaining cDNAs having signal sequences therein were included in a database called SIGNALTAG™.

15 To confirm the accuracy of the above method for identifying signal sequences, the analysis of Example 23 was performed.

## EXAMPLE 23

### Confirmation of Accuracy of Identification of Potential Signal Sequences in 5' ESTs

20 The accuracy of the above procedure for identifying signal sequences encoding signal peptides was evaluated by applying the method to the 43 amino terminal amino acids of all human SwissProt proteins. The computed Von Heijne score for each protein was compared with the known characterization of the protein as being a secreted protein or a non-secreted protein. In this manner, the number of non-secreted proteins having a score higher than 3.5 (false positives) and the number of secreted proteins having a score 25 lower than 3.5 (false negatives) could be calculated.

Using the results of the above analysis, the probability that a peptide encoded by the 5' region of the mRNA is in fact a genuine signal peptide based on its Von Heijne's score was calculated based on either the assumption that 10% of human proteins are secreted or the assumption that 20% of human proteins are secreted. The results of this analysis are shown in Figures 2 and 3.

30 Using the above method of identifying secretory proteins, 5' ESTs for human glucagon, gamma interferon induced monokine precursor, secreted cyclophilin-like protein, human pleiotropin, and human biotinidase precursor all of which are polypeptides which are known to be secreted, were obtained. Thus, the above method successfully identified those 5' ESTs which encode a signal peptide.

To confirm that the signal peptide encoded by the 5' ESTs actually functions as a signal peptide, the 35 signal sequences from the 5' ESTs may be cloned into a vector designed for the identification of signal peptides. Some signal peptide identification vectors are designed to confer the ability to grow in selective

medium on host cells which have a signal sequence operably inserted into the vector. For example, to confirm that a 5' EST encodes a genuine signal peptide, the signal sequence of the 5' EST may be inserted upstream and in frame with a non-secreted form of the yeast invertase gene in signal peptide selection vectors such as those described in U.S. Patent No. 5,536,637. Growth of host cells containing signal sequence selection vectors having the signal sequence from the 5' EST inserted therein confirms that the 5' EST encodes a genuine signal peptide.

Alternatively, the presence of a signal peptide may be confirmed by cloning the extended cDNAs obtained using the ESTs into expression vectors such as pXT1 (as described below), or by constructing promoter-signal sequence-reporter gene vectors which encode fusion proteins between the signal peptide and an assayable reporter protein. After introduction of these vectors into a suitable host cell, such as COS cells or NIH 3T3 cells, the growth medium may be harvested and analyzed for the presence of the secreted protein. The medium from these cells is compared to the medium from cells containing vectors lacking the signal sequence or extended cDNA insert to identify vectors which encode a functional signal peptide or an authentic secreted protein.

Those 5' ESTs which encoded a signal peptide, as determined by the method of Example 22 above, were further grouped into four categories based on their homology to known sequences. The categorization of the 5' ESTs is described in Example 24 below.

#### EXAMPLE 24

##### Categorization of 5' ESTs Encoding a Signal Peptide

Those 5' ESTs having a sequence not matching any known vertebrate sequence nor any publicly available EST sequence were designated "new." Of the sequences in the SIGNALTAG™ database, 947 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those 5' ESTs having a sequence not matching any vertebrate sequence but matching a publicly known EST were designated "EST-ext", provided that the known EST sequence was extended by at least 40 nucleotides in the 5' direction. Of the sequences in the SIGNALTAG™ database, 150 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those ESTs not matching any vertebrate sequence but matching a publicly known EST without extending the known EST by at least 40 nucleotides in the 5' direction were designated "EST." Of the sequences in the SIGNALTAG™ database, 599 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those 5' ESTs matching a human mRNA sequence but extending the known sequence by at least 40 nucleotides in the 5' direction were designated "VERT-ext." Of the sequences in the SIGNALTAG™ database, 23 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category. Included in this category was a 5' EST which extended the known sequence of the human translocase mRNA by more than 200 bases in the 5' direction. A 5' EST which extended the sequence of a human tumor suppressor

gene in the 5' direction was also identified.

Figure 4 shows the distribution of 5' ESTs in each category and the number of 5' ESTs in each category having a given minimum von Heijne's score.

Each of the 5' ESTs was categorized based on the tissue from which its corresponding mRNA was obtained, as described below in Example 25.

#### EXAMPLE 25

##### Categorization of Expression Patterns

Figure 5 shows the tissues from which the mRNAs corresponding to the 5' ESTs in each of the above described categories were obtained.

In addition to categorizing the 5' ESTs by the tissue from which the cDNA library in which they were first identified was obtained, the spatial and temporal expression patterns of the mRNAs corresponding to the 5' ESTs, as well as their expression levels, may be determined as described in Example 26 below. Characterization of the spatial and temporal expression patterns and expression levels of these mRNAs is useful for constructing expression vectors capable of producing a desired level of gene product in a desired spatial or temporal manner, as will be discussed in more detail below.

In addition, 5' ESTs whose corresponding mRNAs are associated with disease states may also be identified. For example, a particular disease may result from lack of expression, over expression, or under expression of an mRNA corresponding to a 5' EST. By comparing mRNA expression patterns and quantities in samples taken from healthy individuals with those from individuals suffering from a particular disease, 5' ESTs responsible for the disease may be identified.

It will be appreciated that the results of the above characterization procedures for 5' ESTs also apply to extended cDNAs (obtainable as described below) which contain sequences adjacent to the 5' ESTs. It will also be appreciated that if it is desired to defer characterization until extended cDNAs have been obtained rather than characterizing the ESTs themselves, the above characterization procedures can be applied to characterize the extended cDNAs after their isolation.

#### EXAMPLE 26

##### Evaluation of Expression Levels and Patterns of mRNAs

##### Corresponding to 5' ESTs or Extended cDNAs

Expression levels and patterns of mRNAs corresponding to 5' ESTs or extended cDNAs (obtainable as described below) may be analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277. Briefly, a 5' EST, extended cDNA, or fragment thereof corresponding to the gene encoding the mRNA to be characterized is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the 5' EST or extended cDNA has 100 or more nucleotides. The plasmid is linearized and

transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridizations are performed under standard stringent conditions (40-50°C for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

The 5' ESTs, extended cDNAs, or fragments thereof may also be tagged with nucleotide sequences for the serial analysis of gene expression (SAGE) as disclosed in UK Patent Application No. 2,305,241 A. In this method, cDNAs are prepared from a cell, tissue, organism or other source of nucleic acid for which it is desired to determine gene expression patterns. The resulting cDNAs are separated into two pools. The cDNAs in each pool are cleaved with a first restriction endonuclease, called an "anchoring enzyme," having a recognition site which is likely to be present at least once in most cDNAs. The fragments which contain the 5' or 3' most region of the cleaved cDNA are isolated by binding to a capture medium such as streptavidin coated beads. A first oligonucleotide linker having a first sequence for hybridization of an amplification primer and an internal restriction site for a "tagging endonuclease" is ligated to the digested cDNAs in the first pool. Digestion with the second endonuclease produces short "tag" fragments from the cDNAs.

A second oligonucleotide having a second sequence for hybridization of an amplification primer and an internal restriction site is ligated to the digested cDNAs in the second pool. The cDNA fragments in the second pool are also digested with the "tagging endonuclease" to generate short "tag" fragments derived from the cDNAs in the second pool. The "tags" resulting from digestion of the first and second pools with the anchoring enzyme and the tagging endonuclease are ligated to one another to produce "ditags." In some embodiments, the ditags are concatamerized to produce ligation products containing from 2 to 200 ditags. The tag sequences are then determined and compared to the sequences of the 5' ESTs or extended cDNAs to determine which 5' ESTs or extended cDNAs are expressed in the cell, tissue, organism, or other source of nucleic acids from which the tags were derived. In this way, the expression pattern of the 5' ESTs or extended cDNAs in the cell, tissue, organism, or other source of nucleic acids is obtained.

Quantitative analysis of gene expression may also be performed using arrays. As used herein, the term array means a one dimensional, two dimensional, or multidimensional arrangement of full length cDNAs (i.e. extended cDNAs which include the coding sequence for the signal peptide, the coding sequence for the mature protein, and a stop codon), extended cDNAs, 5' ESTs or fragments of the full length cDNAs, extended cDNAs, or 5' ESTs of sufficient length to permit specific detection of gene expression. Preferably, the fragments are at least 15 nucleotides in length. More preferably, the fragments are at least 100 nucleotides in length. More preferably, the fragments are more than 100 nucleotides in



length. In some embodiments the fragments may be more than 500 nucleotides in length.

For example, quantitative analysis of gene expression may be performed with full length cDNAs, extended cDNAs, 5' ESTs, or fragments thereof in a complementary DNA microarray as described by Schena et al. *Science* 270:467-470, 1995; *Proc. Natl. Acad. Sci. U.S.A.* 93:10614-10619 (1996). Full length  
5 cDNAs, extended cDNAs, 5' ESTs or fragments thereof are amplified by PCR and arrayed from 96-well microtiter plates onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride solution. The arrays are submerged in water for 2 min at 95°C, transferred into 0.2% SDS for 1 min, rinsed twice with water, air dried and stored in the  
10 dark at 25°C.

Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a single round of reverse transcription. Probes are hybridized to 1 cm<sup>2</sup> microarrays under a 14 x 14 mm glass coverslip for 6-12 hours at 60°C. Arrays are washed for 5 min at 25°C in low stringency wash buffer (1 x SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (0.1 x SSC/0.2%  
15 SDS). Arrays are scanned in 0.1 x SSC using a fluorescence laser scanning device fitted with a custom filter set. Accurate differential expression measurements are obtained by taking the average of the ratios of two independent hybridizations.

Quantitative analysis of the expression of genes may also be performed with full length cDNAs, extended cDNAs, 5' ESTs, or fragments thereof in complementary DNA arrays as described by Pietu et al. *Genome Research* 6:492-503 (1996). The full length cDNAs, extended cDNAs, 5' ESTs or fragments  
20 thereof are PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are detected by phospho-imaging or autoradiography. Duplicate experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

Alternatively, expression analysis of the 5' ESTs or extended cDNAs can be done through high density nucleotide arrays as described by Lockhart et al. *Nature Biotechnology* 14: 1675-1680, 1996. and Sosnowsky et al. *Proc. Natl. Acad. Sci.* 94:1119-1123, 1997. Oligonucleotides of 15-50 nucleotides  
25 corresponding to sequences of the 5' ESTs or extended cDNAs are synthesized directly on the chip (Lockhart et al., *supra*) or synthesized and then addressed to the chip (Sosnowski et al., *supra*). Preferably, the oligonucleotides are about 20 nucleotides in length.  
30

cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart et al., *supra* and application of different electric fields (Sosnowsky et al., *Proc. Natl. Acad. Sci.*  
35 94:1119-1123), the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed. Comparative analysis of the intensity of the signal originating from cDNA probes on the same

target oligonucleotide in different cDNA samples indicates a differential expression of the mRNA corresponding to the 5' EST or extended cDNA from which the oligonucleotide sequence has been designed.

### III. Use of 5' ESTs to Clone Extended cDNAs and to Clone the Corresponding Genomic DNAs

Once 5' ESTs which include the 5' end of the corresponding mRNAs have been selected using the procedures described above, they can be utilized to isolate extended cDNAs which contain sequences adjacent to the 5' ESTs. The extended cDNAs may include the entire coding sequence of the protein encoded by the corresponding mRNA, including the authentic translation start site, the signal sequence, and the sequence encoding the mature protein remaining after cleavage of the signal peptide. Such extended cDNAs are referred to herein as "full length cDNAs." Alternatively, the extended cDNAs may include only the sequence encoding the mature protein remaining after cleavage of the signal peptide, or only the sequence encoding the signal peptide.

Example 27 below describes a general method for obtaining extended cDNAs. Example 28 below describes the cloning and sequencing of several extended cDNAs, including extended cDNAs which include the entire coding sequence and authentic 5' end of the corresponding mRNA for several secreted proteins.

The methods of Examples 27, 28, and 29 can also be used to obtain extended cDNAs which encode less than the entire coding sequence of the secreted proteins encoded by the genes corresponding to the 5' ESTs. In some embodiments, the extended cDNAs isolated using these methods encode at least 10 amino acids of one of the proteins encoded by the sequences of SEQ ID NOs: 134-180. In further embodiments, the extended cDNAs encode at least 20 amino acids of the proteins encoded by the sequences of SEQ ID NOs: 134-180. In further embodiments, the extended cDNAs encode at least 30 amino acids of the sequences of SEQ ID NOs: 134-180. In a preferred embodiment, the extended cDNAs encode a full length protein sequence, which includes the protein coding sequences of SEQ ID NOs: 134-180.

#### EXAMPLE 27

##### General Method for Using 5' ESTs to Clone and Sequence Extended cDNAs which Include the Entire Coding Region and the Authentic 5' End of the Corresponding mRNA

The following general method has been used to quickly and efficiently isolate extended cDNAs including sequence adjacent to the sequences of the 5' ESTs used to obtain them. This method may be applied to obtain extended cDNAs for any 5' EST in the NetGene™ database, including those 5' ESTs encoding secreted proteins. The method is summarized in figure 6.

##### 1. Obtaining Extended cDNAs

###### a) First strand synthesis

The method takes advantage of the known 5' sequence of the mRNA. A reverse transcription reaction is conducted on purified mRNA with a poly 14dT primer containing a 49 nucleotide sequence at its 5' end allowing the addition of a known sequence at the end of the cDNA which corresponds to the 3' end of

the mRNA. For example, the primer may have the following sequence: 5'-ATC GTT GAG ACT CGT ACC AGC AGA GTC ACG AGA GAG ACT ACA CGG TAC TGG TTT TTT TTT TTT TTVN -3' (SEQ ID NO: 14). Those skilled in the art will appreciate that other sequences may also be added to the poly dT sequence and used to prime the first strand synthesis. Using this primer and a reverse transcriptase such as the Superscript II (Gibco BRL) or Rnase H Minus M-MLV (Promega) enzyme, a reverse transcript anchored at the 3' polyA site of the RNAs is generated.

After removal of the mRNA hybridized to the first cDNA strand by alkaline hydrolysis, the products of the alkaline hydrolysis and the residual poly dT primer are eliminated with an exclusion column such as an AcA34 (Biosepra) matrix as explained in Example 11.

#### b) Second strand synthesis

A pair of nested primers on each end is designed based on the known 5' sequence from the 5' EST and the known 3' end added by the poly dT primer used in the first strand synthesis. Softwares used to design primers are either based on GC content and melting temperatures of oligonucleotides, such as OSP (Illier and Green, *PCR Meth. Appl.* 1:124-128, 1991), or based on the octamer frequency disparity method (Griffais et al., *Nucleic Acids Res.* 19: 3887-3891, 1991 such as PC-Rare (<http://bioinformatics.weizmann.ac.il/software/PC-Rare/doc/manuel.html>)).

Preferably, the nested primers at the 5' end are separated from one another by four to nine bases. The 5' primer sequences may be selected to have melting temperatures and specificities suitable for use in PCR.

Preferably, the nested primers at the 3' end are separated from one another by four to nine bases. For example, the nested 3' primers may have the following sequences: (5'- CCA GCA GAG TCA CGA GAG AGA CTA CAC GG -3' (SEQ ID NO: 15), and 5'- CAC GAG AGA GAC TAC ACG GTA CTG G -3' (SEQ ID NO: 16). These primers were selected because they have melting temperatures and specificities compatible with their use in PCR. However, those skilled in the art will appreciate that other sequences may also be used as primers.

The first PCR run of 25 cycles is performed using the Advantage Tth Polymerase Mix (Clontech) and the outer primer from each of the nested pairs. A second 20 cycle PCR using the same enzyme and the inner primer from each of the nested pairs is then performed on 1/2500 of the first PCR product. Thereafter, the primers and nucleotides are removed.

## 2. Sequencing of Full Length Extended cDNAs or Fragments Thereof

Due to the lack of position constraints on the design of 5' nested primers compatible for PCR use using the OSP software, amplicons of two types are obtained. Preferably, the second 5' primer is located upstream of the translation initiation codon thus yielding a nested PCR product containing the whole coding sequence. Such a full length extended cDNA undergoes a direct cloning procedure as described in section a. However, in some cases, the second 5' primer is located downstream of the translation initiation codon, thereby yielding a PCR product containing only part of the ORF. Such incomplete PCR products are

submitted to a modified procedure described in section b.

a) Nested PCR products containing complete ORFs

When the resulting nested PCR product contains the complete coding sequence, as predicted from the 5'EST sequence, it is cloned in an appropriate vector such as pED6dpc2, as described in section 3.

5 b) Nested PCR products containing incomplete ORFs

When the amplicon does not contain the complete coding sequence, intermediate steps are necessary to obtain both the complete coding sequence and a PCR product containing the full coding sequence. The complete coding sequence can be assembled from several partial sequences determined directly from different PCR products as described in the following section.

10 Once the full coding sequence has been completely determined, new primers compatible for PCR use are designed to obtain amplicons containing the whole coding region. However, in such cases, 3' primers compatible for PCR use are located inside the 3' UTR of the corresponding mRNA, thus yielding amplicons which lack part of this region, i.e. the polyA tract and sometimes the polyadenylation signal, as illustrated in figure 6. Such full length extended cDNAs are then cloned into an appropriate vector as  
15 described in section 3.

c) Sequencing extended cDNAs

Sequencing of extended cDNAs is performed using a Die Terminator approach with the AmpliTaq DNA polymerase FS kit available from Perkin Elmer.

In order to sequence PCR fragments, primer walking is performed using software such as OSP to  
20 choose primers and automated computer software such as ASMG (Sutton et al., *Genome Science Technol.* 1: 9-19, 1995) to construct contigs of walking sequences including the initial 5' tag using minimum overlaps of 32 nucleotides. Preferably, primer walking is performed until the sequences of full length cDNAs are obtained.

Completion of the sequencing of a given extended cDNA fragment is assessed as follows. Since  
25 sequences located after a polyA tract are difficult to determine precisely in the case of uncloned products, sequencing and primer walking processes for PCR products are interrupted when a polyA tract is identified in extended cDNAs obtained as described in case b. The sequence length is compared to the size of the nested PCR product obtained as described above. Due to the limited accuracy of the determination of the PCR product size by gel electrophoresis, a sequence is considered complete if the size of the obtained  
30 sequence is at least 70 % the size of the first nested PCR product. If the length of the sequence determined from the computer analysis is not at least 70% of the length of the nested PCR product, these PCR products are cloned and the sequence of the insertion is determined. When Northern blot data are available, the size of the mRNA detected for a given PCR product is used to finally assess that the sequence is complete. Sequences which do not fulfill the above criteria are discarded and will undergo a new isolation procedure.

35 Sequence data of all extended cDNAs are then transferred to a proprietary database, where quality controls and validation steps are carried out as described in example 15.

### 3. Cloning of Full Length Extended cDNAs

The PCR product containing the full coding sequence is then cloned in an appropriate vector. For example, the extended cDNAs can be cloned into the expression vector pED6dpc2 (DiscoverEase, Genetics Institute, Cambridge, MA) as follows. The structure of pED6dpc2 is shown in Figure 7. pED6dpc2 vector DNA is prepared with blunt ends by performing an EcoRI digestion followed by a fill in reaction. The blunt ended vector is dephosphorylated. After removal of PCR primers and ethanol precipitation, the PCR product containing the full coding sequence or the extended cDNA obtained as described above is phosphorylated with a kinase subsequently removed by phenol-Sevag extraction and precipitation. The double stranded extended cDNA is then ligated to the vector and the resulting expression plasmid introduced into appropriate host cells.

Since the PCR products obtained as described above are blunt ended molecules that can be cloned in either direction, the orientation of several clones for each PCR product is determined. Then, 4 to 10 clones are ordered in microtiter plates and subjected to a PCR reaction using a first primer located in the vector close to the cloning site and a second primer located in the portion of the extended cDNA corresponding to the 3' end of the mRNA. This second primer may be the antisense primer used in anchored PCR in the case of direct cloning (case a) or the antisense primer located inside the 3'UTR in the case of indirect cloning (case b). Clones in which the start codon of the extended cDNA is operably linked to the promoter in the vector so as to permit expression of the protein encoded by the extended cDNA are conserved and sequenced. In addition to the ends of cDNA inserts, approximately 50 bp of vector DNA on each side of the cDNA insert are also sequenced.

The cloned PCR products are then entirely sequenced according to the aforementioned procedure. In this case, contig assembly of long fragments is then performed on walking sequences that have already contiguated for uncloned PCR products during primer walking. Sequencing of cloned amplicons is complete when the resulting contigs include the whole coding region as well as overlapping sequences with vector DNA on both ends.

### 4. Computer Analysis of Full Length Extended cDNA

Sequences of all full length extended cDNAs are then submitted to further analysis as described below and using the parameters found in Table I with the following modifications. For screening of miscellaneous subdivisions of Genbank, FASTA was used instead of BLASTN and 15 nucleotide of homology was the limit instead of 17. For Alu detection, BLASTN was used with the following parameters: S=72; identity=70%; and length = 40 nucleotides. Polyadenylation signal and polyA tail which were not searched for the 5' ESTs were searched. For polyadenylation signal detection the signal (AATAAA) was searched with one permissible mismatch in the last ten nucleotides preceding the 5' end of the polyA. For the polyA, a stretch of 8 amino acids in the last 20 nucleotides of the sequence was searched with BLAST2N in the sense strand with the following parameters (W=6, S=10, E=1000, and identity=90%).

Finally, patented sequences and ORF homologies were searched using, respectively, BLASTN and BLASTP on GenSEQ (Derwent's database of patented nucleotide sequences) and SWISSPROT for ORFs with the following parameters (W=8 and B=10). Before examining the extended full length cDNAs for sequences of interest, extended cDNAs which are not of interest are searched as follows.

5 a) Elimination of undesired sequences

Although 5'ESTs were checked to remove contaminants sequences as described in Example 18, a last verification was carried out to identify extended cDNAs sequences derived from undesired sequences such as vector RNAs, transfer RNAs, ribosomal rRNAs, mitochondrial RNAs, prokaryotic RNAs and fungal RNAs using the FASTA and BLASTN programs on both strands of extended cDNAs as described below.

10 To identify the extended cDNAs encoding vector RNAs, extended cDNAs are compared to the known sequences of vector RNA using the FASTA program. Sequences of extended cDNAs with more than 90% homology over stretches of 15 nucleotides are identified as vector RNA.

To identify the extended cDNAs encoding tRNAs, extended cDNA sequences were compared to the sequences of 1190 known tRNAs obtained from EMBL release 38, of which 100 were human.

15 Sequences of extended cDNAs having more than 80% homology over 60 nucleotides using FASTA were identified as tRNA.

To identify the extended cDNAs encoding rRNAs, extended cDNA sequences were compared to the sequences of 2497 known rRNAs obtained from EMBL release 38, of which 73 were human. Sequences of extended cDNAs having more than 80% homology over stretches longer than 40 nucleotides using BLASTN were identified as rRNAs.

20 To identify the extended cDNAs encoding mtRNAs, extended cDNA sequences were compared to the sequences of the two known mitochondrial genomes for which the entire genomic sequences are available and all sequences transcribed from these mitochondrial genomes including tRNAs, rRNAs, and mRNAs for a total of 38 sequences. Sequences of extended cDNAs having more than 80% homology over stretches longer than 40 nucleotides using BLASTN were identified as mtRNAs.

Sequences which might have resulted from other exogenous contaminants were identified by comparing extended cDNA sequences to release 105 of Genbank bacterial and fungal divisions. Sequences of extended cDNAs having more than 90% homology over 40 nucleotides using BLASTN were identified as exogenous prokaryotic or fungal contaminants.

30 In addition, extended cDNAs were searched for different repeat sequences, including Alu sequences, L1 sequences, THE and MER repeats, SSTR sequences or satellite, micro-satellite, or telomeric repeats. Sequences of extended cDNAs with more than 70% homology over 40 nucleotide stretches using BLASTN were identified as repeat sequences and masked in further identification procedures. In addition, clones showing extensive homology to repeats, i.e., matches of either more than 35 50 nucleotides if the homology was at least 75% or more than 40 nucleotides if the homology was at least 85% or more than 30 nucleotides if the homology was at least 90%, were flagged.

## b) Identification of structural features

Structural features, e.g. polyA tail and polyadenylation signal, of the sequences of full length extended cDNAs are subsequently determined as follows.

5 A polyA tail is defined as a homopolymeric stretch of at least 11 A with at most one alternative base within it. The polyA tail search is restricted to the last 20 nt of the sequence and limited to stretches of 11 consecutive A's because sequencing reactions are often not readable after such a polyA stretch. Stretches with 100% homology over 6 nucleotides are identified as polyA tails.

10 To search for a polyadenylation signal, the polyA tail is clipped from the full-length sequence. The 50 bp preceding the polyA tail are searched for the canonic polyadenylation AAUAAA signal allowing one mismatch to account for possible sequencing errors and known variation in the canonical sequence of the polyadenylation signal.

## c) Identification of functional features

Functional features, e.g. ORFs and signal sequences, of the sequences of full length extended cDNAs were subsequently determined as follows.

15 The 3 upper strand frames of extended cDNAs are searched for ORFs defined as the maximum length fragments beginning with a translation initiation codon and ending with a stop codon. ORFs encoding at least 20 amino acids are preferred.

20 Each found ORF is then scanned for the presence of a signal peptide in the first 50 amino-acids or, where appropriate, within shorter regions down to 20 amino acids or less in the ORF, using the matrix method of von Heijne (Nuc. Acids Res. 14: 4683-4690 (1986)), the disclosure of which is incorporated herein by reference and the modification described in Example 22.

## d) Homology to either nucleotidic or proteic sequences

Sequences of full length extended cDNAs are then compared to known sequences on a nucleotidic or proteic basis.

25 Sequences of full length extended cDNAs are compared to the following known nucleic acid sequences: vertebrate sequences (Genbank release # GB), EST sequences (Genbank release # GB), patented sequences (Genseqn release GSEQ) and recently identified sequences (Genbank daily release) available at the time of filing. Full length cDNA sequences are also compared to the sequences of a private database (Genset internal sequences) in order to find sequences that have already been identified by applicants.

30 Sequences of full length extended cDNAs with more than 90% homology over 30 nucleotides using either BLASTN or BLAST2N as indicated in Table II are identified as sequences that have already been described. Matching vertebrate sequences are subsequently examined using FASTA; full length extended cDNAs with more than 70% homology over 30 nucleotides are identified as sequences that have already been described.

35 ORFs encoded by full length extended cDNAs as defined in section c) are subsequently compared to known amino acid sequences found in Swissprot release CHP, PIR release PIR# and Genpept release

GPEPI public databases using BLASTP with the parameter W=8 and allowing a maximum of 10 matches. Sequences of full length extended cDNAs showing extensive homology to known protein sequences are recognized as already identified proteins.

In addition, the three-frame conceptual translation products of the top strand of full length extended cDNAs are compared to publicly known amino acid sequences of Swissprot using BLASTX with the parameter E=0.001. Sequences of full length extended cDNAs with more than 70% homology over 30 amino acid stretches are detected as already identified proteins.

#### 5. Selection of Cloned Full Length Sequences of the Present Invention

Cloned full length extended cDNA sequences that have already been characterized by the aforementioned computer analysis are then submitted to an automatic procedure in order to preselect full length extended cDNAs containing sequences of interest.

##### a) Automatic sequence preselection

All complete cloned full length extended cDNAs clipped for vector on both ends are considered. First, a negative selection is operated in order to eliminate unwanted cloned sequences resulting from either contaminants or PCR artifacts as follows. Sequences matching contaminant sequences such as vector RNA, tRNA, miRNA, rRNA sequences are discarded as well as those encoding ORF sequences exhibiting extensive homology to repeats as defined in section 4 a). Sequences obtained by direct cloning using nested primers on 5' and 3' tags (section 1. case a) but lacking polyA tail are discarded. Only ORFs containing a signal peptide and ending either before the polyA tail (case a) or before the end of the cloned 3'UTR (case b) are kept. Then, ORFs containing unlikely mature proteins such as mature proteins which size is less than 20 amino acids or less than 25% of the immature protein size are eliminated.

In the selection of the ORF, priority was given to the ORF and the frame corresponding to the polypeptides described in SignalTag Patents (United States Patent Application Serial Nos: 08/905,223; 08/905,135; 08/905,051; 08/905,144; 08/905,279; 08/904,468; 08/905,134; and 08/905,133). If the ORF was not found among the ORFs described in the SignalTag Patents, the ORF encoding the signal peptide with the highest score according to Von Heijne method as defined in Example 22 was chosen. If the scores were identical, then the longest ORF was chosen.

Sequences of full length extended cDNA clones are then compared pairwise with BLAST after masking of the repeat sequences. Sequences containing at least 90% homology over 30 nucleotides are clustered in the same class. Each cluster is then subjected to a cluster analysis that detects sequences resulting from internal priming or from alternative splicing, identical sequences or sequences with several frameshifts. This automatic analysis serves as a basis for manual selection of the sequences.

##### b) Manual sequence selection

Manual selection is carried out using automatically generated reports for each sequenced full length extended cDNA clone. During this manual procedures, a selection is operated between clones belonging to the same class as follows. ORF sequences encoded by clones belonging to the same class are aligned and



compared. If the homology between nucleotidic sequences of clones belonging to the same class is more than 90% over 30 nucleotide stretches or if the homology between amino acid sequences of clones belonging to the same class is more than 80% over 20 amino acid stretches, then the clones are considered as being identical. The chosen ORF is the best one according to the criteria mentioned below. If the nucleotide and amino acid homologies are less than 90% and 80% respectively, the clones are said to encode distinct proteins which can be both selected if they contain sequences of interest.

Selection of full length extended cDNA clones encoding sequences of interest is performed using the following criteria. Structural parameters (initial tag, polyadenylation site and signal) are first checked. Then, homologies with known nucleic acids and proteins are examined in order to determine whether the clone sequence match a known nucleic/proteic sequence and, in the latter case, its covering rate and the date at which the sequence became public. If there is no extensive match with sequences other than ESTs or genomic DNA, or if the clone sequence brings substantial new information, such as encoding a protein resulting from alternative slicing of an mRNA coding for an already known protein, the sequence is kept. Examples of such cloned full length extended cDNAs containing sequences of interest are described in Example 28. Sequences resulting from chimera or double inserts as assessed by homology to other sequences are discarded during this procedure.

### EXAMPLE 28

#### Cloning and Sequencing of Extended cDNAs

The procedure described in Example 27 above was used to obtain the extended cDNAs of the present invention. Using this approach, the full length cDNA of SEQ ID NO:17 was obtained. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide MKKVLLITAILAVAVG (SEQ ID NO: 18) having a von Heijne score of 8.2.

The full length cDNA of SEQ ID NO:49 was also obtained using this procedure. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide MWWFQQGLSFLPSALVIWTSA (SEQ ID NO:20) having a von Heijne score of 5.5.

Another full length cDNA obtained using the procedure described above has the sequence of SEQ ID NO:21. This cDNA, falls into the "EST-ext" category described above and encodes the signal peptide MVLTTLPANSANSVPNMPTTGPNLSYASSALSPCLT (SEQ ID NO:22) having a von Heijne score of 5.9.

The above procedure was also used to obtain a full length cDNA having the sequence of SEQ ID NO:23. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide ILSTVTALTFAXA (SEQ ID NO:24) having a von Heijne score of 5.5.

The full length cDNA of SEQ ID NO:25 was also obtained using this procedure. This cDNA falls into the "new" category described above and encodes a signal peptide LVLTLCTLPLAVA (SEQ ID NO:26) having a von Heijne score of 10.1.

The full length cDNA of SEQ ID NO:27 was also obtained using this procedure. This cDNA falls into the "new" category described above and encodes a signal peptide LWLLFFLVTAIHA (SEQ ID NO:28) having a von Heijne score of 10.7.

The above procedures were also used to obtain the extended cDNAs of the present invention. 5' ESTs expressed in a variety of tissues were obtained as described above. The appended sequence listing provides the tissues from which the extended cDNAs were obtained. It will be appreciated that the extended cDNAs may also be expressed in tissues other than the tissue listed in the sequence listing.

5' ESTs obtained as described above were used to obtain extended cDNAs having the sequences of SEQ ID NOs: 40-86. Table II provides the sequence identification numbers of the extended cDNAs of the present invention, the locations of the full coding sequences in SEQ ID NOs: 40-86 (i.e. the nucleotides encoding both the signal peptide and the mature protein, listed under the heading FCS location in Table II), the locations of the nucleotides in SEQ ID NOs: 40-86 which encode the signal peptides (listed under the heading SigPep Location in Table II), the locations of the nucleotides in SEQ ID NOs: 40-86 which encode the mature proteins generated by cleavage of the signal peptides (listed under the heading Mature Polypeptide Location in Table II), the locations in SEQ ID NOs: 40-86 of stop codons (listed under the heading Stop Codon Location in Table II), the locations in SEQ ID NOs: 40-86 of polyA signals (listed under the heading Poly A Signal Location in Table II) and the locations of polyA sites (listed under the heading Poly A Site Location in Table II).

The polypeptides encoded by the extended cDNAs were screened for the presence of known structural or functional motifs or for the presence of signatures, small amino acid sequences which are well conserved amongst the members of a protein family. The conserved regions have been used to derive consensus patterns or matrices included in the PROSITE data bank, in particular in the file prosite.dat (Release 13.0 of November 1995, located at <http://expasy.hcuge.ch/sprot/prosite.html>). Prosite\_convert and prosite\_scan programs ([http://ulrec3.unil.ch/ftpserveur/prosite\\_scan](http://ulrec3.unil.ch/ftpserveur/prosite_scan)) were used to find signatures on the extended cDNAs.

For each pattern obtained with the prosite\_convert program from the prosite.dat file, the accuracy of the detection on a new protein sequence has been tested by evaluating the frequency of irrelevant hits on the population of human secreted proteins included in the data bank SWISSPROT. The ratio between the number of hits on shuffled proteins (with a window size of 20 amino acids) and the number of hits on native (unshuffled) proteins was used as an index. Every pattern for which the ration was greater than 20% (one hit on shuffled proteins for 5 hits on native proteins) was skipped during the search with prosite\_scan. The program used to shuffle protein sequences (db\_shuffled) and the program used to determine the statistics for each pattern in the protein data banks (prosite\_statistics) are available on the ftp site [http://ulrec3.unil.ch/ftpserveur/prosite\\_scan](http://ulrec3.unil.ch/ftpserveur/prosite_scan).

The results of the search are provided in Table III. The first column provides the ID number of the sequence. The second column indicates the beginning and end positions of the signature. The Prosite

definition of the signature is indicated in the third column.

Table IV lists the sequence identification numbers of the polypeptides of SEQ ID NOs: 87-133, the locations of the amino acid residues of SEQ ID NOs: 87-133 in the full length polypeptide (second column), the locations of the amino acid residues of SEQ ID NOs: 87-133 in the signal peptides (third column), and the locations of the amino acid residues of SEQ ID NOs: 87-133 in the mature polypeptide created by cleaving the signal peptide from the full length polypeptide (fourth column). In Table IV, the first amino acid of the signal peptide is designated as amino acid number 1. In the appended sequence listing, the first amino acid of the mature protein resulting from cleavage of the signal peptide is designated as amino acid number 1 and the first amino acid of the signal peptide is designated with the appropriate negative number, in accordance with the regulations governing sequence listings.

The extended cDNAs of the present invention were categorized based on their homology to known sequences. Genebank release #103, division ESTs, and Geneseq release #28 were used to scan the extended cDNAs using Blast. For each extended cDNA ID, the covering rate of the sequence by another sequence was determined as follows. The length in nucleotides of the matching segment was calculated (even when gaps were present) and divided by the length in nucleotides of the extended cDNA sequence. When more than one covering rate was obtained for a given extended cDNA, the higher covering rate was used to classify the extended cDNA. The Geneseq sequences have been categorized as either ESTs or vertebrate, with ESTs being those sequences obtained by random sequencing of cDNA libraries and vertebrate sequences being those sequences containing sequences resembling known functional motifs.

The results of this categorization are provided in Table V. The first column lists the sequence identification number of the sequence being categorized. The second column indicates those sequences having no matches with the database scanned. The third column indicates those sequences having a covering rate of less than 30%. The fourth column indicates those sequences having a covering rate greater than 30%. The fifth column indicates sequences partially or totally covered by vertebrate sequences as described above.

The nucleotide sequences of the sequences of SEQ ID NOs: 40-86 and 134-180, and the amino acid sequences encoded by SEQ ID NOs: 40-86 and 134-180 (i.e. amino acid sequences of SEQ ID NOs: 87-133 and 181-227) are provided in the appended sequence listing. In some instances, the sequences are preliminary and may include some incorrect or ambiguous sequences or amino acids. The sequences of SEQ ID NOs: 40-86 and 134-180 can readily be screened for any errors therein and any sequence ambiguities can be resolved by resequencing a fragment containing such errors or ambiguities on both strands. Nucleic acid fragments for resolving sequencing errors or ambiguities may be obtained from the deposited clones or can be isolated using the techniques described herein. Resolution of any such ambiguities or errors may be facilitated by using primers which hybridize to sequences located close to the ambiguous or erroneous sequences. For example, the primers may hybridize to sequences within 50-75 bases of the ambiguity or error. Upon resolution of an error or ambiguity, the corresponding corrections can be made in the protein

sequences encoded by the DNA containing the error or ambiguity. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein, and determining its sequence.

For each amino acid sequence, Applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing. Some of the amino acid sequences may contain "Xaa" designators. These "Xaa" designators indicate either (1) a residue which cannot be identified because of nucleotide sequence ambiguity or (2) a stop codon in the determined sequence where Applicants believe one should not exist (if the sequence were determined more accurately).

Cells containing the 47 extended cDNAs (SEQ ID NOs: 134-180) of the present invention in the vector pED6dpc2, are maintained in permanent deposit by the inventors at Genset, S.A., 24 Rue Royale, 75008 Paris, France.

A pool of the cells containing the 47 extended cDNAs (SEQ ID NOs: 134-180), from which the cells containing a particular polynucleotide is obtainable, will be deposited with the American Type Culture Collection. Each extended cDNA clone will be transfected into separate bacterial cells (E-coli) in this composite deposit. A pool of cells containing the 43 extended cDNAs (SEQ ID NOs: 134, 136-143, 145-162, 164-174, and 176-180), from which the cells containing a particular polynucleotide is obtainable, were deposited with the American Type Culture Collection on December 16, 1997, under the name SignalTag 1-43, and ATCC accession No. 98619. A pool of cells comprising the 2 extended cDNAs (SEQ ID NOs: 144 and 163), from which the cells containing a particular polynucleotide is obtainable, were deposited with the American Type Culture Collection on October 15, 1998, under the name SignalTag 44-66, and ATCC accession No. 98923. Each extended cDNA can be removed from the pED6dpc2 vector in which it was deposited by performing a NotI, PstI double digestion to produce the appropriate fragment for each clone. The proteins encoded by the extended cDNAs may also be expressed from the promoter in pED6dpc2.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The design of the oligonucleotide probe should preferably follow these parameters:

(a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;

(b) Preferably, the probe is designed to have a  $T_m$  of approx. 80°C (assuming 2 degrees for each A or T and 4 degrees for each G or C). However, probes having melting temperatures between 40 °C and 80 °C may also be used provided that specificity is not lost.

The oligonucleotide should preferably be labeled with  $\gamma$ -<sup>32</sup>PATP (specific activity 6000 Ci/mmol) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe

should be quantified by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately  $4 \times 10^6$  dpm/pmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100  $\mu$ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100  $\mu$ g/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 50(X) distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100  $\mu$ g/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100  $\mu$ g/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to  $1 \times 10^6$  dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

The plasmid DNA obtained using these procedures may then be manipulated using standard cloning techniques familiar to those skilled in the art. Alternatively, a PCR can be done with primers designed at both ends of the extended cDNA insertion. For example, a PCR reaction may be conducted using a primer having the sequence GGCCATACACTTGAGTGAC (SEQ ID NO:38) and a primer having the sequence ATATAGACAAACGCACACC (SEQ. ID. NO:39). The PCR product which corresponds to the extended cDNA can then be manipulated using standard cloning techniques familiar to those skilled in the art.

In addition to PCR based methods for obtaining extended cDNAs, traditional hybridization based methods may also be employed. These methods may also be used to obtain the genomic DNAs which encode the mRNAs from which the 5' ESTs were derived, mRNAs corresponding to the extended cDNAs, or nucleic acids which are homologous to extended cDNAs or 5' ESTs. Example 29 below provides an example of such methods.

## EXAMPLE 29

Methods for Obtaining Extended cDNAs or Nucleic  
Acids Homologous to Extended cDNAs or 5' ESTs

A full length cDNA library can be made using the strategies described in Examples 13, 14, 15, and  
5 16 above by replacing the random nonamer used in Example 14 with an oligo-dT primer. For instance, the  
oligonucleotide of SEQ ID NO: 14 may be used.

Alternatively, a cDNA library or genomic DNA library may be obtained from a commercial source  
or made using techniques familiar to those skilled in the art. The library includes cDNAs which are derived  
from the mRNA corresponding to a 5' EST or which have homology to an extended cDNA or 5' EST. The  
10 cDNA library or genomic DNA library is hybridized to a detectable probe comprising at least 10  
consecutive nucleotides from the 5' EST or extended cDNA using conventional techniques. Preferably, the  
probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST or extended cDNA. More  
preferably, the probe comprises at least 20-30 consecutive nucleotides from the 5' EST or extended cDNA.  
In some embodiments, the probe comprises more than 30 nucleotides from the 5' EST or extended cDNA.

15 Techniques for identifying cDNA clones in a cDNA library which hybridize to a given probe  
sequence are disclosed in Sambrook et al., *Molecular Cloning: A Laboratory Manual* 2d Ed., Cold Spring  
Harbor Laboratory Press, (1989). The same techniques may be used to isolate genomic DNAs.

Briefly, cDNA or genomic DNA clones which hybridize to the detectable probe are identified and  
20 isolated for further manipulation as follows. A probe comprising at least 10 consecutive nucleotides from  
the 5' EST or extended cDNA is labeled with a detectable label such as a radioisotope or a fluorescent  
molecule. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST or  
extended cDNA. More preferably, the probe comprises 20-30 consecutive nucleotides from the 5' EST or  
extended cDNA. In some embodiments, the probe comprises more than 30 nucleotides from the 5' EST or  
25 extended cDNA.

Techniques for labeling the probe are well known and include phosphorylation with polynucleotide  
kinase, nick translation, in vitro transcription, and non-radioactive techniques. The cDNAs or genomic  
DNAs in the library are transferred to a nitrocellulose or nylon filter and denatured. After incubation of the  
filter with a blocking solution, the filter is contacted with the labeled probe and incubated for a sufficient  
30 amount of time for the probe to hybridize to cDNAs or genomic DNAs containing a sequence capable of  
hybridizing to the probe.

By varying the stringency of the hybridization conditions used to identify extended cDNAs or  
genomic DNAs which hybridize to the detectable probe, extended cDNAs having different levels of  
homology to the probe can be identified and isolated. To identify extended cDNAs or genomic DNAs  
35 having a high degree of homology to the probe sequence, the melting temperature of the probe may be  
calculated using the following formulas:

For probes between 14 and 70 nucleotides in length the melting temperature ( $T_m$ ) is calculated using the formula:  $T_m = 81.5 + 16.6(\log [Na^+]) + 0.41(\text{fraction G+C}) - (600/N)$  where  $N$  is the length of the probe.

If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation  $T_m = 81.5 + 16.6(\log [Na^+]) + 0.41(\text{fraction G+C}) - (0.63\% \text{ formamide}) - (600/N)$  where  $N$  is the length of the probe.

Prehybridization may be carried out in 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100 $\mu$ g denatured fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100 $\mu$ g denatured fragmented salmon sperm DNA, 50% formamide. The formulas for SSC and Denhardt's solutions are listed in Sambrook et al., *supra*.

Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured before addition to the hybridization solution. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to extended cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the hybridization may be carried out at 15-25°C below the  $T_m$ . For shorter probes, such as oligonucleotide probes, the hybridization may be conducted at 15-25°C below the  $T_m$ . Preferably, for hybridizations in 6X SSC, the hybridization is conducted at approximately 68°C. Preferably, for hybridizations in 50% formamide containing solutions, the hybridization is conducted at approximately 42°C.

All of the foregoing hybridizations would be considered to be under "stringent" conditions.

Following hybridization, the filter is washed in 2X SSC, 0.1% SDS at room temperature for 15 minutes. The filter is then washed with 0.1X SSC, 0.5% SDS at room temperature for 30 minutes to 1 hour. Thereafter, the solution is washed at the hybridization temperature in 0.1X SSC, 0.5% SDS. A final wash is conducted in 0.1X SSC at room temperature.

Extended cDNAs, nucleic acids homologous to extended cDNAs or 5' ESTs, or genomic DNAs which have hybridized to the probe are identified by autoradiography or other conventional techniques.

The above procedure may be modified to identify extended cDNAs, nucleic acids homologous to extended cDNAs, or genomic DNAs having decreasing levels of homology to the probe sequence. For example, to obtain extended cDNAs, nucleic acids homologous to extended cDNAs, or genomic DNAs of decreasing homology to the detectable probe, less stringent conditions may be used. For example, the hybridization temperature may be decreased in increments of 5°C from 68°C to 42°C in a hybridization buffer having a  $Na^+$  concentration of approximately 1M. Following hybridization, the filter may be washed with 2X SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be "moderate" conditions above 50°C and "low" conditions below 50°C.

Alternatively, the hybridization may be carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42°C. In this case, the concentration of formamide in the hybridization

buffer may be reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of homology to the probe. Following hybridization, the filter may be washed with 6X SSC, 0.5% SDS at 50°C. These conditions are considered to be "moderate" conditions above 25% formamide and "low" conditions below 25% formamide.

5 Extended cDNAs, nucleic acids homologous to extended cDNAs, or genomic DNAs which have hybridized to the probe are identified by autoradiography.

If it is desired to obtain nucleic acids homologous to extended cDNAs, such as allelic variants thereof or nucleic acids encoding proteins related to the proteins encoded by the extended cDNAs, the level of homology between the hybridized nucleic acid and the extended cDNA or 5' EST used as the probe may  
10 readily be determined. To determine the level of homology between the hybridized nucleic acid and the extended cDNA or 5'EST from which the probe was derived, the nucleotide sequences of the hybridized nucleic acid and the extended cDNA or 5'EST from which the probe was derived are compared. For example, using the above methods, nucleic acids having at least 95% nucleic acid homology to the extended cDNA or 5'EST from which the probe was derived may be obtained and identified. Similarly, by using  
15 progressively less stringent hybridization conditions one can obtain and identify nucleic acids having at least 90%, at least 85%, at least 80% or at least 75% homology to the extended cDNA or 5'EST from which the probe was derived.

To determine whether a clone encodes a protein having a given amount of homology to the protein encoded by the extended cDNA or 5' EST, the amino acid sequence encoded by the extended cDNA or 5'  
20 EST is compared to the amino acid sequence encoded by the hybridizing nucleic acid. Homology is determined to exist when an amino acid sequence in the extended cDNA or 5' EST is closely related to an amino acid sequence in the hybridizing nucleic acid. A sequence is closely related when it is identical to that of the extended cDNA or 5' EST or when it contains one or more amino acid substitutions therein in which amino acids having similar characteristics have been substituted for one another. Using the above  
25 methods, one can obtain nucleic acids encoding proteins having at least 95%, at least 90%, at least 85%, at least 80% or at least 75% homology to the proteins encoded by the extended cDNA or 5'EST from which the probe was derived.

Alternatively, extended cDNAs may be prepared by obtaining mRNA from the tissue, cell, or organism of interest using mRNA preparation procedures utilizing poly A selection procedures or other  
30 techniques known to those skilled in the art. A first primer capable of hybridizing to the poly A tail of the mRNA is hybridized to the mRNA and a reverse transcription reaction is performed to generate a first cDNA strand.

The first cDNA strand is hybridized to a second primer containing at least 10 consecutive nucleotides of the sequences of the 5' EST for which an extended cDNA is desired. Preferably, the primer  
35 comprises at least 12, 15, or 17 consecutive nucleotides from the sequences of the 5' EST. More preferably, the primer comprises 20-30 consecutive nucleotides from the sequences of the 5' EST. In some



embodiments, the primer comprises more than 30 nucleotides from the sequences of the 5' EST. If it is desired to obtain extended cDNAs containing the full protein coding sequence, including the authentic translation initiation site, the second primer used contains sequences located upstream of the translation initiation site. The second primer is extended to generate a second cDNA strand complementary to the first cDNA strand. Alternatively, RTPCR may be performed as described above using primers from both ends of the cDNA to be obtained.

Extended cDNAs containing 5' fragments of the mRNA may be prepared by contacting an mRNA comprising the sequence of the 5' EST for which an extended cDNA is desired with a primer comprising at least 10 consecutive nucleotides of the sequences complementary to the 5' EST, hybridizing the primer to the mRNAs, and reverse transcribing the hybridized primer to make a first cDNA strand from the mRNAs. Preferably, the primer comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the primer comprises 20-30 consecutive nucleotides from the 5' EST.

Thereafter, a second cDNA strand complementary to the first cDNA strand is synthesized. The second cDNA strand may be made by hybridizing a primer complementary to sequences in the first cDNA strand to the first cDNA strand and extending the primer to generate the second cDNA strand.

The double stranded extended cDNAs made using the methods described above are isolated and cloned. The extended cDNAs may be cloned into vectors such as plasmids or viral vectors capable of replicating in an appropriate host cell. For example, the host cell may be a bacterial, mammalian, avian, or insect cell.

Techniques for isolating mRNA, reverse transcribing a primer hybridized to mRNA to generate a first cDNA strand, extending a primer to make a second cDNA strand complementary to the first cDNA strand, isolating the double stranded cDNA and cloning the double stranded cDNA are well known to those skilled in the art and are described in Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. (1997); and Sambrook et al. *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, (1989).

Alternatively, kits for obtaining full length cDNAs, such as the GeneTrapper (Cat. No. 10356-020, Gibco, BRL), may be used for obtaining full length cDNAs or extended cDNAs. In this approach, full length or extended cDNAs are prepared from mRNA and cloned into double stranded phagemids. The cDNA library in the double stranded phagemids is then rendered single stranded by treatment with an endonuclease, such as the Gene II product of the phage FI, and Exonuclease III as described in the manual accompanying the GeneTrapper kit. A biotinylated oligonucleotide comprising the sequence of a 5' EST, or a fragment containing at least 10 nucleotides thereof, is hybridized to the single stranded phagemids. Preferably, the fragment comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the fragment comprises 20-30 consecutive nucleotides from the 5' EST. In some procedures, the fragment may comprise more than 30 consecutive nucleotides from the 5' EST.

Hybrids between the biotinylated oligonucleotide and phagemids having inserts containing the 5'

EST sequence are isolated by incubating the hybrids with streptavidin coated paramagnetic beads and retrieving the beads with a magnet. Thereafter, the resulting phagemids containing the 5' EST sequence are released from the beads and converted into double stranded DNA using a primer specific for the 5' EST sequence. The resulting double stranded DNA is transformed into bacteria. Extended cDNAs containing the 5' EST sequence are identified by colony PCR or colony hybridization.

A plurality of extended cDNAs containing full length protein coding sequences or sequences encoding only the mature protein remaining after the signal peptide is cleaved may be provided as cDNA libraries for subsequent evaluation of the encoded proteins or use in diagnostic assays as described below.

#### IV. Expression of Proteins Encoded by Extended cDNAs Isolated Using 5' EST's

Extended cDNAs containing the full protein coding sequences of their corresponding mRNAs or portions thereof, such as cDNAs encoding the mature protein, may be used to express the secreted proteins or portions thereof which they encode as described in Example 30 below. If desired, the extended cDNAs may contain the sequences encoding the signal peptide to facilitate secretion of the expressed protein. It will be appreciated that a plurality of extended cDNAs containing the full protein coding sequences or portions thereof may be simultaneously cloned into expression vectors to create an expression library for analysis of the encoded proteins as described below.

### EXAMPLE 30

#### Expression of the Proteins Encoded by Extended cDNAs or Portions Thereof

To express the proteins encoded by the extended cDNAs or portions thereof, nucleic acids containing the coding sequence for the proteins or portions thereof to be expressed are obtained as described in Examples 27-29 and cloned into a suitable expression vector. If desired, the nucleic acids may contain the sequences encoding the signal peptide to facilitate secretion of the expressed protein. For example, the nucleic acid may comprise the sequence of one of SEQ ID NOs: 134-180 listed in Table VII and in the accompanying sequence listing. Alternatively, the nucleic acid may comprise those nucleotides which make up the full coding sequence of one of the sequences of SEQ ID NOs: 134-180 as defined in Table VII above.

It will be appreciated that should the extent of the full coding sequence (i.e. the sequence encoding the signal peptide and the mature protein resulting from cleavage of the signal peptide) differ from that listed in Table VII as a result of a sequencing error, reverse transcription or amplification error, mRNA splicing, post-translational modification of the encoded protein, enzymatic cleavage of the encoded protein, or other biological factors, one skilled in the art would be readily able to identify the extent of the full coding sequences in the sequences of SEQ ID NOs. 134-180. Accordingly, the scope of any claims herein relating to nucleic acids containing the full coding sequence of one of SEQ ID NOs. 134-180 is not to be construed as excluding any readily identifiable variations from or equivalents to the full coding sequences listed in Table VII. Similarly, should the extent of the full length polypeptides differ from those indicated in Table VIII as a result of any of the preceding factors, the scope of claims relating to polypeptides

comprising the amino acid sequence of the full length polypeptides is not to be construed as excluding any readily identifiable variations from or equivalents to the sequences listed in Table VIII.

Alternatively, the nucleic acid used to express the protein or portion thereof may comprise those nucleotides which encode the mature protein (i.e. the protein created by cleaving the signal peptide off) encoded by one of the sequences of SEQ ID NOs: 134-180 as defined in Table VII.

It will be appreciated that should the extent of the sequence encoding the mature protein differ from that listed in Table VII as a result of a sequencing error, reverse transcription or amplification error, mRNA splicing, post-translational modification of the encoded protein, enzymatic cleavage of the encoded protein, or other biological factors, one skilled in the art would be readily able to identify the extent of the sequence encoding the mature protein in the sequences of SEQ ID NOs: 134-180. Accordingly, the scope of any claims herein relating to nucleic acids containing the sequence encoding the mature protein encoded by one of SEQ ID NOs: 134-180 is not to be construed as excluding any readily identifiable variations from or equivalents to the sequences listed in Table VII. Thus, claims relating to nucleic acids containing the sequence encoding the mature protein encompass equivalents to the sequences listed in Table VII, such as sequences encoding biologically active proteins resulting from post-translational modification, enzymatic cleavage, or other readily identifiable variations from or equivalents to the proteins in addition to cleavage of the signal peptide. Similarly, should the extent of the mature polypeptides differ from those indicated in Table VIII as a result of any of the preceding factors, the scope of claims relating to polypeptides comprising the sequence of a mature protein included in the sequence of one of SEQ ID NOs. 181-227 is not to be construed as excluding any readily identifiable variations from or equivalents to the sequences listed in Table VIII. Thus, claims relating to polypeptides comprising the sequence of the mature protein encompass equivalents to the sequences listed in Table VIII, such as biologically active proteins resulting from post-translational modification, enzymatic cleavage, or other readily identifiable variations from or equivalents to the proteins in addition to cleavage of the signal peptide. It will also be appreciated that should the biologically active form of the polypeptides included in the sequence of one of SEQ ID NOs. 181-227 or the nucleic acids encoding the biologically active form of the polypeptides differ from those identified as the mature polypeptide in Table VIII or the nucleotides encoding the mature polypeptide in Table VII as a result of a sequencing error, reverse transcription or amplification error, mRNA splicing, post-translational modification of the encoded protein, enzymatic cleavage of the encoded protein, or other biological factors, one skilled in the art would be readily able to identify the amino acids in the biologically active form of the polypeptides and the nucleic acids encoding the biologically active form of the polypeptides. In such instances, the claims relating to polypeptides comprising the mature protein included in one of SEQ ID NOs. 181-227 or nucleic acids comprising the nucleotides of one of SEQ ID NOs. 134-180 encoding the mature protein shall not be construed to exclude any readily identifiable variations from the sequences listed in Table VII and Table VIII.

In some embodiments, the nucleic acid used to express the protein or portion thereof may comprise

those nucleotides which encode the signal peptide encoded by one of the sequences of SEQ ID NOs: 134-180 as defined in Table VII above.

It will be appreciated that should the extent of the sequence encoding the signal peptide differ from that listed in Table VII as a result of a sequencing error, reverse transcription or amplification error, mRNA splicing, post-translational modification of the encoded protein, enzymatic cleavage of the encoded protein, or other biological factors, one skilled in the art would be readily able to identify the extent of the sequence encoding the signal peptide in the sequences of SEQ ID NOs. 134-180. Accordingly, the scope of any claims herein relating to nucleic acids containing the sequence encoding the signal peptide encoded by one of SEQ ID NOs. 134-180 is not to be construed as excluding any readily identifiable variations from the sequences listed in Table VII. Similarly, should the extent of the signal peptides differ from those indicated in Table VIII as a result of any of the preceding factors, the scope of claims relating to polypeptides comprising the sequence of a signal peptide included in the sequence of one of SEQ ID NOs. 181-227 is not to be construed as excluding any readily identifiable variations from the sequences listed in Table VIII.

Alternatively, the nucleic acid may encode a polypeptide comprising at least 10 consecutive amino acids of one of the sequences of SEQ ID NOs: 181-227. In some embodiments, the nucleic acid may encode a polypeptide comprising at least 15 consecutive amino acids of one of the sequences of SEQ ID NOs: 181-227. In other embodiments, the nucleic acid may encode a polypeptide comprising at least 25 consecutive amino acids of one of the sequences of SEQ ID NOs: 181-227.

The nucleic acids inserted into the expression vectors may also contain sequences upstream of the sequences encoding the signal peptide, such as sequences which regulate expression levels or sequences which confer tissue specific expression.

The nucleic acid encoding the protein or polypeptide to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The expression vector may be any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence may be optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, et al., U.S. Patent No. 5,082,767.

The following is provided as one exemplary method to express the proteins encoded by the extended cDNAs corresponding to the 5' ESTs or the nucleic acids described above. First, the methionine initiation codon for the gene and the poly A signal of the gene are identified. If the nucleic acid encoding the polypeptide to be expressed lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the extended cDNA lacks a poly A signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglI and SalI restriction endonuclease enzymes and

incorporating it into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion of the *gag* gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene. The extended cDNA or portion thereof encoding the polypeptide to be expressed is obtained by PCR from the bacterial vector using oligonucleotide primers complementary to the extended cDNA or portion thereof and containing restriction endonuclease sequences for Pst I incorporated into the 5' primer and Bgl II at the 5' end of the corresponding cDNA 3' primer, taking care to ensure that the extended cDNA is positioned in frame with the poly A signal. The purified fragment obtained from the resulting PCR reaction is digested with Pst I, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXT1, now containing a poly A signal and digested with Bgl II.

The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri). Preferably the expressed protein is released into the culture medium, thereby facilitating purification.

Alternatively, the extended cDNAs may be cloned into pED6dpc2 as described above. The resulting pED6dpc2 constructs may be transfected into a suitable host cell, such as COS 1 cells. Methotrexate resistant cells are selected and expanded. Preferably, the protein expressed from the extended cDNA is released into the culture medium thereby facilitating purification.

Proteins in the culture medium are separated by gel electrophoresis. If desired, the proteins may be ammonium sulfate precipitated or separated based on size or charge prior to electrophoresis.

As a control, the expression vector lacking a cDNA insert is introduced into host cells or organisms and the proteins in the medium are harvested. The secreted proteins present in the medium are detected using techniques such as Coomassie or silver staining or using antibodies against the protein encoded by the extended cDNA. Coomassie and silver staining techniques are familiar to those skilled in the art.

Antibodies capable of specifically recognizing the protein of interest may be generated using synthetic 15-mer peptides having a sequence encoded by the appropriate 5' EST, extended cDNA, or portion thereof. The synthetic peptides are injected into mice to generate antibody to the polypeptide encoded by the 5' EST, extended cDNA, or portion thereof.

Secreted proteins from the host cells or organisms containing an expression vector which contains the extended cDNA derived from a 5' EST or a portion thereof are compared to those from the control cells or organism. The presence of a band in the medium from the cells containing the expression vector which is absent in the medium from the control cells indicates that the extended cDNA encodes a secreted protein. Generally, the band corresponding to the protein encoded by the extended cDNA will have a mobility near that expected based on the number of amino acids in the open reading frame of the extended cDNA.

However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

Alternatively, if the protein expressed from the above expression vectors does not contain sequences directing its secretion, the proteins expressed from host cells containing an expression vector containing an insert encoding a secreted protein or portion thereof can be compared to the proteins expressed in host cells containing the expression vector without an insert. The presence of a band in  
5 samples from cells containing the expression vector with an insert which is absent in samples from cells containing the expression vector without an insert indicates that the desired protein or portion thereof is being expressed. Generally, the band will have the mobility expected for the secreted protein or portion thereof. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

10 The protein encoded by the extended cDNA may be purified using standard immunochromatography techniques. In such procedures, a solution containing the secreted protein, such as the culture medium or a cell extract, is applied to a column having antibodies against the secreted protein attached to the chromatography matrix. The secreted protein is allowed to bind the immunochromatography column. Thereafter, the column is washed to remove non-specifically bound proteins. The specifically  
15 bound secreted protein is then released from the column and recovered using standard techniques.

If antibody production is not possible, the extended cDNA sequence or portion thereof may be incorporated into expression vectors designed for use in purification schemes employing chimeric polypeptides. In such strategies the coding sequence of the extended cDNA or portion thereof is inserted in frame with the gene encoding the other half of the chimera. The other half of the chimera may be  $\beta$ -globin  
20 or a nickel binding polypeptide encoding sequence. A chromatography matrix having antibody to  $\beta$ -globin or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites may be engineered between the  $\beta$ -globin gene or the nickel binding polypeptide and the extended cDNA or portion thereof. Thus, the two polypeptides of the chimera may be separated from one another by protease digestion.

25 One useful expression vector for generating  $\beta$ -globin chimerics is pSG5 (Stratagene), which encodes rabbit  $\beta$ -globin. Intron II of the rabbit  $\beta$ -globin gene facilitates splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques as described are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis et al., (*Basic Methods in Molecular Biology*, L.G. Davis, M.D.  
30 Dibner, and J.F. Battey, ed., Elsevier Press, NY, 1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using in vitro translation systems such as the In vitro Express™ Translation Kit (Stratagene).

Following expression and purification of the secreted proteins encoded by the 5' ESTs, extended cDNAs, or fragments thereof, the purified proteins may be tested for the ability to bind to the surface of  
35 various cell types as described in Example 31 below. It will be appreciated that a plurality of proteins expressed from these cDNAs may be included in a panel of proteins to be simultaneously evaluated for the

activities specifically described below, as well as other biological roles for which assays for determining activity are available.

### EXAMPLE 31

#### Analysis of Secreted Proteins to Determine Whether they Bind to the Cell Surface

The proteins encoded by the 5' ESTs, extended cDNAs, or fragments thereof are cloned into expression vectors such as those described in Example 30. The proteins are purified by size, charge, immunoaffinity or other techniques familiar to those skilled in the art. Following purification, the proteins are labeled using techniques known to those skilled in the art. The labeled proteins are incubated with cells or cell lines derived from a variety of organs or tissues to allow the proteins to bind to any receptor present on the cell surface. Following the incubation, the cells are washed to remove non-specifically bound protein. The labeled proteins are detected by autoradiography. Alternatively, unlabeled proteins may be incubated with the cells and detected with antibodies having a detectable label, such as a fluorescent molecule, attached thereto.

Specificity of cell surface binding may be analyzed by conducting a competition analysis in which various amounts of unlabeled protein are incubated along with the labeled protein. The amount of labeled protein bound to the cell surface decreases as the amount of competitive unlabeled protein increases. As a control, various amounts of an unlabeled protein unrelated to the labeled protein is included in some binding reactions. The amount of labeled protein bound to the cell surface does not decrease in binding reactions containing increasing amounts of unrelated unlabeled protein, indicating that the protein encoded by the cDNA binds specifically to the cell surface.

As discussed above, secreted proteins have been shown to have a number of important physiological effects and, consequently, represent a valuable therapeutic resource. The secreted proteins encoded by the extended cDNAs or portions thereof made according to Examples 27-29 may be evaluated to determine their physiological activities as described below.

### EXAMPLE 32

#### Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Cytokine, Cell Proliferation or Cell Differentiation Activity

As discussed above, secreted proteins may act as cytokines or may affect cellular proliferation or differentiation. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7c and CMK. The proteins encoded by the above extended cDNAs or portions thereof

may be evaluated for their ability to regulate T cell or thymocyte proliferation in assays such as those described above or in the following references: *Current Protocols in Immunology*, Ed. by J.E. Coligan et al., Greene Publishing Associates and Wiley-Interscience; Takai et al. *J. Immunol.* 137:3494-3500 (1986); Bertagnolli et al. *J. Immunol.* 145:1706-1712 (1990); Bertagnolli et al., *Cellular Immunology* 133:327-341 (1991); Bertagnolli, et al. *J. Immunol.* 149:3778-3783 (1992); and Bowman et al., *J. Immunol.* 152:1756-1761 (1994).

In addition, numerous assays for cytokine production and/or the proliferation of spleen cells, lymph node cells and thymocytes are known. These include the techniques disclosed in *Current Protocols in Immunology*, J.E. Coligan et al. Eds., Vol 1 pp. 3.12.1-3.12.14 John Wiley and Sons, Toronto. (1994); and Schreiber, R.D. *Current Protocols in Immunology*, supra Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. (1994).

The proteins encoded by the cDNAs may also be assayed for the ability to regulate the proliferation and differentiation of hematopoietic or lymphopoietic cells. Many assays for such activity are familiar to those skilled in the art, including the assays in the following references: Bottomly, K., Davis, L.S. and Lipsky, P.E., Measurement of Human and Murine Interleukin 2 and Interleukin 4, *Current Protocols in Immunology*, J.E. Coligan et al. Eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. (1991); deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature* 36:690-692, (1988); Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, (1983); Nordan, R., Measurement of Mouse and Human Interleukin 6. *Current Protocols in Immunology*, J.E. Coligan et al. Eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. (1991); Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Bennett, F., Giannotti, J., Clark, S.C. and Turner, K.J., Measurement of Human Interleukin 11. *Current Protocols in Immunology*, J.E. Coligan et al. Eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. (1991); and Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J., Measurement of Mouse and Human Interleukin 9. *Current Protocols in Immunology*, J.E. Coligan et al., Eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. (1991).

The proteins encoded by the cDNAs may also be assayed for their ability to regulate T-cell responses to antigens. Many assays for such activity are familiar to those skilled in the art, including the assays described in the following references: Chapter 3 (In Vitro Assays for Mouse Lymphocyte Function), Chapter 6 (Cytokines and Their Cellular Receptors) and Chapter 7, (Immunologic Studies in Humans) *Current Protocols in Immunology*, J.E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Interscience; Weinberger et al., *Proc. Natl. Acad. Sci. USA* 77:6091-6095 (1980); Weinberger et al., *Eur. J. Immun.* 11:405-411 (1981); Takai et al., *J. Immunol.* 137:3494-3500 (1986); and Takai et al., *J. Immunol.* 140:508-512 (1988).

Those proteins which exhibit cytokine, cell proliferation, or cell differentiation activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which induction of cell proliferation or differentiation is beneficial. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host



cells to increase or decrease the expression of the proteins as desired.

### EXAMPLE 33

#### Assaying the Proteins Expressed from Extended cDNAs or Portions

##### Thereof for Activity as Immune System Regulators

The proteins encoded by the cDNAs may also be evaluated for their effects as immune regulators. For example, the proteins may be evaluated for their activity to influence thymocyte or splenocyte cytotoxicity. Numerous assays for such activity are familiar to those skilled in the art including the assays described in the following references: Chapter 3 (In Vitro Assays for Mouse Lymphocyte Function 3.1-3.19) and Chapter 7 (Immunologic studies in Humans) *Current Protocols in Immunology*, J.E. Coligan et al. Eds, Greene Publishing Associates and Wiley-Interscience; Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492 (1981); Herrmann et al., *J. Immunol.* 128:1968-1974 (1982); Handa et al., *J. Immunol.* 135:1564-1572 (1985); Takai et al., *J. Immunol.* 137:3494-3500 (1986); Takai et al., *J. Immunol.* 140:508-512 (1988); Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492 (1981); Herrmann et al *J. Immunol.* 128:1968-1974 (1982); Handa et al., *J. Immunol.* 135:1564-1572 (1985); Takai et al., *J. Immunol.* 137:3494-3500 (1986); Bowman et al., *J. Virology* 61:1992-1998; Takai et al., *J. Immunol.* 140:508-512 (1988); Bertagnolli et al., *Cellular Immunology* 133:327-341 (1991); and Brown et al., *J. Immunol.* 153:3079-3092 (1994).

The proteins encoded by the cDNAs may also be evaluated for their effects on T-cell dependent immunoglobulin responses and isotype switching. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Maliszewski, *J. Immunol.* 144:3028-3033 (1990); and Mond, J.J. and Brunswick, M. Assays for B Cell Function: *In vitro* Antibody Production, Vol 1 pp. 3.8.1-3.8.16 *Current Protocols in Immunology*, J.E. Coligan et al Eds., John Wiley and Sons, Toronto. (1994).

The proteins encoded by the cDNAs may also be evaluated for their effect on immune effector cells, including their effect on Th1 cells and cytotoxic lymphocytes. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Chapter 3 (In Vitro Assays for Mouse Lymphocyte Function 3.1-3.19) and Chapter 7 (Immunologic Studies in Humans) *Current Protocols in Immunology*, J.E. Coligan et al. Eds., Greene Publishing Associates and Wiley-Interscience; Takai et al., *J. Immunol.* 137:3494-3500 (1986); Takai et al., *J. Immunol.* 140:508-512 (1988); and Bertagnolli et al., *J. Immunol.* 149:3778-3783 (1992).

The proteins encoded by the cDNAs may also be evaluated for their effect on dendritic cell mediated activation of naive T-cells. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Guery et al., *J. Immunol.* 134:536-544 (1995); Inaba et al., *Journal of Experimental Medicine* 173:549-559 (1991); Macatonia et al., *J. Immunol.* 154:5071-5079 (1995); Porgador et al., *Journal of Experimental Medicine* 182:255-260 (1995); Nair et al.,

*Journal of Virology* 67:4062-4069 (1993); Huang et al., *Science* 264:961-965 (1994); Macatonia et al., *Journal of Experimental Medicine* 169:1255-1264 (1989); Bhardwaj et al., *Journal of Clinical Investigation* 94:797-807 (1994); and Inaba et al., *Journal of Experimental Medicine* 172:631-640 (1990).

The proteins encoded by the cDNAs may also be evaluated for their influence on the lifetime of lymphocytes. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Darzynkiewicz et al., *Cytometry* 13:795-808 (1992); Gorczyca et al., *Leukemia* 7:659-670 (1993); Gorczyca et al., *Cancer Research* 53:1945-1951 (1993); Itoh et al., *Cell* 66:233-243 (1991); Zacharchuk et al., *J. Immunol.* 145:4037-4045 (1990); Zanui et al., *Cytometry* 14:891-897 (1993); and Gorczyca et al., *International Journal of Oncology* 1:639-648 (1992).

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., *Blood* 84:111-117 (1994); Fine et al., *Cellular Immunology* 155:111-122 (1994); Galy et al., *Blood* 85:2770-2778 (1995); and Toki et al., *Proc. Nat. Acad. Sci. USA* 88:7548-7551 (1991).

Those proteins which exhibit activity as immune system regulators activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of immune activity is beneficial. For example, the protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, *Leishmania* spp., *malaria* spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T-

cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this manner prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., *Science* 257:789-792 (1992) and Turka et al., *Proc. Natl. Acad. Sci USA*, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., *Fundamental Immunology*, Raven Press, New York, (1989), pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.

Administration of reagents which block costimulation of T cells by disrupting receptor ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/pr/pr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in OD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., *Fundamental Immunology*, Raven Press, New York, (1989), pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory form of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to T cells in vivo, thereby activating the T cells.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acids encoding all or a portion of (e.g., a

cytoplasmic-domain truncated portion) of an MHC class I  $\alpha$  chain protein and  $\beta_2$  macroglobulin protein or an MHC class II  $\alpha$  chain protein and an MHC class II  $\beta$  chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class II or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

#### EXAMPLE 34

##### Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Hematopoiesis Regulating Activity

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their hematopoiesis regulating activity. For example, the effect of the proteins on embryonic stem cell differentiation may be evaluated. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Johansson et al. *Cellular Biology* 15:141-151 (1995); Keller et al., *Molecular and Cellular Biology* 13:473-486 (1993); and McClanahan et al., *Blood* 81:2903-2915 (1993).

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their influence on the lifetime of stem cells and stem cell differentiation. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Freshney, M.G. Methylcellulose Colony Forming Assays, *Culture of Hematopoietic Cells*. R.I. Freshney, et al. Eds. pp. 265-268, Wiley-Liss, Inc., New York, NY. (1994); Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911 (1992); McNiece, I.K. and Briddell, R.A. Primitive Hematopoietic Colony Forming Cells with High Proliferative Potential, *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. (1994); Neben et al., *Experimental Hematology* 22:353-359 (1994); Ploemacher, R.E. Cobblestone Area Forming Cell Assay, *Culture of Hematopoietic Cells*. R.I. Freshney, et al. Eds. pp. 1-21, Wiley-Liss, Inc., New York, NY. (1994); Spooncer, E., Dexter, M. and Allen, T. Long Term Bone Marrow Cultures in the Presence of Stromal Cells, *Culture of Hematopoietic Cells*. R.I. Freshney, et al. Eds. pp. 163-179, Wiley-Liss, Inc., New York, NY. (1994); and Sutherland, H.J. Long Term Culture Initiating Cell Assay, *Culture of Hematopoietic Cells*. R.I. Freshney, et al. Eds. pp. 139-162, Wiley-Liss, Inc., New York, NY. (1994).

Those proteins which exhibit hematopoiesis regulatory activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of hematopoiesis is beneficial. For example, a protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem-cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

### EXAMPLE 35

#### Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Regulation of Tissue Growth

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their effect on tissue growth. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in International Patent Publication No. WO95/16035, International Patent Publication No. WO95/05846 and International Patent Publication No. WO91/07491.

Assays for wound healing activity include, without limitation, those described in: Winter, *Epidermal Wound Healing*, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, *J. Invest. Dermatol.* 71:382-84 (1978).

Those proteins which are involved in the regulation of tissue growth may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of tissue growth is beneficial. For example, a protein of the present invention also may have utility in compositions used for bone, cartilage,

tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue.

De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e., for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and

localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium) muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to generate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

### EXAMPLE 36

#### Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Regulation of Reproductive Hormones or Cell Movement

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their ability to regulate reproductive hormones, such as follicle stimulating hormone. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Vale et al., *Endocrinology* 91:562-572 (1972); Ling et al., *Nature* 321:779-782 (1986); Vale et al., *Nature* 321:776-779 (1986); Mason et al., *Nature* 318:659-663 (1985); Forage et al., *Proc. Natl. Acad. Sci. USA* 83:3091-3095 (1986). Chapter 6.12 (Measurement of Alpha and Beta Chemokines) *Current Protocols in Immunology*, J.E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Interscience; Taub et al. *J. Clin. Invest.* 95:1370-1376 (1995); Lind et al. *APMIS* 103:140-146 (1995); Muller et al. *Eur. J. Immunol.*



25:1744-1748; Gruber et al. *J. of Immunol.* 152:5860-5867 (1994); and Johnston et al. *J. of Immunol.* 153:1762-1768 (1994).

Those proteins which exhibit activity as reproductive hormones or regulators of cell movement may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of reproductive hormones or cell movement are beneficial. For example, a protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin  $\alpha$  family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals.

Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-B group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

### EXAMPLE 36A

#### Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Chemotactic/Chemokinetic Activity

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for chemotactic/chemokinetic activity. For example, a protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has

chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Tanb et al. *J. Clin. Invest.* **95**:1370-1376 (1995); Lind et al. *APMIS* **103**:140-146 (1995); Mueller et al. *Eur. J. Immunol.* **25**:1744-1748; Gruber et al. *J. of Immunol.* **152**:5860-5867 (1994); and Johnston et al. *J. of Immunol.* **153**:1762-1768 (1994).

### EXAMPLE 37

## Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Regulation of Blood Clotting

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their effects on blood clotting. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references: Linet et al., *J. Clin. Pharmacol.* 26:131-140 (1986); Burdick et al., *Thrombosis Res.* 45:413-419 (1987); Humphrey et al., *Fibrinolysis* 5:71-79 (1991); and Schaub, *Prostaglandins* 35:467-474 (1988).

Those proteins which are involved in the regulation of blood clotting may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of blood clotting is beneficial. For example, a protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulations disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke). Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

**EXAMPLE 38**

Assaying the Proteins Expressed from Extended cDNAs or  
Portions Thereof for Involvement in Receptor/Ligand Interactions

The proteins encoded by the extended cDNAs or a portion thereof may also be evaluated for their involvement in receptor/ligand interactions. Numerous assays for such involvement are familiar to those skilled in the art, including the assays disclosed in the following references: Chapter 7.28 (Measurement of Cellular Adhesion under Static Conditions 7.28.1-7.28.22) *Current Protocols in Immunology*, J.E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Interscience; Takai et al., *Proc. Natl. Acad. Sci. USA* 84:6864-6868 (1987); Bierer et al., *J. Exp. Med.* 168:1145-1156 (1988); Rosenstein et al., *J. Exp. Med.* 169:149-160 (1989); Stoltzenberg et al., *J. Immunol. Methods* 175:59-68 (1994); Stitt et al., *Cell* 80:661-670 (1995); and Gyuris et al., *Cell* 75:791-803 (1993).

For example, the proteins of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

**EXAMPLE 38A**

Assaying the Proteins Expressed from Extended cDNAs or  
Portions Thereof for Anti-Inflammatory Activity

The proteins encoded by the extended cDNAs or a portion thereof may also be evaluated for anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the

invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

### EXAMPLE 38B

#### Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Tumor Inhibition Activity

The proteins encoded by the extended cDNAs or a portion thereof may also be evaluated for tumor inhibition activity. In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

### EXAMPLE 39

#### Identification of Proteins which Interact with Polypeptides Encoded by Extended cDNAs

Proteins which interact with the polypeptides encoded by extended cDNAs or portions thereof, such

as receptor proteins, may be identified using two hybrid systems such as the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech). As described in the manual accompanying the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech), the extended cDNAs or portions thereof, are inserted into an expression vector such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4. cDNAs in a cDNA library which encode proteins which might interact with the polypeptides encoded by the extended cDNAs or portions thereof are inserted into a second expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the yeast are plated on selection medium which selects for expression of selectable markers on each of the expression vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay contain plasmids encoding proteins which interact with the polypeptide encoded by the extended cDNAs or portions thereof.

Alternatively, the system described in Lustig et al., *Methods in Enzymology* 283: 83-99 (1997), may be used for identifying molecules which interact with the polypeptides encoded by extended cDNAs. In such systems, *in vitro* transcription reactions are performed on a pool of vectors containing extended cDNA inserts cloned downstream of a promoter which drives *in vitro* transcription. The resulting pools of mRNAs are introduced into *Xenopus laevis* oocytes. The oocytes are then assayed for a desired activity.

Alternatively, the pooled *in vitro* transcription products produced as described above may be translated *in vitro*. The pooled *in vitro* translation products can be assayed for a desired activity or for interaction with a known polypeptide.

Proteins or other molecules interacting with polypeptides encoded by extended cDNAs can be found by a variety of additional techniques. In one method, affinity columns containing the polypeptide encoded by the extended cDNA or a portion thereof can be constructed. In some versions, of this method the affinity column contains chimeric proteins in which the protein encoded by the extended cDNA or a portion thereof is fused to glutathione S-transferase. A mixture of cellular proteins or pool of expressed proteins as described above and is applied to the affinity column. Proteins interacting with the polypeptide attached to the column can then be isolated and analyzed on 2-D electrophoresis gel as described in Ramunsen et al. *Electrophoresis* 18:588-598 (1997). Alternatively, the proteins retained on the affinity column can be purified by electrophoresis based methods and sequenced. The same method can be used to isolate antibodies, to screen phage display products, or to screen phage display human antibodies.

Proteins interacting with polypeptides encoded by extended cDNAs or portions thereof can also be screened by using an Optical Biosensor as described in Edwards & Leatherbarrow, *Analytical Biochemistry*, 246:1-6 (1997). The main advantage of the method is that it allows the determination of the association rate between the protein and other interacting molecules. Thus, it is possible to

specifically select interacting molecules with a high or low association rate. Typically a target molecule is linked to the sensor surface (through a carboxymethyl dextran matrix) and a sample of test molecules is placed in contact with the target molecules. The binding of a test molecule to the target molecule causes a change in the refractive index and/or thickness. This change is detected by the Biosensor provided it occurs in the evanescent field (which extend a few hundred nanometers from the sensor surface). In these screening assays, the target molecule can be one of the polypeptides encoded by extended cDNAs or a portion thereof and the test sample can be a collection of proteins extracted from tissues or cells, a pool of expressed proteins, combinatorial peptide and/or chemical libraries, or phage displayed peptides. The tissues or cells from which the test proteins are extracted can originate from any species.

In other methods, a target protein is immobilized and the test population is a collection of unique polypeptides encoded by the extended cDNAs or portions thereof.

To study the interaction of the proteins encoded by the extended cDNAs or portions thereof with drugs, the microdialysis coupled to HPLC method described by Wang et al., *Chromatographia* 44:205-208(1997) or the affinity capillary electrophoresis method described by Busch et al., *J. Chromatogr.* 777:311-328 (1997).

The system described in U.S. Patent No. 5,654,150, may also be used to identify molecules which interact with the polypeptides encoded by the extended cDNAs. In this system, pools of extended cDNAs are transcribed and translated *in vitro* and the reaction products are assayed for interaction with a known polypeptide or antibody.

It will be appreciated by those skilled in the art that the proteins expressed from the extended cDNAs or portions may be assayed for numerous activities in addition to those specifically enumerated above. For example, the expressed proteins may be evaluated for applications involving control and regulation of inflammation, tumor proliferation or metastasis, infection, or other clinical conditions. In addition, the proteins expressed from the extended cDNAs or portions thereof may be useful as nutritional agents or cosmetic agents.

The proteins expressed from the extended cDNAs or portions thereof may be used to generate antibodies capable of specifically binding to the expressed protein or fragments thereof as described in Example 40 below. The antibodies may be capable of binding a full length protein encoded by one of the sequences of SEQ ID NOs. 134-180, a mature protein encoded by one of the sequences of SEQ ID NOs. 134-180, or a signal peptide encoded by one of the sequences of SEQ ID Nos. 134-180. Alternatively, the antibodies may be capable of binding fragments of the proteins expressed from the extended cDNAs which comprise at least 10 amino acids of the sequences of SEQ ID NOs: 181-227. In some embodiments, the antibodies may be capable of binding fragments of the proteins expressed from the extended cDNAs which comprise at least 15 amino acids of the sequences of SEQ ID NOs: 181-227. In other embodiments, the antibodies may be capable of binding fragments of the proteins expressed from the extended cDNAs which comprise at least 25 amino acids of the sequences of SEQ ID NOs: 181-227. In further embodiments, the

antibodies may be capable of binding fragments of the proteins expressed from the extended cDNAs which comprise at least 40 amino acids of the sequences of SEQ ID NOs: 181-227.

#### EXAMPLE 40

##### 5                    Production of an Antibody to a Human Protein

Substantially pure protein or polypeptide is isolated from the transfected or transformed cells as described in Example 30. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

##### 10    A.        Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes of any of the peptides identified and isolated as described can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., *Nature* 256:495 (1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein or peptides derived therefrom over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoussay procedures, such as Elisa, as originally described by Engvall, E., *Meth. Enzymol.* 70:419 (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. *Basic Methods in Molecular Biology* Elsevier, New York. Section 21-2.

##### 20    B.        Polyclonal Antibody Production by Immunization

25        Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein or peptides derived therefrom described above, which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. *J. Clin. Endocrinol. Metab.* 33:988-991 (1971).

35        Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19 in:

*Handbook of Experimental Immunology* D. Wier (ed) Blackwell (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12  $\mu$ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: *Manual of Clinical Immunology*, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

#### V. Use of Extended cDNAs or Portions Thereof as Reagents

The extended cDNAs of the present invention may be used as reagents in isolation procedures, diagnostic assays, and forensic procedures. For example, sequences from the extended cDNAs (or genomic DNAs obtainable therefrom) may be detectably labeled and used as probes to isolate other sequences capable of hybridizing to them. In addition, sequences from the extended cDNAs (or genomic DNAs obtainable therefrom) may be used to design PCR primers to be used in isolation, diagnostic, or forensic procedures.

### EXAMPLE 41

#### Preparation of PCR Primers and Amplification of DNA

The extended cDNAs (or genomic DNAs obtainable therefrom) may be used to prepare PCR primers for a variety of applications, including isolation procedures for cloning nucleic acids capable of hybridizing to such sequences, diagnostic techniques and forensic techniques. The PCR primers are at least 10 bases, and preferably at least 12, 15, or 17 bases in length. More preferably, the PCR primers are at least 20-30 bases in length. In some embodiments, the PCR primers may be more than 30 bases in length. It is preferred that the primer pairs have approximately the same G/C ratio, so that melting temperatures are approximately the same. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see Molecular Cloning to Genetic Engineering White, B.A. Ed. in *Methods in Molecular Biology* 67: Humana Press, Totowa (1997). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites.



**EXAMPLE 42**Use of Extended cDNAs as Probes

Probes derived from extended cDNAs or portions thereof (or genomic DNAs obtainable therefrom) may be labeled with detectable labels familiar to those skilled in the art, including radioisotopes and non-radioactive labels, to provide a detectable probe. The detectable probe may be single stranded or double stranded and may be made using techniques known in the art, including in vitro transcription, nick translation, or kinase reactions. A nucleic acid sample containing a sequence capable of hybridizing to the labeled probe is contacted with the labeled probe. If the nucleic acid in the sample is double stranded, it may be denatured prior to contacting the probe. In some applications, the nucleic acid sample may be immobilized on a surface such as a nitrocellulose or nylon membrane. The nucleic acid sample may comprise nucleic acids obtained from a variety of sources, including genomic DNA, cDNA libraries, RNA, or tissue samples.

Procedures used to detect the presence of nucleic acids capable of hybridizing to the detectable probe include well known techniques such as Southern blotting, Northern blotting, dot blotting, colony hybridization, and plaque hybridization. In some applications, the nucleic acid capable of hybridizing to the labeled probe may be cloned into vectors such as expression vectors, sequencing vectors, or in vitro transcription vectors to facilitate the characterization and expression of the hybridizing nucleic acids in the sample. For example, such techniques may be used to isolate and clone sequences in a genomic library or cDNA library which are capable of hybridizing to the detectable probe as described in Example 30 above.

PCR primers made as described in Example 41 above may be used in forensic analyses, such as the DNA fingerprinting techniques described in Examples 43-47 below. Such analyses may utilize detectable probes or primers based on the sequences of the extended cDNAs isolated using the 5' ESTs (or genomic DNAs obtainable therefrom).

**EXAMPLE 43**Forensic Matching by DNA Sequencing

In one exemplary method, DNA samples are isolated from forensic specimens of, for example, hair, semen, blood or skin cells by conventional methods. A panel of PCR primers based on a number of the extended cDNAs (or genomic DNAs obtainable therefrom), is then utilized in accordance with Example 41 to amplify DNA of approximately 100-200 bases in length from the forensic specimen. Corresponding sequences are obtained from a test subject. Each of these identification DNAs is then sequenced using standard techniques, and a simple database comparison determines the differences, if any, between the sequences from the subject and those from the sample. Statistically significant differences between the suspect's DNA sequences and those from the sample conclusively prove a lack of identity. This lack of identity can be proven, for example, with only one sequence. Identity, on the other hand, should be demonstrated with a large number of sequences, all matching. Preferably, a minimum of 50 statistically

identical sequences of 100 bases in length are used to prove identity between the suspect and the sample.

#### EXAMPLE 44

##### Positive Identification by DNA Sequencing

The technique outlined in the previous example may also be used on a larger scale to provide a unique fingerprint-type identification of any individual. In this technique, primers are prepared from a large number of sequences from Table II and the appended sequence listing. Preferably, 20 to 50 different primers are used. These primers are used to obtain a corresponding number of PCR-generated DNA segments from the individual in question in accordance with Example 41. Each of these DNA segments is sequenced, using the methods set forth in Example 43. The database of sequences generated through this procedure uniquely identifies the individual from whom the sequences were obtained. The same panel of primers may then be used at any later time to absolutely correlate tissue or other biological specimen with that individual.

#### EXAMPLE 45

##### Southern Blot Forensic Identification

The procedure of Example 44 is repeated to obtain a panel of at least 10 amplified sequences from an individual and a specimen. Preferably, the panel contains at least 50 amplified sequences. More preferably, the panel contains 100 amplified sequences. In some embodiments, the panel contains 200 amplified sequences. This PCR-generated DNA is then digested with one or a combination of, preferably, four base specific restriction enzymes. Such enzymes are commercially available and known to those of skill in the art. After digestion, the resultant gene fragments are size separated in multiple duplicate wells on an agarose gel and transferred to nitrocellulose using Southern blotting techniques well known to those with skill in the art. For a review of Southern blotting see Davis et al. *Basic Methods in Molecular Biology*, (1986), Elsevier Press, pp 62-65).

A panel of probes based on the sequences of the extended cDNAs (or genomic DNAs obtainable therefrom), or fragments thereof of at least 10 bases, are radioactively or colorimetrically labeled using methods known in the art, such as nick translation or end labeling, and hybridized to the Southern blot using techniques known in the art (Davis et al., *supra*). Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). More preferably, the probe comprises at least 20-30 consecutive nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). In some embodiments, the probe comprises more than 30 nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom).

Preferably, at least 5 to 10 of these labeled probes are used, and more preferably at least about 20 or 30 are used to provide a unique pattern. The resultant bands appearing from the hybridization of a large sample of extended cDNAs (or genomic DNAs obtainable therefrom) will be a unique identifier. Since the

restriction enzyme cleavage will be different for every individual, the band pattern on the Southern blot will also be unique. Increasing the number of extended cDNA probes will provide a statistically higher level of confidence in the identification since there will be an increased number of sets of bands used for identification.

#### EXAMPLE 46

##### Dot Blot Identification Procedure

Another technique for identifying individuals using the extended cDNA sequences disclosed herein utilizes a dot blot hybridization technique.

Genomic DNA is isolated from nuclei of subject to be identified. Oligonucleotide probes of approximately 30 bp in length are synthesized that correspond to at least 10, preferably 50 sequences from the extended cDNAs or genomic DNAs obtainable therefrom. The probes are used to hybridize to the genomic DNA through conditions known to those in the art. The oligonucleotides are end labeled with  $P^{32}$  using polynucleotide kinase (Pharmacia). Dot Blots are created by spotting the genomic DNA onto nitrocellulose or the like using a vacuum dot blot manifold (BioRad, Richmond California). The nitrocellulose filter containing the genomic sequences is baked or UV linked to the filter, prehybridized and hybridized with labeled probe using techniques known in the art (Davis et al. *supra*). The  $P^{32}$  labeled DNA fragments are sequentially hybridized with successively stringent conditions to detect minimal differences between the 30 bp sequence and the DNA. Tetramethylammonium chloride is useful for identifying clones containing small numbers of nucleotide mismatches (Wood et al., *Proc. Natl. Acad. Sci. USA* 82(6):1585-1588 (1985)). A unique pattern of dots distinguishes one individual from another individual.

Extended cDNAs or oligonucleotides containing at least 10 consecutive bases from these sequences can be used as probes in the following alternative fingerprinting technique. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). More preferably, the probe comprises at least 20-30 consecutive nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom). In some embodiments, the probe comprises more than 30 nucleotides from the extended cDNA (or genomic DNAs obtainable therefrom).

Preferably, a plurality of probes having sequences from different genes are used in the alternative fingerprinting technique. Example 47 below provides a representative alternative fingerprinting procedure in which the probes are derived from extended cDNAs.

#### EXAMPLE 47

##### Alternative "Fingerprint" Identification Technique

20-mer oligonucleotides are prepared from a large number, e.g. 50, 100, or 200, of extended cDNA sequences (or genomic DNAs obtainable therefrom) using commercially available oligonucleotide services such as Genset, Paris, France. Cell samples from the test subject are processed for DNA using

techniques well known to those with skill in the art. The nucleic acid is digested with restriction enzymes such as EcoRI and XbaI. Following digestion, samples are applied to wells for electrophoresis. The procedure, as known in the art, may be modified to accommodate polyacrylamide electrophoresis, however in this example, samples containing 5 ug of DNA are loaded into wells and separated on 0.8% agarose gels.

5 The gels are transferred onto nitrocellulose using standard Southern blotting techniques.

10 ng of each of the oligonucleotides are pooled and end-labeled with  $^{32}$ P. The nitrocellulose is prehybridized with blocking solution and hybridized with the labeled probes. Following hybridization and washing, the nitrocellulose filter is exposed to X-Omat AR X-ray film. The resulting hybridization pattern will be unique for each individual.

10 It is additionally contemplated within this example that the number of probe sequences used can be varied for additional accuracy or clarity.

The antibodies generated in Examples 30 and 40 above may be used to identify the tissue type or cell species from which a sample is derived as described above.

15

#### EXAMPLE 48

##### Identification of Tissue Types or Cell Species by Means of Labeled Tissue Specific Antibodies

Identification of specific tissues is accomplished by the visualization of tissue specific antigens by means of antibody preparations according to Examples 30 and 40 which are conjugated, directly or  
20 indirectly to a detectable marker. Selected labeled antibody species bind to their specific antigen binding partner in tissue sections, cell suspensions, or in extracts of soluble proteins from a tissue sample to provide a pattern for qualitative or semi-qualitative interpretation.

Antisera for these procedures must have a potency exceeding that of the native preparation, and for that reason, antibodies are concentrated to a mg/ml level by isolation of the gamma globulin fraction, for  
25 example, by ion-exchange chromatography or by ammonium sulfate fractionation. Also, to provide the most specific antisera, unwanted antibodies, for example to common proteins, must be removed from the gamma globulin fraction, for example by means of insoluble immunoabsorbents, before the antibodies are labeled with the marker. Either monoclonal or heterologous antisera is suitable for either procedure.

##### A. Immunohistochemical Techniques

30 Purified, high-titer antibodies, prepared as described above, are conjugated to a detectable marker, as described, for example, by Fudenberg, H., Chap. 26 in: *Basic 503 Clinical Immunology*, 3rd Ed. Lange, Los Altos, California (1980) or Rose, N. et al., Chap. 12 in: *Methods in Immunodiagnosis*, 2d Ed. John Wiley 503 Sons, New York (1980).

35 A fluorescent marker, either fluorescein or rhodamine, is preferred, but antibodies can also be labeled with an enzyme that supports a color producing reaction with a substrate, such as horseradish peroxidase. Markers can be added to tissue-bound antibody in a second step, as described below.

Alternatively, the specific antitissue antibodies can be labeled with ferritin or other electron dense particles, and localization of the ferritin coupled antigen-antibody complexes achieved by means of an electron microscope. In yet another approach, the antibodies are radiolabeled, with, for example  $^{125}\text{I}$ , and detected by overlaying the antibody treated preparation with photographic emulsion.

5 Preparations to carry out the procedures can comprise monoclonal or polyclonal antibodies to a single protein or peptide identified as specific to a tissue type, for example, brain tissue, or antibody preparations to several antigenically distinct tissue specific antigens can be used in panels, independently or in mixtures, as required.

10 Tissue sections and cell suspensions are prepared for immunohistochemical examination according to common histological techniques. Multiple cryostat sections (about 4  $\mu\text{m}$ , unfixed) of the unknown tissue and known control, are mounted and each slide covered with different dilutions of the antibody preparation. Sections of known and unknown tissues should also be treated with preparations to provide a positive control, a negative control, for example, pre-immune sera, and a control for non-specific staining, for example, buffer.

15 Treated sections are incubated in a humid chamber for 30 min at room temperature, rinsed, then washed in buffer for 30-45 min. Excess fluid is blotted away, and the marker developed.

If the tissue specific antibody was not labeled in the first incubation, it can be labeled at this time in a second antibody-antibody reaction, for example, by adding fluorescein- or enzyme-conjugated antibody against the immunoglobulin class of the antiserum-producing species, for example, fluorescein labeled antibody to mouse IgG. Such labeled sera are commercially available.

20 The antigen found in the tissues by the above procedure can be quantified by measuring the intensity of color or fluorescence on the tissue section, and calibrating that signal using appropriate standards.

#### B. Identification of Tissue Specific Soluble Proteins

25 The visualization of tissue specific proteins and identification of unknown tissues from that procedure is carried out using the labeled antibody reagents and detection strategy as described for immunohistochemistry; however the sample is prepared according to an electrophoretic technique to distribute the proteins extracted from the tissue in an orderly array on the basis of molecular weight for detection.

30 A tissue sample is homogenized using a Virtis apparatus; cell suspensions are disrupted by Dounce homogenization or osmotic lysis, using detergents in either case as required to disrupt cell membranes, as is the practice in the art. Insoluble cell components such as nuclei, microsomes, and membrane fragments are removed by ultracentrifugation, and the soluble protein-containing fraction concentrated if necessary and reserved for analysis.

35 A sample of the soluble protein solution is resolved into individual protein species by conventional SDS polyacrylamide electrophoresis as described, for example, by Davis, L. et al., Section 19-2 in: *Basic*

*Methods in Molecular Biology* (P. Leder, ed), Elsevier, New York (1986), using a range of amounts of polyacrylamide in a set of gels to resolve the entire molecular weight range of proteins to be detected in the sample. A size marker is run in parallel for purposes of estimating molecular weights of the constituent proteins. Sample size for analysis is a convenient volume of from 5 to 55  $\mu$ l, and containing from about 1 to 100  $\mu$ g protein. An aliquot of each of the resolved proteins is transferred by blotting to a nitrocellulose filter paper, a process that maintains the pattern of resolution. Multiple copies are prepared. The procedure, known as Western Blot Analysis, is well described in Davis, L. et al., (above) Section 19-3. One set of nitrocellulose blots is stained with Coomassie Blue dye to visualize the entire set of proteins for comparison with the antibody bound proteins. The remaining nitrocellulose filters are then incubated with a solution of one or more specific antisera to tissue specific proteins prepared as described in Examples 30 and 40. In this procedure, as in procedure A above, appropriate positive and negative sample and reagent controls are run.

In either procedure A or B, a detectable label can be attached to the primary tissue antigen-primary antibody complex according to various strategies and permutations thereof. In a straightforward approach, the primary specific antibody can be labeled; alternatively, the unlabeled complex can be bound by a labeled secondary anti-IgG antibody. In other approaches, either the primary or secondary antibody is conjugated to a biotin molecule, which can, in a subsequent step, bind an avidin conjugated marker. According to yet another strategy, enzyme labeled or radioactive protein A, which has the property of binding to any IgG, is bound in a final step to either the primary or secondary antibody.

The visualization of tissue specific antigen binding at levels above those seen in control tissues to one or more tissue specific antibodies, prepared from the gene sequences identified from extended cDNA sequences, can identify tissues of unknown origin, for example, forensic samples, or differentiated tumor tissue that has metastasized to foreign bodily sites.

In addition to their applications in forensics and identification, extended cDNAs (or genomic DNAs obtainable therefrom) may be mapped to their chromosomal locations. Example 49 below describes radiation hybrid (RH) mapping of human chromosomal regions using extended cDNAs. Example 50 below describes a representative procedure for mapping an extended cDNA (or a genomic DNA obtainable therefrom) to its location on a human chromosome. Example 51 below describes mapping of extended cDNAs (or genomic DNAs obtainable therefrom) on metaphase chromosomes by Fluorescence In Situ Hybridization (FISH).

#### EXAMPLE 49

##### Radiation hybrid mapping of Extended cDNAs to the human genome

Radiation hybrid (RH) mapping is a somatic cell genetic approach that can be used for high resolution mapping of the human genome. In this approach, cell lines containing one or more human chromosomes are lethally irradiated, breaking each chromosome into fragments whose size depends on the radiation dose. These fragments are rescued by fusion with cultured rodent cells, yielding subclones

containing different portions of the human genome. This technique is described by Benham et al. *Genomics* 4:509-517 (1989) and Cox et al., *Science* 250:245-250 (1990). The random and independent nature of the subclones permits efficient mapping of any human genome marker. Human DNA isolated from a panel of 80-100 cell lines provides a mapping reagent for ordering extended cDNAs (or genomic DNAs obtainable therefrom). In this approach, the frequency of breakage between markers is used to measure distance, allowing construction of fine resolution maps as has been done using conventional ESTs Schuler et al., *Science* 274:540-546 (1996).

RH mapping has been used to generate a high-resolution whole genome radiation hybrid map of human chromosome 17q22-q25.3 across the genes for growth hormone (GH) and thymidine kinase (TK) Foster et al., *Genomics* 33:185-192 (1996), the region surrounding the Gorlin syndrome gene (Obermayr et al., *Eur. J. Hum. Genet.* 4:242-245, 1996), 60 loci covering the entire short arm of chromosome 12 (Raeymaekers et al., *Genomics* 29:170-178, (1995)), the region of human chromosome 22 containing the neurofibromatosis type 2 locus (Frazer et al., *Genomics* 14:574-584 (1992)) and 13 loci on the long arm of chromosome 5 (Warrington et al., *Genomics* 11:701-708 (1991)).

#### EXAMPLE 50

##### Mapping of Extended cDNAs to Human Chromosomes using PCR techniques

Extended cDNAs (or genomic DNAs obtainable therefrom) may be assigned to human chromosomes using PCR based methodologies. In such approaches, oligonucleotide primer pairs are designed from the extended cDNA sequence (or the sequence of a genomic DNA obtainable therefrom) to minimize the chance of amplifying through an intron. Preferably, the oligonucleotide primers are 18-23 bp in length and are designed for PCR amplification. The creation of PCR primers from known sequences is well known to those with skill in the art. For a review of PCR technology see Erlich, H.A., *PCR Technology; Principles and Applications for DNA Amplification*. (1992). W.H. Freeman and Co., New York.

The primers are used in polymerase chain reactions (PCR) to amplify templates from total human genomic DNA. PCR conditions are as follows: 60 ng of genomic DNA is used as a template for PCR with 80 ng of each oligonucleotide primer, 0.6 unit of Taq polymerase, and 1  $\mu$ Cu of a  $^{32}$ P-labeled deoxycytidine triphosphate. The PCR is performed in a microplate thermocycler (Techne) under the following conditions: 30 cycles of 94°C, 1.4 min; 55°C, 2 min; and 72°C, 2 min; with a final extension at 72°C for 10 min. The amplified products are analyzed on a 6% polyacrylamide sequencing gel and visualized by autoradiography. If the length of the resulting PCR product is identical to the distance between the ends of the primer sequences in the extended cDNA from which the primers are derived, then the PCR reaction is repeated with DNA templates from two panels of human-rodent somatic cell hybrids, BIOS PCRable DNA (BIOS Corporation) and NIGMS Human-Rodent Somatic Cell Hybrid Mapping Panel Number 1 (NIGMS,

Camden, NJ).

PCR is used to screen a series of somatic cell hybrid cell lines containing defined sets of human chromosomes for the presence of a given extended cDNA (or genomic DNA obtainable therefrom). DNA is isolated from the somatic hybrids and used as starting templates for PCR reactions using the primer pairs from the extended cDNAs (or genomic DNAs obtainable therefrom). Only those somatic cell hybrids with chromosomes containing the human gene corresponding to the extended cDNA (or genomic DNA obtainable therefrom) will yield an amplified fragment. The extended cDNAs (or genomic DNAs obtainable therefrom) are assigned to a chromosome by analysis of the segregation pattern of PCR products from the somatic hybrid DNA templates. The single human chromosome present in all cell hybrids that give rise to an amplified fragment is the chromosome containing that extended cDNA (or genomic DNA obtainable therefrom). For a review of techniques and analysis of results from somatic cell gene mapping experiments. (See Ledbetter et al., *Genomics* 6:475-481 (1990).)

Alternatively, the extended cDNAs (or genomic DNAs obtainable therefrom) may be mapped to individual chromosomes using FISH as described in Example 51 below.

#### EXAMPLE 51

##### Mapping of Extended 5' ESTs to Chromosomes

##### Using Fluorescence in situ Hybridization

Fluorescence in situ hybridization allows the extended cDNA (or genomic DNA obtainable therefrom) to be mapped to a particular location on a given chromosome. The chromosomes to be used for fluorescence in situ hybridization techniques may be obtained from a variety of sources including cell cultures, tissues, or whole blood.

In a preferred embodiment, chromosomal localization of an extended cDNA (or genomic DNA obtainable therefrom) is obtained by FISH as described by Cherif et al. *Proc. Natl. Acad. Sci. U.S.A.*, 87:6639-6643 (1990). Metaphase chromosomes are prepared from phytohemagglutinin (PHA)-stimulated blood cell donors. PHA-stimulated lymphocytes from healthy males are cultured for 72 h in RPMI-1640 medium. For synchronization, methotrexate (10  $\mu$ M) is added for 17 h, followed by addition of 5-bromodeoxyuridine (5-BudR, 0.1 mM) for 6 h. Colcemid (1  $\mu$ g/ml) is added for the last 15 min before harvesting the cells. Cells are collected, washed in RPMI, incubated with a hypotonic solution of KCl (75 mM) at 37°C for 15 min and fixed in three changes of methanol:acetic acid (3:1). The cell suspension is dropped onto a glass slide and air dried. The extended cDNA (or genomic DNA obtainable therefrom) is labeled with biotin-16 dUTP by nick translation according to the manufacturer's instructions (Bethesda Research Laboratories, Bethesda, MD), purified using a Sephadex G-50 column (Pharmacia, Upssala, Sweden) and precipitated. Just prior to hybridization, the DNA pellet is dissolved in hybridization buffer (50% formamide, 2 X SSC, 10% dextran sulfate, 1 mg/ml sonicated salmon sperm DNA, pH 7) and the probe is denatured at 70°C for 5-10 min.



Slides kept at -20°C are treated for 1 h at 37°C with RNase A (100 µg/ml), rinsed three times in 2 X SSC and dehydrated in an ethanol series. Chromosome preparations are denatured in 70% formamide, 2 X SSC for 2 min at 70°C, then dehydrated at 4°C. The slides are treated with proteinase K (10 µg/100 ml in 20 mM Tris-HCl, 2 mM CaCl<sub>2</sub>) at 37°C for 8 min and dehydrated. The hybridization mixture containing the probe is placed on the slide, covered with a coverslip, sealed with rubber cement and incubated overnight in a humid chamber at 37°C. After hybridization and post-hybridization washes, the biotinylated probe is detected by avidin-FITC and amplified with additional layers of biotinylated goat anti-avidin and avidin-FITC. For chromosomal localization, fluorescent R-bands are obtained as previously described (Cherif et al., *supra*). The slides are observed under a LEICA fluorescence microscope (DMRXA). Chromosomes are counterstained with propidium iodide and the fluorescent signal of the probe appears as two symmetrical yellow-green spots on both chromatids of the fluorescent R-band chromosome (red). Thus, a particular extended cDNA (or genomic DNA obtainable therefrom) may be localized to a particular cytogenetic R-band on a given chromosome.

Once the extended cDNAs (or genomic DNAs obtainable therefrom) have been assigned to particular chromosomes using the techniques described in Examples 49-51 above, they may be utilized to construct a high resolution map of the chromosomes on which they are located or to identify the chromosomes in a sample.

## EXAMPLE 52

### Use of Extended cDNAs to Construct or Expand Chromosome Maps

Chromosome mapping involves assigning a given unique sequence to a particular chromosome as described above. Once the unique sequence has been mapped to a given chromosome, it is ordered relative to other unique sequences located on the same chromosome. One approach to chromosome mapping utilizes a series of yeast artificial chromosomes (YACs) bearing several thousand long inserts derived from the chromosomes of the organism from which the extended cDNAs (or genomic DNAs obtainable therefrom) are obtained. This approach is described in Ramaiah Nagaraja et al. *Genome Research* 7:210-222, (March, 1997). Briefly, in this approach each chromosome is broken into overlapping pieces which are inserted into the YAC vector. The YAC inserts are screened using PCR or other methods to determine whether they include the extended cDNA (or genomic DNA obtainable therefrom) whose position is to be determined. Once an insert has been found which includes the extended cDNA (or genomic DNA obtainable therefrom), the insert can be analyzed by PCR or other methods to determine whether the insert also contains other sequences known to be on the chromosome or in the region from which the extended cDNA (or genomic DNA obtainable therefrom) was derived. This process can be repeated for each insert in the YAC library to determine the location of each of the extended cDNAs (or genomic DNAs obtainable therefrom) relative to one another and to other known chromosomal markers. In this way, a high resolution map of the distribution of numerous unique markers along each of the organisms chromosomes may be

obtained.

As described in Example 53 below extended cDNAs (or genomic DNAs obtainable therefrom) may also be used to identify genes associated with a particular phenotype, such as hereditary disease or drug response.

### EXAMPLE 53

#### Identification of genes associated with hereditary diseases or drug response

This example illustrates an approach useful for the association of extended cDNAs (or genomic DNAs obtainable therefrom) with particular phenotypic characteristics. In this example, a particular extended cDNA (or genomic DNA obtainable therefrom) is used as a test probe to associate that extended cDNA (or genomic DNA obtainable therefrom) with a particular phenotypic characteristic.

Extended cDNAs (or genomic DNAs obtainable therefrom) are mapped to a particular location on a human chromosome using techniques such as those described in Examples 49 and 50 or other techniques known in the art. A search of Mendelian Inheritance in Man (V. McKusick, *Mendelian Inheritance in Man* (available on line through Johns Hopkins University Welch Medical Library) reveals the region of the human chromosome which contains the extended cDNA (or genomic DNA obtainable therefrom) to be a very gene rich region containing several known genes and several diseases or phenotypes for which genes have not been identified. The gene corresponding to this extended cDNA (or genomic DNA obtainable therefrom) thus becomes an immediate candidate for each of these genetic diseases.

Cells from patients with these diseases or phenotypes are isolated and expanded in culture. PCR primers from the extended cDNA (or genomic DNA obtainable therefrom) are used to screen genomic DNA, mRNA or cDNA obtained from the patients. Extended cDNAs (or genomic DNAs obtainable therefrom) that are not amplified in the patients can be positively associated with a particular disease by further analysis. Alternatively, the PCR analysis may yield fragments of different lengths when the samples are derived from an individual having the phenotype associated with the disease than when the sample is derived from a healthy individual, indicating that the gene containing the extended cDNA may be responsible for the genetic disease.

#### **VI. Use of Extended cDNAs (or genomic DNAs obtainable therefrom) to Construct Vectors**

The present extended cDNAs (or genomic DNAs obtainable therefrom) may also be used to construct secretion vectors capable of directing the secretion of the proteins encoded by genes inserted in the vectors. Such secretion vectors may facilitate the purification or enrichment of the proteins encoded by genes inserted therein by reducing the number of background proteins from which the desired protein must be purified or enriched. Exemplary secretion vectors are described in Example 54 below.

## EXAMPLE 54

Construction of Secretion Vectors

The secretion vectors of the present invention include a promoter capable of directing gene expression in the host cell, tissue, or organism of interest. Such promoters include the Rous Sarcoma Virus promoter, the SV40 promoter, the human cytomegalovirus promoter, and other promoters familiar to those skilled in the art.

A signal sequence from an extended cDNA (or genomic DNA obtainable therefrom), such as one of the signal sequences in SEQ ID NOs: 134-180 as defined in Table VII above, is operably linked to the promoter such that the mRNA transcribed from the promoter will direct the translation of the signal peptide.

The host cell, tissue, or organism may be any cell, tissue, or organism which recognizes the signal peptide encoded by the signal sequence in the extended cDNA (or genomic DNA obtainable therefrom). Suitable hosts include mammalian cells, tissues or organisms, avian cells, tissues, or organisms, insect cells, tissues or organisms, or yeast.

In addition, the secretion vector contains cloning sites for inserting genes encoding the proteins which are to be secreted. The cloning sites facilitate the cloning of the insert gene in frame with the signal sequence such that a fusion protein in which the signal peptide is fused to the protein encoded by the inserted gene is expressed from the mRNA transcribed from the promoter. The signal peptide directs the extracellular secretion of the fusion protein.

The secretion vector may be DNA or RNA and may integrate into the chromosome of the host, be stably maintained as an extrachromosomal replicon in the host, be an artificial chromosome, or be transiently present in the host. Many nucleic acid backbones suitable for use as secretion vectors are known to those skilled in the art, including retroviral vectors, SV40 vectors, Bovine Papilloma Virus vectors, yeast integrating plasmids, yeast episomal plasmids, yeast artificial chromosomes, human artificial chromosomes, P element vectors, baculovirus vectors, or bacterial plasmids capable of being transiently introduced into the host.

The secretion vector may also contain a polyA signal such that the polyA signal is located downstream of the gene inserted into the secretion vector.

After the gene encoding the protein for which secretion is desired is inserted into the secretion vector, the secretion vector is introduced into the host cell, tissue, or organism using calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection, viral particles or as naked DNA. The protein encoded by the inserted gene is then purified or enriched from the supernatant using conventional techniques such as ammonium sulfate precipitation, immunoprecipitation, immunochromatography, size exclusion chromatography, ion exchange chromatography, and hplc. Alternatively, the secreted protein may be in a sufficiently enriched or pure state in the supernatant or growth media of the host to permit it to be used for its intended purpose without further enrichment.

The signal sequences may also be inserted into vectors designed for gene therapy. In such vectors,

the signal sequence is operably linked to a promoter such that mRNA transcribed from the promoter encodes the signal peptide. A cloning site is located downstream of the signal sequence such that a gene encoding a protein whose secretion is desired may readily be inserted into the vector and fused to the signal sequence. The vector is introduced into an appropriate host cell. The protein expressed from the promoter is secreted extracellularly, thereby producing a therapeutic effect.

The extended cDNAs or 5' ESTs may also be used to clone sequences located upstream of the extended cDNAs or 5' ESTs which are capable of regulating gene expression, including promoter sequences, enhancer sequences, and other upstream sequences which influence transcription or translation levels. Once identified and cloned, these upstream regulatory sequences may be used in expression vectors designed to direct the expression of an inserted gene in a desired spatial, temporal, developmental, or quantitative fashion. Example 55 describes a method for cloning sequences upstream of the extended cDNAs or 5' ESTs.

#### EXAMPLE 55

##### Use of Extended cDNAs or 5' ESTs to Clone Upstream

##### Sequences from Genomic DNA

Sequences derived from extended cDNAs or 5' ESTs may be used to isolate the promoters of the corresponding genes using chromosome walking techniques. In one chromosome walking technique, which utilizes the GenomeWalker™ kit available from Clontech, five complete genomic DNA samples are each digested with a different restriction enzyme which has a 6 base recognition site and leaves a blunt end. Following digestion, oligonucleotide adapters are ligated to each end of the resulting genomic DNA fragments.

For each of the five genomic DNA libraries, a first PCR reaction is performed according to the manufacturer's instructions using an outer adaptor primer provided in the kit and an outer gene specific primer. The gene specific primer should be selected to be specific for the extended cDNA or 5' EST of interest and should have a melting temperature, length, and location in the extended cDNA or 5' EST which is consistent with its use in PCR reactions. Each first PCR reaction contains 5ng of genomic DNA, 5 µl of 10X Tth reaction buffer, 0.2 mM of each dNTP, 0.2 µM each of outer adaptor primer and outer gene specific primer, 1.1 mM of Mg(OAc)<sub>2</sub>, and 1 µl of the Tth polymerase 50X mix in a total volume of 50 µl. The reaction cycle for the first PCR reaction is as follows: 1 min - 94°C / 2 sec - 94°C, 3 min - 72°C (7 cycles) / 2 sec - 94°C, 3 min - 67°C (32 cycles) / 5 min - 67°C.

The product of the first PCR reaction is diluted and used as a template for a second PCR reaction according to the manufacturer's instructions using a pair of nested primers which are located internally on the amplicon resulting from the first PCR reaction. For example, 5 µl of the reaction product of the first PCR reaction mixture may be diluted 180 times. Reactions are made in a 50 µl volume having a composition identical to that of the first PCR reaction except the nested primers are used. The first nested

primer is specific for the adaptor, and is provided with the GenomeWalker™ kit. The second nested primer is specific for the particular extended cDNA or 5' EST for which the promoter is to be cloned and should have a melting temperature, length, and location in the extended cDNA or 5' EST which is consistent with its use in PCR reactions. The reaction parameters of the second PCR reaction are as follows: 1 min - 94°C /  
5 2 sec - 94°C, 3 min - 72°C (6 cycles) / 2 sec - 94°C, 3 min - 67°C (25 cycles) / 5 min - 67°C

The product of the second PCR reaction is purified, cloned, and sequenced using standard techniques. Alternatively, two or more human genomic DNA libraries can be constructed by using two or more restriction enzymes. The digested genomic DNA is cloned into vectors which can be converted into single stranded, circular, or linear DNA. A biotinylated oligonucleotide comprising at least 15 nucleotides  
10 from the extended cDNA or 5' EST sequence is hybridized to the single stranded DNA. Hybrids between the biotinylated oligonucleotide and the single stranded DNA containing the extended cDNA or EST sequence are isolated as described in Example 29 above. Thereafter, the single stranded DNA containing the extended cDNA or EST sequence is released from the beads and converted into double stranded DNA using a primer specific for the extended cDNA or 5' EST sequence or a primer corresponding to a sequence  
15 included in the cloning vector. The resulting double stranded DNA is transformed into bacteria. DNAs containing the 5' EST or extended cDNA sequences are identified by colony PCR or colony hybridization.

Once the upstream genomic sequences have been cloned and sequenced as described above, prospective promoters and transcription start sites within the upstream sequences may be identified by comparing the sequences upstream of the extended cDNAs or 5' ESTs with databases containing known  
20 transcription start sites, transcription factor binding sites, or promoter sequences.

In addition, promoters in the upstream sequences may be identified using promoter reporter vectors as described in Example 56.

#### EXAMPLE 56

##### Identification of Promoters in Cloned Upstream Sequences

The genomic sequences upstream of the extended cDNAs or 5' ESTs are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-Enhancer, pβgal-Basic, pβgal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable  
30 protein such as secreted alkaline phosphatase, β galactosidase, or green fluorescent protein. The sequences upstream of the extended cDNAs or 5' ESTs are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates  
35 the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for augmenting transcription levels from weak promoter sequences. A

significant level of expression above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

Appropriate host cells for the promoter reporter vectors may be chosen based on the results of the above described determination of expression patterns of the extended cDNAs and ESTs. For example, if the expression pattern analysis indicates that the mRNA corresponding to a particular extended cDNA or 5' EST is expressed in fibroblasts, the promoter reporter vector may be introduced into a human fibroblast cell line.

Promoter sequences within the upstream genomic DNA may be further defined by constructing nested deletions in the upstream DNA using conventional techniques such as Exonuclease III digestion.

The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity. In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into the cloning sites in the promoter reporter vectors.

#### EXAMPLE 57

##### Cloning and Identification of Promoters

Using the method described in Example 55 above with 5' ESTs, sequences upstream of several genes were obtained. Using the primer pairs GGG AAG ATG GAG ATA GTA TTG CCT G (SEQ ID NO:29) and CTG CCA TGT ACA TGA TAG AGA GAT TC (SEQ ID NO:30), the promoter having the internal designation P13H2 (SEQ ID NO:31) was obtained.

Using the primer pairs GTA CCA GGGG ACT GTG ACC ATT GC (SEQ ID NO:32) and CTG TGA CCA TTG CTC CCA AGA GAG (SEQ ID NO:33), the promoter having the internal designation P15B4 (SEQ ID NO:34) was obtained.

Using the primer pairs CTG GGA TGG AAG GCA CGG TA (SEQ ID NO:35) and GAG ACC ACA CAG CTA GAC AA (SEQ ID NO:36), the promoter having the internal designation P29B6 (SEQ ID NO:37) was obtained.

Figure 7 provides a schematic description of the promoters isolated and the way they are assembled with the corresponding 5' tags. The upstream sequences were screened for the presence of motifs resembling transcription factor binding sites or known transcription start sites using the computer program MatInspector release 2.0, August 1996.

Figure 8 describes the transcription factor binding sites present in each of these promoters. The columns labeled matrices provides the name of the MatInspector matrix used. The column labeled position provides the 5' position of the promoter site. Numeration of the sequence starts from the transcription site as determined by matching the genomic sequence with the 5' EST sequence. The column labeled

"orientation" indicates the DNA strand on which the site is found, with the + strand being the coding strand as determined by matching the genomic sequence with the sequence of the 5' EST. The column labeled "score" provides the MatInspector score found for this site. The column labeled "length" provides the length of the site in nucleotides. The column labeled "sequence" provides the sequence of the site found.

5 The promoters and other regulatory sequences located upstream of the extended cDNAs or 5' ESTs may be used to design expression vectors capable of directing the expression of an inserted gene in a desired spatial, temporal, developmental, or quantitative manner. A promoter capable of directing the desired spatial, temporal, developmental, and quantitative patterns may be selected using the results of the expression analysis described in Example 26 above. For example, if a promoter which confers a high level  
10 of expression in muscle is desired, the promoter sequence upstream of an extended cDNA or 5' EST derived from an mRNA which is expressed at a high level in muscle, as determined by the method of Example 26, may be used in the expression vector.

Preferably, the desired promoter is placed near multiple restriction sites to facilitate the cloning of the desired insert downstream of the promoter, such that the promoter is able to drive expression of the  
15 inserted gene. The promoter may be inserted in conventional nucleic acid backbones designed for extrachromosomal replication, integration into the host chromosomes or transient expression. Suitable backbones for the present expression vectors include retroviral backbones, backbones from eukaryotic episomes such as SV40 or Bovine Papilloma Virus, backbones from bacterial episomes, or artificial chromosomes.

20 Preferably, the expression vectors also include a polyA signal downstream of the multiple restriction sites for directing the polyadenylation of mRNA transcribed from the gene inserted into the expression vector.

Following the identification of promoter sequences using the procedures of Examples 55-57, proteins which interact with the promoter may be identified as described in Example 58 below.

#### EXAMPLE 58

##### Identification of Proteins Which Interact with Promoter Sequences,

##### Upstream Regulatory Sequences, or mRNA

Sequences within the promoter region which are likely to bind transcription factors may be  
30 identified by homology to known transcription factor binding sites or through conventional mutagenesis or deletion analyses of reporter plasmids containing the promoter sequence. For example, deletions may be made in a reporter plasmid containing the promoter sequence of interest operably linked to an assayable reporter gene. The reporter plasmids carrying various deletions within the promoter region are transfected into an appropriate host cell and the effects of the deletions on expression levels is assessed. Transcription  
35 factor binding sites within the regions in which deletions reduce expression levels may be further localized using site directed mutagenesis, linker scanning analysis, or other techniques familiar to those skilled in the

art. Nucleic acids encoding proteins which interact with sequences in the promoter may be identified using one-hybrid systems such as those described in the manual accompanying the Matchmaker One-Hybrid System kit available from Clontech (Catalog No. K1603-1). Briefly, the Matchmaker One-hybrid system is used as follows. The target sequence for which it is desired to identify binding proteins is cloned upstream of a selectable reporter gene and integrated into the yeast genome. Preferably, multiple copies of the target sequences are inserted into the reporter plasmid in tandem.

A library comprised of fusions between cDNAs to be evaluated for the ability to bind to the promoter and the activation domain of a yeast transcription factor, such as GAL4, is transformed into the yeast strain containing the integrated reporter sequence. The yeast are plated on selective media to select cells expressing the selectable marker linked to the promoter sequence. The colonies which grow on the selective media contain genes encoding proteins which bind the target sequence. The inserts in the genes encoding the fusion proteins are further characterized by sequencing. In addition, the inserts may be inserted into expression vectors or in vitro transcription vectors. Binding of the polypeptides encoded by the inserts to the promoter DNA may be confirmed by techniques familiar to those skilled in the art, such as gel shift analysis or DNase protection analysis.

#### VII. Use of Extended cDNAs (or Genomic DNAs Obtainable Therefrom) in Gene Therapy

The present invention also comprises the use of extended cDNAs (or genomic DNAs obtainable therefrom) in gene therapy strategies, including antisense and triple helix strategies as described in Examples 57 and 58 below. In antisense approaches, nucleic acid sequences complementary to an mRNA are hybridized to the mRNA intracellularly, thereby blocking the expression of the protein encoded by the mRNA. The antisense sequences may prevent gene expression through a variety of mechanisms. For example, the antisense sequences may inhibit the ability of ribosomes to translate the mRNA. Alternatively, the antisense sequences may block transport of the mRNA from the nucleus to the cytoplasm, thereby limiting the amount of mRNA available for translation. Another mechanism through which antisense sequences may inhibit gene expression is by interfering with mRNA splicing. In yet another strategy, the antisense nucleic acid may be incorporated in a ribozyme capable of specifically cleaving the target mRNA.

#### EXAMPLE 59

##### Preparation and Use of Antisense Oligonucleotides

The antisense nucleic acid molecules to be used in gene therapy may be either DNA or RNA sequences. They may comprise a sequence complementary to the sequence of the extended cDNA (or genomic DNA obtainable therefrom). The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., *Ann. Rev. Biochem.* 55:569-597 (1986) and Izant and Weintraub, *Cell* 36:1007-1015 (1984).



In some strategies, antisense molecules are obtained from a nucleotide sequence encoding a protein by reversing the orientation of the coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of the antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in an expression vector.

Alternatively, oligonucleotides which are complementary to the strand normally transcribed in the cell may be synthesized in vitro. Thus, the antisense nucleic acids are complementary to the corresponding mRNA and are capable of hybridizing to the mRNA to create a duplex. In some embodiments, the antisense sequences may contain modified sugar phosphate backbones to increase stability and make them less sensitive to RNase activity. Examples of modifications suitable for use in antisense strategies are described by Rossi et al., *Pharmacol. Ther.* 50(2):245-254 (1991).

Various types of antisense oligonucleotides complementary to the sequence of the extended cDNA (or genomic DNA obtainable therefrom) may be used. In one preferred embodiment, stable and semi-stable antisense oligonucleotides described in International Application No. PCT WO94/23026 are used. In these molecules, the 3' end or both the 3' and 5' ends are engaged in intramolecular hydrogen bonding between complementary base pairs. These molecules are better able to withstand exonuclease attacks and exhibit increased stability compared to conventional antisense oligonucleotides.

In another preferred embodiment, the antisense oligodeoxynucleotides against herpes simplex virus types 1 and 2 described in International Application No. WO 95/04141, are used.

In yet another preferred embodiment, the covalently cross-linked antisense oligonucleotides described in International Application No. WO 96/31523, are used. These double- or single-stranded oligonucleotides comprise one or more, respectively, inter- or intra-oligonucleotide covalent cross-linkages, wherein the linkage consists of an amide bond between a primary amine group of one strand and a carboxyl group of the other strand or of the same strand, respectively, the primary amine group being directly substituted in the 2' position of the strand nucleotide monosaccharide ring, and the carboxyl group being carried by an aliphatic spacer group substituted on a nucleotide or nucleotide analog of the other strand or the same strand, respectively.

The antisense oligodeoxynucleotides and oligonucleotides disclosed in International Application No. WO 92/18522, may also be used. These molecules are stable to degradation and contain at least one transcription control recognition sequence which binds to control proteins and are effective as decoys therefor. These molecules may contain "hairpin" structures, "dumbbell" structures, "modified dumbbell" structures, "cross-linked" decoy structures and "loop" structures.

In another preferred embodiment, the cyclic double-stranded oligonucleotides described in European Patent Application No. 0 572 287 A2 are used. These ligated oligonucleotide "dumbbells" contain the binding site for a transcription factor and inhibit expression of the gene under control of the

transcription factor by sequestering the factor.

Use of the closed antisense oligonucleotides disclosed in International Application No. WO 92/19732, is also contemplated. Because these molecules have no free ends, they are more resistant to degradation by exonucleases than are conventional oligonucleotides. These oligonucleotides may be multifunctional, interacting with several regions which are not adjacent to the target mRNA.

The appropriate level of antisense nucleic acids required to inhibit gene expression may be determined using in vitro expression analysis. The antisense molecule may be introduced into the cells by diffusion, injection, infection or transfection using procedures known in the art. For example, the antisense nucleic acids can be introduced into the body as a bare or naked oligonucleotide, oligonucleotide encapsulated in lipid, oligonucleotide sequence encapsulated by viral protein, or as an oligonucleotide operably linked to a promoter contained in an expression vector. The expression vector may be any of a variety of expression vectors known in the art, including retroviral or viral vectors, vectors capable of extrachromosomal replication, or integrating vectors. The vectors may be DNA or RNA.

The antisense molecules are introduced onto cell samples at a number of different concentrations preferably between  $1 \times 10^{-10}$  M to  $1 \times 10^{-4}$  M. Once the minimum concentration that can adequately control gene expression is identified, the optimized dose is translated into a dosage suitable for use in vivo. For example, an inhibiting concentration in culture of  $1 \times 10^{-7}$  translates into a dose of approximately 0.6 mg/kg bodyweight. Levels of oligonucleotide approaching 100 mg/kg bodyweight or higher may be possible after testing the toxicity of the oligonucleotide in laboratory animals. It is additionally contemplated that cells from the vertebrate are removed, treated with the antisense oligonucleotide, and reintroduced into the vertebrate.

It is further contemplated that the antisense oligonucleotide sequence is incorporated into a ribozyme sequence to enable the antisense to specifically bind and cleave its target mRNA. For technical applications of ribozyme and antisense oligonucleotides see Rossi et al., *supra*.

In a preferred application of this invention, the polypeptide encoded by the gene is first identified, so that the effectiveness of antisense inhibition on translation can be monitored using techniques that include but are not limited to antibody-mediated tests such as RIAs and ELISA, functional assays, or radiolabeling.

The extended cDNAs of the present invention (or genomic DNAs obtainable therefrom) may also be used in gene therapy approaches based on intracellular triple helix formation. Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity as it is associated with a particular gene. The extended cDNAs (or genomic DNAs obtainable therefrom) of the present invention or, more preferably, a portion of those sequences, can be used to inhibit gene expression in individuals having diseases associated with expression of a particular gene. Similarly, a portion of the extended cDNA (or genomic DNA obtainable therefrom) can be used to study the effect of inhibiting transcription of a particular gene within a cell. Traditionally, homopurine

sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences from the extended cDNA or from the gene corresponding to the extended cDNA are contemplated within the scope of this invention.

## EXAMPLE 60

### Preparation and use of Triple Helix Probes

The sequences of the extended cDNAs (or genomic DNAs obtainable therefrom) are scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting gene expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting gene expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which normally express the target gene. The oligonucleotides may be prepared on an oligonucleotide synthesizer or they may be purchased commercially from a company specializing in custom oligonucleotide synthesis, such as GENSET, Paris, France.

The oligonucleotides may be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

Treated cells are monitored for altered cell function or reduced gene expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to monitor the transcription levels of the target gene in cells which have been treated with the oligonucleotide. The cell functions to be monitored are predicted based upon the homologies of the target gene corresponding to the extended cDNA from which the oligonucleotide was derived with known gene sequences that have been associated with a particular function. The cell functions can also be predicted based on the presence of abnormal physiologies within cells derived from individuals with a particular inherited disease, particularly when the extended cDNA is associated with the disease using techniques described in Example 53.

The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells may then be introduced in vivo using the techniques described above and in Example 59 at a dosage calculated based on the in vitro results, as described in Example 59.

In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al. *Science* 245:967-971 (1989).

## EXAMPLE 61

Use of Extended cDNAs to Express an Encoded Protein in a Host Organism

The extended cDNAs of the present invention may also be used to express an encoded protein in a host organism to produce a beneficial effect. In such procedures, the encoded protein may be transiently expressed in the host organism or stably expressed in the host organism. The encoded protein may have any of the activities described above. The encoded protein may be a protein which the host organism lacks or, alternatively, the encoded protein may augment the existing levels of the protein in the host organism.

A full length extended cDNA encoding the signal peptide and the mature protein, or an extended cDNA encoding only the mature protein is introduced into the host organism. The extended cDNA may be introduced into the host organism using a variety of techniques known to those of skill in the art. For example, the extended cDNA may be injected into the host organism as naked DNA such that the encoded protein is expressed in the host organism, thereby producing a beneficial effect.

Alternatively, the extended cDNA may be cloned into an expression vector downstream of a promoter which is active in the host organism. The expression vector may be any of the expression vectors designed for use in gene therapy, including viral or retroviral vectors.

The expression vector may be directly introduced into the host organism such that the encoded protein is expressed in the host organism to produce a beneficial effect. In another approach, the expression vector may be introduced into cells *in vitro*. Cells containing the expression vector are thereafter selected and introduced into the host organism, where they express the encoded protein to produce a beneficial effect.

## EXAMPLE 62

Use Of Signal Peptides Encoded By 5' Ests Or SequencesObtained Therefrom To Import Proteins Into Cells

The short core hydrophobic region (h) of signal peptides encoded by the 5'ESTS or extended cDNAs derived from the 5'ESTs of the present invention may also be used as a carrier to import a peptide or a protein of interest, so-called cargo, into tissue culture cells (Lin *et al.*, *J. Biol. Chem.*, 270: 14225-14258 (1995); Du *et al.*, *J. Peptide Res.*, 51: 235-243 (1998); Rojas *et al.*, *Nature Biotech.*, 16: 370-375 (1998)).

When cell permeable peptides of limited size (approximately up to 25 amino acids) are to be translocated across cell membrane, chemical synthesis may be used in order to add the h region to either the C-terminus or the N-terminus to the cargo peptide of interest. Alternatively, when longer peptides or proteins are to be imported into cells, nucleic acids can be genetically engineered, using techniques familiar to those skilled in the art, in order to link the extended cDNA sequence encoding the h region to the 5' or the 3' end of a DNA sequence coding for a cargo polypeptide. Such genetically engineered nucleic acids are then translated either *in vitro* or *in vivo* after transfection into appropriate cells, using conventional

techniques to produce the resulting cell permeable polypeptide. Suitable hosts cells are then simply incubated with the cell permeable polypeptide which is then translocated across the membrane.

This method may be applied to study diverse intracellular functions and cellular processes. For instance, it has been used to probe functionally relevant domains of intracellular proteins and to examine protein-protein interactions involved in signal transduction pathways (Lin *et al.*, *supra*; Lin *et al.*, *J. Biol. Chem.*, 271: 5305-5308 (1996); Rojas *et al.*, *J. Biol. Chem.*, 271: 27456-27461 (1996); Liu *et al.*, *Proc. Natl. Acad. Sci. USA*, 93: 11819-11824 (1996); Rojas *et al.*, *Bioch. Biophys. Res. Commun.*, 234: 675-680 (1997)).

Such techniques may be used in cellular therapy to import proteins producing therapeutic effects. For instance, cells isolated from a patient may be treated with imported therapeutic proteins and then re-introduced into the host organism.

Alternatively, the h region of signal peptides of the present invention could be used in combination with a nuclear localization signal to deliver nucleic acids into cell nucleus. Such oligonucleotides may be antisense oligonucleotides or oligonucleotides designed to form triple helixes, as described in examples 59 and 60 respectively, in order to inhibit processing and maturation of a target cellular RNA.

### EXAMPLE 63

#### Reassembling & Resequencing of Clones

Further study of the clones reported in SEQ ID NOs: 40 to 86 revealed a series of abnormalities. As a result, the clones were resequenced twice, reanalyzed and the open reading frames were reassigned. The corrected nucleotide sequences have been disclosed in SEQ ID NOs: 134 to 180 and the predicted amino acid sequences for the corresponding polypeptides have also been corrected and disclosed in SEQ ID NOs: 181 to 227. The corrected sequences have been placed in the Sequence Listing in the same order as the original sequences from which they were derived.

After this reanalysis process a few apparent abnormalities persisted. The sequences presented in SEQ ID NOs: 134, 149, 151, and 164 are apparently unlikely to be genuine full length cDNAs. These clones are missing a stop codon and are thus more probably 3' truncated cDNA sequences. Similarly, the sequences presented in SEQ ID NOs: 145, 155, and 166 may also not be genuine full length cDNAs based on homology studies with existing protein sequences. Although both of these sequences encode a potential start methionine each could represent of 5' truncated cDNA.

In addition, after the reassignment of open reading frames for the clones, new open reading frames were chosen in some instances. In case of SEQ ID NOs: 135, 149, 155, 160, 166, 171, and 175 the new open reading frames were no longer predicted to contain a signal peptide.

Table VII provides the sequence identification numbers of the extended cDNAs of the present invention, the locations of the full coding sequences in SEQ ID NOs: 134-180 (i.e. the nucleotides encoding both the signal peptide and the mature protein, listed under the heading FCS location in Table VII), the

locations of the nucleotides in SEQ ID NOs: 134-180 which encode the signal peptides (listed under the heading SigPep Location in Table VII), the locations of the nucleotides in SEQ ID NOs: 134-180 which encode the mature proteins generated by cleavage of the signal peptides (listed under the heading Mature Polypeptide Location in Table VII), the locations in SEQ ID NOs: 134-180 of stop codons (listed under the heading Stop Codon Location in Table VII), the locations in SEQ ID NOs: 134-180 of polyA signals (listed under the heading PolyA Signal Location in Table VII) and the locations of polyA sites (listed under the heading PolyA Site Location in Table VII).

Table VIII lists the sequence identification numbers of the polypeptides of SEQ ID NOs: 181-227, the locations of the amino acid residues of SEQ ID NOs: 181-227 in the full length polypeptide (second column), the locations of the amino acid residues of SEQ ID NOs: 181-227 in the signal peptides (third column), and the locations of the amino acid residues of SEQ ID NOs: 181-227 in the mature polypeptide created by cleaving the signal peptide from the full length polypeptide (fourth column). In Table VIII, and in the appended sequence listing, the first amino acid of the mature protein resulting from cleavage of the signal peptide is designated as amino acid number 1 and the first amino acid of the signal peptide is designated with the appropriate negative number, in accordance with the regulations governing sequence listings.

#### EXAMPLE 64

##### Functional Analysis of Predicted Protein Sequences

Following double-sequencing, new contigs were assembled for each of the extended cDNAs of the present invention and each was compared to known sequences available at the time of filing. These sequences originate from the following databases: Genbank (release 108 and daily releases up to October, 15, 1998), Genseq (release 32) PIR (release 53) and Swissprot (release 35). The predicted proteins of the present invention matching known proteins were further classified into 3 categories depending on the level of homology.

It should be noted that the numbering of amino acids in the protein sequences discussed in Figures 9 to 16, and Table VI, the first methionine encountered is designated as amino acid number 1. In the appended sequence listing, the first amino acid of the mature protein resulting from cleavage of the signal peptide is designated as amino acid number 1 and the first amino acid of the signal peptide is designated with the appropriate negative number, in accordance with the regulations governing sequence listings.

The first category contains proteins of the present invention exhibiting more than 90% identical amino acid residues on the whole length of the matched protein. They are clearly close homologues which most probably have the same function or a very similar function as the matched protein.

The second category contains proteins of the present invention exhibiting more remote homologies (40 to 90% over the whole protein) indicating that the protein of the present invention is

susceptible to have functions similar to those of matched protein.

The third category contains proteins exhibiting high homology (90 to 100%) to a domain of a known protein indicating that the matched protein and the protein of the invention may share similar features.

5 In addition all of the corrected amino acid sequences (SEQ ID NOs: 181 to 227) were scanned for the presence of known protein signatures and motifs. This search was performed against the Prosite 34.0 database, using the Proscan software from the GCG package. Functional signatures and their locations are indicated in Table VI.

A) Proteins which are closely related to known proteins

10 Protein of SEQ ID NO: 214:

The protein of SEQ ID NO: 214 encoded by the extended cDNA SEQ ID NO: 167 isolated from brain shows extensive homology to a human SH3 binding domain glutamic acid-rich like protein or SH3BGR (Egeo *et al.*, *Biochem. Biophys. Res. Commun.*, 247:302-306 (1998)) with Genbank accession number is AF042081. As shown by the alignments of Figure 9, the amino acid residues are identical  
15 except for positions 63 and 101 in the 114 amino acid long matched sequence. This SH3BGR protein is itself homologous to the middle proline-rich region of a protein containing an SH3 binding domain, the SH3BGR protein (Scartezzini *et al.*, *Hum. Genet.*, 99:387-392 (1997)). This proline-rich region is also highly conserved in mice. Both SH3BGR and SH3BGR proteins are thought to be involved in the Down syndrome pathogenesis. The protein SEQ ID NO: 214 also contains the proline-rich SH3 binding  
20 domain (bold) and a potential RGD cell attachment sequence (underlined).

SH3 domains are small important functional modules found in several proteins from all eukaryotic organisms that are involved in a whole range of regulation of protein-protein interaction, e.g. in regulating enzymatic activities, recruiting specific substrates to the enzyme in signal transduction pathways, in interacting with viral proteins and they are also thought to play a role in determining the  
25 localization of proteins to the plasma membrane or the cytoskeleton (for a review, see Cohen *et al.*, *Cell*, 80:237-248 (1995)).

The Arg-Gly-Asp (RGD) attachment site promote cell adhesion of a large number of adhesive extracellular matrix, blood and cell surface proteins to their integrin receptors which have been shown to regulate cell migration, growth, differentiation and apoptosis. This cell adhesion activity is also  
30 maintained in short RGD containing synthetic peptides which were shown to exhibit anti-thrombolytic and anti-metastatic activities and to inhibit bone degradation *in vivo* (for review, see Ruoslahti, *Annu. Rev. Cell Dev. Biol.*, 12:697-715 (1996)).

Taken together, these data suggest that the protein of SEQ ID NO: 214 may be important in regulating protein-protein interaction in signal transduction pathways, and/or may play a role of  
35 localization of proteins to the plasma membrane or cytoskeleton, and/or may play a role in cell adhesion. Moreover, this protein or part therein, especially peptides containing the RGD motif, may be useful in

diagnosing and treating cancer, thrombosis, osteoporosis and/or in diagnosing and treating disorders associated with the Down syndrome.

Proteins of SEQ ID NOs: 185 and 215:

The nearly homologous proteins of SEQ ID NOs: 185 and 215 encoded by the extended cDNA  
5 SEQ ID NOs: 138 and 168, respectively, exhibit an extensive homology with a murine protein named  
MP1 for MEK binding partner 1 (Genbank accession number AF082526). The amino acid residues are  
identical to the murine protein except for positions 39, 118 and 119 of the Genbank MP1 sequence for  
SEQ ID NO: 215 and except for positions 33, 39, 118 and 119 of the Genbank MP1 sequence for SEQ ID  
10 NO: 185. The Genbank MP1 sequence is the 124 amino acid long matched protein region. See the  
amino acid sequence alignment in Figure 10. MP1 was shown to enhance enzymatic activation of  
mitogen-activated protein (MAP) kinase cascade. The MAP kinase pathway is one of the important  
enzymatic cascade that is conserved among all eukaryotes from yeast to human. This kind of pathway is  
involved in vital functions such as the regulation of growth, differentiation and apoptosis. MP1 probably  
acts by facilitating the interaction of the two sequentially acting kinases MEK1 and ERK1 (Schaffer *et*  
15 *al.*, *Science*, 281:1668-1671 (1998)).

Taken together, these data suggest that the proteins of SEQ ID NO: 185 and 215 may be involved  
in regulating protein-protein interaction in the signal transduction pathways. Thus, these proteins may be  
useful in diagnosing and/or treating several types of disorders including, but not limited to, cancer,  
neurodegenerative diseases, cardiovascular disorders, hypertension, renal injury and repair and septic  
20 shock.

Protein of SEQ ID NO: 186

The protein of SEQ ID NO: 186 encoded by the extended cDNA SEQ ID NO: 139 exhibits an  
extensive homology with a murine protein named claudin-2 (Genbank accession number AF072128).  
The amino acid residues are identical except for the conservative substitutions observed at positions: 6,  
25 22, 23, 29, 31, 90, 110, 120, 130, 171, 176, 179, 187, 192, 197, 211, 212, 214, and 217 of the 230 amino  
acids long matched protein claudin-2. One drastic substitution from glycine to arginine was observed at  
position 189. See the amino acid sequence alignment in Figure 11. The murine homologue claudin-2 is  
a integral membrane proteins with 4 putative transmembrane domains belonging to a family of proteins  
thought to be involved in the formation of tight junctions between cells in epithelial or endothelial cell  
30 sheets (Furuse *et al.*, *J. Cell. Biol.*, 141:1539-1550, (1998)).

In addition, the protein of SEQ ID NO: 186 shows more remote homology to a family of  
transmembrane proteins among which are receptors for *Clostridium perfringens* enterotoxin (CPE) with  
either high or low affinity for CPE (Katahira *et al.*, *J. Biol. Chem.*, 452:26652-26658 (1997)). The  
matched region include the 4 putative transmembrane regions.

35 Taken together, these data suggest that the protein of SEQ ID NO: 186 may be involved in the  
formation and/or regulation of tight junction, and more generally in cell-cell adhesion. This protein may



also function as a receptor for a yet unknown ligand that may show homology to CPE. This protein may thus be useful in diagnosing and/or treating disorders associated with changes in epithelium permeability such as infectious diseases caused by *Clostridium* parasites.

Protein of SEQ ID NO: 213

5 The protein of SEQ ID NO: 213 encoded by the extended cDNA SEQ ID NO: 166 and expressed in lymphocytes exhibits an extensive homology to a stretch of 121 amino acid of a human hematopoietic maturation factor named glia maturation factor gamma or GMF- $\gamma$  (Genbank accession number AB001993) and also to other glia maturation factors found in human, bovine and rodent species. The amino acid residues are identical as shown below except for conservative substitutions at positions 50,  
10 and 77 of the 142 amino acids long matched protein GMF- $\gamma$  which is itself highly homologous to GMF- $\beta$  (Asai *et al.*, *Biochem. Biophys. Acta*, 1396:242-244 (1998)). See the amino acid sequence alignment in Figure 12. GMF- $\beta$  was shown to act as a growth and differentiation factor for neurons and glial cells in human brain (Lim *et al.*, *Proc Natl Acad Sci U S A* 86:3901-3905 (1989); and Harman *et al.*, *Brain Res.* 56:332-335 (1991)) and is also thought to regulate ERK proteins of the evolutionarily conserved  
15 mitogen-activated protein (MAP) kinase cascade which is important in the regulation of growth, differentiation and apoptosis (Zaheer and Lim, *J. Biol. Chem.*, 272:5183-5186 (1997)).

Taken together, these data suggest that the protein of SEQ ID NO: 213 may be involved in cell growth and differentiation and/or in apoptosis and/or in intracellular signaling. Thus, this protein may be useful in diagnosing and/or treating several types of disorders including, but not limiting to, cancer,  
20 neurodegenerative diseases, cardiovascular disorders, hypertension, renal injury and repair and septic shock.

Protein of SEQ ID NO: 191

The protein of SEQ ID NO: 191 encoded by the extended cDNA SEQ ID NO: 144 and expressed in lymphocytes exhibits an extensive homology to a stretch of 91 amino acid of a human secreted protein  
25 expressed in peripheral blood mononucleocytes (Genpep accession number W36955 and Genseq accession number VOO433). The amino acid residues are identical except for the substitution of asparagine to isoleucine at positions 94, and the conservative substitutions at positions 108, 109 and 110 of the 110 amino acids long matched protein. See the amino acid sequence alignment in Figure 13.

Protein of SEQ ID NO: 200

30 The protein of SEQ ID NO: 200 encoded by the extended cDNA SEQ ID NO: 153 exhibits extensive homologies to proteins encoding RING zinc finger proteins of the human, chicken and rodent species, as well as an EGF-like domain. Two stretches of 341 and of 13 amino acids of the human RING zinc finger protein which might bind DNA (Genbank accession number AF037204). The amino acid residues are identical except for conservative substitutions at positions 18, 29, 156 and 282 of the 381  
35 amino acid long human RING zinc finger. See the amino acid sequence alignment in Figure 14. Such RING zinc finger proteins are thought to be involved in protein-protein interaction and are especially

found in nucleic acid binding proteins. Secreted proteins may have nucleic acid binding domain as shown by a nematode protein thought to regulate gene expression which exhibits zinc fingers as well as a functional signal peptide (Holst and Zipfel, *J. Biol. Chem.*, 271:16275-16733 (1996)).

Taken together, these data suggest that the protein of SEQ ID NO: 200 may play a role in protein-protein interaction or be a nucleic acid binding protein.

#### Protein of SEQ ID NO: 192

The protein of SEQ ID NO: 192 encoded by the extended cDNA SEQ ID NO: 145 exhibits extensive homologies to stretches of proteins encoding vacuolar proton-ATPase subunits M9.2 of either human (Genbank accession number Y15286) or bovine species (Genbank accession number Y15285). These two highly conserved proteins are extremely hydrophobic membrane proteins with two membrane-spanning helices and a potential metal-binding domain conserved in mammalian protein homologues (Ludwig *et al.*, *J. Biol. Chem.*, 273:10939-10947 (1998)). The amino acid residues are completely identical as shown in the alignment in Figure 15. However, the protein of SEQ ID NO: 192 is missing amino acids 1 to 92 from the Genbank sequences. The protein of SEQ ID NO: 192 contains the second putative transmembrane domain as well as the potential metal-binding site.

Taken together, these data suggest that the protein of SEQ ID NO: 192 may play a role in energy conservation, secondary active transport, acidification of intracellular compartments and/or cellular pH homeostasis.

#### **B) Proteins which are remotely related to proteins with known functions**

##### Proteins of SEQ ID NOs: 201 and 227

The proteins of SEQ ID NOs: 201 and 227 encoded by the extended cDNA SEQ ID NOs: 154 and 180, respectively, belong to the stomatin or band 7 family. The human stomatin is an integral membrane phosphoprotein thought to be involved to regulate the cation conductance by interacting with other proteins of the junctional complex of the membrane skeleton (Gallagher and Forget, *J. Biol. Chem.*, 270:26358-26363 (1995)). The proteins of SEQ ID NOs: 201 and 227 exhibit the PROSITE signature typical for the band 7 family signature. See the amino acid sequence alignment in Figure 16.

Taken together, these data suggest that the proteins of SEQ ID NOs: 201 and 227 play a role in the regulation of ion transport, hence in the control of cellular volume. These proteins may then be useful in diagnosing and/or treating stomatocytosis and/or cryohydrocytosis.

##### Protein of SEQ ID NO: 198

The protein of SEQ ID NO: 198 encoded by the extended cDNA SEQ ID NO: 151 shows homologies with different DNA or RNA binding proteins such as the human Staf50 transcription factor (Genbank accession number X82200), the human Ro/SS-A ribonucleoprotein autoantigen (Swissprot accession number P19474) or the murine RPT1 transcription factor (Swissprot accession number P15533). The protein of SEQ ID NO: 198 exhibits a putative signal peptide and also a PROSITE signature for a RING type zinc finger domain located from positions 15 to 59. Secreted proteins may

have nucleic acid binding domain as shown by a nematode protein thought to regulate gene expression which exhibits zinc fingers as well as a functional signal peptide (Holst and Zipfel, *J. Biol. Chem.*, 271:16275-16733 (1996)).

Taken together, these data suggest that the protein of SEQ ID NO: 198 may play a role in protein-protein interaction in intracellular signaling and eventually may directly or indirectly bind to DNA and/or RNA, hence regulating gene expression.

Protein of SEQ ID NO: 216

The protein of SEQ ID NO: 216 found in testis encoded by the extended cDNA SEQ ID NO: 169 shows homologies to protein domains with a 4-disulfide core signature found in either an extracellular proteinase inhibitor named chelonianin (Swissprot accession number P00993) or in rabbit and human proteins specifically expressed in epididymes (Genbank accession numbers U26725 and R13329). The matched domain in red sea turtle chelonianin is known to inhibit subtilisin, a serine protease (Kato and Tominaga, *Fed. Proc.*, 38:832 (1979)). All cysteines of the 4 disulfide core signature thought to be crucial for biological activity are present in the protein of SEQ ID NO: 216. The 4 disulfide core signature is present except for a conservative substitution of asparagine to glutamine.

Taken together, these data suggest that the protein of SEQ ID NO: 216 may play a role in protein-protein interaction, act as a protease inhibitor and/or may also be related to male fertility.

Protein of SEQ ID NO: 197

The protein of SEQ ID NO: 197 encoded by the extended cDNA SEQ ID NO: 150 shows extensive homology to the connexin family conserved in the rodent, chicken, human, frog, sheep species. Connexins are a family of integral membrane proteins that oligomerize into clusters of intercellular channels called gap junctions, which join cells in virtually all metazoans. These channels permit exchange of ions between neurons and between neurons and excitable cells such as myocytes (for review, see Goodenough *et al.*, *Ann. Rev. Biochem.*, 65:475-502 (1996)).

Taken together, these data suggest that the protein of SEQ ID NO: 197 may play a role in cell growth, differentiation and developmental signaling. Moreover, the protein of SEQ ID NO: 197 may be useful in diagnosing and/or treating cancer, neurodegenerative diseases and cardiovascular disorders.

C) Proteins homologous to a domain of a protein with known function

Protein of SEQ ID NO: 183

The protein of SEQ ID NO: 183 encoded by the extended cDNA SEQ ID NO: 136 shows homology to a rabbit soluble protein called PiUS (Genbank accession number U74297) which is a stimulator of inorganic phosphate uptake and is thought to be involved in cellular phosphate metabolism and/or binding (Norris *et al.*, *J. Memb. Biol.*, 156:19-24 (1997)).

Taken together, these data suggest that the protein of SEQ ID NO: 183 may play a role in

phosphate metabolism.

Protein of SEQ ID NO: 223

The protein of SEQ ID NO: 223 encoded by the extended cDNA SEQ ID NO: 176 shows homology to short stretches of a human protein called Tspan-1 (Genbank accession number AF054838) which belongs to the 4 transmembrane superfamily of molecular facilitators called tetraspanin (Meakers *et al.*, *FASEB J.*, 11:428-442 (1997)).

Taken together, these data suggest that the protein of SEQ ID NO: 223 may play a role in cell activation and proliferation, and/or adhesion and motility and/or differentiation and cancer.

Protein of SEQ ID NO: 193

The protein of SEQ ID NO: 193 encoded by the extended cDNA SEQ ID NO: 146 shows homology to short stretches of *Drosophila*, *C. elegans* and chloroplast proteins similar to *E. coli* ribosomal protein L16.

Taken together, these data suggest that the protein of SEQ ID NO: 193 may be a ribosomal protein.

As discussed above, the extended cDNAs of the present invention or portions thereof can be used for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosomal markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination for expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris *et al.*, *Cell* 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins or polypeptides provided by the present invention can similarly be used in assays to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative

receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

5 Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation *Molecular Cloning: A Laboratory Manual*, 2d ed., Cole Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., (1989), and *Methods in*  
10 *Enzymology: Guide to Molecular Cloning Techniques*, Academic Press, Berger, S.L. and A.R. Kimmel eds., (1987).

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or  
15 polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules.

In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Although this invention has been described in terms of certain preferred embodiments, other  
20 embodiments which will be apparent to those of ordinary skill in the art in view of the disclosure herein are also within the scope of this invention. Accordingly, the scope of the invention is intended to be defined only by reference to the appended claims.

Step	Search Characteristics			Selection Characteristics	
	Program	Strand	Parameters	Identity (%)	Length (bp)
Miscellaneous	blastn	both	S=61 X=16	90	17
tRNA	fasta	both	-	80	60
rRNA	blastn	both	S=108	80	40
mtRNA	blastn	both	S=108	80	40
Prokaryotic	blastn	both	S=144	90	40
Fungal	blastn	both	S=144	90	40
Alu	fasta*	both	-	70	40
L1	blastn	both	S=72	70	40
Repeats	blastn	both	S=72	70	40
Promoters	blastn	top	S=54 X=16	90	15†
Vertebrate	fasta*	both	S=108	90	30
ESTs	blastn	both	S=108 X=16	90	30
Proteins	blastx♦	top	E=0.001	-	-

Table 1: Parameters used for each step of EST analysis

- \* use "Quick Fast" Database Scanner
- † alignment further constrained to begin closer than 10bp to EST \ 5' end
- ♦ using BLOSUM62 substitution matrix

TABLE II

Id	FCS Location	SigPep Location	Mature Polypeptide Location	Stop Codon Location	PolyA Signal Location	PolyA Site Location
40	173-565	173-211	212-565	566	1063-1068	1087-1098
41	267-455	267-371	372-455	456	817-822	842-855
42	174-662	174-266	267-662	663	1144-1149	1165-1176
43	460-615	460-555	556-615	616	614-619	635-648
44	79-450	79-369	370-450	451	1217-1222	1240-1251
45	160-849	160-231	232-849	850	1510-1515	1506-1519
46	106-321	106-201	202-321	322	577-582	598-610
47	359-631	359-466	467-631	632	1334-1339	1357-1370
48	191-508	191-286	287-508	509	755-760	780-791
49	346-861	346-408	409-861	862	1400-1405	1420-1433
50	214-381	214-339	340-381	382	1133-1138	1146-1158
51	372-509	372-437	438-509	510	812-817	838-850
52	132-884	132-215	216-884	885	1069-1074	1094-1107
53	199-429	199-288	289-429	430	464-469	489-500
54	293-535	293-385	386-535	536	733-738	752-765
55	130-507	130-189	190-507	508	546-551	572-584
56	191-1009	191-325	326-1009	1010	1348-1353	1374-1387
57	141-614	141-251	252-614	615	1354-1359	1375-1385
58	212-364	212-268	269-364	365	1465-1470	1489-1497
59	147-1223	147-248	249-1223	1224	1538-1543	1558-1570
60	112-984	112-237	238-984	985	976-981	1010-1022
61	239-439	239-316	317-439	440	586-591	603-615
62	157-537	157-345	346-537	538	771-776	791-804
63	194-484	194-253	254-484	485	768-773	780-792
64	148-405	148-207	208-405	406	789-794	820-832
65	156-368	156-230	231-368	369	706-711	709-721
66	272-451	272-397	398-451	452	503-508	518-531
67	381-734	381-629	630-734	735	736-741	770-783
68	140-367	140-205	206-367	368	965-970	984-996
69	183-467	183-338	339-467	468	620-625	644-657
70	140-385	140-205	206-385	386	383-388	405-416
71	129-395	129-176	177-395	396	513-518	530-543
72	285-374	285-341	342-374	375	575-580	592-605
73	136-480	136-444	445-480	481	835-840	851-864
74	200-514	200-427	428-514	515	1001-1006	1022-1033
75	68-346	68-133	134-346	347	472-477	490-499
76	274-600	274-399	400-600	601	943-948	966-978
77	421-573	421-465	466-573	574	553-558	575-587
78	198-365	198-278	279-365	366	364-369	387-400
79	167-652	167-229	230-652	653	1133-1138	1154-1166

Id	FCS Location	SigPep Location	Mature Polypeptide Location	Stop Codon Location	PolyA Signal Location	PolyA Site Location
80	180-557	180-383	384-557	558	722-727	743-754
81	179-598	179-298	299-598	599	680-685	697-708
82	100-228	100-171	172-228	229	211-216	230-243
83	346-552	346-408	409-552	553	792-797	817-829
84	177-410	177-233	234-410	411	644-649	663-674
85	179-418	179-319	320-418	419	461-466	465-478
86	112-270	112-237	238-270	271	910-915	940-952

TABLE2:11  
111397



TABLE III

Id	Motif Location	Motif
55	160-226	Zinc finger, C2H2 type, domain
56	683-734	Connexins signatures
57	231-261	Zinc finger, C3HC4 type, signature

TABLE III  
111397

TABLE IV

Id	Full Length Polypeptide Location	Signal Peptide Location	Mature Polypeptide Location
87	1-131	1-13	14-131
88	1-63	1-35	36-63
89	1-163	1-31	32-163
90	1-52	1-32	33-52
91	1-124	1-97	98-124
92	1-230	1-24	25-230
93	1-72	1-32	33-72
94	1-91	1-36	37-91
95	1-106	1-32	33-106
96	1-172	1-21	22-172
97	1-56	1-42	43-56
98	1-46	1-22	23-46
99	1-251	1-28	29-251
100	1-77	1-30	31-77
101	1-81	1-31	32-81
102	1-126	1-20	21-126
103	1-273	1-45	46-273
104	1-158	1-37	38-158
105	1-51	1-19	20-51
106	1-359	1-34	35-359
107	1-291	1-42	43-291
108	1-67	1-26	27-67
109	1-127	1-63	64-127
110	1-97	1-20	21-97
111	1-86	1-20	21-86
112	1-71	1-25	26-71
113	1-60	1-42	43-60
114	1-118	1-83	84-118
115	1-76	1-22	23-76
116	1-95	1-52	53-95
117	1-82	1-22	23-82
118	1-89	1-16	17-89
119	1-30	1-19	20-30
120	1-115	1-103	104-115
121	1-105	1-76	77-105
122	1-93	1-22	23-93
123	1-109	1-42	43-109

Id	Full Length Polypeptide Location	Signal Peptide Location	Mature Polypeptide Location
124	1-51	1-15	16-51
125	1-56	1-27	28-56
126	1-162	1-21	22-162
127	1-126	1-68	69-126
128	1-140	1-40	41-140
129	1-43	1-24	25-43
130	1-69	1-21	22-69
131	1-78	1-19	20-78
132	1-80	1-47	48-80
133	1-53	1-42	43-53

TABLE4:11  
111397

TABLE V

Id	No-matches	Est <30%	Est >30%	Vrt
40			X	
41		X		
42			X	
43	X			
44			X	
45		X		
46			X	
47		X		
48			X	
49			X	
50		X		
51			X	
52			X	
53			X	
54			X	
55	X			
56			X	
57		X		
58			X	
59			X	
60	X			
61			X	
62			X	
63			X	
64			X	
65			X	
66			X	
67		X		
68			X	
69		X		
70		X		
71			X	
72				X
73			X	
74			X	
75	X			
76			X	
77			X	
78	X			

Id	No-matches	Est <30%	Est >30%	Vrt
79			X	
80			X	
81			X	
82			X	
83			X	
84			X	
85			X	
86	X			

TABLES:11  
111397

## - PROTEIN SIGNATURE -

SEQ ID	LOCATION	MOTIF
214	76 - 78	cell attachment site
	32 - 53	Leucine zipper
201	289 - 291	Microbodies C-terminal targeting signal
	164 - 192	Band 7 protein family
227	239 - 241	Microbodies C-terminal targeting signal
	114 - 142	Band 7 protein family
205	179 - 182	Endoplasmic reticulum targeting signal
226	78 - 81	Microbodies C-terminal targeting signal
181	99 - 101	cell attachment site
200	264 - 278	EGF like domain
	240 - 282	C3HC4 zinc finger (RING finger)
196	10 - 32	C2H2 zinc finger
198	15 - 59	C3HC4 zinc finger (RING finger)
218	21 - 42	Leucine zipper
197	164 - 180	connexins

TABLE VI

109  
Table VII

SEQ ID	FCS Location	SigPep Location	Mature Polypeptide Location	Stop Codon Location	PolyA Signal Location	PolyA Site Location
134	131/1042	131/169	170/1042	-	-	1042/1053
135	100/276	-	100/276	277	638/643	662/675
136	111/401	111/194	195/401	402	1080/1085	1101/1112
137	359/514	359/454	455/514	515	-	536/547
138	26/397	26/316	317/397	398	1164/1169	1187/1198
139	36/725	36/107	108/725	726	1302/1307	1389/1400
140	35/250	35/130	131/250	251	505/510	526/538
141	169/432	169/267	268/432	433	1132/1137	1155/1167
142	143/460	143/238	239/460	461	697/702	721/730
143	108/908	108/170	171/908	909	1141/1146	1161/1174
144	209/532	-	209/532	533	1133/1138	1146/1158
145	5/211	5/142	143/211	212	716/721	742/754
146	98/850	98/181	182/850	851	1035/1040	1060/1073
147	46/342	46/189	190/342	343	377/382	402/413
148	139/381	139/231	232/381	382	579/584	598/609
149	72/512	-	72/512	-	-	512/522
150	126/944	126/260	261/944	945	1283/1288	1309/1322
151	50/1279	50/160	161/1279	-	-	1280/1290
152	83/1261	83/139	140/1261	1262	-	1356/1354
153	57/1199	57/95	96/1199	1200	1438/1443	1458/1470
154	72/944	72/197	198/944	945	-	970/982
155	4/279	-	4/279	280	425/430	443/455
156	90/470	90/278	279/470	471	704/709	724/738
157	88/339	88/147	148/339	340	619/624	637/649
158	33/578	33/92	93/578	579	-	703/714
159	33/245	33/107	108/245	246	546/551	584/596
160	125/343	-	125/343	344	375/380	390/403
161	126/632	126/575	576/632	633	670/675	721/727
162	90/317	90/155	156/317	318	913/918	932/944
163	126/410	126/287	288/410	411	561/566	587/598
164	85/348	85/150	151/348	-	-	349/360
165	77/343	77/124	125/343	344	461/466	477/490
166	38/364	-	38/364	365	458/463	475/488
167	48/389	48/356	357/389	390	742/747	760/771
168	69/440	69/359	360/440	441	927/932	947/959
169	33/311	33/98	99/311	312	437/442	455/464
170	110/730	110/235	236/730	731	764/769	787/799
171	38/214	-	38/214	215	-	308/320
172	129/296	129/209	210/296	297	-	318/331
173	78/563	78/359	360/563	564	1042/1047	1063/1075
174	62/523	62/265	266/523	524	602/607	621/632
175	24/320	-	24/320	321	402/407	419/430
176	42/170	42/113	114/170	171	-	172/185
177	108/314	108/170	171/314	315	550/555	574/585
178	118/351	118/171	172/351	352	583/588	602/613
179	128/367	128/268	269/367	368	410/415	424/427
180	149/871	149/457	458/871	872	-	893/912

Table VIII

SEQ ID	Full Length Polypeptide Location	Signal Peptide Location	Mature Polypeptide Location
134	-13/291	-13/-1	1/291
135	1/59	.	1/59
136	-28/69	-28/-1	1/69
137	-32/20	-32/-1	1/20
138	-97/27	-97/-1	1/27
139	-24/206	-24/-1	1/206
140	-32/40	-32/-1	1/40
141	-33/55	-33/-1	1/55
142	-32/74	-32/-1	1/74
143	-21/246	-21/-1	1/246
144	1/108	.	1/108
145	-46/23	-46/-1	1/23
146	-28/223	-28/-1	1/223
147	-48/51	-48/-1	1/51
148	-31/50	-31/-1	1/50
149	1/147	.	1/147
150	-45/228	-45/-1	1/228
151	-37/373	-37/-1	1/373
152	-19/374	-19/-1	1/374
153	-13/368	-13/-1	1/368
154	-42/249	-42/-1	1/249
155	1/92	.	1/92
156	-63/64	-63/-1	1/64
157	-20/64	-20/-1	1/64
158	-20/162	-20/-1	1/162
159	-25/46	-25/-1	1/46
160	1/73	.	1/73
161	-150/19	-150/-1	1/19
162	-22/54	-22/-1	1/54
163	-54/41	-54/-1	1/41
164	-22/66	-22/-1	1/66
165	-16/73	-16/-1	1/73
166	1/109	.	1/109
167	-103/11	-103/-1	1/11
168	-97/27	-97/-1	1/27
169	-22/71	-22/-1	1/71
170	-42/165	-42/-1	1/165
171	1/59	.	1/59
172	-27/29	-27/-1	1/29
173	-94/68	-94/-1	1/68
174	-68/86	-68/-1	1/86
175	1/99	.	1/99
176	-24/19	-24/-1	1/19
177	-21/48	-21/-1	1/48
178	-18/60	-18/-1	1/60
179	-47/33	-47/-1	1/33
180	-103/138	-103/-1	1/138
180	-103/138	-103/-1	1/138



CLAIMSWhat Is Claimed Is:

1. A purified or isolated nucleic acid comprising the sequence of one of SEQ ID NOs: 134-180 or a sequence complementary thereto.
- 5 2. A purified or isolated nucleic acid comprising at least 10 consecutive bases of the sequence of one of SEQ ID NOs: 134-180 or one of the sequences complementary thereto.
3. A purified or isolated nucleic acid comprising the full coding sequences of one of SEQ ID NOs: 136-148, 150, 152-154, 156-159, 161-163, 165, 167-170, 172-174, and 176-180, wherein the full coding sequence comprises the sequence encoding signal peptide and the sequence  
10 encoding mature protein.
4. A purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 135-148, 150, 152-163, and 165-180 which encode a mature protein.
5. A purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 134, 136-148, 150-154, 156-159, 161-165, 167-170, 172-174, and 176-180 which encode the  
15 signal peptide.
6. A purified or isolated nucleic acid encoding a polypeptide having the sequence of one of the sequences of SEQ ID NOs: 181-227.
7. A purified or isolated nucleic acid encoding a polypeptide having the sequence of a mature protein included in one of the sequences of SEQ ID NOs: 182-195, 197, 199-210, and 212-  
20 227.
8. A purified or isolated nucleic acid encoding a polypeptide having the sequence of a signal peptide included in one of the sequences of SEQ ID NOs: 181, 183-195, 197-201, 203-206, 208-212, 214-217, 219-221, and 223-227.
9. A purified or isolated protein comprising the sequence of one of SEQ ID NOs:  
25 181-227.
10. A purified or isolated polypeptide comprising at least 10 consecutive amino acids of one of the sequences of SEQ ID NOs: 181-227.
11. An isolated or purified polypeptide comprising a signal peptide of one of the polypeptides of SEQ ID NOs: 181, 183-195, 197-201, 203-206, 208-212, 214-217, 219-221, and  
30 223-227.
12. An isolated or purified polypeptide comprising a mature protein of one of the polypeptides of SEQ ID NOs: 182-195, 197, 199-210, and 212-227.
13. A method of making a protein comprising one of the sequences of SEQ ID NO:

181-227, comprising the steps of:

obtaining a cDNA comprising one of the sequences of sequence of SEQ ID NO: 134-180;

inserting said cDNA in an expression vector such that said cDNA is operably linked to a promoter; and

5 introducing said expression vector into a host cell whereby said host cell produces the protein encoded by said cDNA.

14. The method of Claim 13, further comprising the step of isolating said protein.

15. A protein obtainable by the method of Claim 14.

16. A host cell containing a recombinant nucleic acid of Claim 1.

10 17. A purified or isolated antibody capable of specifically binding to a protein having the sequence of one of SEQ ID NOs: 181-227.

18. In an array of polynucleotides of at least 15 nucleotides in length, the improvement comprising inclusion in said array of at least one of the sequences of SEQ ID NOs: 134-180, or one of the sequences complementary to the sequences of SEQ ID NOs: 134-180, or a fragment thereof  
15 of at least 15 consecutive nucleotides.

1/16




Figure 1

2/16

Minimum signal peptide score	falso positivo rate	falso negativo rate	proba(0.1)	proba(0.2)
3,5	0,121	0,036	0,467	0,664
4	0,096	0,06	0,518	0,708
4,5	0,078	0,079	0,565	0,745
5	0,062	0,098	0,616	0,782
5,5	0,05	0,127	0,659	0,813
6	0,04	0,163	0,694	0,838
6,5	0,033	0,202	0,725	0,855
7	0,025	0,248	0,763	0,878
7,5	0,021	0,304	0,78	0,888
8	0,015	0,368	0,816	0,908
8,5	0,012	0,418	0,836	0,92
9	0,008	0,612	0,856	0,93
9,5	0,007	0,681	0,863	0,934
10	0,006	0,678	0,835	0,918

FIGURE 2

## Score curves




FIGURE 3

4/16

Minimum signal peptide score	All ESTs	New ESTs	ESTs matching public EST closer than 40 bp from beginning	ESTs extending known mRNA more than 40 bp	ESTs extending public EST more than 40 bp
3,5	2674	947	599	23	150
4	2278	784	498	23	126
4,5	1843	647	425	22	112
5	1657	523	353	21	96
5,5	1417	418	307	19	80
6	1180	340	238	18	68
6,5	1035	280	186	18	60
7	893	218	161	15	48
7,5	753	173	132	12	36
8	636	133	101	11	29
8,5	643	104	83	8	26
9	456	81	63	6	24
9,5	364	57	48	6	18
10	303	47	35	6	15


FIGURE 4

5/16

Tissue	All ESTs	New ESTs	ESTs matching public EST closer than 40 bp from beginning	ESTs extending known mRNA more than 40 bp	ESTs extending public EST more than 40 bp
Brain	329	131	75	3	24
Cancerous prostate	134	40	37	1	6
Cerebellum	17	9	1	0	6
Colon	21	11	4	0	0
Dystrophic muscle	41	18	8	0	1
Fetal brain	70	37	16	0	1
Fetal kidney	227	116	46	1	19
Fetal liver	13	7	2	0	0
Heart	30	15	7	0	1
Hypertrophic prostate	86	23	22	2	2
Kidney	10	7	3	0	0
Large intestine	21	8	4	0	1
Liver	23	9	6	0	0
Lung	24	12	4	0	1
Lung (cells)	57	38	6	0	4
Lymph ganglia	163	60	23	2	12
Lymphocytes	23	6	4	0	2
Muscle	33	16	6	0	4
Normal prostate	181	61	45	7	11
Ovary	90	57	12	1	2
Pancreas	48	11	6	0	1
Placenta	24	5	1	0	0
Prostate	34	16	4	0	2
Spleen	56	28	10	0	1
Substantia nigra	108	47	27	1	6
Surrenals	15	3	3	1	0
Testis	131	68	25	1	8
Thyroid	17	8	2	0	2
Umbilical cord	55	17	12	1	3
Uterus	28	15	3	0	2
Non tissue-specific	568	48	177	2	28
Total	2677	947	601	23	150

Figure 5

6/16



Plasmid name: pED6dpc2

Plasmid size: 5374 bp

Figure 6



Description of Promoter structure isolated from SignalTag 5'ESTs




FIGURE 7

**Description of Transcription Factor Binding Sites present on promoters isolated from SignalTag sequences**

**Promoter sequence P13H2 (546 bp):**

Matrix	Position	Orientation	Score	Length	Sequence
CMYB_01	-502	+	0.983	9	TGTCAGTTG
MYOD_Q6	-501	-	0.961	10	CCCAACTGAC
S8_01	-444	-	0.960	11	AATAGAATTAG
S8_01	-425	+	0.966	11	AACTAAATTAG
DELTAEF1_01	-390	-	0.960	11	GCACACCTCAG
GATA_C	-364	-	0.964	11	AGATAAAATCCA
CMYB_01	-349	+	0.958	9	CTTCAGTTG
GATA1_02	-343	+	0.959	14	TTGTAGATAGGACA
GATA_C	-339	+	0.953	11	AGATAGGACAT
TAL1ALPHAE47_01	-235	+	0.973	16	CATAACAGATGGTAAG
TAL1BETAE47_01	-235	+	0.983	16	CATAACAGATGGTAAG
TAL1BETAIF2_01	-235	+	0.978	16	CATAACAGATGGTAAG
MYOD_Q6	-232	-	0.954	10	ACCATCTGTT
GATA1_04	-217	-	0.953	13	TCAAGATAAAGTA
IK1_01	-126	+	0.963	13	AGTTGGGAATTCC
IK2_01	-126	+	0.985	12	AGTTGGGAATTC
CREL_01	-123	+	0.962	10	TGGGAATTCC
GATA1_02	-96	+	0.950	14	TCAGTGATATGGCA
SRY_02	-41	-	0.951	12	TAAAACAAAACA
E2F_02	-33	+	0.957	8	TTTAGCGC
MZF1_01	-5	-	0.975	8	TGAGGGGA

**Promoter sequence P15B4 (861bp) :**

Matrix	Position	Orientation	Score	Length	Sequence
NFY_Q6	-748	-	0.956	11	GGACCAATCAT
MZF1_01	-738	+	0.962	8	CCTGGGGA
CMYB_01	-684	+	0.994	9	TGACCGTTG
VMYB_02	-682	-	0.985	9	TCCAACGGT
STAT_01	-673	+	0.968	9	TTCTTGGA
STAT_01	-673	-	0.951	9	TTCCAGGAA
MZF1_01	-556	-	0.956	8	TTGGGGGA
IK2_01	-451	+	0.965	12	GAATGGGATTC
MZF1_01	-424	+	0.986	8	AGAGGGGA
SRY_02	-398	-	0.955	12	GAAAACAAAACA
MZF1_01	-216	+	0.960	8	GAAGGGGA
MYOD_Q6	-190	+	0.981	10	AGCATCTGCC
DELTAEF1_01	-176	+	0.958	11	TCCCACCTTC
S8_01	5	-	0.992	11	GAGGCAATTAT
MZF1_01	16	-	0.986	8	AGAGGGGA

**Promoter sequence P29B6 (555 bp) :**

Matrix	Position	Orientation	Score	Length	Sequence
ARNT_01	-311	+	0.964	16	GGACTCACGTGCTGCT
NMYC_01	-309	+	0.965	12	ACTCACGTGCTG
USF_01	-309	+	0.985	12	ACTCACGTGCTG
USF_01	-309	-	0.985	12	CAGCACGTGAGT
NMYC_01	-309	-	0.956	12	CAGCACGTGAGT
MYCMAX_02	-309	-	0.972	12	CAGCACGTGAGT
USF_C	-307	+	0.997	8	TCACGTGC
USF_C	-307	-	0.991	8	GCACGTGA
MZF1_01	-292	-	0.968	8	CATGGGGA
ELK1_02	-105	+	0.963	14	CTCTCCGGAAGCCT
CETS1P54_01	-102	+	0.974	10	TCCGGAAGCC
AP1_Q4	-42	-	0.963	11	AGTGACTGAAC
AP1FJ_Q2	-42	-	0.961	11	AGTGACTGAAC
PADS_C	45	+	1.000	9	TGTGGTCTC

**Figure 8**

9/16

98.2% identity in 113 aa overlap

```
          10      20      30      40      50      60
SeqID214  MVIRVYIASSSGSTAIKKKQDVLGFLANKIGFEEKDIAANEENRKWMRENVPE  
          10      20      30      40      50      60
AF042081  MVIRVYIASSSGSTAIKKKQDVLGFLANKIGFEEKDIAANEENRKWMRENVPE  
          70      80      90     100     110
SeqID214  TGNPLPPQIFNESQYRQDYDAFFEARENNAVYAFLGLTAPSGSKEAEVQAKQ  
          70      80      90     100     110
AF042081  TGYPLPPQIFNESQYRQDYDAFFEARENNAVYAFLGLTAPPGSKEAEVQAKQ
```

FIGURE 9

10/16

seqID215	MADDLKRFLYKKLPSVEGLHAIVVSDRGVPVIKVANDNAPEHALRPGFLSTFALATDQG
seqID185	MADDLKRFLYKKLPSVEGLHAIVVSDRGVPVVKVANDNAPEHALRPGFLSTFALATDQG
AF082526	MADDLKRFLYKKLPSVEGLHAIVVSDRGVPVIKVANDSAPEHALRPGFLSTFALATDQG .....
seqID215	SKLGLSKNKSIIICYNTYQVVQFNRLPLVVSFIASSSANTGLIVSLEKELAPLFEELRQV
seqID185	SKLGLSKNKSIIICYNTYQVVQFNRLPLVVSFIASSSANTGLIVSLEKELAPLFEELRQV
AF082526	SKLGLSKNKSIIICYNTYQVVQFNRLPLVVSFIASSSANTGLIVSLEKELAPLFEELIKV .....
seqID215	VEVS
seqID185	VEVS
AF082526	VEVS ....

FIGURE 10

91.3% identity in 230 aa overlap

	10	20	30	40	50	60
SeqID186	MASLGQLGVGYILGLLGLLGLTLVAMLLPSWKTSSYVGCASIVTAVGFSKGLWHECATHSTG					
	.....	.....	.....	.....	.....	.....
AF072128	MASLGVLGVGYILGLLGLLGLTSIAMLLPNWRTSSYVGCASIVTAVGFSKGLWHECATHSTG					
	10	20	30	40	50	60
	70	80	90	100	110	120
SeqID186	ITQCDIYSTLLGLPADIQAAQAAMVMTSSAISSLACIISVVGMRICTVFCQESRAKDRVAVA					
	.....	.....	.....	.....	.....	.....
AF072128	ITQCDIYSTLLGLPADIQAAQAAMVMTSSAMSSLACIISVVGMRICTVFCODSRAKDRVAVV					
	70	80	90	100	110	120
	130	140	150	160	170	180
SeqID186	GGVFFILGGLLGFIPVAMNLHGILRDFYSPLVPDSMKFEIGEALYLGIISSFLSLIAGII					
	.....	.....	.....	.....	.....	.....
AF072128	GGVFFILGGLLGFIPVAMNLHGILRDFYSPLVPDSMKFEIGEALYLGIIISALFSLVAGVI					
	130	140	150	160	170	180
	190	200	210	220	230	
SeqID186	LCFSCSSQRNRSNYDAYQAQPLATRSSPRPGQPPKVKSEFNYSYSLTGYV					
	.....	.....	.....	.....	.....	.....
AF072128	LCFSCSPQGNRTNYYDGYQAQPLATRSSPRSAQPPKAKSEFNYSYSLTGYV					
	190	200	210	220	230	

FIGURE 11

12/16

98.3% identity in 121 aa overlap

```

                                10      20      30
seqID213      RFRKETDNAAIIMKVDRQMVVLEEEFRNISPEELKME
               ::::::::::::::::::::::::::::::::::::::
AB001993 MSDSLVVCEVDPELTKLRKFRFRKETDNAAIIMKVDRQMVVLEEEFQNISPEELKME
               10      20      30      40      50      60

               40      50      60      70      80      90
seqID213 LPEROPRFVVYSYKYVRDDGRVSYPLCFIFSSPVGCKPEQQMMYAGSKNRLVOTAELTKV
               ::::::::::::::::::::::::::::::::::::::
AB001993 LPEROPRFVVYSYKYVHDDGRVSYPLCFIFSSPVGCKPEQQMMYAGSKNRLVOTAELTKV
               70      80      90      100     110     120

               100     110     120
seqID213 FEIRTTDDLTEAWLQEKLSFFR
               ::::::::::::::::::::::
AB001993 FEIRTTDDLTEAWLQEKLSFFR
               130     140
```

FIGURE 12

13/16

95.6% identity in 91 aa overlap

```
seq ID191                                10      20
                                         MCCVFQSTEDKCIFKIDWTLS
W36955  MFCPLKLILLPVLLDYSLSGLNDLNVSPPELTVHVGDSALMCCVFQSTEDKCIFKIDWTLS
          10      20      30      40      50      60
          30      40      50      60      70      80
seq ID191  PGEHAKDEYVLYYYSNLSVPIGRFONRVHLMGDILCNDGSLLLQDVQEADQGTYYICEIRL
W36955  PGEHAKDEYVLYYYSNLSVPIGRFONRVHLMGDNLCDGSLLLQDVQDVE
          70      80      90     100     110
          90     100
seq ID191  KGESQVFKKAVVLHVLPEEPKGTQMLT
```

FIGURE 13

14/16

99.0% identity in 381 aa overlap:

```

      10      20      30      40      50      60
seqID200  MLLSIGMLMLSATQVYTVLTQVLF AFLNPLPVEADILAYNFENASQTFDDL PARFGYRLP
      10      20      30      40      50      60
AF037204  MLLSIGMLMLSATQVYTVLTQVLF AFLNLLPVEADILAYNFENASQTFDDL PARFGYRLP

      70      80      90     100     110     120
id200     AEGLKGF LINSK PENACEPIVPPPVKDNSSGTFIVLIRRLDCNFDIKVLNAQRAGYKAAI
      70      80      90     100     110     120
AF037204  AEGLKGF LINSK PENACEPIVPPPVKDNSSGTFIVLIRRLDCNFDIKVLNAQRAGYKAAI

      130     140     150     160     170     180
id200     VHNVDSDDLISMGSNDIEVLKKIDIPSVFIGESSASSLKDEFTYEKG GHLILVPEFSLPL
      130     140     150     160     170     180
AF037204  VHNVDSDDLISMGSNDIEVLKKIDIPSVFIGESSANS LKDEFTYEKG GHLILVPEFSLPL

      190     200     210     220     230     240
id200     EYYLIPFLIIVGICLILIVIFMITKFVQDRHRARRNRLRKDQLKKLPVHKFKKGDEYDV
      190     200     210     220     230     240
AF037204  EYYLIPFLIIVGICLILIVIFMITKFVQDRHRARRNRLRKDQLKKLPVHKFKKGDEYDV

      250     260     270     280     290     300
id200     AICLDEYEDGDKLRILPCSHAYHCKCVD PMLTKTKTCPVQRQKVVP SQGDS DSDT DSSQ
      250     260     270     280     290     300
AF037204  AICLDEYEDGDKLRILPCSHAYHCKCVD PMLTKTKTCPVQRQKVVP SQGDS DSDT DSSQ

      310     320     330     340     350     360
id200     EENEVTEHTPLLRLASVSAQSF GALS ESRSHQNMTESSDY EEDNEDT DSSDAENEINE
      310     320     330     340     350     360
AF037204  EENEVTEHTPLLRLASVSAQSF GALS ESRSHQNMTESSDY EEDNEDT DSSDAENEINE

      370     380
id200     HDVVVQLQPNGERDYN IANTV
      370     380
AF037204  HDVVVQLQPNGERDYN IANTV

```

FIGURE 14



15/16

100.0% identity in 68 aa overlap

	10	20	30	40	50	60
seqID192	MSVFWG	FVGFLVPWF	IPKGNRGV	IITMLVTCS	VCCYLF	WLIAILAQLNPLFGPOLKNET
	:	:	:	:	:	:
Y15286	MSVFWG	FVGFLVPWF	IPKGNRGV	IITMLVTCS	VCCYLF	WLIAILAQLNPLFGPOLKNET
	20	30	40	50	60	70

seqID192	IWYLKYHW
	:::::::
Y15286	IWYLKYHW
	80

FIGURE 15

16/16

```

seqID201      -MDSRVS--SPEKQDKENFVGVNNKRLGVCGWILFSLFLLVIITFPISIMCLKIIREY
seqID227      -----MWLDP-----VFPLFPVG-----DH
X85116        MAEKRHTRDSEAQRLPDSFKDSPSKGLGCGWILVAFSFLFTVITFPISIMCIKIKEY
               ..
               ..

seqID201      ERAVVFRLGRIQADKAKGPGLILVLPIDVFVKVDLRTVTCNIPPQEILTRDSVTTQVVG
seqID227      Y-----LPHLHMDVLEG--LILVLPIDVFVKVDLRTVTCNIPPQEILTRDSVTTQVVG
X85116        ERAIIFRLGRILQCGAKGPGLFFILPCTDSFIKVDHRTISFDIPPQEILTKDSVTISVVG
               ..
               ..
               ..

seqID201      VVYRIYSAVSAVANVNDVHQATFLLAQTTLRNVLTOTLSOILACREEIAHS IQTLLDD
seqID227      VVYRIYSAVSAVANVNDVHQATFLLAQTTLRNVLTOTLSOILACREEIAHS IQTLLDD
X85116        VVYRVONATLAVANITNADSATRLLAQTTLRNVLTOTLSOILSREEIAHNMOSTLDD
               ..
               ..
               ..

seqID201      ATELWGIRVARVEIKDVRI PVQLORSMAAEAEATREARAKVLAEEGENSASKSLKSASHV
seqID227      ATELWGIRVARVEIKDVRI PVQLORSMAAEAEATREARAKVLAEEGENNASKSLKSASHV
X85116        ATDAWGIKVERVEIKDVKL PVQLORAMAAEAEASREARAKVIAAEGENNASRALKEASHV
               ..
               ..
               ..

seqID201      LAESPIALQLRYLQTLSTVATEKNSTIVFPLPMNILEGIGGVSYDNHKKLPNKA
seqID227      LAESPIALQLRYLQTLSTVATEKNSTIVFPLPMNILEGIGGVSYDNHKKLPNKA
X85116        ITESPAALQLRYLQTLTTIAAEKNSTIVFPLPIDMLGGIIGAKHSHLG-----
               ..
               ..
               ..

```

FIGURE 16

## SEQUENCE LISTING

<110> Genset SA  
<120> Extended cDNAs for Secreted Proteins  
<160> 227  
<170> Patent.pm  
<210> 1  
<211> 47  
<212> RNA  
<213> -  
<220>  
<221> modified\_base  
<222> 1  
<223> m7Gppp added to 1  
<300>  
<400> 1  
ggcauccuac ucccauccaa uuccacccua acuccucca ucuccac 47  
<210> 2  
<211> 46  
<212> RNA  
<213> -  
<220>  
<300>  
<400> 2  
gcauccuacu cccauccaau uccacccuaa cuccuccau cuccac 46  
<210> 3  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 3  
atcaagaatt cgcacgagac catta 25  
<210> 4  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 4  
taatggtctc gtgcgaattc ttgat 25  
<210> 5  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 5  
ccgacaagac caacgtcaag gccgc 25  
<210> 6  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 6  
tcaccagcag gcagtggctt aggag 25  
<210> 7  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 7  
agtgattcct gctactttgg atggc 25

<210> 8  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 8  
gcttgggtctt gttctggagt ttaga  
<210> 9 25  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 9  
cccagaatgg gagacaagcc aattt  
<210> 10 25  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 10  
agggaggagg aaacagcgtg agtcc  
<210> 11 25  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 11  
atgggaaagg aaaagactca tatca  
<210> 12 25  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 12  
agcagcaaca atcaggacag cacag  
<210> 13 25  
<211> 25  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 13  
atcaagaatt cgcacgagac catta  
<210> 14 25  
<211> 67  
<212> DNA  
<213> -  
<220>  
<300>  
<400> 14  
atcgttgaga ctctaccag cagagtcacg agagagacta cacggtactg gttttttttt 60  
ttttttvn 67  
<210> 15  
<211> 29  
<212> DNA  
<213> -  
<220>  
<300>

```

<400> 15
ccagcagagt cacgagagag actacacgg
<210> 16
<211> 25
<212> DNA
<213> -
<220>
<300>
<400> 16
cacgagagag actacacggg actgg
<210> 17
<211> 526
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<222> complement(261..376)
<223> blastn
<221> misc_feature
<222> complement(380..486)
<223> blastn
<221> misc_feature
<222> complement(110..145)
<223> blastn
<221> misc_feature
<222> complement(196..229)
<223> blastn
<221> sig_peptide
<222> 90..140
<223> Von Heijne matrix
<300>
<400> 17
aatatrarac agctacaata ttccagggcc artcacttgc catttctcat aacagcgtca
gagagaaaga actgactgar acgtttgag atg aag aaa gtt ctc ctc ctg atc
Met Lys Lys Val Leu Leu Leu Ile
-15 -10
aca gcc atc ttg gca gtg gct gtw ggt ttc cca gtc tct caa gac cag
Thr Ala Ile Leu Ala Val Ala Val Gly Phe Pro Val Ser Gln Asp Gln
-5 1 5
gaa cga gaa aaa aga agt atc agt gac agc gat gaa tta gct tca ggr
Glu Arg Glu Lys Arg Ser Ile Ser Asp Ser Asp Glu Leu Ala Ser Gly
10 15 20
wtt ttt gtg ttc cct tac cca tat cca ttt cgc cca ctt cca cca att
Xaa Phe Val Phe Pro Tyr Pro Tyr Pro Phe Arg Pro Leu Pro Pro Ile
25 30 35
cca ttt cca aga ttt cca tgg ttt aga cgt aan ttt cct att cca ata
Pro Phe Pro Arg Phe Pro Trp Phe Arg Arg Xaa Phe Pro Ile Pro Ile
40 45 50 55
cct gaa tct gcc cct aca act ccc ctt cct agc gaa aag taaacaaraa
Pro Glu Ser Ala Pro Thr Thr Pro Leu Pro Ser Glu Lys
60 65
ggaaaagtca crataaacct ggtcacctga aattgaaatt gagccacttc cttgaaraat
caaaattcct gttaataaaa raaaaacaaa tgtaattgaa atagcacaca gcattctcta
gtcaatatct ttagtgatct tctttaataa acatgaaagc aaaaaaaaaa aa
<210> 18
<211> 17
<212> PRT
<213> Homo Sapiens
<220>
<221> SIGNAL
<222> 1..17
<223> Von Heijne matrix
score 8.2

```

```

      seq LLLITAILAVAVG/FP
<300>
<400> 18
Met Lys Lys Val Leu Leu Leu Ile Thr Ala Ile Leu Ala Val Ala Val
 1             5             10             15
Gly
<210> 19
<211> 822
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<222> 260..464
<223> blastn
<221> misc_feature
<222> 118..184
<223> blastn
<221> misc_feature
<222> 56..113
<223> blastn
<221> misc_feature
<222> 454..485
<223> blastn
<221> misc_feature
<222> 118..545
<223> blastn
<221> misc_feature
<222> 65..369
<223> blastn
<221> misc_feature
<222> 61..399
<223> blastn
<221> misc_feature
<222> 408..458
<223> blastn
<221> misc_feature
<222> 60..399
<223> blastn
<221> misc_feature
<222> 393..432
<223> blastn
<221> sig_peptide
<222> 346..408
<223> Von Heijne matrix
<300>
<400> 19
actccttttta gcataggggc ttcgggcgcca gcggccagcg ctagtcgggc tggtaagtgc      60
ctgatgccga gtccggtctc tcggtctctt tcctgggtccc aggcaaagcg gasgnagatc      120
ctcaaacggc ctagtgcttc gcgcttcggg agaaaatcag cggctctaatt aattcctctg      180
gtttgttgaa gcagttacca agaattctca accctttccc acaaaagcta attgagtaca      240
cgttcctgtt gagtacacgt tcctgttgat ttacaaaagg tgcaggtatg agcaggtctg      300
aagactaaca ttttgtgaag ctgtaaaaca gaaaacctgt tagaa atg tgg tgg ttt      357
                                     Met Trp Trp Phe
                                     -20
cag caa ggc ctc agt ttc ctt cct tca gcc ctt gta att tgg aca tct      405
Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val Ile Trp Thr Ser
      -15             -10             -5
gct gct ttc ata ttt tca tac att act gca gta aca ctc cac cat ata      453
Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr Leu His His Ile
      1             5             10             15
gac ccg gct tta cct tat atc agt gac act ggt aca gta gct cca raa      501
Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr Val Ala Pro Xaa
      20             25             30

```

5

```

aaa tgc tta ttt ggg gca atg cta aat      att gcg gca gtt tta tgt caa      549
Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala Val Leu Cys Gln
      35              40              45
aaa tagaaatcag gaarataatt caacttaaag aakttcattt catgaccaa      602
Lys
ctcttcaraa acatgtctttt acaagcatat ctcttgattt gctttctaca ctgttgaatt      662
gtctggcaat atttctgcag tggaaaattt gatttarmta gttcttgact gataaatatg      722
gtaagggtggg cttttccccc tgtgtaattg gctactatgt cttactgagc caagttgtaw      782
tttgaataaa aatgatatga gagtgacaca aaaaaaaaaa      822
<210> 20
<211> 21
<212> PRT
<213> Homo Sapiens
<220>
<221> SIGNAL
<222> 1..21
<223> Von Heijne matrix
      score 5.5
      seq SFLPSALVIWTS/AF
<300>
<400> 20
Met Trp Trp Phe Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val
1              5              10              15
Ile Trp Thr Ser Ala
      20
<210> 21
<211> 405
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<222> complement(103..398)
<223> blastn
<221> sig_peptide
<222> 185..295
<223> Von Heijne matrix
<300>
<400> 21
atcaccttct tctccatcct tctctgggcc agtccccarc ccagtccctc tcttgacctg      60
cccagcccaa gtcagccttc agcagcgctt tttctgcaca cagatattcc aggcctacct      120
ggcattccag gacctccgma atgatgctcc agtcccttac aagcgcttcc tggatgaggg      180
tggc atg gtg ctg acc acc ctc ccc ttg ccc tct gcc aac agc cct gtg      229
      Met Val Leu Thr Thr Leu Pro Leu Pro Ser Ala Asn Ser Pro Val
      -35              -30              -25
aac atg ccc acc act ggc ccc aac agc ctg agt tat gct agc tct gcc      277
Asn Met Pro Thr Thr Gly Pro Asn Ser Leu Ser Tyr Ala Ser Ser Ala
      -20              -15              -10
ctg tcc ccc tgt ctg acc gct cca aak tcc ccc cgg ctt gct atg atg      325
Leu Ser Pro Cys Leu Thr Ala Pro Xaa Ser Pro Arg Leu Ala Met Met
      -5              1              5              10
cct gac aac taaatatacct tatccaaatc aataaarwra raatcctccc      374
Pro Asp Asn
tccaraaggg tttctaaaaa caaaaaaaaaa a      405
<210> 22
<211> 37
<212> PRT
<213> Homo Sapiens
<220>
<221> SIGNAL
<222> 1..37
<223> Von Heijne matrix
      score 5.9
      seq LSYASSALSPCLT/AP

```

```

<300>
<400> 22
Met Val Leu Thr Thr Leu Pro Leu Pro Ser Ala Asn Ser Pro Val Asn
1          5          10          15
Met Pro Thr Thr Gly Pro Asn Ser Leu Ser Tyr Ala Ser Ser Ala Leu
20          25          30
Ser Pro Cys Leu Thr
35
<210> 23
<211> 496
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<222> 149..331
<223> blastn
<221> misc_feature
<222> 328..485
<223> blastn
<221> misc_feature
<222> complement(182..496)
<223> blastn
<221> sig_peptide
<222> 196..240
<223> Von Heijne matrix
<300>
<400> 23
aaaaaattgg tcccagtttt caccctgccg cagggctggc tggggagggc agcggttttag      60
attagccgtg gcctaggccg tttaacgggg tgacacgagc ntgcagggcc gagtccaagg      120
cccgagagata ggaccaaccg tcaggaatgc gaggaatgtt tttcttcgga ctctatcgag      180
gcacacagac agacc atg ggg att ctg tct aca gtg aca gcc tta aca ttt      231
                Met Gly Ile Leu Ser Thr Val Thr Ala Leu Thr Phe
                -15          -10          -5
gcc ara gcc ctg gac ggc tgc aga aat ggc att gcc cac cct gca agt      279
Ala Xaa Ala Leu Asp Gly Cys Arg Asn Gly Ile Ala His Pro Ala Ser
1          5          10
gag aag cac aga ctc gag aaa tgt agg gaa ctc gag asc asc cac tcg      327
Glu Lys His Arg Leu Glu Lys Cys Arg Glu Leu Glu Xaa Xaa His Ser
15          20          25
gcc cca gga tca acc cas cac cga aga aaa aca acc aga aga aat tat      375
Ala Pro Gly Ser Thr Xaa His Arg Arg Lys Thr Thr Arg Arg Asn Tyr
30          35          40          45
tct tca gcc tgaaatgaak ccgggatcaa atggttgctg atcaragccc      424
Ser Ser Ala
atatttaaatt tggaaaagtc aaattgasca ttattaaata aagcttggtt aatatgtctc      484
aaacaaaaaa aa      496
<210> 24
<211> 15
<212> PRT
<213> Homo Sapiens
<220>
<221> SIGNAL
<222> 1..15
<223> Von Heijne matrix
score 5.5
seq ILSTVTALTFAXA/LD
<300>
<400> 24
Met Gly Ile Leu Ser Thr Val Thr Ala Leu Thr Phe Ala Xaa Ala
1          5          10          15
<210> 25
<211> 623
<212> DNA

```



```

<213> Homo Sapiens
<220>
<221> sig_peptide
<222> 49..96
<223> Von Heijne matrix
<300>
<400> 25
aaagatccct gcagcccggc aggagagaag gctgagcctt ctggcgctc atg gag agg      57
                                     Met Glu Arg
                                     -15
ctc gtc cta acc ctg tgc acc ctc ccg ctg gct gtg gcg tct gct ggc      105
Leu Val Leu Thr Leu Cys Thr Leu Pro Leu Ala Val Ala Ser Ala Gly
      -10      -5      1
tgc gcc acg acg cca gct cgc aac ctg agc tgc tac cag tgc ttc aag      153
Cys Ala Thr Thr Pro Ala Arg Asn Leu Ser Cys Tyr Gln Cys Phe Lys
      5      10      15
gtc agc agc tgg acg gag tgc ccg ccc acc tgg tgc agc ccg ctg gac      201
Val Ser Ser Trp Thr Glu Cys Pro Pro Thr Trp Cys Ser Pro Leu Asp
20      25      30      35
caa gtc tgc atc tcc aac gag gtg gtc gtc tct ttt aaa tgg agt gta      249
Gln Val Cys Ile Ser Asn Glu Val Val Ser Phe Lys Trp Ser Val
      40      45      50
cgc gtc ctg ctc agc aaa cgc tgt gct ccc aga tgt ccc aac gac aac      297
Arg Val Leu Leu Ser Lys Arg Cys Ala Pro Arg Cys Pro Asn Asp Asn
      55      60      65
atg aak ttc gaa tgg tcg ccg gcc ccc atg gtg caa ggc gtg atc acc      345
Met Xaa Phe Glu Trp Ser Pro Ala Pro Met Val Gln Gly Val Ile Thr
      70      75      80
agg cgc tgc tgt tcc tgg gct ctc tgc aac agg gca ctg acc cca cag      393
Arg Arg Cys Cys Ser Trp Ala Leu Cys Asn Arg Ala Leu Thr Pro Gln
      85      90      95
gag ggg cgc tgg gcc ctg cra ggg ggg ctc ctg ctc cag gac cct tcg      441
Glu Gly Arg Trp Ala Leu Xaa Gly Gly Leu Leu Leu Gln Asp Pro Ser
100      105      110      115
agg ggc ara aaa acc tgg gtg cgg cca cag ctg ggg ctc cca ctc tgc      489
Arg Gly Xaa Lys Thr Trp Val Arg Pro Gln Leu Gly Leu Pro Leu Cys
      120      125      130
ctt ccc awt tcc aac ccc ctc tgc cca rgg gaa acc cag gaa gga      534
Leu Pro Xaa Ser Asn Pro Leu Cys Pro Xaa Glu Thr Gln Glu Gly
      135      140      145
taacactgtg ggtgccccca cctgtgcatt gggaccacra cttcacccctc ttggaracaa      594
taaactctca tgcccccaaa aaaaaaaaaa
623
<210> 26
<211> 16
<212> PRT
<213> Homo Sapiens
<220>
<221> SIGNAL
<222> 1..16
<223> Von Heijne matrix
      score 10.1
      seq LVLTLCCTLPLAVA/SA
<300>
<400> 26
Met Glu Arg Leu Val Leu Thr Leu Cys Thr Leu Pro Leu Ala Val Ala
1      5      10      15
<210> 27
<211> 848
<212> DNA
<213> Homo Sapiens
<220>
<221> sig_peptide
<222> 32..73

```

&lt;223&gt; Von Heijne matrix

&lt;300&gt;

&lt;400&gt; 27

```

aactttgcct tgtgttttcc accctgaaag a atg ttg tgg ctg ctc ttt ttt      52
                                Met Leu Trp Leu Leu Phe Phe
                                -10
ctg gtg act gcc att cat gct gaa ctc tgt caa cca ggt gca gaa aat      100
Leu Val Thr Ala Ile His Ala Glu Leu Cys Gln Pro Gly Ala Glu Asn
-5                               1                               5
gct ttt aaa gtg aga ctt agt atc aga aca gct ctg gga gat aaa gca      148
Ala Phe Lys Val Arg Leu Ser Ile Arg Thr Ala Leu Gly Asp Lys Ala
10                               15                               20                               25
tat gcc tgg gat acc aat gaa gaa tac ctc ttc aaa gcg atg gta gct      196
Tyr Ala Trp Asp Thr Asn Glu Glu Tyr Leu Phe Lys Ala Met Val Ala
30                               35                               40
ttc tcc atg aga aaa gtt ccc aac aga gaa gca aca gaa att tcc cat      244
Phe Ser Met Arg Lys Val Pro Asn Arg Glu Ala Thr Glu Ile Ser His
45                               50                               55
gtc cta ctt tgc aat gta acc cag agg gta tca ttc tgg ttt gtg gtt      292
Val Leu Leu Cys Asn Val Thr Gln Arg Val Ser Phe Trp Phe Val Val
60                               65                               70
aca gac cct tca aaa aat cac acc ctt cct gct gtt gag gtg caa tca      340
Thr Asp Pro Ser Lys Asn His Thr Leu Pro Ala Val Glu Val Gln Ser
75                               80                               85
gcc ata aga atg aac aag aac cgg atc aac aat gcc ttc ttt cta aat      388
Ala Ile Arg Met Asn Lys Asn Arg Ile Asn Asn Ala Phe Phe Leu Asn
90                               95                               100                               105
gac caa act ctg gaa ttt tta aaa atc cct tcc aca ctt gca cca ccc      436
Asp Gln Thr Leu Glu Phe Leu Lys Ile Pro Ser Thr Leu Ala Pro Pro
110                               115                               120
atg gac cca tct gtg ccc atc tgg att att ata ttt ggt gtg ata ttt      484
Met Asp Pro Ser Val Pro Ile Trp Ile Ile Ile Phe Gly Val Ile Phe
125                               130                               135
tgc atc atc ata gtt gca att gca cta ctg att tta tca ggg atc tgg      532
Cys Ile Ile Ile Val Ala Ile Ala Leu Leu Ile Leu Ser Gly Ile Trp
140                               145                               150
caa cgt ada ara aag aac aaa gaa cca tct gaa gtg gat gac gct gaa      580
Gln Arg Xaa Xaa Lys Asn Lys Glu Pro Ser Glu Val Asp Asp Ala Glu
155                               160                               165
rat aak tgt gaa aac atg atc aca att gaa aat ggc atc ccc tct gat      628
Xaa Xaa Cys Glu Asn Met Ile Thr Ile Glu Asn Gly Ile Pro Ser Asp
170                               175                               180                               185
ccc ctg gac atg aag gga ggg cat att aat gat gcc ttc atg aca gag      676
Pro Leu Asp Met Lys Gly Gly His Ile Asn Asp Ala Phe Met Thr Glu
190                               195                               200
gat gag agg ctc acc cct ctc tgaagggtg ttgttctgct tcctcaaraa      727
Asp Glu Arg Leu Thr Pro Leu
205
attaaacatt tgtttctgtg tgactgctga gcatacctgaa ataccaagag cagatcatat      787
wttttgtttc accattcttc ttttgtaata aattttgaat gtgcttgaaa aaaaaaaaaa      847
c                                                                    848
<210> 28
<211> 14
<212> PRT
<213> Homo Sapiens
<220>
<221> SIGNAL
<222> 1..14
<223> Von Heijne matrix
      score 10.7
      seq LWLLFFLVTAIHA/EL
<300>
<400> 28

```

Met Leu Trp Leu Leu Phe Phe Leu Val Thr Ala Ile His Ala  
 1 5 10

<210> 29  
 <211> 25  
 <212> DNA  
 <213> -

<220>  
 <300>  
 <400> 29

gggaagatgg agatagtatt gcctg

25

<210> 30  
 <211> 26  
 <212> DNA  
 <213> -

<220>  
 <300>  
 <400> 30

ctgccatgta catgatagag agattc

26

<210> 31  
 <211> 546  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> promoter  
 <222> 1..517

<221> transcription start site  
 <222> 518

<221> protein\_bind  
 <222> 17..25

<223> matinspector prediction  
 name CMYB\_01  
 score 0.983  
 sequence tgtcagttg

<221> protein\_bind  
 <222> complement(18..27)

<223> matinspector prediction  
 name MYOD\_Q6  
 score 0.961  
 sequence cccaactgac

<221> protein\_bind  
 <222> complement(75..85)

<223> matinspector prediction  
 name S8\_01  
 score 0.960  
 sequence aatagaattag

<221> protein\_bind  
 <222> 94..104

<223> matinspector prediction  
 name S8\_01  
 score 0.966  
 sequence aactaaattag

<221> protein\_bind  
 <222> complement(129..139)

<223> matinspector prediction  
 name DELTAEF1\_01  
 score 0.960  
 sequence gcacacctcag

<221> protein\_bind  
 <222> complement(155..165)

<223> matinspector prediction  
 name GATA\_C  
 score 0.964  
 sequence agataaatcca

<221> protein\_bind  
<222> 170..178  
<223> matinspector prediction  
    name CMYB\_01  
    score 0.958  
    sequence cttcagttg  
<221> protein\_bind  
<222> 176..189  
<223> matinspector prediction  
    name GATA1\_02  
    score 0.959  
    sequence ttgtagataggaca  
<221> protein\_bind  
<222> 180..190  
<223> matinspector prediction  
    name GATA\_C  
    score 0.953  
    sequence agataggacat  
<221> protein\_bind  
<222> 284..299  
<223> matinspector prediction  
    name TAL1ALPHA47\_01  
    score 0.973  
    sequence cataacagatggtaag  
<221> protein\_bind  
<222> 284..299  
<223> matinspector prediction  
    name TAL1BETA47\_01  
    score 0.983  
    sequence cataacagatggtaag  
<221> protein\_bind  
<222> 284..299  
<223> matinspector prediction  
    name TAL1BETA1TF2\_01  
    score 0.978  
    sequence cataacagatggtaag  
<221> protein\_bind  
<222> complement(287..296)  
<223> matinspector prediction  
    name MYOD\_Q6  
    score 0.954  
    sequence accatctgtt  
<221> protein\_bind  
<222> complement(302..314)  
<223> matinspector prediction  
    name GATA1\_04  
    score 0.953  
    sequence tcaagataaagta  
<221> protein\_bind  
<222> 393..405  
<223> matinspector prediction  
    name IK1\_01  
    score 0.963  
    sequence agttgggaattcc  
<221> protein\_bind  
<222> 393..404  
<223> matinspector prediction  
    name IK2\_01  
    score 0.985  
    sequence agttgggaattc  
<221> protein\_bind  
<222> 396..405  
<223> matinspector prediction

```

name CREL_01
score 0.962
sequence tgggaattcc
<221> protein_bind
<222> 423..436
<223> matinspector prediction
name GATA1_02
score 0.950
sequence tcagtgatatggca
<221> protein_bind
<222> complement(478..489)
<223> matinspector prediction
name SRY_02
score 0.951
sequence taaaacaaaaca
<221> protein_bind
<222> 486..493
<223> matinspector prediction
name E2F_02
score 0.957
sequence ttttagcgc
<221> protein_bind
<222> complement(514..521)
<223> matinspector prediction
name MZF1_01
score 0.975
sequence tgagggga
<300>
<400> 31
tgagtgcagt gttacatgtc agttgggtta agtttggttaa tgtcattcaa atcttctatg      60
tcttgatttg cctgctaatt ctattatttc tggaaactaaa ttagtttgat ggttctatta      120
gttattgact gaggtgtgct aatctcccat tatgtggatt tatctatttc ttcagttgta      180
gataggacat tgatagatac ataagtacca ggacaaaagc agggagatct tttttccaaa      240
atcaggagaa aaaaatgaca tctggaaaac ctatagggaa aggcataaca gatggtaagg      300
atactttatc ttgagtagga gagccttcct gtggcaacgt ggagaaggga agaggtcgta      360
gaattgagga gtcagctcag ttagaagcag ggagttggga attccgttca tgtgatttag      420
catcagtgat atggcaaatg tgggactaag ggtagtgtatc agagggttaa aattgtgtgt      480
tttgtttttag cgctgctggg gcatcgcctt ggggtcccctc aaacagattc ccatgaatct      540
cttcat
<210> 32
<211> 23
<212> DNA
<213> -
<220>
<300>
<400> 32
gtaccagggga ctgtgaccat tgc
<210> 33
<211> 24
<212> DNA
<213> -
<220>
<300>
<400> 33
ctgtgaccat tgctcccaag agag
<210> 34
<211> 861
<212> DNA
<213> Homo Sapiens
<220>
<221> promoter
<222> 1..806
<221> transcription start site

```

<222> 807  
<221> protein\_bind  
<222> complement(60..70)  
<223> matinspector prediction  
    name NFY\_Q6  
    score 0.956  
    sequence ggaccaatcat  
<221> protein\_bind  
<222> 70..77  
<223> matinspector prediction  
    name MZF1\_01  
    score 0.962  
    sequence cctggggga  
<221> protein\_bind  
<222> 124..132  
<223> matinspector prediction  
    name CMYB\_01  
    score 0.994  
    sequence tgaccgttg  
<221> protein\_bind  
<222> complement(126..134)  
<223> matinspector prediction  
    name VMYB\_02  
    score 0.985  
    sequence tccaacggt  
<221> protein\_bind  
<222> 135..143  
<223> matinspector prediction  
    name STAT\_01  
    score 0.968  
    sequence ttcctggaa  
<221> protein\_bind  
<222> complement(135..143)  
<223> matinspector prediction  
    name STAT\_01  
    score 0.951  
    sequence ttccaggaa  
<221> protein\_bind  
<222> complement(252..259)  
<223> matinspector prediction  
    name MZF1\_01  
    score 0.956  
    sequence ttgggggga  
<221> protein\_bind  
<222> 357..368  
<223> matinspector prediction  
    name IK2\_01  
    score 0.965  
    sequence gaatgggatttc  
<221> protein\_bind  
<222> 384..391  
<223> matinspector prediction  
    name MZF1\_01  
    score 0.986  
    sequence agaggggga  
<221> protein\_bind  
<222> complement(410..421)  
<223> matinspector prediction  
    name SRY\_02  
    score 0.955  
    sequence gaaaacaaaaca  
<221> protein\_bind  
<222> 592..599

```

<223> matinspector prediction
      name MZF1_01
      score 0.960
      sequence gaagggga
<221> protein_bind
<222> 618..627
<223> matinspector prediction
      name MYOD_Q6
      score 0.981
      sequence agcatctgcc
<221> protein_bind
<222> 632..642
<223> matinspector prediction
      name DELTAEF1_01
      score 0.958
      sequence tcccaccttcc
<221> protein_bind
<222> complement(813..823)
<223> matinspector prediction
      name S8_01
      score 0.992
      sequence gaggcaattat
<221> protein_bind
<222> complement(824..831)
<223> matinspector prediction
      name MZF1_01
      score 0.986
      sequence agagggga
<300>
<400> 34
tactataggg cagcgtggt cgacggccgg gctgttctgg agcagagggc atgtcagtaa      60
tgattggtcc ctggggaagg tctggctggc tccagcacag tgaggcattt aggtatctct      120
cggtgaccgt tggattcctg gaagcagtag ctgttctgtt tggatctggt agggacaggg      180
ctcagagggc taggcacgag ggaaggctcag aggagaaggs aggsarggcc cagtgagarg      240
ggagcatgcc ttccccaac cctggcttsc ycttgymam agggcgkttt tgggmacttr      300
aaytcagggc ccaascagaa scacaggccc aktcntggct smaagcacia tagcctgaat      360
gggatttcag gttagncagg gtgagagggg aggcctctctg gcttagtttt gttttgtttt      420
ccaaatcaag gtaacttgct cccttctgct acgggccttg gtcttggctt gtcctcacc      480
agtcggaact ccctaccact ttcaggagag tgggttttagg cccgtggggc tgttctgttc      540
caagcagtggt gagaacatgg ctggtagagg ctctagctgt gtgcggggcc tgaaggggag      600
tgggttctcg cccaaagagc atctgcccac ttcccacctt cccttctccc accagaagct      660
tgcctgagct gtttggacaa aaatccaaac cccacttggc tactctggcc tggcttcagc      720
ttggaaccca atacctaggc ttacaggcca tcctgagcca ggggcctctg gaaattctct      780
tcctgatggg cctttagggt tgggcacaaa atataattgc ctctcccctc tcccattttc      840
tctcttggga gcaatggtca c
<210> 35
<211> 20
<212> DNA
<213> -
<220>
<300>
<400> 35
ctgggatgga aggcacggta
<210> 36
<211> 20
<212> DNA
<213> -
<220>
<300>
<400> 36
gagaccacac agctagacaa
<210> 37
<211> 555

```

<212> DNA  
<213> Homo Sapiens  
<220>  
<221> promoter  
<222> 1..500  
<221> transcription start site  
<222> 501  
<221> protein\_bind  
<222> 191..206  
<223> matinspector prediction  
    name ARNT\_01  
    score 0.964  
    sequence ggactcacgtgctgct  
<221> protein\_bind  
<222> 193..204  
<223> matinspector prediction  
    name NMYC\_01  
    score 0.965  
    sequence actcacgtgctg  
<221> protein\_bind  
<222> 193..204  
<223> matinspector prediction  
    name USF\_01  
    score 0.985  
    sequence actcacgtgctg  
<221> protein\_bind  
<222> complement(193..204)  
<223> matinspector prediction  
    name USF\_01  
    score 0.985  
    sequence cagcacgtgagt  
<221> protein\_bind  
<222> complement(193..204)  
<223> matinspector prediction  
    name NMYC\_01  
    score 0.956  
    sequence cagcacgtgagt  
<221> protein\_bind  
<222> complement(193..204)  
<223> matinspector prediction  
    name MYC\_MAX\_02  
    score 0.972  
    sequence cagcacgtgagt  
<221> protein\_bind  
<222> 195..202  
<223> matinspector prediction  
    name USF\_C  
    score 0.997  
    sequence tcacgtgc  
<221> protein\_bind  
<222> complement(195..202)  
<223> matinspector prediction  
    name USF\_C  
    score 0.991  
    sequence gcacgtga  
<221> protein\_bind  
<222> complement(210..217)  
<223> matinspector prediction  
    name MZF1\_01  
    score 0.968  
    sequence catgggga  
<221> protein\_bind  
<222> 397..410



```

<223> matinspector prediction
      name ELK1_02
      score 0.963
      sequence ctctccggaagcct
<221> protein_bind
<222> 400..409
<223> matinspector prediction
      name CETS1P54_01
      score 0.974
      sequence tccggaagcc
<221> protein_bind
<222> complement(460..470)
<223> matinspector prediction
      name AP1_Q4
      score 0.963
      sequence agtgactgaac
<221> protein_bind
<222> complement(460..470)
<223> matinspector prediction
      name AP1FJ_Q2
      score 0.961
      sequence agtgactgaac
<221> protein_bind
<222> 547..555
<223> matinspector prediction
      name PADS_C
      score 1.000
      sequence tgtggtctc
<300>
<400> 37
ctatagggca cgcktggtcg acggcccggg ctggtctggt ctgkgtgga gtcggggtga      60
aggacagcat ttgtkacatc tgggtctactg caccctccct ctgccgtgca cttggccttt      120
kawaagctca gcaccggtgc ccatcacagg gccggcagca cacacatccc attactcaga      180
aggaactgac ggactcacgt gctgctccgt ccccatgagc tcagtggacc tgtctatgta      240
gagcagtcag acagtgcctg ggatagagtg agagtccagc cagtaaatcc aagtgattgt      300
cattcctgtc tgcattagta actcccaacc tagatgtgaa aacttagttc tttctcatag      360
gttgctctgc ccatggtccc actgcagacc caggcactct ccggaagcct ggaaatcacc      420
cgtgtcttct gcctgtctcc gctcacatcc cacacttggt ttcagtcact gagttacaga      480
ttttgcctcc tcaatttctc ttgtcttagt cccatcctct gttcccctgg ccagtttgtc      540
tagctgtgtg gtctc                                     555
<210> 38
<211> 19
<212> DNA
<213> -
<220>
<300>
<400> 38
ggccatacac ttgagtgac                                     19
<210> 39
<211> 19
<212> DNA
<213> -
<220>
<300>
<400> 39
atatagacaa acgcacacc                                     19
<210> 40
<211> 1098
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 173..211

```

```
<223> Von Heijne matrix
      score 4.19999980926514
      seq MLAVSLTVPLLGA/MM
<221> polyA_signal
<222> 1063..1068
<221> polyA_site
<222> 1087..1098
<221> misc_feature
<222> 144..467
<223> homology
      id :AA057573
      est
<221> misc_feature
<222> 510..640
<223> homology
      id :AA057573
      est
<221> misc_feature
<222> 436..523
<223> homology
      id :AA057573
      est
<221> misc_feature
<222> 708..786
<223> homology
      id :AA057573
      est
<221> misc_feature
<222> 635..682
<223> homology
      id :AA057573
      est
<221> misc_feature
<222> 625..1084
<223> homology
      id :N57409
      est
<221> misc_feature
<222> 779..1084
<223> homology
      id :R71351
      est
<221> misc_feature
<222> 144..506
<223> homology
      id :H12619
      est
<221> misc_feature
<222> 90..467
<223> homology
      id :T03538
      est
<221> misc_feature
<222> 314..523
<223> homology
      id :T34150
      est
<221> misc_feature
<222> 567..687
<223> homology
      id :T34150
      est
<221> misc_feature
```

<222> 686..730  
 <223> homology  
     id :T34150  
     est  
 <221> misc\_feature  
 <222> 510..553  
 <223> homology  
     id :T34150  
     est  
 <221> misc\_feature  
 <222> 550..579  
 <223> homology  
     id :T34150  
     est  
 <221> misc\_feature  
 <222> 144..523  
 <223> homology  
     id :N32314  
     est  
 <221> misc\_feature  
 <222> 510..553  
 <223> homology  
     id :N32314  
     est  
 <221> misc\_feature  
 <222> 352..523  
 <223> homology  
     id :T77966  
     est  
 <221> misc\_feature  
 <222> 218..351  
 <223> homology  
     id :T77966  
     est  
 <221> misc\_feature  
 <222> 510..553  
 <223> homology  
     id :T77966  
     est  
 <221> misc\_feature  
 <222> 550..917  
 <223> homology  
     id :AA464128  
     est

<300>

<400> 40

agtgagggtgg tttctgcggg tgaggctggc gcccgtacca tgagcgaggc ggacgggctg	60
cgacagcgcc ggcccctgcg gcccgcgaagt cgtcacagac gatgatggcc aggccccgga	120
ggctaaggac ggcagctcct ttagcggcag agttttccga gtgaccttct tg atg ctg	178
	Met Leu
gct gtt tct ctc acc gtt ccc ctg ctt gga gcc atg atg ctg ctg gaa	226
Ala Val Ser Leu Thr Val Pro Leu Leu Gly Ala Met Met Leu Leu Glu	
-10 -5 1 5	
tct cct ata gat cca cag cct ctc agc ttc aaa gaa ccc ccg ctc ttg	274
Ser Pro Ile Asp Pro Gln Pro Leu Ser Phe Lys Glu Pro Pro Leu Leu	
10 15 20	
ctt ggt gtt ctg cat cca aat acg aag ctg cga cag gca gaa agg ctg	322
Leu Gly Val Leu His Pro Asn Thr Lys Leu Arg Gln Ala Glu Arg Leu	
25 30 35	
ttt gaa aat caa ctt gtt gga ccg gag tcc ata gca cat att ggg gat	370
Phe Glu Asn Gln Leu Val Gly Pro Glu Ser Ile Ala His Ile Gly Asp	
40 45 50	
gtg atg ttt act ggg aca gca gat ggc cgg gtc gta aaa ctt gaa aat	418

18

Val	Met	Phe	Thr	Gly	Thr	Ala	Asp	Gly	Arg	Val	Val	Lys	Leu	Glu	Asn	
55						60				65						
ggt	gaa	ata	gag	acc	att	gcc	cgg	ttt	ggt	tgc	ggc	cct	tgc	aaa	acc	466
Gly	Glu	Ile	Glu	Thr	Ile	Ala	Arg	Phe	Gly	Ser	Gly	Pro	Cys	Lys	Thr	
70					75				80					85		
cga	ggt	gat	gag	cct	gtg	tgt	ggg	aga	ccc	ctg	ggg	atc	cgt	ggc	agg	514
Arg	Gly	Asp	Glu	Pro	Val	Cys	Gly	Arg	Pro	Leu	Gly	Ile	Arg	Gly	Arg	
				90				95						100		
gcc	caa	tgg	gac	tct	ctt	tgt	ggc	cga	tgc	ata	caa	agg	gac	tat	ttg	562
Ala	Gln	Trp	Asp	Ser	Leu	Cys	Gly	Arg	Cys	Ile	Gln	Arg	Asp	Tyr	Leu	
			105				110						115			
aag	taa	atccctg	gaaacgtgaa	gtgaaactgc	tgctgtcctc	cgagacaccc										615
Lys																
attgagggga	agaacatgtc	ctttgtgaat	gatcttacag	tcactcagga	tgggaggaag											675
atattattca	ccgattctag	cagcaaatgg	caaagacgag	actacctgct	tctgggtgatg											735
gagggcacag	atgacgggag	cctgctggag	tatgatactg	tgaccagggg	agtaaaagtt											795
ttattggacc	agctgcgggt	cccgaatgga	gtccagctgt	ctcctgcaga	agactttgtc											855
ctgggtggcag	aaacaacccat	ggccaggata	cgaagagtct	acgtttctgg	cctgatgaag											915
ggcggggctg	atctgtttgt	ggagaacatg	cctggatttc	cagacaacat	ccggcccagc											975
agctctgggg	gggtactgggt	gggcatgtcg	accatccgcc	ctaaccctgg	gttttccatg											1035
ctggatttct	tatctgagag	accctggatt	aaaaggatga	tttttaangg	taaaaaaaaa											1095
aaa																1098

<210> 41  
 <211> 855  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 267..371  
 <223> Von Heijne matrix  
       score 5.90000009536743  
       seq LCGLLHLWLKVFS/LK  
 <221> polyA\_signal  
 <222> 817..822  
 <221> polyA\_site  
 <222> 842..855  
 <221> misc\_feature  
 <222> 608..811  
 <223> homology  
       id :M85769  
       est  
 <300>  
 <400> 41

acaatcagtt	tgccaatacc	tcagaaacaa	atacctcgga	caaattcttc	tctaaagacc		60
tcagtcagat	actagtcaat	atcaaatcat	gtagatggcg	gcatttttagg	cctcggacac		120
catccctaca	tgacagtgc	aatgatgaac	tctcctgtag	aaaattatat	aggagtataa		180
accgaacagg	aacagcacia	cctgggaccc	agacatgcag	tacctctacg	caaagtaaaa		240
gtagcagtg	ttcagcacac	tttgggt	atg ttg	act gtt	aat gat	gta cgt	ttc
			Met	Leu	Thr	Val	Asn
			-35				-30
tat aga	aat gtc	agg tcc	aac cat	ttc cca	ttt gtt	cga cta	tgt ggt
Tyr Arg	Asn Val	Arg Ser	Asn His	Phe Pro	Phe Val	Arg Leu	Cys Gly
-25			-20			-15	
ctg tta	cat tta	tgg ctt	aaa gtc	ttt tct	ctt aaa	cag tta	aaa aaa
Leu Leu	His Leu	Trp Leu	Lys Val	Phe Ser	Leu Lys	Gln Leu	Lys Lys
-10		-5		1		5	
aaa tct	tgg tct	aag tat	tta ttt	gaa tcc	tgt tgc	tat agg	agt ttg
Lys Ser	Trp Ser	Lys Tyr	Leu Phe	Glu Ser	Cys Cys	Tyr Arg	Ser Leu
	10		15		20		
tat gtg	tgt gtc	ttc att	taa	acatacc	tgcat	acaaa	gatgggttat
Tyr Val	Cys Val	Phe Ile					
25							
ttctatttaa	tatgtgacat	ttgtttcctg	gatatagtcc	gtgaaccaca	agattttatca		545

```

tatttttcaa taatatgaga agaaaatggg          ccgtaaattg ttaaccattt tatgttcaga
605
tattttctcta gtttttacct agtttgcttt aacatagaga ccagcaagtg aatatatatg      665
cataacctta tatgttgaca caataattca gaataatttg ttaaagataa actaatTTTT      725
cagagaagaa catttaaagg gttaatatTT ttgaaacgtt ttcagataat atctatttga      785
ttattgtggc ttctatttga aatgtgtcta aaataaaatg ctgtttattt aaaatgaaaa      845
aaaaaaaaaa                                     855
<210> 42
<211> 1176
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 174..266
<223> Von Heijne matrix
      score 3.5
      seq WSPLSTRSGGTHA/CS
<221> polyA_signal
<222> 1144..1149
<221> polyA_site
<222> 1165..1176
<221> misc_feature
<222> 886..1134
<223> homology
      id :AA595193
      est
<221> misc_feature
<222> 756..894
<223> homology
      id :AA595193
      est
<221> misc_feature
<222> 655..755
<223> homology
      id :AA595193
      est
<221> misc_feature
<222> 167..367
<223> homology
      id :W81213
      est
<221> misc_feature
<222> 66..172
<223> homology
      id :W81213
      est
<221> misc_feature
<222> 429..508
<223> homology
      id :W81213
      est
<221> misc_feature
<222> 756..894
<223> homology
      id :AA150887
      est
<221> misc_feature
<222> 536..643
<223> homology
      id :AA150887
      est
<221> misc_feature
<222> 655..755

```

```

<223> homology
      id :AA150887
      est
<221> misc_feature
<222> 429..643
<223> homology
      id :AA493644
      est
<221> misc_feature
<222> 655..755
<223> homology
      id :AA493644
      est
<221> misc_feature
<222> 429..643
<223> homology
      id :AA493494
      est
<221> misc_feature
<222> 655..755
<223> homology
      id :AA493494
      est
<221> misc_feature
<222> 500..643
<223> homology
      id :AA179182
      est
<221> misc_feature
<222> 655..755
<223> homology
      id :AA179182
      est
<221> misc_feature
<222> 756..847
<223> homology
      id :AA179182
      est
<221> misc_feature
<222> 3..338
<223> homology
      id :HUM524F05B
      est
<221> misc_feature
<222> 334..374
<223> homology
      id :HUM524F05B
      est
<221> misc_feature
<222> 886..1134
<223> homology
      id :AA398156
      est
<221> misc_feature
<222> 756..894
<223> homology
      id :AA398156
      est
<300>
<400> 42
aaaaacaata ggacggaaac gccgaggaac ccggctgagg cggcagagca tcctggccag      60
aacaagccaa ggagccaaga cgagaggac acacggacaa acaacagaca gaagacgtac      120
tggccgctgg actccgctgc ctccccatc tccccgcat ctgcgcccg agg atg      176

```

21

Met

```

agc cca gcc ttc agg gcc atg gat gtg gag ccc cgc gcc aaa ggc tcc 224
Ser Pro Ala Phe Arg Ala Met Asp Val Glu Pro Arg Ala Lys Gly Ser
-30 -25 -20 -15
ttc tgg agc cct ttg tcc acc agg tgc ggg ggc act cat gcg tgc tcc 272
Phe Trp Ser Pro Leu Ser Thr Arg Ser Gly Gly Thr His Ala Cys Ser
-10 -5 1
gct tca atg aga caa ccc tgg gca agc ccc tgg tcc caa ggg aac atc 320
Ala Ser Met Arg Gln Pro Trp Ala Ser Pro Trp Ser Gln Gly Asn Ile
5 10 15
agt tct acg aga ccc tcc ctg ctg aga tgc gca aat tct ctc ccc agt 368
Ser Ser Thr Arg Pro Ser Leu Leu Arg Cys Ala Asn Ser Leu Pro Ser
20 25 30
aca aag gac aaa gcc aaa ggc ccc ttg tta gct ggc cat ccc tgc ccc 416
Thr Lys Asp Lys Ala Lys Gly Pro Leu Leu Ala Gly His Pro Cys Pro
35 40 45 50
att ttt tcc cct ggt cct ttc ccc tgt ggc cac agg gaa gtg tgg cct 464
Ile Phe Ser Pro Gly Pro Phe Pro Cys Gly His Arg Glu Val Trp Pro
55 60 65
gaa tac ccc acc ccg gct cct ctg cac cca gag ctg ggg gcc acc tca 512
Glu Tyr Pro Thr Pro Ala Pro Leu His Pro Glu Leu Gly Ala Thr Ser
70 75 80
gaa gtg tca tct ctc tct gag cac gsa ttc ccc tgc agc agt cga gga 560
Glu Val Ser Ser Leu Ser Glu His Xaa Phe Pro Cys Ser Ser Arg Gly
85 90 95
ctg agc aga ttg agt gat gct ggg gca gan adg cct gag ang aaa ggt 608
Leu Ser Arg Leu Ser Asp Ala Gly Ala Xaa Xaa Pro Glu Xaa Lys Gly
100 105 110
gtt cag cca gtc gtt tgt aag gcg ctc gkc ggm act gct gaa acg ccc 656
Val Gln Pro Val Val Cys Lys Ala Leu Xaa Gly Thr Ala Glu Thr Pro
115 120 125 130
cca ccc tgacagcccc atcctcaaag actgtcttaa ttactcatgg caggttctag 712
Pro Pro
agacttaagg ggaaaagctg ctttcaaggc caccacatgt ctggtgctcc ccmaccagst 772
statctgcct wgtgttcatt ttgytatttt gtgasgtgag acagcaaaga ccaataaaaa 832
catattttat aagaacaaaa ggcytgggtg cctacccgkg tgggggcacw gtgggaagcc 892
ttctgmtagg gtgtcttgtg ctgtrtgggt tgttttgttt gccccyttat tttgctttgc 952
ttaccagtc ttcccytamt yttggatgst tyttaaccct caggcaaacc tgtgttcccc 1012
ctgtattcag gstygtcttt aaagcaagcc atgaggctgt tggagtttct gtttagggca 1072
ttaaaaattc ccgcaaacta taaagagcaa tgttttcagt ytttttaggat tagaagaatt 1132
acataaaaat taataaacat tttcaatgat ggaaaaaaaa aaaa 1176
<210> 43
<211> 648
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 460..555
<223> Von Heijne matrix
score 4
seq FSFMLLGMGCLP/GF
<221> polyA_signal
<222> 614..619
<221> polyA_site
<222> 635..648
<300>
<400> 43
aattctggcc cagcttcttc ccagctcta tcctgcttcc ctccatctcc tataggattc 60
tccttagagt tctccctcca ttagtagttg tcttagggtc tgtttctggg gagccctgcc 120
taagactcat gctacaagaa gttaaataag ttcccggaag tcacacagct agcctctcat 180
cccttttcta ctgagaggaa gtggaatgca ctccgacaag gataagggttt tattgtgagc 240
tggccttgga attaaaccac caccaacaca cttttggatt atcagaaggt ggaaggagtg 300
caaatgccag ttacggtgat gcgttcaaca tccttatttc cagtctttat gacgcctttc 360

```

22

```

ctgaatcaca ggtgcattgg ggtgcttcct      cctccccagg actccacccc aactttgtga
420
acacaaccca cttagaggag ttatctcagc acattatga atg ttg ggg acc acg      474
                                     Met Leu Gly Thr Thr
                                     -30
ggc ctc ggg aca cag ggt cct tcc cag cag gct ctg ggc ttt ttc tcc      522
Gly Leu Gly Thr Gln Gly Pro Ser Gln Gln Ala Leu Gly Phe Phe Ser
      -25      -20      -15
ttt atg tta ctt gga atg ggc ggg tgc ctg cct gga ttc ctg cta cag      570
Phe Met Leu Leu Gly Met Gly Gly Cys Leu Pro Gly Phe Leu Leu Gln
      -10      -5      1      5
cct ccc aat cga tct cct act ttg cct gca tcc acc ttt gcc cat      615
Pro Pro Asn Arg Ser Pro Thr Leu Pro Ala Ser Thr Phe Ala His
      10      15      20
taaagtcaat tctccaccca taaaaaaaaa aaa      648
<210> 44
<211> 1251
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 79..369
<223> Von Heijne matrix
      score 4
      seq RLPLVVSFIASSS/AN
<221> polyA_signal
<222> 1217..1222
<221> polyA_site
<222> 1240..1251
<221> misc_feature
<222> 2..423
<223> homology
      id :AA056667
      est
<221> misc_feature
<222> 463..520
<223> homology
      id :AA056667
      est
<221> misc_feature
<222> 418..467
<223> homology
      id :AA056667
      est
<221> misc_feature
<222> 159..636
<223> homology
      id :AA044187
      est
<221> misc_feature
<222> 629..684
<223> homology
      id :AA044187
      est
<221> misc_feature
<222> 5..453
<223> homology
      id :AA131958
      est
<221> misc_feature
<222> 446..494
<223> homology
      id :AA131958

```



```
      est
<221> misc_feature
<222> 14..343
<223> homology
      id :W95957
      est
<221> misc_feature
<222> 323..467
<223> homology
      id :W95957
      est
<221> misc_feature
<222> 463..494
<223> homology
      id :W95957
      est
<221> misc_feature
<222> 14..475
<223> homology
      id :W95790
      est
<221> misc_feature
<222> 410..876
<223> homology
      id :AA461134
      est
<221> misc_feature
<222> 974..1195
<223> homology
      id :AA595195
      est
<221> misc_feature
<222> 769..982
<223> homology
      id :AA595195
      est
<221> misc_feature
<222> 1208..1237
<223> homology
      id :AA595195
      est
<221> misc_feature
<222> 223..522
<223> homology
      id :AA041216
      est
<221> misc_feature
<222> 518..636
<223> homology
      id :AA041216
      est
<221> misc_feature
<222> 774..1127
<223> homology
      id :N94607
      est
<221> misc_feature
<222> 690..765
<223> homology
      id :N94607
      est
<221> misc_feature
<222> 833..1195
```

```

<223> homology
      id :AA076410
      est
<300>
<400> 44
aaagtgcacag cggagagaaac caggsagccc agaaacccca ggcgtggaga ttgatcctgc      60
gagagaaggg gggttcac atg gcg gat gac cta aag cga ttc ttg tat aaa      111
              Met Ala Asp Asp Leu Lys Arg Phe Leu Tyr Lys
              -95                      -90
aag tta cca agt gtt gaa ggg ctc cat gcc att gtt gtg tca gat aga      159
Lys Leu Pro Ser Val Glu Gly Leu His Ala Ile Val Val Ser Asp Arg
      -85                      -80                      -75
gat gga gta cct gtt att aaa gtg gca aat gac aat gct cca gag cat      207
Asp Gly Val Pro Val Ile Lys Val Ala Asn Asp Asn Ala Pro Glu His
      -70                      -65                      -60                      -55
gct ttg cga cct ggt ttc tta tcc act ttt gcc ctt gca aca gac caa      255
Ala Leu Arg Pro Gly Phe Leu Ser Thr Phe Ala Leu Ala Thr Asp Gln
      -50                      -45                      -40
gga agc aaa ctt gga ctt tcc aaa aat aaa agt atc atc tgt tac tat      303
Gly Ser Lys Leu Gly Leu Ser Lys Asn Lys Ser Ile Ile Cys Tyr Tyr
      -35                      -30                      -25
aac acc tac cag gtg gtt caa ttt aat cgt tta cct ttg gtg gtg agt      351
Asn Thr Tyr Gln Val Val Gln Phe Asn Arg Leu Pro Leu Val Val Ser
      -20                      -15                      -10
ttc ata gcc agc agc agt gcc aat aca gga cta att gtc agc cta gaa      399
Phe Ile Ala Ser Ser Ser Ala Asn Thr Gly Leu Ile Val Ser Leu Glu
      -5                      1                      5                      10
aag gag ctt gct cca ttg ttt gaa gaa ctg aga caa gtt gtg gaa att      447
Lys Glu Leu Ala Pro Leu Phe Glu Glu Leu Arg Gln Val Val Glu Ile
      15                      20                      25
tct taatctgaca gtgggtttcag tgtgtacctt atcttccatta taacaacaca      500
Ser
atatcaatcc agcaatcttt agactacaat aatgcttttta tccatgtgct caagaaaggg      560
cccccttttc caacttatac taaagaacta gcatatagat gtaatttata gatagatcag      620
ttgctatatt ttctggtgta aggtctttct tatttagtga gatctaggga taccacagaa      680
atggttcagt ctatcacagc tcccatggag ttagtctggt caccagatat ggatgagaga      740
ttctattcag tggattagaa tcaaactggt acattgatcc acttgagccg ttaagtgtg      800
ccaattgtac aatatgccca ggcttcgaga ataaagccaa ctttttattg tgaataataa      860
taaggacata tttttcttca gattatgttc tatttctttg cattgagtga ggtacataaa      920
atggcttggg aaaagtaata aaatcagtac aatcactaac tttcctttgt acatattatt      980
ttgcagtata gatgaatatt actaatcagt ttgattattc tcagagggtg ctgctcttta      1040
atgaaaatga aaattatagc taatgttttt tcttcataaa atttaaatac ctgctttctg taaccaatca      1100
gtgttttaat gtttgtgtgt tcttcataaa atttaaatac aattcgttat tctgtttcca      1160
atgttagtat gtatgtaaac atgatagtac agccattttt ttcatatgtg agtaaaaata      1220
aaatagtatt tttaaaagta aaaaaaaaaa a
<210> 45
<211> 1524
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 160..231
<223> Von Heijne matrix
      score 5.69999980926514
      seq ILGLLGLLGLTLVA/ML
<221> polyA_signal
<222> 1510..1515
<221> polyA_site
<222> 1506..1519
<221> misc_feature
<222> 1048..1504
<223> homology
      id :AA552647

```

```

      est
<221> misc_feature
<222> 597..846
<223> homology
      id :AA345449
      est
<221> misc_feature
<222> 39..93
<223> homology
      id :AA345449
      est
<221> misc_feature
<222> 113..149
<223> homology
      id :AA345449
      est
<221> misc_feature
<222> 98..400
<223> homology
      id :T86266
      est
<221> misc_feature
<222> 1210..1489
<223> homology
      id :T86158
      est
<221> misc_feature
<222> 954..983
<223> homology
      id :AA116709
      est
<300>
<400> 45
agctgcttgt ggccacccac agacacttgt aaggaggaga gaagtcagcc tggcagagag      60
actctgaaat gassgattag aggtgttcaa ggragcaaag agcttcagcc tgaagacaag      120
ggagcagtcct ctgaagacgc ttctactgag aggtctgcc atg gcc tct ctt ggc      174
                                Met Ala Ser Leu Gly
                                -20
ctc caa ctt gtg ggc tac atc cta ggc ctt ctg ggg ctt ttg ggc aca      222
Leu Gln Leu Val Gly Tyr Ile Leu Gly Leu Leu Gly Leu Leu Gly Thr
                                -10
ctg gtt gcc atg ctg ctc ccc agc tgg aaa aca agt tct tat gtc ggt      270
Leu Val Ala Met Leu Leu Pro Ser Trp Lys Thr Ser Ser Tyr Val Gly
                                1
gcc agc att gtg aca gca gtt ggc ttc tcc aag ggc ctc tgg atg gaa      318
Ala Ser Ile Val Thr Ala Val Gly Phe Ser Lys Gly Leu Trp Met Glu
                                15
tgt gcc aca cac agc aca ggc atc acc cag tgt gac atc tat agc acc      366
Cys Ala Thr His Ser Thr Gly Ile Thr Gln Cys Asp Ile Tyr Ser Thr
                                30
ctt ctg ggc ctg ccc gct gac atc cak gct gcc cag gcc atg atg gtg      414
Leu Leu Gly Leu Pro Ala Asp Ile Xaa Ala Ala Gln Ala Met Met Val
                                50
aca tcc agt gca atc tcc tcc ctg gcc tgc att atc tct gtg gtg ggc      462
Thr Ser Ser Ala Ile Ser Ser Leu Ala Cys Ile Ile Ser Val Val Gly
                                65
atg ara tgc aca gtc ttc tgc cag gaa tcc cga gcc aaa gac aga gtg      510
Met Xaa Cys Thr Val Phe Cys Gln Glu Ser Arg Ala Lys Asp Arg Val
                                80
gcg gta gca ggt gga gtc ttt ttc atc ctt gga ggc ctc ctg gga ttc      558
Ala Val Ala Gly Gly Val Phe Phe Ile Leu Gly Gly Leu Leu Gly Phe
                                95
att cct gtt gcc tgg aat ctt cat ggg atc cta cgg gac ttc tac tca      606
                                105

```

26

Ile	Pro	Val	Ala	Trp	Asn	Leu	His	Gly		Ile	Leu	Arg	Asp	Phe	Tyr	Ser	
110					115					120					125		
cca	ctg	gtg	cct	gac	agc	atg	aaa	ttt	gag	att	gga	gag	gct	ctt	tac		654
Pro	Leu	Val	Pro	Asp	Ser	Met	Lys	Phe	Glu	Ile	Gly	Glu	Ala	Leu	Tyr		
				130					135					140			
ttg	ggc	att	att	tct	tcc	ctg	ttc	tcc	ctg	ata	gct	gga	atc	atc	ctc		702
Leu	Gly	Ile	Ile	Ser	Ser	Leu	Phe	Ser	Leu	Ile	Ala	Gly	Ile	Ile	Leu		
				145					150					155			
tgc	ttt	tcc	tgc	tca	tcc	cag	aga	aat	cgc	tcc	aac	tac	tac	gat	gcc		750
Cys	Phe	Ser	Cys	Ser	Ser	Gln	Arg	Asn	Arg	Ser	Asn	Tyr	Tyr	Asp	Ala		
				160					165					170			
tac	caa	gcc	caa	cct	ctt	gcc	aca	agg	agc	tct	cca	agg	cct	ggt	caa		798
Tyr	Gln	Ala	Gln	Pro	Leu	Ala	Thr	Arg	Ser	Ser	Pro	Arg	Pro	Gly	Gln		
				175					180					185			
cct	ccc	aaa	gtc	aag	agt	gag	ttc	aat	tcc	tac	agc	ctg	aca	ggg	tat		846
Pro	Pro	Lys	Val	Lys	Ser	Glu	Phe	Asn	Ser	Tyr	Ser	Leu	Thr	Gly	Tyr		
190					195				200					205			
gtg	tgaagaacca	ggggccagag	ctgggggggtg	gctgggtctg	tgaaaaacag												899
Val																	
tggacagcac	cccgaggggcc	acaggtgagg	gacactacca	ctggatcgtg	tcagaaggtg												959
ctgctgaggg	tagactgact	ttggccattg	gattgagcaa	aggcagaaat	gggggctagt												1019
gtaacagcat	gcaggttgaa	ttgccaagga	tgctcgccat	gccagccttt	ctgttttctt												1079
caccttgctg	ctcccctgcc	ctaagtcccc	aaccctcaac	ttgaaacccc	attcccttaa												1139
gccaggamtc	agaggatccc	tytgccctck	ggtttamctg	ggactccatc	cccaaaccce												1199
ctaatacat	cccactgact	gaccctctgt	gatcaaagac	cctccctctg	gctgaggttg												1259
gstyttagct	cattgctggg	gatgggaagg	agaagcagtg	gctttystgg	gcattgctyt												1319
aacctamtty	tcaagcttcc	ctccaaagaa	amtgattggc	cctggaaacct	ccatcccact												1379
yttgttatga	ctccacagtg	tccagamtaa	tttgtgcatg	aactgaaata	aaaccatcct												1439
acgggtatyca	gggaacagaa	agcaggatgc	aggatgggag	gacaggaagg	cagcctggga												1499
catttaaaaa	aataaaaaaa	aaaaa															1524

<210> 46  
 <211> 610  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 106..201  
 <223> Von Heijne matrix  
       score 8.80000019073486  
       seq VPMLLLIVGGSFG/LR  
 <221> polyA\_signal  
 <222> 577..582  
 <221> polyA\_site  
 <222> 598..610  
 <221> misc\_feature  
 <222> 68..167  
 <223> homology  
       id :AA531561  
       est  
 <221> misc\_feature  
 <222> 166..262  
 <223> homology  
       id :AA531561  
       est  
 <221> misc\_feature  
 <222> 423..520  
 <223> homology  
       id :AA531561  
       est  
 <221> misc\_feature  
 <222> 518..564  
 <223> homology  
       id :AA531561

```
    est
<221> misc_feature
<222> 276..313
<223> homology
      id :AA531561
    est
<221> misc_feature
<222> 41..70
<223> homology
      id :AA531561
    est
<221> misc_feature
<222> 41..262
<223> homology
      id :AA535454
    est
<221> misc_feature
<222> 423..520
<223> homology
      id :AA535454
    est
<221> misc_feature
<222> 518..564
<223> homology
      id :AA535454
    est
<221> misc_feature
<222> 276..313
<223> homology
      id :AA535454
    est
<221> misc_feature
<222> 46..262
<223> homology
      id :H81225
    est
<221> misc_feature
<222> 2..39
<223> homology
      id :H81225
    est
<221> misc_feature
<222> 455..493
<223> homology
      id :H81225
    est
<221> misc_feature
<222> 276..313
<223> homology
      id :H81225
    est
<221> misc_feature
<222> 423..458
<223> homology
      id :H81225
    est
<221> misc_feature
<222> 53..262
<223> homology
      id :AA044291
    est
<221> misc_feature
<222> 423..520
```

```

<223> homology
      id :AA044291
      est
<221> misc_feature
<222> 518..564
<223> homology
      id :AA044291
      est
<221> misc_feature
<222> 276..313
<223> homology
      id :AA044291
      est
<221> misc_feature
<222> 125..262
<223> homology
      id :W47031
      est
<300>
<400> 46
aaagtgaagt aaggacgtac tcgtcttggg gagagcgtga stgctgagat ttgggagttc      60
gcgctaggcc cgcttgaggt tctgagccga tggaagagtt cactc atg ttt gca ccc      117
                                         Met Phe Ala Pro
                                         -30
gcg gtg atg cgt gct ttt cgc aag aac aag act ctc ggc tat gga gtc      165
Ala Val Met Arg Ala Phe Arg Lys Asn Lys Thr Leu Gly Tyr Gly Val
      -25                               -20                               -15
ccc atg ttg ttg ctg att gtt gga ggt tct ttt ggt ctt cgt gag ttt      213
Pro Met Leu Leu Leu Ile Val Gly Gly Ser Phe Gly Leu Arg Glu Phe
      -10                               -5                               1
tct caa atc cga tat gat gct gtg aag agt aaa atg gat cct gag ctt      261
Ser Gln Ile Arg Tyr Asp Ala Val Lys Ser Lys Met Asp Pro Glu Leu
      5                               10                               15                               20
gaa aaa aaa ccg aaa gag aat aaa ata tct tta gag tcg gaa tat gag      309
Glu Lys Lys Pro Lys Glu Asn Lys Ile Ser Leu Glu Ser Glu Tyr Glu
      25                               30                               35
gga agt atc tgt tgaagggtta ctatctttcc ttggcccttc tcccttggtg      361
Gly Ser Ile Cys
      40
ggactcaatc tccagactat ctccccagag aatcttgtca aggcttggct ttaagctttg      421
ttgggaaaaa caaagactcc aagtttgatg actggaagaa tattcgagga cccaggcctt      481
gggaagatcc tgacctcctc caaggaagaa atccaggaaa gccttaagac taagacaact      541
tgactctgct gattcttttt tccttttttt ttttaataaa aaatactatt aactggaaaa      601
aaaaaaaaaa
<210> 47
<211> 1370
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 359..466
<223> Von Heijne matrix
      score 7.80000019073486
      seq LTFLFLHLPSTS/LF
<221> polyA_signal
<222> 1334..1339
<221> polyA_site
<222> 1357..1370
<221> misc_feature
<222> 113..420
<223> homology
      id :R79290
      est

```

<221> misc\_feature  
<222> 406..482  
<223> homology  
    id :R79290  
    est  
<221> misc\_feature  
<222> 199..420  
<223> homology  
    id :R81173  
    est  
<221> misc\_feature  
<222> 406..514  
<223> homology  
    id :R81173  
    est  
<221> misc\_feature  
<222> 2..269  
<223> homology  
    id :R81277  
    est  
<221> misc\_feature  
<222> 406..646  
<223> homology  
    id :R74123  
    est  
<221> misc\_feature  
<222> 647..682  
<223> homology  
    id :R74123  
    est  
<221> misc\_feature  
<222> 439..646  
<223> homology  
    id :AA450228  
    est  
<221> misc\_feature  
<222> 647..739  
<223> homology  
    id :AA450228  
    est  
<221> misc\_feature  
<222> 406..646  
<223> homology  
    id :R02473  
    est  
<221> misc\_feature  
<222> 406..604  
<223> homology  
    id :T71107  
    est  
<221> misc\_feature  
<222> 71..282  
<223> homology  
    id :C06030  
    est  
<221> misc\_feature  
<222> 319..365  
<223> homology  
    id :C06030  
    est  
<221> misc\_feature  
<222> 2..57  
<223> homology

```

id :C06030
est
<221> misc_feature
<222> 1173..1277
<223> homology
id :N54909
est
<221> misc_feature
<222> 1080..1177
<223> homology
id :N54909
est
<221> misc_feature
<222> 1273..1356
<223> homology
id :N54909
est
<221> misc_feature
<222> 1173..1277
<223> homology
id :AA196824
est
<221> misc_feature
<222> 1080..1177
<223> homology
id :AA196824
est
<221> misc_feature
<222> 1273..1356
<223> homology
id :AA196824
est
<300>
<400> 47
acaaggcaga gcttctgaat ttcaggcctt cattccagag ccctcttctg gccaggcctt      60
ccttttgctgg aggaaggtac acaggggtgaa gctgawgstg tacttggggg atctccttgg      120
cctgttccac caagtgagag aaggtactta ctcttgtacc tcctgttcag ccagggtgcat      180
taacagacct ccctacagct gtaggaacta ctgtcccaga gctgaggcaa ggggatttct      240
caggtcattt ggagaacaag tgcttttagta gtagttttaa gtagtaactg ctactgtatt      300
tagtggggtg gaattcagaa gaaatttgaa gaccagatca tgggtggtct gcatgtga      358
atg aac ach ttt gag cca gac agc ctg gct gtc att gct ttc ttc ctc      406
Met Asn Thr Phe Glu Pro Asp Ser Leu Ala Val Ile Ala Phe Phe Leu
-35 -30 -25
ccc att tgg acc ttc tct gcc ctt aca ttt ttg ttt ctc cat cta cca      454
Pro Ile Trp Thr Phe Ser Ala Leu Thr Phe Leu Phe Leu His Leu Pro
-20 -15 -10 -5
cca tcc acc agt cta ttt att aac tta gca aga gga caa ata aag ggc      502
Pro Ser Thr Ser Leu Phe Ile Asn Leu Ala Arg Gly Gln Ile Lys Gly
1 5 10
cct ctt ggc ttg att ttg ctt ctt tct ttc tgt gga gga tat act aag      550
Pro Leu Gly Leu Ile Leu Leu Leu Ser Phe Cys Gly Gly Tyr Thr Lys
15 20 25
tgc gac ttt gcc cta tcc tat ttg gaa atc cct aac aga att gag ttt      598
Cys Asp Phe Ala Leu Ser Tyr Leu Glu Ile Pro Asn Arg Ile Glu Phe
30 35 40
tct att atg gat cca aaa aga aaa aca aaa tgc taatgaagcc atcasgtcaa      651
Ser Ile Met Asp Pro Lys Arg Lys Thr Lys Cys
45 50 55
gggtcacatg ccaataaaca ataaattttc cagaagaaat gaaatccaac tagacaaata      711
aagtagagct tatgaaatgg ttcagtaagg atgagcttgt tgttttttgt tttgttttgt      771
tttgtttttt taaagacgga gtctcgctct gtcactcagg ctggagtgca gtggtatgat      831
cttggctcac tgtaacctcc gcctcccggg ttcaagccat tctcctgcct cagtctcctg      891
agtagctggg attgcagggt cgtgccacca tgccctggcta attttttgtg ttttggtaga      951

```



31

```

gacaggggttt caccacgttg gtcgggctgg          tctcgggctc ctgacctctt gatccgcctg
1011
ccttggcctc ccaaagtgat gggattacag atgtgagcca ccgtgcctag ccaaggatga 1071
gattttttaa gtatgttcca gttctgtgtc atggttggaa gacagagtag gaaggatatg 1131
gaaaagggtca tggggaagca gaggtgattc atggctctgt ggaatttgag gtgaatgggtt 1191
ccttattgtc taggcacttt gtgaagaata tgagtcagtt attgccagcc ttggaattta 1251
cttctctagc ttacaatgga cctttttgaa ctgggaaaca ccttgtctgc attcacttta 1311
aaatgtcaaa actaattttt ataataaatg tttattttca catygaaaaa aaaaaaaaaa 1370
<210> 48
<211> 791
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 191..286
<223> Von Heijne matrix
      score 8.80000019073486
      seq VPMLLLIVGGSFG/LR
<221> polyA_signal
<222> 755..760
<221> polyA_site
<222> 780..791
<221> misc_feature
<222> 361..531
<223> homology
      id :W73841
      est
<221> misc_feature
<222> 210..347
<223> homology
      id :W73841
      est
<221> misc_feature
<222> 548..637
<223> homology
      id :W73841
      est
<221> misc_feature
<222> 181..210
<223> homology
      id :W73841
      est
<221> misc_feature
<222> 361..530
<223> homology
      id :HSU74317
      est
<221> misc_feature
<222> 238..347
<223> homology
      id :HSU74317
      est
<221> misc_feature
<222> 568..637
<223> homology
      id :HSU74317
      est
<221> misc_feature
<222> 698..733
<223> homology
      id :HSU74317
      est
<221> misc_feature

```

```

<222> 361..531
<223> homology
      id :W47031
      est
<221> misc_feature
<222> 210..347
<223> homology
      id :W47031
      est
<221> misc_feature
<222> 148..210
<223> homology
      id :W47031
      est
<221> misc_feature
<222> 548..600
<223> homology
      id :W47031
      est
<221> misc_feature
<222> 129..347
<223> homology
      id :AA044118
      est
<221> misc_feature
<222> 437..531
<223> homology
      id :AA044118
      est
<221> misc_feature
<222> 361..454
<223> homology
      id :AA044118
      est
<221> misc_feature
<222> 176..347
<223> homology
      id :AA293342
      est
<221> misc_feature
<222> 361..531
<223> homology
      id :AA293342
      est
<221> misc_feature
<222> 548..605
<223> homology
      id :AA293342
      est
<221> misc_feature
<222> 361..531
<223> homology
      id :AA531561
      est
<221> misc_feature
<222> 153..252
<223> homology
      id :AA531561
      est
<300>
<400> 48
aacaagtatg ttacgatggc tcgattgctt ttgcctagcg gaaaccattc actaaggacc      60
gagcaccaaa taaccaagga aaaggaagtg agttaaggac gtactcgtct tggtagagac      120

```

33

```

gtgagctgct gagatttggg agtctgcgct      aggcccgctt ggagttctga gccgatggaa
180
gagttcactc atg ttt gca ccc gcg gtg atg cgt gct ttt cgc aag aac      229
      Met Phe Ala Pro Ala Val Met Arg Ala Phe Arg Lys Asn
      -30      -25      -20
aag act ctc ggc tat gga gtc ccc atg ttg ttg ctg att gtt gga ggt      277
Lys Thr Leu Gly Tyr Gly Val Pro Met Leu Leu Leu Ile Val Gly Gly
      -15      -10      -5
tct ttt ggt ctt cgt gag ttt tct caa atc cga tat gat gct gtg aag      325
Ser Phe Gly Leu Arg Glu Phe Ser Gln Ile Arg Tyr Asp Ala Val Lys
      1      5      10
ggg aaa atg gat cct gag ctt gaa aaa aaa ctg aaa gag aat aaa ata      373
Gly Lys Met Asp Pro Glu Leu Glu Lys Lys Leu Lys Glu Asn Lys Ile
      15      20      25
tct tta gag tgc gaa tat gag aaa atc aaa gac tcc aag ttt gat gac      421
Ser Leu Glu Ser Glu Tyr Glu Lys Ile Lys Asp Ser Lys Phe Asp Asp
      30      35      40      45
tgg aag aat att cga gga ccc agg cct tgg gaa gat cct gac ctc ctc      469
Trp Lys Asn Ile Arg Gly Pro Arg Pro Trp Glu Asp Pro Asp Leu Leu
      50      55      60
caa gga aga aat cca gaa agc ctt aag act aag aca act tgactctgct      518
Gln Gly Arg Asn Pro Glu Ser Leu Lys Thr Lys Thr Thr
      65      70
gattctcttt tccttttttt ttttaataaa aaatactatt aactggactt cctaatatat      578
acttctatca agtggaaagg aaattccagg cccatggaaa cttggatatg ggtaatttgg      638
atggacaaaa ktaatctktc actaaaggtc atgtaccagg tttttatact tcccagctaa      698
ttccatctgt ggatgaaagt tgcaatgttg gcccccgat kattttacac cntcgaaata      758
aaaaatgtga ataactgctc caaaaaaaaaaaa aaa      791
<210> 49
<211> 1433
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 346..408
<223> Von Heijne matrix
      score 5.5
      seq SFLPSALVIWTS/AF
<221> polyA_signal
<222> 1400..1405
<221> polyA_site
<222> 1420..1433
<221> misc_feature
<222> 268..634
<223> homology
      id :W02860
      est
<221> misc_feature
<222> 118..564
<223> homology
      id :N27248
      est
<221> misc_feature
<222> 268..697
<223> homology
      id :N44490
      est
<221> misc_feature
<222> 582..687
<223> homology
      id :AA274731
      est
<221> misc_feature

```

<222> 65..369  
<223> homology  
    id :H94779  
    est  
<221> misc\_feature  
<222> 471..519  
<223> homology  
    id :H94779  
    est  
<221> misc\_feature  
<222> 61..399  
<223> homology  
    id :H09880  
    est  
<221> misc\_feature  
<222> 408..452  
<223> homology  
    id :H09880  
    est  
<221> misc\_feature  
<222> 484..699  
<223> homology  
    id :H04537  
    est  
<221> misc\_feature  
<222> 685..772  
<223> homology  
    id :H04537  
    est  
<221> misc\_feature  
<222> 454..486  
<223> homology  
    id :H04537  
    est  
<221> misc\_feature  
<222> 410..439  
<223> homology  
    id :H04537  
    est  
<221> misc\_feature  
<222> 572..687  
<223> homology  
    id :AA466632  
    est  
<221> misc\_feature  
<222> 260..444  
<223> homology  
    id :AA459511  
    est  
<221> misc\_feature  
<222> 449..567  
<223> homology  
    id :AA459511  
    est  
<221> misc\_feature  
<222> 117..184  
<223> homology  
    id :AA459511  
    est  
<221> misc\_feature  
<222> 260..464  
<223> homology  
    id :H57434

```

      est
<221> misc_feature
<222> 118..184
<223> homology
      id :H57434
      est
<221> misc_feature
<222> 56..113
<223> homology
      id :H57434
      est
<221> misc_feature
<222> 454..485
<223> homology
      id :H57434
      est
<300>
<400> 49
actcctttta gcataggggc ttcggcgcca gcggccagcg ctagtcggtc tggtaagtgc      60
ctgatgccga gttccgtctc tcgcgtcttt tcctgggtccc aggcaaagcg gasgnagatc      120
ctcaaacggc ctagtgcttc gcgcttccgg agaaaatcag cggctctaatt aattcctctg      180
gtttgttgaa gcagttacca agaattcttca accctttccc acaaaaagcta attgagtaca      240
cgttcctgtt gagtacacgt tcctgttgat ttacaaaagg tgcaggatatg agcagggtctg      300
aagactaaca ttttgtgaag ttgtaaaaca gaaaacctgt tagaa atg tgg tgg ttt      357
                                     Met Trp Trp Phe
                                     -20
cag caa ggc ctc agt ttc ctt cct tca gcc ctt gta att tgg aca tct      405
Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val Ile Trp Thr Ser
      -15      -10      -5
gct gct ttc ata ttt tca tac att act gca gta aca ctc cac cat ata      453
Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr Leu His His Ile
      1      5      10      15
gac ccg gct tta cct tat atc agt gac act ggt aca gta gct cca gaa      501
Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr Val Ala Pro Glu
      20      25      30
aaa tgc tta ttt ggg gca atg cta aat att gcg gca gtt tta tgc att      549
Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala Val Leu Cys Ile
      35      40      45
gct acc att tat gtt cgt tat aag caa gtt cat gct ctg agt cct gaa      597
Ala Thr Ile Tyr Val Arg Tyr Lys Gln Val His Ala Leu Ser Pro Glu
      50      55      60
gag aac gtt atc atc aaa tta aac aag gct ggc ctt gta ctt gga ata      645
Glu Asn Val Ile Ile Lys Leu Asn Lys Ala Gly Leu Val Leu Gly Ile
      65      70      75
ctg agt tgt tta gga ctt tct att gtg gca aac ttc cag gaa aac aac      693
Leu Ser Cys Leu Gly Leu Ser Ile Val Ala Asn Phe Gln Glu Asn Asn
      80      85      90      95
cct ttt tgc tgc aca tgt aag tgg agc tgt gct tac ctt tgg tat ggg      741
Pro Phe Cys Cys Thr Cys Lys Trp Ser Cys Ala Tyr Leu Trp Tyr Gly
      100      105      110
ctc att ata tat gtt tgt tca gac cat cct ttc cta cca aaa tgc agc      789
Leu Ile Ile Tyr Val Cys Ser Asp His Pro Phe Leu Pro Lys Cys Ser
      115      120      125
cca aaa tcc aat ggc aaa aca agt ctt ctg gat cag act gtt gtt ggt      837
Pro Lys Ser Asn Gly Lys Thr Ser Leu Leu Asp Gln Thr Val Val Gly
      130      135      140
tat ctg gtg tgg agt aag tgc act tagcatgctg acttgctcat cagttttgca      891
Tyr Leu Val Trp Ser Lys Cys Thr
      145      150
cagtggcaat tttgggactg atttagaaca gaaactccat tggaaaccccg aggacaaagg      951
ttatgcgctt cacatgatca ctactgcagc agaatggctc atgtcatttt ccttctttgg      1011
ttttttcctg acttacattc gtgattttca gaaaatttcc ttacgggttg aagccaactt      1071
acatggatta accctctatg acactgcacc ttgccctatt aacaatgaac gaacacggct      1131

```

```

actttccags aagatattag atgaaaggat      1191
aaaatatatttc tgtaantgan ttastgastt
ctcagggant tggggaaang gttcacagaa gttgcttavl tcttcacert gaanattttc 1251
aanccactta antcaaggct gacagstaac acgtgatgaa tgctgataat caggaaacat 1311
gaaagaagcc atttgcatag attatttytaa aggatatcat caagaagamt attaaaaaca 1371
cctatgccta tactttttta tytcagaaaa taaagtcaaa agactatgaa aaaaaaaaaa 1431
aa 1433
<210> 50
<211> 1158
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 214..339
<223> Von Heijne matrix
      score 6.099999990463257
      seq AILLLQSQAYWA/LP
<221> polyA_signal
<222> 1133..1138
<221> polyA_site
<222> 1146..1158
<221> misc_feature
<222> 840..968
<223> homology
      id :H64717
      est
<221> misc_feature
<222> 858..968
<223> homology
      id :H65208
      est
<300>
<400> 50
aarttgagct tggggactgc agctgtgggg agatttcagt gcattgcctc ccctgggtgc 60
tcttcacertt ggatttgaaa gttgagagca gcatgttttg cccactgaaa ctcatcctgs 120
tgrsagtgtat mtggattatt ccttgggcct gaatgacttg aatgtttccc cgcctgagct 180
aacagtcctat gtgggtgatt cagctctgat ggg atg tgt ttt cca gag cac aga 234
                               Met Cys Phe Pro Glu His Arg
                               -40
aga caa atg tat att caa gat aga ctg gac tct gtc acc agg aga gca 282
Arg Gln Met Tyr Ile Gln Asp Arg Leu Asp Ser Val Thr Arg Arg Ala
-35 -30 -25 -20
cgc caa gga cga ata tgt gct ata cta tta ctc caa tct cag tgt gcc 330
Arg Gln Gly Arg Ile Cys Ala Ile Leu Leu Leu Gln Ser Gln Cys Ala
-15 -10 -5
tat tgg gcg ctt cca gaa ccg cgt aca ctt gat ggg gga cat ctt atg 378
Tyr Trp Ala Leu Pro Glu Pro Arg Thr Leu Asp Gly Gly His Leu Met
1 5 10
caa tgatgggtct ctctctgtcc aagatgtgca agaggctgac cagggaacct 431
Gln
atatctgtga aatccgcctc aaaggggaga gccagggtgtt caagaaggcg gtgggtactgc 491
atgtgcttcc agaggagccc aaagggtacgc aaatgcttac ttaaagaggg gccaggggc 551
aagagctttc atgtgcaaga ggcaaggaaa ctgattatct tgagtaaagt ccagcctttg 611
ggctaagtac ttaccacaga gtgaatcttc aaagaaatga ntcattaaat tatttcagrt 671
cagaataaaa atakgagtta ttttagttta kaataaaata ttgataatta ttgtattatt 731
actttaaaca cacttcccc tcacaaaagc cctgtgaagg atgttttgtt cacatataat 791
gtccaaatat gttttggaca catatttatt aaatggaata aatagtamtt gaaccctggc 851
accthtgaca acaaagtcya tgtyttttt actatgccct aataccttts atcagttatc 911
cacattgatg ctacatytgt attttatagg taccctatgt taggtgtttt gggggataga 971
aaagaaataa gcagkycagg ctcatgtggc catgcctgta atcctagcat tttgggaggg 1031
tgaggcagca gaamtgcctg agccccaggg ttcaagactg cagttagcta tgawggcacc 1091
actgcattyt agcctgggwg acagagcaag actytgttta aaataaaaaa agagaaaaaa 1151
aaaaaa 1158

```

<210> 51  
<211> 850  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> sig\_peptide  
<222> 372..437  
<223> Von Heijne matrix  
score 6.09999990463257  
seq LFLTCLFWPLAAL/NV  
<221> polyA\_signal  
<222> 812..817  
<221> polyA\_site  
<222> 838..850  
<221> misc\_feature  
<222> 128..424  
<223> homology  
id :N78012  
est  
<221> misc\_feature  
<222> 61..128  
<223> homology  
id :N78012  
est  
<221> misc\_feature  
<222> 483..554  
<223> homology  
id :N78012  
est  
<221> misc\_feature  
<222> 417..464  
<223> homology  
id :N78012  
est  
<221> misc\_feature  
<222> 460..500  
<223> homology  
id :N78012  
est  
<221> misc\_feature  
<222> 577..612  
<223> homology  
id :N78012  
est  
<221> misc\_feature  
<222> 612..649  
<223> homology  
id :N78012  
est  
<221> misc\_feature  
<222> 546..577  
<223> homology  
id :N78012  
est  
<221> misc\_feature  
<222> 29..63  
<223> homology  
id :N78012  
est  
<221> misc\_feature  
<222> 128..294  
<223> homology  
id :W37233

```

      est
<221> misc_feature
<222> 370..509
<223> homology
      id :W37233
      est
<221> misc_feature
<222> 505..591
<223> homology
      id :W37233
      est
<221> misc_feature
<222> 293..330
<223> homology
      id :W37233
      est
<221> misc_feature
<222> 22..57
<223> homology
      id :W37233
      est
<221> misc_feature
<222> 95..128
<223> homology
      id :W37233
      est
<221> misc_feature
<222> 128..326
<223> homology
      id :AA186399
      est
<221> misc_feature
<222> 418..605
<223> homology
      id :AA186399
      est
<221> misc_feature
<222> 326..423
<223> homology
      id :AA186399
      est
<221> misc_feature
<222> 39..128
<223> homology
      id :AA186399
      est
<221> misc_feature
<222> 206..640
<223> homology
      id :W52489
      est
<300>
<400> 51
agacacttcc tgggtgggac cgagtgaggc gacggggtag ggggttggcgc tcaggcggcg      60
accatggcgt atcacggcct cactgtgcct ctcattgtga tgagcgtggt ctggggcttc      120
gtcggcttcc ttggtgcctt gggtcatccc taagggtcct aaccggggag ttatcattac      180
catgttggtg acctgttcag tttgctgcta tctcttttgg ctgattgcaa ttctggccca      240
actcaaccct ctctttggac cgcaattgaa aaatgaaacc atctgggtatc tgaagtatca      300
ttggccttga ggaagaagac atgctctaca gtgctcagtc tttgagggtca cgagaagaga      360
atgccttcta g atg caa aat cac ctc caa acc aga cca ctt ttc ttg act      410
          Met Gln Asn His Leu Gln Thr Arg Pro Leu Phe Leu Thr
          -20                      -15                      -10
tgc ctg ttt tgg cca tta gct gcc tta aac gtt aac agc aca ttt gaa      458

```



Cys	Leu	Phe	Trp	Pro	Leu	Ala	Ala	Leu	39	Asn	Val	Asn	Ser	Thr	Phe	Glu	
				-5					1				5				
tgc	ctt	att	cta	caa	tgc	agc	gtg	ttt	tcc	ttt	gcc	ttt	ttt	gca	ctt		506
Cys	Leu	Ile	Leu	Gln	Cys	Ser	Val	Phe	Ser	Phe	Ala	Phe	Phe	Ala	Leu		
	10					15					20						
tgg	tgaattacgt	gcctccataa	cctgaactgt	gccgactcca	caaaacgatt												559
Trp																	
atgtactctt	ctgagataga	agatgctgtt	cttctgagag	atacgttact	ctctccttgg												619
aatctgtgga	tttgaaaatg	gctcctgcct	tctcacgtgg	gaatcagtga	agtgtttaga												679
aactgctgca	agacaaacaa	gactccagtg	gggtgggtcag	taggaaaaca	cgttcagagg												739
gaagaaccat	ctcaacagaa	tgcgacccaa	ctatactttc	aggatgaatt	tcttctttct												799
gccatctttt	ggaataaata	ttttcctcct	ctytatgtaa	aaaaaaaaaa	a												850
<210>	52																
<211>	1107																
<212>	DNA																
<213>	Homo sapiens																
<220>																	
<221>	sig_peptide																
<222>	132..215																
<223>	Von Heijne matrix																
	score 3.599999990463257																
	seq PLSDSWALLPASA/GV																
<221>	polyA_signal																
<222>	1069..1074																
<221>	polyA_site																
<222>	1094..1107																
<221>	misc_feature																
<222>	177..392																
<223>	homology																
	id :W80978																
	est																
<221>	misc_feature																
<222>	425..542																
<223>	homology																
	id :W80978																
	est																
<221>	misc_feature																
<222>	43..114																
<223>	homology																
	id :W80978																
	est																
<221>	misc_feature																
<222>	387..441																
<223>	homology																

```
<223> homology
      id :AA043154
      est
<221> misc_feature
<222> 425..564
<223> homology
      id :AA043154
      est
<221> misc_feature
<222> 387..441
<223> homology
      id :AA043154
      est
<221> misc_feature
<222> 309..352
<223> homology
      id :AA043154
      est
<221> misc_feature
<222> 549..580
<223> homology
      id :AA043154
      est
<221> misc_feature
<222> 601..1071
<223> homology
      id :AA126732
      est
<221> misc_feature
<222> 576..605
<223> homology
      id :AA126732
      est
<221> misc_feature
<222> 387..477
<223> homology
      id :AA161280
      est
<221> misc_feature
<222> 292..362
<223> homology
      id :AA161280
      est
<221> misc_feature
<222> 46..113
<223> homology
      id :AA161280
      est
<221> misc_feature
<222> 217..277
<223> homology
      id :AA161280
      est
<221> misc_feature
<222> 113..160
<223> homology
      id :AA161280
      est
<221> misc_feature
<222> 173..217
<223> homology
      id :AA161280
      est
```

&lt;300&gt;

&lt;400&gt; 52

aacaacttcc ggccccactg agcgggtgtcc tgagccgatt acagctaggt agtggagcgc 60  
cgctgcttac ctgggtgcag gagacagccg gagtcgctgg gggagctccg cgccgcccga 120  
cgcccgtagac c atg tgg agg ctg ctg gct cgc gct agt gcg ccg ctc ctg 170  
Met Trp Arg Leu Leu Ala Arg Ala Ser Ala Pro Leu Leu  
-25 -20  
cgg gtg ccc ttg tca gat tcc tgg gca ctc ctc ccc gcc agt gct ggc 218  
Arg Val Pro Leu Ser Asp Ser Trp Ala Leu Leu Pro Ala Ser Ala Gly  
-15 -10 -5 1  
gta aag aca ctg ctc cca gta cca agt ttt gaa gat gtt tcc att cct 266  
Val Lys Thr Leu Leu Pro Val Pro Ser Phe Glu Asp Val Ser Ile Pro  
5 10 15  
gaa aaa ccc aag ctt aga ttt att gaa agg gca cca ctt gtg cca aaa 314  
Glu Lys Pro Lys Leu Arg Phe Ile Glu Arg Ala Pro Leu Val Pro Lys  
20 25 30  
gta aga aga gaa cct aaa aat tta agt gac ata cgg gga cct tcc act 362  
Val Arg Arg Glu Pro Lys Asn Leu Ser Asp Ile Arg Gly Pro Ser Thr  
35 40 45  
gaa gct acg gag kkk aca gaa ggc aat ttt gca atc ttg gca ttg ggt 410  
Glu Ala Thr Glu Xaa Thr Glu Gly Asn Phe Ala Ile Leu Ala Leu Gly  
50 55 60 65  
ggg ggc tac ctg cat tgg ggc cac ttt gaa atg atg cgc ctg aca atc 458  
Gly Gly Tyr Leu His Trp Gly His Phe Glu Met Met Arg Leu Thr Ile  
70 75 80  
aac cgc tct atg gac ccc aag aac atg ttt gcc ata tgg cga gta cca 506  
Asn Arg Ser Met Asp Pro Lys Asn Met Phe Ala Ile Trp Arg Val Pro  
85 90 95  
gcc cct ttc aag ccc atc act cgc aaa agt gtt ggg cat cgc atg ggg 554  
Ala Pro Phe Lys Pro Ile Thr Arg Lys Ser Val Gly His Arg Met Gly  
100 105 110  
gga ggc aaa ggt gct att gac cac tac gtg aca cct gtg aag gct ggc 602  
Gly Gly Lys Gly Ala Ile Asp His Tyr Val Thr Pro Val Lys Ala Gly  
115 120 125  
cgc mww gww gta gag atg ggt ggg cgt tgt gma ttt gaa gaa gtg caa 650  
Arg Xaa Xaa Val Glu Met Gly Gly Arg Cys Xaa Phe Glu Glu Val Gln  
130 135 140 145  
ggg ttc ctt gac cag gtt gcc cac aag ttg ccc tty gca gca aag gct 698  
Gly Phe Leu Asp Gln Val Ala His Lys Leu Pro Phe Ala Ala Lys Ala  
150 155 160  
gtg agc cgc ggg act yta gag aag atg cga aaa gat caa gag gaa aga 746  
Val Ser Arg Gly Thr Leu Glu Lys Met Arg Lys Asp Gln Glu Glu Arg  
165 170 175  
gaa mgt aac aac cag aac ccc tgg aca ttt gag cga ata gcc act gcc 794  
Glu Xaa Asn Asn Gln Asn Pro Trp Thr Phe Glu Arg Ile Ala Thr Ala  
180 185 190  
mac atg ctg ggc ata cgg aaa gta ctg agc cca tat gac ttg acc cac 842  
Xaa Met Leu Gly Ile Arg Lys Val Leu Ser Pro Tyr Asp Leu Thr His  
195 200 205  
aag ggg aaa tam tgg ggc aag tty tac atg ccc mam cgt gtg 884  
Lys Gly Lys Xaa Trp Gly Lys Phe Tyr Met Pro Xaa Arg Val  
210 215 220  
tagtgagtgt aggagataac tgtatatagg stactgaaag aaggattytg catttytatt 944  
cccctcagcc taccactga agtytttggg tagctytaa gccataamta aggagcagca 1004  
tttgagttaga ttttgaaaa acgatgttat ttgttgattt aaaaagaaaa cwgtattttt 1064  
attaaataaa atttaaacat cacttcagga aaaaaaaaaa aaa 1107  
<210> 53  
<211> 500  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> sig\_peptide  
<222> 199..288

```
<223> Von Heijne matrix
      score 5.59999990463257
      seq IVSVLALIPETTT/LT
<221> polyA_signal
<222> 464..469
<221> polyA_site
<222> 489..500
<221> misc_feature
<222> 197..412
<223> homology
      id :AA429945
      est
<221> misc_feature
<222> 61..195
<223> homology
      id :AA429945
      est
<221> misc_feature
<222> 425..488
<223> homology
      id :AA429945
      est
<221> misc_feature
<222> 197..412
<223> homology
      id :AA455042
      est
<221> misc_feature
<222> 61..195
<223> homology
      id :AA455042
      est
<221> misc_feature
<222> 425..488
<223> homology
      id :AA455042
      est
<221> misc_feature
<222> 207..412
<223> homology
      id :W93646
      est
<221> misc_feature
<222> 58..195
<223> homology
      id :W93646
      est
<221> misc_feature
<222> 425..488
<223> homology
      id :W93646
      est
<221> misc_feature
<222> 197..412
<223> homology
      id :AA516431
      est
<221> misc_feature
<222> 90..195
<223> homology
      id :AA516431
      est
<221> misc_feature
```

```

<222> 425..488
<223> homology
      id :AA516431
      est
<221> misc_feature
<222> 52..195
<223> homology
      id :W38899
      est
<221> misc_feature
<222> 197..324
<223> homology
      id :W38899
      est
<221> misc_feature
<222> 443..477
<223> homology
      id :W38899
      est
<221> misc_feature
<222> 197..338
<223> homology
      id :W52820
      est
<221> misc_feature
<222> 71..195
<223> homology
      id :W52820
      est
<221> misc_feature
<222> 339..401
<223> homology
      id :W52820
      est
<221> misc_feature
<222> 425..469
<223> homology
      id :W52820
      est
<221> misc_feature
<222> 40..195
<223> homology
      id :W19506
      est
<300>
<400> 53
agagctgtnn cnsaagtagg ggagggcggt gctccgcmgm ggtggcggdh tgctatcgct      60
tcgcagaacc tactcaggca gccagctgag aagagttgag ggaaagtgct gctgctgggt      120
ctgcagacgc gatggataac gtgcagccga aaataaaaca tcgccccctt tgcttcagtg      180
tgaaaggcca cgtgayag atg ctg cgg ctg gat att atc aac tca ctg gta      231
                Met Leu Arg Leu Asp Ile Ile Asn Ser Leu Val
                -30                -25                -20
aca aca gta ttc atg ctc atc gta tct gtg ttg gca ctg ata cca gaa      279
Thr Thr Val Phe Met Leu Ile Val Ser Val Leu Ala Leu Ile Pro Glu
                -15                -10                -5
acc aca aca ttg aca gtt ggt gga ggg gtg ttt gca ctt gtg aca gca      327
Thr Thr Thr Leu Thr Val Gly Gly Gly Val Phe Ala Leu Val Thr Ala
                1                5                10
gta tgc tgt ctt gcc gac ggg gcc ctt att tac cgg aag ctt ctg ttc      375
Val Cys Cys Leu Ala Asp Gly Ala Leu Ile Tyr Arg Lys Leu Leu Phe
                15                20                25
aat ccc agc ggt cct tac cag aaa aag cct gtg cat gaa aaa aaa gaa      423
Asn Pro Ser Gly Pro Tyr Gln Lys Lys Pro Val His Glu Lys Lys Glu

```

30	35	44	40	45	
ggt ttg taattttata ttacttttta gtttgatact aagtattaaa catatttctg					479
Val Leu					
tattctttcca aaaaaaaaaa a					500
<210> 54					
<211> 765					
<212> DNA					
<213> Homo sapiens					
<220>					
<221> sig_peptide					
<222> 293..385					
<223> Von Heijne matrix					
score 4.40000009536743					
seq TCCHLGLPHVRA/PR					
<221> polyA_signal					
<222> 733..738					
<221> polyA_site					
<222> 752..765					
<221> misc_feature					
<222> 310..576					
<223> homology					
id :HUM426A07B					
est					
<300>					
<400> 54					
aaaccttgtt gctagggacc gggcggtttg cggcaaccgt gggcactgct gaatttgaat					60
tgagggggcga gggaaaagt ttcttcaggt gtggtgggga gaggggaggcg gatgccggng					120
aaaccgtagg kacgcggtca gaaaggcgac gggctgtcgg agttggaaag ggacgcctgg					180
tttcccccca agcgaaccgg gatgggaagt gacttcaatg agattgaact tcagctggat					240
tgaaagagag gctagaagt cgccttgcca gcagcctcct tagtagagcg ga atg agt					298
Met Ser					
-30					
aat acc cac acg gtg ctt gtc tca ctt ccc cat ccg cac ccg gcc ctc					346
Asn Thr His Thr Val Leu Val Ser Leu Pro His Pro His Pro Ala Leu					
-25 -20 -15					
acc tgc tgt cac ctc ggc ctc cca cac ccg gtc cgc gct ccc cgc cct					394
Thr Cys Cys His Leu Gly Leu Pro His Pro Val Arg Ala Pro Arg Pro					
-10 -5 1					
ctt cct cgc gta gaa ccg tgg gat cct agg tgg cag gac tca gag cta					442
Leu Pro Arg Val Glu Pro Trp Asp Pro Arg Trp Gln Asp Ser Glu Leu					
5 10 15					
agg tat cca cag gcc atg aat tcc ttc cta aat gag cgg tca tcg ccg					490
Arg Tyr Pro Gln Ala Met Asn Ser Phe Leu Asn Glu Arg Ser Ser Pro					
20 25 30 35					
tgc agg acc tta agg caa gaa gca tcg gct gac aga tgt gat ctc					535
Cys Arg Thr Leu Arg Gln Glu Ala Ser Ala Asp Arg Cys Asp Leu					
40 45 50					
tgaacctgat agattgctga ttttatctta ttttatcctt gacttggtac aagttttggg					595
atattctgaaa agaccataca gataaccaca aatatcaaga aagtcgtctt cagtattaag					655
tagaatttag atttaggttt ccttcctgct tcccacctcc ttcgaataag gaaacgtctt					715
tgggaccaac tttatggaat aaataagctg agctgcacaaa waaaaaaaaa					765
<210> 55					
<211> 584					
<212> DNA					
<213> Homo sapiens					
<220>					
<221> sig_peptide					
<222> 130..189					
<223> Von Heijne matrix					
score 3.5					
seq KFCLICLLTFIFH/HC					
<221> polyA_signal					
<222> 546..551					

<221> polyA\_site  
 <222> 572..584  
 <300>  
 <400> 55  
 aagacgcgcc ggtttctgcg acgcagtttag cgcagtctgc tttggtgaat acacgatttg 60  
 gtgcagccgg ggtttggtac cgagcggaga ggagatgcac acggcactcg agtgtgagga 120  
 aaaatagaa atg aag gta cat atg cac aca aaa ttt tgc ctc att tgt ttg 171  
           Met Lys Val His Met His Thr Lys Phe Cys Leu Ile Cys Leu  
           -20                               -15                               -10  
 ctg aca ttt att ttt cat cat tgc aac cat tgc cat gaa gaa cat gac 219  
 Leu Thr Phe Ile Phe His His Cys Asn His Cys His Glu Glu His Asp  
           -5                               1                               5                               10  
 cat ggc cct gaa gcg ctt cac aga cag cat cgt gga atg aca gaa ttg 267  
 His Gly Pro Glu Ala Leu His Arg Gln His Arg Gly Met Thr Glu Leu  
                           15                               20                               25  
 gag cca agc aaa ttt tca aag caa gct gct gaa aat gaa aaa aaa tac 315  
 Glu Pro Ser Lys Phe Ser Lys Gln Ala Ala Glu Asn Glu Lys Lys Tyr  
                           30                               35                               40  
 tat att gaa aaa ctt ttt gag cgt tat ggt gaa aat gga aga tta tcc 363  
 Tyr Ile Glu Lys Leu Phe Glu Arg Tyr Gly Glu Asn Gly Arg Leu Ser  
                           45                               50                               55  
 ttt ttt ggt ttg gag aaa ctt tta aca aac ttg ggc ctt gga gag aga 411  
 Phe Phe Gly Leu Glu Lys Leu Leu Thr Asn Leu Gly Leu Gly Glu Arg  
                           60                               65                               70  
 aaa gta gtt gag att aat cat gag gat ctt ggc cac gat cat gtt tct 459  
 Lys Val Val Glu Ile Asn His Glu Asp Leu Gly His Asp His Val Ser  
                           75                               80                               85                               90  
 cat tta agg tat ttt ggc agt tca aga ggg aaa gca ttt tca ctc aca 507  
 His Leu Arg Tyr Phe Gly Ser Ser Arg Gly Lys Ala Phe Ser Leu Thr  
                           95                               100                               105  
 taaccaccca gcattcccat aatcatttaa attcagaaaa tcaaaactgt gaccagtgt 567  
 wtccacaaaa aaaaaaa 584  
 <210> 56  
 <211> 1387  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 191..325  
 <223> Von Heijne matrix  
           score 4.59999990463257  
           seq VLVYLVTAERVWS/DD  
 <221> polyA\_signal  
 <222> 1348..1353  
 <221> polyA\_site  
 <222> 1374..1387  
 <221> misc\_feature  
 <222> 1258..1372  
 <223> homology  
           id :AA417826  
           est  
 <221> misc\_feature  
 <222> 791..887  
 <223> homology  
           id :AA417826  
           est  
 <221> misc\_feature  
 <222> 94..524  
 <223> homology  
           id :AA235826  
           est  
 <221> misc\_feature  
 <222> 44..94

<223> homology  
id :AA235826  
est  
<221> misc\_feature  
<222> 1258..1372  
<223> homology  
id :AA236941  
est  
<221> misc\_feature  
<222> 935..1279  
<223> homology  
id :AA480326  
est  
<221> misc\_feature  
<222> 1258..1372  
<223> homology  
id :AA480326  
est  
<221> misc\_feature  
<222> 724..1148  
<223> homology  
id :AA234245  
est  
<221> misc\_feature  
<222> 944..1279  
<223> homology  
id :AA479344  
est  
<221> misc\_feature  
<222> 1258..1372  
<223> homology  
id :AA479344  
est  
<221> misc\_feature  
<222> 1070..1212  
<223> homology  
id :AA133636  
est  
<221> misc\_feature  
<222> 1258..1372  
<223> homology  
id :AA133636  
est  
<221> misc\_feature  
<222> 938..1054  
<223> homology  
id :AA133636  
est  
<221> misc\_feature  
<222> 94..436  
<223> homology  
id :AA133635  
est  
<221> misc\_feature  
<222> 32..94  
<223> homology  
id :AA133635  
est  
<221> misc\_feature  
<222> 895..1273  
<223> homology  
id :AA479453  
est



&lt;221&gt; misc\_feature

&lt;222&gt; 1258..1371

&lt;223&gt; homology

id :AA253214

est

&lt;221&gt; misc\_feature

&lt;222&gt; 94..268

&lt;223&gt; homology

id :AA482378

est

&lt;300&gt;

&lt;400&gt; 56

```

actcccaggc tggggccagca caccggcag gctctgtcct ggaaacaggc ttcaacgggc 60
ttccccgaaa accttccccg cttctggata tgaavattca agctgcttgc tgagtcctat 120
tgccggctgc tgggagccag gagagccctg aggagtagtc actcagtagc agctgacgcg 180
tgggtccacc atg aac tgg agt atc ttt gag gga ctc ctg agt ggg gtc 229
Met Asn Trp Ser Ile Phe Glu Gly Leu Leu Ser Gly Val
-45 -40 -35
aac aag tac tcc aca gcc ttt ggg cgc atc tgg ctg tct ctg gtc ttc 277
Asn Lys Tyr Ser Thr Ala Phe Gly Arg Ile Trp Leu Ser Leu Val Phe
-30 -25 -20
atc ttc cgc gtg ctg gtg tac ctg gtg acg gcc gag cgt gtg tgg agt 325
Ile Phe Arg Val Leu Val Tyr Leu Val Thr Ala Glu Arg Val Trp Ser
-15 -10 -5
gat gac cac aag gac ttc gac tgc aat act cgc cag ccc ggc tgc tcc 373
Asp Asp His Lys Asp Phe Asp Cys Asn Thr Arg Gln Pro Gly Cys Ser
1 5 10 15
aac gtc tgc ttt gat gag ttc ttc cct gtg tcc cat gtg cgc ctc tgg 421
Asn Val Cys Phe Asp Glu Phe Phe Pro Val Ser His Val Arg Leu Trp
20 25 30
gcc ctg cag ctt atc ctg gtg aca tgc ccc tca ctg ctc gtg gtc atg 469
Ala Leu Gln Leu Ile Leu Val Thr Cys Pro Ser Leu Leu Val Val Met
35 40 45
cac gtg gcc tac cgg gag gtt cag gag aag agg cac cga gaa gcc cat 517
His Val Ala Tyr Arg Glu Val Gln Glu Lys Arg His Arg Glu Ala His
50 55 60
ggg gag aac agt ggg cgc ctc tac ctg aac ccc ggc aag aar cgg ggt 565
Gly Glu Asn Ser Gly Arg Leu Tyr Leu Asn Pro Gly Lys Lys Arg Gly
65 70 75 80
ggg ctc tgg tgg aca tat gtc tgc agc cta gtg ttc aag gcg agc gtg 613
Gly Leu Trp Trp Thr Tyr Val Cys Ser Leu Val Phe Lys Ala Ser Val
85 90 95
gac atc gcc ttt ctc tat gtg ttc cac tca ttc tac ccc aaa tat atc 661
Asp Ile Ala Phe Leu Tyr Val Phe His Ser Phe Tyr Pro Lys Tyr Ile
100 105 110
ctc cct cct gtg gtc aag tgc cac gca gat cca tgt ccc aat ata gtg 709
Leu Pro Pro Val Val Lys Cys His Ala Asp Pro Cys Pro Asn Ile Val
115 120 125
gac tgc ttc atc tcc aag ccc tca gag aag aac att ttc acc ctc ttc 757
Asp Cys Phe Ile Ser Lys Pro Ser Glu Lys Asn Ile Phe Thr Leu Phe
130 135 140
atg gtg gcc aca gct gcc atc tgc atc ctg ctc aac ctc gtg gag ctc 805
Met Val Ala Thr Ala Ala Ile Cys Ile Leu Leu Asn Leu Val Glu Leu
145 150 155 160
atc tac ctg gtg agc aag aga tgc cac gag tgc ctg gca gca agg aaa 853
Ile Tyr Leu Val Ser Lys Arg Cys His Glu Cys Leu Ala Ala Arg Lys
165 170 175
gct caa gcc atg kgc aca ggt cat cac ccc cav gat acc acy ttt tcc 901
Ala Gln Ala Met Xaa Thr Gly His His Pro Xaa Asp Thr Thr Phe Ser
180 185 190
kgc aaa caa gas gac ytc ytt tgc ggc gac ytc atc ttt ctg ggn tca 949
Xaa Lys Gln Xaa Asp Xaa Xaa Ser Gly Asp Xaa Ile Phe Leu Gly Ser
195 200 205

```

48

gac agt cat cyt cct ytc tta cca gac cgc ccc cga gac cat gtg aag 997  
 Asp Ser His Xaa Pro Xaa Leu Pro Asp Arg Pro Arg Asp His Val Lys  
 210 215 220  
 aaa acc aty ttg tgaggggctg cctggamtgg tytggcagggt tgggcctgga 1049  
 Lys Thr Ile Leu  
 225  
 tggggaggct ytagcatyty tcataggtgc aacctgagag tgggggagct aagccatgag 1109  
 gtaggggag gcaagagaga ggattcagac gytytgggag ccagttccta gtcctcaamt 1169  
 ccagccacct gccccagsth gacggcamtg ggccagttcc cctytgsty tgcagstcgg 1229  
 tttcctttty tagaatggaa atagtgagg ccaatgccca gggttggagg gaggagggcg 1289  
 ttcatagaag aacacacatg cgggcacctt catygtgtgt ggccactgt cagaacttaa 1349  
 taaaagtcaa mtcatttgct ggtaaaaaa aaaaaaaa 1387  
 <210> 57  
 <211> 1385  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 141..251  
 <223> Von Heijne matrix  
 score 4  
 seq PLSLDCGHSLCRA/CI  
 <221> polyA\_signal  
 <222> 1354..1359  
 <221> polyA\_site  
 <222> 1375..1385  
 <221> misc\_feature  
 <222> 1183..1240  
 <223> homology  
 id :AA463623  
 est  
 <221> misc\_feature  
 <222> 176..239  
 <223> homology  
 id :AA258927  
 est  
 <221> misc\_feature  
 <222> 803..854  
 <223> homology  
 id :AA286417  
 est  
 <221> misc\_feature  
 <222> 1183..1213  
 <223> homology  
 id :AA608077  
 est  
 <300>  
 <400> 57  
 aacacccacc ctggcttttc ttcacctctt caaccaggag ccgagatttc tggtgctctg 60  
 aagccatcca ggggtcttta accagaagag agaggagagc ctcaggagtt aggaccagaa 120  
 gaagccaggg aagcagtgca atg gct tca aaa atc ttg ctt aac gta caa gag 173  
 Met Ala Ser Lys Ile Leu Leu Asn Val Gln Glu  
 -35 -30  
 gag gtg acc tgt ccc atc tgc ctg gag ctg ttg aca gaa ccc ttg agt 221  
 Glu Val Thr Cys Pro Ile Cys Leu Glu Leu Leu Thr Glu Pro Leu Ser  
 -25 -20 -15  
 cta gac tgt ggc cac agc ctc tgc cga gcc tgc atc act gtg agc aac 269  
 Leu Asp Cys Gly His Ser Leu Cys Arg Ala Cys Ile Thr Val Ser Asn  
 -10 -5 1 5  
 aag gag gca gtg acc agc atg gga gga aaa agc agc tgt cct gtg tgt 317  
 Lys Glu Ala Val Thr Ser Met Gly Gly Lys Ser Ser Cys Pro Val Cys  
 10 15 20  
 ggt atc agt tac tca ttt gaa cat cta cag gct aat cag cat cgg gcc 365

49

Gly	Ile	Ser	Tyr	Ser	Phe	Glu	His	Leu	Gln	Ala	Asn	Gln	His	Arg	Ala	
	25						30				35					
aac	ata	gtg	gag	aga	ctc	aag	gag	gtc	aag	ttg	agc	cca	gac	aat	ggg	413
Asn	Ile	Val	Glu	Arg	Leu	Lys	Glu	Val	Lys	Leu	Ser	Pro	Asp	Asn	Gly	
	40					45				50						
aag	aag	aga	gat	ctc	tgt	gat	cat	cat	gga	gag	aaa	ctc	cta	ctc	ttc	461
Lys	Lys	Arg	Asp	Leu	Cys	Asp	His	His	Gly	Glu	Lys	Leu	Leu	Leu	Phe	
55					60				65					70		
tgt	aag	gag	gat	agg	aaa	gtc	att	tgc	tgg	ctt	tgt	gag	cgg	tct	cag	509
Cys	Lys	Glu	Asp	Arg	Lys	Val	Ile	Cys	Trp	Leu	Cys	Glu	Arg	Ser	Gln	
				75				80						85		
gag	cac	cgt	ggt	cac	cac	aca	ggt	cct	cac	gga	gga	agt	att	caa	gga	557
Glu	His	Arg	Gly	His	His	Thr	Gly	Pro	His	Gly	Gly	Ser	Ile	Gln	Gly	
				90				95					100			
atg	tca	gga	gaa	act	cca	ggc	agt	cct	caa	gag	gct	gaa	gaa	gga	aga	605
Met	Ser	Gly	Glu	Thr	Pro	Gly	Ser	Pro	Gln	Glu	Ala	Glu	Glu	Gly	Arg	
				105			110					115				
gga	gga	agc	tgagaagctg	gaagctgaca	tcagagaaga	gaaaacttcc										654
Gly	Gly	Ser														
	120															
tggaagtatc	aggtacaaac	tgagagacaa	aggatacaaa	cagaatttga	tcagcttaga											714
agcatcctaa	ataatgagga	gcagagagag	ctgcaaagat	tggaagaaga	agaaaagaag											774
acgctggata	agtttgcaga	ggctgaggat	gagctagtcc	agcagaagca	gttggtgaga											834
gagctcatct	cagatgtgga	gtgtcggagt	cagtgggtcaa	caatggagct	gctgcaggac											894
atgagtggaa	tcatgaaatg	gagtgcagatc	tggaaggctga	aaaagccaaa	aatgggtttcc											954
aagaaactga	agactgtatt	ccatgtctcca	gatctgagta	ggatgctgcr	aatgttttaga											1014
ggaactgaca	gctgtccggg	gctactgggt	ggatgtcaca	ctgaattcag	tcaacctaaa											1074
tttgaatckt	gtcctttcag	aagatcagag	acaagtgata	tctgtgccaa	tttggccttt											1134
tcagtgttat	aattatgggtg	tkbttgggat	cccaatatct	btcctsstgg	gaaacattac											1194
tggaagtgg	acgtgtccaa	gaaaactgcc	tggaatcctgg	gggtatactg	tagaacatat											1254
tcccgcata	tgaagtatgt	tgtagaaga	tgtgcaaaty	gtcaaatbt	ttacaccaa											1314
tacagacctc	tatttggsta	ctgggttata	gggttacaga	ataaatgtaa	gtatggtgcc											1374
aaaaaaaaa	a															1385

&lt;210&gt; 58

&lt;211&gt; 1497

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; sig\_peptide

&lt;222&gt; 212..268

&lt;223&gt; Von Heijne matrix

score 8.60000038146973

seq LLWLALACSPVHT/TL

&lt;221&gt; polyA\_signal

&lt;222&gt; 1465..1470

&lt;221&gt; polyA\_site

&lt;222&gt; 1489..1497

&lt;221&gt; misc\_feature

&lt;222&gt; 958..1110

&lt;223&gt; homology

id :W72124

est

&lt;221&gt; misc\_feature

&lt;222&gt; 1362..1488

&lt;223&gt; homology

id :W72124

est

&lt;221&gt; misc\_feature

&lt;222&gt; 1202..1312

&lt;223&gt; homology

id :W72124

est

&lt;221&gt; misc\_feature

<222> 1115..1190  
<223> homology  
    id :W72124  
    est  
<221> misc\_feature  
<222> 1312..1370  
<223> homology  
    id :W72124  
    est  
<221> misc\_feature  
<222> 653..942  
<223> homology  
    id :AA009415  
    est  
<221> misc\_feature  
<222> 454..605  
<223> homology  
    id :AA009415  
    est  
<221> misc\_feature  
<222> 598..639  
<223> homology  
    id :AA009415  
    est  
<221> misc\_feature  
<222> 805..1032  
<223> homology  
    id :AA088502  
    est  
<221> misc\_feature  
<222> 633..807  
<223> homology  
    id :AA088502  
    est  
<221> misc\_feature  
<222> 598..639  
<223> homology  
    id :AA088502  
    est  
<221> misc\_feature  
<222> 564..605  
<223> homology  
    id :AA088502  
    est  
<221> misc\_feature  
<222> 653..807  
<223> homology  
    id :AA181148  
    est  
<221> misc\_feature  
<222> 907..1046  
<223> homology  
    id :AA181148  
    est  
<221> misc\_feature  
<222> 475..605  
<223> homology  
    id :AA181148  
    est  
<221> misc\_feature  
<222> 598..639  
<223> homology  
    id :AA181148

```

      est
<221> misc_feature
<222> 1069..1190
<223> homology
      id :AA181149
      est
<221> misc_feature
<222> 1162..1475
<223> homology
      id :AA181149
      est
<221> misc_feature
<222> 1202..1312
<223> homology
      id :AA181149
      est
<221> misc_feature
<222> 1312..1370
<223> homology
      id :AA181149
      est
<300>
<400> 58
atccggcgcg ctggagcggt ttccggccgt gcgtttgtgg ccgtccggcc tccctgacat      60
gcagatttcc anssagaaga cagagaagga gcnagtgggc atggaatggg ctgggggtcaa      120
agactgggtg cctgggagct gaggcagcca ccgtttcagc ctggccagcc ctctggaccc      180
cgaggttggg ccctactgtg acacacctac c atg cgg aca ctc ttc aac ctc      232
                                   Met Arg Thr Leu Phe Asn Leu
                                   -15
ctc tgg ctt gcc ctg gcc tgc agc cct gtt cac act acc ctg tca aag      280
Leu Trp Leu Ala Leu Ala Cys Ser Pro Val His Thr Thr Leu Ser Lys
      -10      -5      1
tca gat gcc asa aaa ccg cct caa aga cgc tgc tgg aga aga gtc agt      328
Ser Asp Ala Xaa Lys Pro Pro Gln Arg Arg Cys Trp Arg Arg Val Ser
      5      10      15      20
ttt cag ata agc cgg tgc aar acc ggg gtt tgg tgg tgacggacct      374
Phe Gln Ile Ser Arg Cys Lys Thr Gly Val Trp Trp
      25      30
caaagctgag agtgtgggtc ttgagcatcg cagctactgc tcggcaaagg cccgggacag      434
acactttgct ggggatgtac tgggctatgt cactccatgg aacagccatg gctacgatgt      494
caccaaggte tttgggagca agttcacaca gatctcaccg gtctggctgc agttgaagag      554
acgtggccgt gagatgtttg aggtcacggg cctccacgac gtggaccaag ggtggatgcy      614
agctgtcagg aagcatgcca agggcctgca catagtgcct cggtcctgt ttgaggactg      674
gacttacgat gatttccgga acgtcttaga cagtgaggat gagatagagg agctgagcaa      734
gaccgtggtc cagggtggca agaaccagca ttctgatggc ttctgtgggtg aggtctggaa      794
ccagctgcta agccagaagc gcgtgggcct catccacatg ctacccact tggccgaggc      854
cctgcaccag gcccggtgct tggccctcct ggcatcccg cctgccatca ccccggggac      914
cgaccagctg ggcattgtca cgcacaagga gtttgagcag ctggcccccg tgctggatgg      974
tttcagcctc atgacctacg actactctac agcgcatcag cctggcccta atgcaccct      1034
gtcctgggtt cgagcctgcy tccaggtcct ggacccggaa gtccaagtgg cgaagcaaaa      1094
tcttcctggg gctcaacttc tatgggatgg actacgcgac ctccaaggat gcccgtagc      1154
ctgtttgtcg ggccaggtag atccagacac tgaadggacc acaggccccg ggaatgggtg      1214
gggacagcca ggccctcagag cacttcttcg agtacaagaa gagccgcagt gggaggcacg      1274
tcgtcttcta cccaacctg aagtccttgc aggtgcgggc tggagctggc cggggagctg      1334
ggcgttgggg tctctatytg ggagctgggc cagggcctgg actacttyta cgacctgcty      1394
taggtgggga ttgcggcctc cgcggtggac gtgttyttt ytaagccatg gagtgagtga      1454
gcaggtgtga aatacaggcc tccactccgt ttgcaaaaaa aaa      1497
<210> 59
<211> 1570
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide

```

<222> 147..248  
<223> Von Heijne matrix  
score 4.30000019073486  
seq QLFAFLNLLPVEA/DI  
<221> polyA\_signal  
<222> 1538..1543  
<221> polyA\_site  
<222> 1558..1570  
<221> misc\_feature  
<222> 466..968  
<223> homology  
id :AA506103  
est  
<221> misc\_feature  
<222> 142..664  
<223> homology  
id :AA237105  
est  
<221> misc\_feature  
<222> 114..269  
<223> homology  
id :AA317201  
est  
<221> misc\_feature  
<222> 2..122  
<223> homology  
id :AA317201  
est  
<221> misc\_feature  
<222> 401..443  
<223> homology  
id :AA317201  
est  
<221> misc\_feature  
<222> 103..385  
<223> homology  
id :T80259  
est  
<221> misc\_feature  
<222> 21..120  
<223> homology  
id :T80259  
est  
<221> misc\_feature  
<222> 109..459  
<223> homology  
id :N32697  
est  
<221> misc\_feature  
<222> 45..87  
<223> homology  
id :N32697  
est  
<221> misc\_feature  
<222> 92..122  
<223> homology  
id :N32697  
est  
<221> misc\_feature  
<222> 1220..1409  
<223> homology  
id :AA449621  
est

```

<221> misc_feature
<222> 928..1092
<223> homology
      id :AA449621
      est
<221> misc_feature
<222> 1178..1222
<223> homology
      id :AA449621
      est
<221> misc_feature
<222> 1220..1545
<223> homology
      id :N34685
      est
<221> misc_feature
<222> 1168..1222
<223> homology
      id :N34685
      est
<221> misc_feature
<222> 1220..1545
<223> homology
      id :N22990
      est
<221> misc_feature
<222> 1178..1222
<223> homology
      id :N22990
      est
<221> misc_feature
<222> 114..325
<223> homology
      id :AA330462
      est
<221> misc_feature
<222> 18..122
<223> homology
      id :AA330462
      est
<221> misc_feature
<222> 135..475
<223> homology
      id :HUMEST5H12
      est
<300>
<400> 59
agtcgtccct gctagtactc cgggctgtgg gggtcgggtgc ggatattcag tcatgaaatc      60
agggtaggga cttctccgc agcgacgcgg ctggcaagac tgtttgtgtt gcgggggccc      120
gaacttcaag gtgattttac aacgag atg ctg ctc tcc ata ggg atg ctc atg      173
                               Met Leu Leu Ser Ile Gly Met Leu Met
                               -30
ctg tca gcc aca caa gtc tac acc atc ttg act gtc cag ctc ttt gca      221
Leu Ser Ala Thr Gln Val Tyr Thr Ile Leu Thr Val Gln Leu Phe Ala
-25                               -20                               -15                               -10
ttc tta aac cta ctg cct gta gaa gca gac att tta gca tat aac ttt      269
Phe Leu Asn Leu Leu Pro Val Glu Ala Asp Ile Leu Ala Tyr Asn Phe
-5                               1                               5
gaa aat gca tct cag aca ttt gat gac ctc ccc gca ara ttt ggt tat      317
Glu Asn Ala Ser Gln Thr Phe Asp Asp Leu Pro Ala Xaa Phe Gly Tyr
10                               15                               20
aga ctt cca gct gaa ggt tta aag ggt ttt tta att aac tca aaa cca      365
Arg Leu Pro Ala Glu Gly Leu Lys Gly Phe Leu Ile Asn Ser Lys Pro

```

25	30	54	35	
gag aat gcc tgt gaa ccc ata gtg cct cca cca gta aaa gac aat tca	413			
Glu Asn Ala Cys Glu Pro Ile Val Pro Pro Pro Val Lys Asp Asn Ser				
40 45 50 55				
tct ggc act ttc atc gtg tta att ara ara ctt gat tgt aat ttt gat	461			
Ser Gly Thr Phe Ile Val Leu Ile Xaa Xaa Leu Asp Cys Asn Phe Asp				
60 65 70				
ata aag gtt tta aat gca cag aga gca gga tac aag gca gcc ata gtt	509			
Ile Lys Val Leu Asn Ala Gln Arg Ala Gly Tyr Lys Ala Ala Ile Val				
75 80 85				
cac aat gtt gat tct gat gac ctc att agc atg gga tcc aac gac att	557			
His Asn Val Asp Ser Asp Asp Leu Ile Ser Met Gly Ser Asn Asp Ile				
90 95 100				
gag gta cta aag aaa att gac att cca tct gtc ttt att ggt gaa tca	605			
Glu Val Leu Lys Lys Ile Asp Ile Pro Ser Val Phe Ile Gly Glu Ser				
105 110 115				
tca gct agt tct ctg aaa gat gaa ttc aca tak gaa aaa ggg ggc cac	653			
Ser Ala Ser Ser Leu Lys Asp Glu Phe Thr Xaa Glu Lys Gly Gly His				
120 125 130 135				
ctt atc tta gtt cca gaa ttt agt ctt cct ttg gaa tac tac cta att	701			
Leu Ile Leu Val Pro Glu Phe Ser Leu Pro Leu Glu Tyr Tyr Leu Ile				
140 145 150				
ccc ttc ctt atc atr gtg ggc atc tgt ctc atc ttg ata gtc att ttc	749			
Pro Phe Leu Ile Xaa Val Gly Ile Cys Leu Ile Leu Ile Val Ile Phe				
155 160 165				
atg atc aca aaa ttg tcc agg gat aga cat aga gct aga aac aga	797			
Met Ile Thr Lys Leu Ser Arg Asp Arg His Arg Ala Arg Arg Asn Arg				
170 175 180				
ctt cgt aaa gat caa ctt aag aaa ctt cct gta cat aaa ttc aag aaa	845			
Leu Arg Lys Asp Gln Leu Lys Lys Leu Pro Val His Lys Phe Lys Lys				
185 190 195				
gga gat gag tat gat gta tgt gcc att tgt ttg gat gag tat gaa gat	893			
Gly Asp Glu Tyr Asp Val Cys Ala Ile Cys Leu Asp Glu Tyr Glu Asp				
200 205 210 215				
gga gac aaa ctc aga atc ctt ccc tgt tcc cat gct tat cat tgc aag	941			
Gly Asp Lys Leu Arg Ile Leu Pro Cys Ser His Ala Tyr His Cys Lys				
220 225 230				
tgt gta gac cct tgg cta act aaa acc aaa acc tgt cca gtg tgc	989			
Cys Val Asp Pro Trp Leu Thr Lys Thr Lys Lys Thr Cys Pro Val Cys				
235 240 245				
agg caa aaa gtt gtt cct tct caa ggc gat tca gac tct gac aca gac	1037			
Arg Gln Lys Val Val Pro Ser Gln Gly Asp Ser Asp Ser Asp Thr Asp				
250 255 260				
agt agt caa gaa gaa aat gaa gtg aca gaa cat acc cct tta ctg aga	1085			
Ser Ser Gln Glu Glu Asn Glu Val Thr Glu His Thr Pro Leu Leu Arg				
265 270 275				
cct tta gnc ttc tgt cag tgc cca rgt cam ttt ggg gct tta ntc gga	1133			
Pro Leu Xaa Phe Cys Gln Cys Pro Xaa Xaa Phe Gly Ala Leu Xaa Gly				
280 285 290 295				
ant ccc gct cac ant cag aak cat gac aga atc att cag act ast gag	1181			
Xaa Pro Ala His Xaa Gln Xaa His Asp Arg Ile Ile Gln Thr Xaa Glu				
300 305 310				
gaa gac gac aat gaa gat act gac agt agt gat gca gaa gaa	1223			
Glu Asp Asp Asn Glu Asp Thr Asp Ser Ser Asp Ala Glu Glu				
315 320 325				
tgaaattaat gaacatgatg tcgtgggtcca gttgcagcct aatgggtgaac gggattacaa	1283			
catagcaaat actggtttgac tttcagaaga tgattgggttt atttcccttt aaaatgatta	1343			
ggatatatact tgaatttgat tttttgctcc cttaaaagat ttttgtagaa ataacttatt	1403			
tttttagtact ytacagttta atcaaatattc tgaacacagga cttttgatyt ggtattttatc	1463			
tgccaagaat atacttcatt cactaataat agactgggtgc tgtaactcaa gcatcaattc	1523			
agctytttyt ttggaatgaa agtatagcca aaacaaaaaa aaaaaaa	1570			
<210> 60				
<211> 1022				



```

<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 112..237
<223> Von Heijne matrix
      score 7.19999980926514
      seq ILFSLSFLLVIIT/FP
<221> polyA_signal
<222> 976..981
<221> polyA_site
<222> 1010..1022
<300>
<400> 60
aatactttct cctctccctt ctccaagca catctgagtt gctgcctgtt cttcacactt      60
agctccaaac ccatgaaaaa ttgccaagta taaaagcttc tcaagaatga g atg gat      117
                                     Met Asp
tct agg gtg tct tca cct gag aag caa gat aaa gag aat ttc gtg ggt      165
Ser Arg Val Ser Ser Pro Glu Lys Gln Asp Lys Glu Asn Phe Val Gly
-40                               -35                               -30                               -25
gtc aac aat aaa cgg ctt ggt gta tgt ggc tgg atc ctg ttt tcc ctc      213
Val Asn Asn Lys Arg Leu Gly Val Cys Gly Trp Ile Leu Phe Ser Leu
-20                               -15                               -10
tct ttc ctg ttg gtg atc att acc ttc ccc atc tcc ata tgg atg tgc      261
Ser Phe Leu Leu Val Ile Ile Thr Phe Pro Ile Ser Ile Trp Met Cys
-5                               1                               5
ttg aag atc att aag gag tat gaa cgt gct gtt gta ttc cgt ctg gga      309
Leu Lys Ile Ile Lys Glu Tyr Glu Arg Ala Val Val Phe Arg Leu Gly
10                               15                               20
cgc atc caa gct gac aaa gcc aag ggg cca ggt ttg atc ctg gtc ctg      357
Arg Ile Gln Ala Asp Lys Ala Lys Gly Pro Gly Leu Ile Leu Val Leu
25                               30                               35                               40
cca tgc ata gat gtg ttt gtc aag gtt gac ctc cga aca gtt act tgc      405
Pro Cys Ile Asp Val Phe Val Lys Val Asp Leu Arg Thr Val Thr Cys
45                               50                               55
aac att cct cca caa gag atc ctc acc aga gac tcc gta act act cag      453
Asn Ile Pro Pro Gln Glu Ile Leu Thr Arg Asp Ser Val Thr Thr Gln
60                               65                               70
gta gat gga gtt gtc tat tac aga atc tat agt gct gtc tca gca gtg      501
Val Asp Gly Val Val Tyr Tyr Arg Ile Tyr Ser Ala Val Ser Ala Val
75                               80                               85
gct aat gtc aac gat gtc cat caa gca aca ttt ctg ctg gct caa acc      549
Ala Asn Val Asn Asp Val His Gln Ala Thr Phe Leu Leu Ala Gln Thr
90                               95                               100
act ctg aga aat gtc tta ggg aca cag acc ttg tcc cag atc tta gct      597
Thr Leu Arg Asn Val Leu Gly Thr Gln Thr Leu Ser Gln Ile Leu Ala
105                               110                               115                               120
gga cga gaa gag atc gcc cat agc atc cag act tta ctt gat gat gcc      645
Gly Arg Glu Glu Ile Ala His Ser Ile Gln Thr Leu Leu Asp Asp Ala
125                               130                               135
acc gaa ctg tgg ggg atc cgg gtg gcc cga gtg gaa atc aaa gat gtt      693
Thr Glu Leu Trp Gly Ile Arg Val Ala Arg Val Glu Ile Lys Asp Val
140                               145                               150
cgg att ccc gtg cag ttg cag aga tcc atg gca gcc gag gct gag gcc      741
Arg Ile Pro Val Gln Leu Gln Arg Ser Met Ala Ala Glu Ala Glu Ala
155                               160                               165
acc cgg gaa gcg aga gcc aag gtc ctt gca gct gaa gga gaa atg agt      789
Thr Arg Glu Ala Arg Ala Lys Val Leu Ala Ala Glu Gly Glu Met Ser
170                               175                               180
gct tcc aaa tcc ctg aag tca gcc tcc atg gtg ctg gct gag tct ccc      837
Ala Ser Lys Ser Leu Lys Ser Ala Ser Met Val Leu Ala Glu Ser Pro
185                               190                               195                               200
ata gct ctc cag ctg cgc tac ctg cag acc ttg agc acg gta gcc acc      885

```

56

Ile	Ala	Leu	Gln	Leu	Arg	Tyr	Leu	Gln	Thr	Leu	Ser	Thr	Val	Ala	Thr	
			205					210					215			
gag	aag	aat	tct	acg	att	gtg	ttt	cct	ctg	ccc	atg	aat	ata	cta	gag	933
Glu	Lys	Asn	Ser	Thr	Ile	Val	Phe	Pro	Leu	Pro	Met	Asn	Ile	Leu	Glu	
			220					225					230			
ggc	att	ggg	ggc	gtc	agc	tat	gat	aac	cac	aag	aag	ctt	cca	aat	aaa	981
Gly	Ile	Gly	Gly	Val	Ser	Tyr	Asp	Asn	His	Lys	Lys	Leu	Pro	Asn	Lys	
			235					240				245				
gcc	tgagg	tcctc	ttgcg	gtagt	cagct	aaaaa	aaaaaaaa									1022
Ala																

<210> 61  
 <211> 615  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 239..316  
 <223> Von Heijne matrix  
       score 3.90000009536743  
       seq ITWVSLFIDCVMT/RK  
 <221> polyA\_signal  
 <222> 586..591  
 <221> polyA\_site  
 <222> 603..615  
 <221> misc\_feature  
 <222> 341..574  
 <223> homology  
       id :AA453275  
       est  
 <221> misc\_feature  
 <222> 174..332  
 <223> homology  
       id :AA453275  
       est  
 <221> misc\_feature  
 <222> 85..171  
 <223> homology  
       id :AA453275  
       est  
 <221> misc\_feature  
 <222> 341..574  
 <223> homology  
       id :AA149631  
       est  
 <221> misc\_feature  
 <222> 170..339  
 <223> homology  
       id :AA149631  
       est  
 <221> misc\_feature  
 <222> 43..123  
 <223> homology  
       id :AA149631  
       est  
 <221> misc\_feature  
 <222> 88..339  
 <223> homology  
       id :AA588414  
       est  
 <221> misc\_feature  
 <222> 341..574  
 <223> homology  
       id :AA588414

```
      est
<221> misc_feature
<222> 1..345
<223> homology
      id :AA156847
      est
<221> misc_feature
<222> 342..414
<223> homology
      id :AA156847
      est
<221> misc_feature
<222> 341..574
<223> homology
      id :AA501739
      est
<221> misc_feature
<222> 110..339
<223> homology
      id :AA501739
      est
<221> misc_feature
<222> 341..574
<223> homology
      id :AA131792
      est
<221> misc_feature
<222> 153..259
<223> homology
      id :AA131792
      est
<221> misc_feature
<222> 259..339
<223> homology
      id :AA131792
      est
<221> misc_feature
<222> 59..338
<223> homology
      id :AA131842
      est
<221> misc_feature
<222> 344..415
<223> homology
      id :AA131842
      est
<221> misc_feature
<222> 400..434
<223> homology
      id :AA131842
      est
<221> misc_feature
<222> 341..574
<223> homology
      id :AA152042
      est
<221> misc_feature
<222> 183..339
<223> homology
      id :AA152042
      est
<300>
<400> 61
```

58

```

atctttgaag aagaagaagt tgaatttattc      agtgtgcctg tcccagagtt tgcagatagt
60
gatcctgccca acattgttca tgactttaac aagaaactta cagcctatatt agatcttaac      120
ctggataagt gctatgtgat ccctctgaac acttccattg ttatgccacc cagaaaccta      180
ctggagttac ttattaacat caaggctgga acctatttgc ctcagtccta tctgattc      238
atg agc aca tgg tta tta ctg atc gca ttg aaa aca ttg atc acc tgg      286
Met Ser Thr Trp Leu Leu Leu Ile Ala Leu Lys Thr Leu Ile Thr Trp
-25 -20 -15
gtt tct tta ttt atc gac tgt gtc atg aca agg aaa ctt aca aac tgc      334
Val Ser Leu Phe Ile Asp Cys Val Met Thr Arg Lys Leu Thr Asn Cys
-10 -5 1 5
aac gct aga gaa act att aaa ggt att cag aaa cgt gaa gcc agc aat      382
Asn Ala Arg Glu Thr Ile Lys Gly Ile Gln Lys Arg Glu Ala Ser Asn
10 15 20
tgt ttc gca att cgg cat ttt gaa aac aaa ttt gcc gtg gaa act tta      430
Cys Phe Ala Ile Arg His Phe Glu Asn Lys Phe Ala Val Glu Thr Leu
25 30 35
att tgt tct tgaacagtca agaaaaacat tattgaggaa aattaatatc      479
Ile Cys Ser
40
acagcataac cccacccttt acattttgtg cagtgattat tttttaagt cttctttcat      539
gtaagtagca aacagggctt tactatcttt tcatctcatt aattcaatta aaaccattac      599
cccaaaaaaa aaaaaa      615
<210> 62
<211> 804
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 157..345
<223> Von Heijne matrix
score 3.5
seq GLVCAGLADMARPAE
<221> polyA_signal
<222> 771..776
<221> polyA_site
<222> 791..804
<221> misc_feature
<222> 244..789
<223> homology
id :AA576425
est
<221> misc_feature
<222> 286..790
<223> homology
id :AA236527
est
<221> misc_feature
<222> 287..790
<223> homology
id :AA435919
est
<221> misc_feature
<222> 520..790
<223> homology
id :AA165350
est
<221> misc_feature
<222> 389..522
<223> homology
id :AA165350
est
<221> misc_feature

```

<222> 336..386  
<223> homology  
    id :AA165350  
    est  
<221> misc\_feature  
<222> 326..790  
<223> homology  
    id :AA490322  
    est  
<221> misc\_feature  
<222> 326..790  
<223> homology  
    id :AA490310  
    est  
<221> misc\_feature  
<222> 515..780  
<223> homology  
    id :AA164559  
    est  
<221> misc\_feature  
<222> 325..522  
<223> homology  
    id :AA164559  
    est  
<221> misc\_feature  
<222> 350..790  
<223> homology  
    id :AA427895  
    est  
<221> misc\_feature  
<222> 378..790  
<223> homology  
    id :AA532390  
    est  
<221> misc\_feature  
<222> 186..382  
<223> homology  
    id :AA082259  
    est  
<221> misc\_feature  
<222> 61..141  
<223> homology  
    id :AA082259  
    est  
<221> misc\_feature  
<222> 426..478  
<223> homology  
    id :AA082259  
    est  
<221> misc\_feature  
<222> 29..61  
<223> homology  
    id :AA082259  
    est  
<221> misc\_feature  
<222> 389..790  
<223> homology  
    id :AA157009  
    est  
<221> misc\_feature  
<222> 425..790  
<223> homology  
    id :AA034912

```

      est
<221> misc_feature
<222> 186..430
<223> homology
      id :AA428006
      est
<221> misc_feature
<222> 59..132
<223> homology
      id :AA428006
      est
<300>
<400> 62
aacagcgggc agggaaagcc gcgggaaggg tactccaggc gagaggcgga cgcgagtcgt      60
cgtggcagga aaagtgacta gctccccttc gttgtcagcc agggacgaga acacagccac      120
gctcccaccc ggctgcchaa ggatccctcg gcggcg atg tcg gcc gcc ggt gcc      174
                                   Met Ser Ala Ala Gly Ala
                                   -60
cga ggc ctg cgg gcc acc tac cac cgg ctc ctc gat aaa gtg gag ctg      222
Arg Gly Leu Arg Ala Thr Tyr His Arg Leu Leu Asp Lys Val Glu Leu
      -55                               -50                               -45
atg ctg ccc gag aaa ttg agg ccg ttg tac aac cat cca gca ggt ccc      270
Met Leu Pro Glu Lys Leu Arg Pro Leu Tyr Asn His Pro Ala Gly Pro
      -40                               -35                               -30
aga aca gtt ttc ttc tgg gct cca att atg aaa tgg ggg ttg gtg tgt      318
Arg Thr Val Phe Phe Trp Ala Pro Ile Met Lys Trp Gly Leu Val Cys
      -25                               -20                               -15                               -10
gct gga ttg gct gat atg gcc aga cct gca gaa aaa ctt agc aca gct      366
Ala Gly Leu Ala Asp Met Ala Arg Pro Ala Glu Lys Leu Ser Thr Ala
      -5                               1                               5
caa tct gct gtt ttg atg gct aca ggg ttt att tgg tca aga tac tca      414
Gln Ser Ala Val Leu Met Ala Thr Gly Phe Ile Trp Ser Arg Tyr Ser
      10                               15                               20
ctt gta att att ccg aaa aat tgg agt ctg ttt gct gtt aat ttc ttt      462
Leu Val Ile Ile Pro Lys Asn Trp Ser Leu Phe Ala Val Asn Phe Phe
      25                               30                               35
gtg ggg gca gca gga gcc tct cag ctt ttt cgt att tgg aga tat aac      510
Val Gly Ala Ala Gly Ala Ser Gln Leu Phe Arg Ile Trp Arg Tyr Asn
      40                               45                               50                               55
caa gaa cta aaa gct aaa gca cac aaa taaaagagtt cctgatcacc      557
Gln Glu Leu Lys Ala Lys Ala His Lys
      60
tgaacaatct agatgtggac aaaaccattg ggacctagtt tattatttgg ttattgataa      617
agcaaagcta actgtgtgtt tagaaggcac tgtaactggt agctagttct tgattcaata      677
gaaaaatgca gcaaactttt aataacagtc tctctacatg acttaaggaa cttatctatg      737
gatattagta acatttttct accatttgtc cgtaataaaa catacttgct cgtaaaaaaa      797
aaaaaaa
      804
<210> 63
<211> 792
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 194..253
<223> Von Heijne matrix
      score 12.3999996185303
      seq ALLLGALLGTAWA/RR
<221> polyA_signal
<222> 768..773
<221> polyA_site
<222> 780..792
<221> misc_feature
<222> 154..428

```

<223> homology  
    id :R22491  
    est  
<221> misc\_feature  
<222> 104..160  
<223> homology  
    id :R22491  
    est  
<221> misc\_feature  
<222> 47..218  
<223> homology  
    id :AA136163  
    est  
<221> misc\_feature  
<222> 265..403  
<223> homology  
    id :AA136163  
    est  
<221> misc\_feature  
<222> 3..40  
<223> homology  
    id :AA136163  
    est  
<221> misc\_feature  
<222> 123..265  
<223> homology  
    id :N57089  
    est  
<221> misc\_feature  
<222> 47..127  
<223> homology  
    id :N57089  
    est  
<221> misc\_feature  
<222> 282..323  
<223> homology  
    id :N57089  
    est  
<221> misc\_feature  
<222> 128..403  
<223> homology  
    id :AA314970  
    est  
<221> misc\_feature  
<222> 138..403  
<223> homology  
    id :AA314807  
    est  
<221> misc\_feature  
<222> 164..403  
<223> homology  
    id :AA271811  
    est  
<221> misc\_feature  
<222> 163..385  
<223> homology  
    id :AA103053  
    est  
<221> misc\_feature  
<222> 154..403  
<223> homology  
    id :AA042016  
    est

```

<221> misc_feature
<222> 2..250
<223> homology
      id :AA315322
      est
<221> misc_feature
<222> 154..403
<223> homology
      id :AA470189
      est
<221> misc_feature
<222> 217..403
<223> homology
      id :AA462839
      est
<221> misc_feature
<222> 154..403
<223> homology
      id :AA120322
      est
<221> misc_feature
<222> 163..403
<223> homology
      id :W71694
      est
<221> misc_feature
<222> 164..385
<223> homology
      id :AA250603
      est
<221> misc_feature
<222> 266..403
<223> homology
      id :AA036242
      est
<300>
<400> 63
aagggcgtcg ccgggacacc ccgtgtgtgg cagggcggcg asgctctgga gaatcccgga      60
cagccctgct ccctgcagcc aggtgtagtt tcgggagcca ctggggccaa agtgagagtc      120
cagcgggtctt ccagcgcttg ggccacggcg gcggccctgg gagcagaggt ggagcgaccc      180
cattacgcta aag atg aaa ggc tgg ggt tgg ctg gcc ctg ctt ctg ggg      229
          Met Lys Gly Trp Gly Trp Leu Ala Leu Leu Leu Gly
          -20                      -15                      -10
gcc ctg ctg gga acc gcc tgg gct cgg agg agc cgg gat ctc cac tgt      277
Ala Leu Leu Gly Thr Ala Trp Ala Arg Arg Ser Arg Asp Leu His Cys
          -5                      1                      5
gga gca tgc agg gct ctg gtg gat gaa cta gaa tgg gaa att gcc cag      325
Gly Ala Cys Arg Ala Leu Val Asp Glu Leu Glu Trp Glu Ile Ala Gln
          10                      15                      20
gtg gac ccc aag aag acc att cag atg gga tcc ttc cgg atc aat cca      373
Val Asp Pro Lys Lys Thr Ile Gln Met Gly Ser Phe Arg Ile Asn Pro
          25                      30                      35                      40
gat ggc agc cag tca gtg gtg gag gta act gtt act gkt tcc ccc aaa      421
Asp Gly Ser Gln Ser Val Val Glu Val Thr Val Thr Xaa Ser Pro Lys
          45                      50                      55
aca aaa gta gct cac tct ggc ttt tgg atg aaa att cga ctg ctt aaa      469
Thr Lys Val Ala His Ser Gly Phe Trp Met Lys Ile Arg Leu Leu Lys
          60                      65                      70
aaa gga cct tgg tct taatagaaaa tgaagraaaa cagactcaga aaaaaagatt      524
Lys Gly Pro Trp Ser
          75
tbggctctgt ctcaawtttg aagaaggctg_gcaggcttat tccccaatgc aactttgctt      584
cctggctgca aaccyttaat acytttgttt ctgctgtaga aatttgtag ccaaaacawg      644

```



63

```
ggagtcctga twcagcaacc ccttcttcca      caatccacca tgactgggtt ttaatgtamc
704
acttggggta tacatgcaaa accatccggt cmaaaatctg aatycggagc ttaaaaattt      764
aaaaatgaaa aacchaaaaa aaaaaaaaaa      792
<210> 64
<211> 832
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 148..207
<223> Von Heijne matrix
      score 12.3999996185303
      seq ALLLGALLGTAWA/RR
<221> polyA_signal
<222> 789..794
<221> polyA_site
<222> 820..832
<221> misc_feature
<222> 258..553
<223> homology
      id :AA435303
      est
<221> misc_feature
<222> 117..219
<223> homology
      id :AA435303
      est
<221> misc_feature
<222> 552..645
<223> homology
      id :AA435303
      est
<221> misc_feature
<222> 217..258
<223> homology
      id :AA435303
      est
<221> misc_feature
<222> 258..553
<223> homology
      id :AA314807
      est
<221> misc_feature
<222> 92..258
<223> homology
      id :AA314807
      est
<221> misc_feature
<222> 258..554
<223> homology
      id :AA314970
      est
<221> misc_feature
<222> 82..258
<223> homology
      id :AA314970
      est
<221> misc_feature
<222> 258..553
<223> homology
      id :AA547310
      est
```

```

<221> misc_feature
<222> 119..258
<223> homology
      id :AA547310
      est
<221> misc_feature
<222> 359..553
<223> homology
      id :AA565602
      est
<221> misc_feature
<222> 552..683
<223> homology
      id :AA565602
      est
<221> misc_feature
<222> 684..751
<223> homology
      id :AA565602
      est
<221> misc_feature
<222> 742..783
<223> homology
      id :AA565602
      est
<221> misc_feature
<222> 364..553
<223> homology
      id :AA136094
      est
<221> misc_feature
<222> 552..683
<223> homology
      id :AA136094
      est
<221> misc_feature
<222> 684..751
<223> homology
      id :AA136094
      est
<221> misc_feature
<222> 258..461
<223> homology
      id :AA136163
      est
<221> misc_feature
<222> 2..172
<223> homology
      id :AA136163
      est
<221> misc_feature
<222> 216..258
<223> homology
      id :AA136163
      est
<300>
<400> 64
aggagaatcc cggacagccc tgctccctgc agccaggtgt agtttcggga gccactgggg      60
ccaaagtgag agtccagcgg tcttccagcg cttggggccac ggcggcggcc ctgggagcag      120
aggtggagcg accccattac gctaaag atg aaa ggc tgg ggt tgg ctg gcc ctg      174
                               Met Lys Gly Trp Gly Trp Leu Ala Leu
                               -20                               -15
ctt ctg ggg gcc ctg ctg gga acc gcc tgg gct cgg agg agc cag gat      222

```

65

Leu	Leu	Gly	Ala	Leu	Leu	Gly	Thr	Ala	Trp	Ala	Arg	Arg	Ser	Gln	Asp	
-10					-5				1					5		
ctc	cac	tgt	gga	gca	tgc	agg	gct	ctg	gtg	gat	gaa	act	aga	atg	gga	270
Leu	His	Cys	Gly	Ala	Cys	Arg	Ala	Leu	Val	Asp	Glu	Thr	Arg	Met	Gly	
			10					15					20			
aat	tgc	cca	ggc	gga	ccc	caa	gaa	gac	cat	tca	gat	ggg	atc	ttt	ccg	318
Asn	Cys	Pro	Gly	Gly	Pro	Gln	Glu	Asp	His	Ser	Asp	Gly	Ile	Phe	Pro	
			25				30						35			
gat	caa	tcc	aga	tgg	cag	cca	gtc	agt	ggc	gga	ggc	tta	tgc	ccg		366
Asp	Gln	Ser	Arg	Trp	Gln	Pro	Val	Ser	Gly	Gly	Gly	Ala	Leu	Cys	Pro	
			40				45					50				
ctc	aga	ggc	cca	cct	cac	aga	gct	gct	gga	gga	gat	atg	tgaccggatg			415
Leu	Arg	Gly	Pro	Pro	His	Arg	Ala	Ala	Gly	Gly	Asp	Met				
			55				60				65					
aaggagtatg	gggaacagat	tgatcctccc	acccatcgca	agaactacgt	acgtgtagtg											475
ggccggaatg	gagaatccag	tgaactggac	ctacaaggca	tccgaatcga	ctcagatatt											535
agcggcaccc	tcaagbtttg	cgtgtgggaa	cattgtggag	gaatacgagg	atgaactcat											595
tgaattcttc	ccccgagagg	ctgacaatgt	taaagacaaa	ctttgcagta	agcgaacaga											655
tctttgtgac	catgccctgc	acatatcggc	atgatgagct	atgaaccact	ggagcagccc											715
acactggctt	gatggatcac	ccccaggnaa	gggaaaatgg	tggcaatgcc	ttttatatat											775
tatgtttttac	tgaaattaac	tgaaaaatat	gaaacaaaaa	gtscaaaaaa	aaaaaaa											832

<210> 65  
 <211> 721  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 156..230  
 <223> Von Heijne matrix  
     score 5  
     seq MFAASLLAMCAGA/EV  
 <221> polyA\_signal  
 <222> 706..711  
 <221> polyA\_site  
 <222> 709..721  
 <221> misc\_feature  
 <222> 351..688  
 <223> homology  
     id :H98648  
     est  
 <221> misc\_feature  
 <222> 289..353  
 <223> homology  
     id :H98648  
     est  
 <221> misc\_feature  
 <222> 274..641  
 <223> homology  
     id :AA181022  
     est  
 <221> misc\_feature  
 <222> 255..286  
 <223> homology  
     id :AA181022  
     est  
 <221> misc\_feature  
 <222> 242..641  
 <223> homology  
     id :AA143192  
     est  
 <221> misc\_feature  
 <222> 261..646  
 <223> homology

```
      id :AA594850
      est
<221> misc_feature
<222> 165..474
<223> homology
      id :AA563681
      est
<221> misc_feature
<222> 1..74
<223> homology
      id :AA563681
      est
<221> misc_feature
<222> 261..643
<223> homology
      id :AA287457
      est
<221> misc_feature
<222> 352..646
<223> homology
      id :N22567
      est
<221> misc_feature
<222> 299..354
<223> homology
      id :N22567
      est
<221> misc_feature
<222> 265..303
<223> homology
      id :N22567
      est
<221> misc_feature
<222> 30..165
<223> homology
      id :AA186657
      est
<221> misc_feature
<222> 270..349
<223> homology
      id :AA186657
      est
<221> misc_feature
<222> 213..261
<223> homology
      id :AA186657
      est
<221> misc_feature
<222> 165..214
<223> homology
      id :AA186657
      est
<221> misc_feature
<222> 346..387
<223> homology
      id :AA186657
      est
<221> misc_feature
<222> 52..400
<223> homology
      id :HSC1ED081
      est
<221> misc_feature
```

```

<222> 398..436
<223> homology
      id :HSC1ED081
      est
<221> misc_feature
<222> 171..316
<223> homology
      id :AA143136
      est
<300>
<400> 65
atcttggttc cggcctgttc gcmgtccgct ccgtccgccc ttagacctgt tgcccagcat      60
ccctgcagtt cgcggwacag tctctattag agcgcgtgta tagaggcaga kaggagtga      120
gtccacagtt cctctctctc tagagcctgc cgacc atg ccc gcg ggc gtg ccc      173
                               Met Pro Ala Gly Val Pro
                               -25 -20
atg tcc acc tac ctg aaa atg ttc gca gcc agt ctc ctg gcc atg tgc      221
Met Ser Thr Tyr Leu Lys Met Phe Ala Ala Ser Leu Leu Ala Met Cys
                               -15 -10 -5
gca ggg gca gaa gtg gtg cac agg tac tac cga ccg gac ctg aca ata      269
Ala Gly Ala Glu Val Val His Arg Tyr Tyr Arg Pro Asp Leu Thr Ile
                               1 5 10
cct gaa att cca cca aag cgt gga gaa ctc aaa acg gag ctt ttg gga      317
Pro Glu Ile Pro Pro Lys Arg Gly Glu Leu Lys Thr Glu Leu Leu Gly
                               15 20 25
ctg aaa gaa aga aaa cac aaa cct caa gtt tct caa cag gag gaa ctt      365
Leu Lys Glu Arg Lys His Lys Pro Gln Val Ser Gln Gln Glu Glu Leu
30 35 40 45
aaa taactatgcc aagaattctg tgaataatat agtctttaa tatgtatttc      418
Lys
ttaatttatt gcatcaaact acttgtcctt aagcacttag tctaattgcta actgcaagag      478
gaggtgtcca gtggatgttt agccgatacg ttgaaattta attacggttt gattgatatt      538
tcttgaaaac tgccaaagca catatcatca aaccatttca tgaatatggt ttggaagatg      598
tttagtcttg aatataacgc gaaatagaat atttgtaagt ctactatatg gggtgtcttt      658
atttcatata aattaagaaa ttatttaaaa actatgaact aggttttcatt aaaaaaaaaa      718
gaa      721
<210> 66
<211> 531
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 272..397
<223> Von Heijne matrix
      score 4.59999990463257
      seq RIPS LPGSPVCWA/WP
<221> polyA_signal
<222> 503..508
<221> polyA_site
<222> 518..531
<221> misc_feature
<222> 235..517
<223> homology
      id :AA524403
      est
<221> misc_feature
<222> 52..208
<223> homology
      id :AA524403
      est
<221> misc_feature
<222> 259..517
<223> homology

```

```
      id :N93600
      est
<221> misc_feature
<222> 85..207
<223> homology
      id :N93600
      est
<221> misc_feature
<222> 353..517
<223> homology
      id :AA594610
      est
<221> misc_feature
<222> 258..363
<223> homology
      id :AA594610
      est
<221> misc_feature
<222> 105..207
<223> homology
      id :AA594610
      est
<221> misc_feature
<222> 202..517
<223> homology
      id :AA074748
      est
<221> misc_feature
<222> 116..153
<223> homology
      id :AA074748
      est
<221> misc_feature
<222> 167..202
<223> homology
      id :AA074748
      est
<221> misc_feature
<222> 258..517
<223> homology
      id :N93603
      est
<221> misc_feature
<222> 208..251
<223> homology
      id :N93603
      est
<221> misc_feature
<222> 163..202
<223> homology
      id :N93603
      est
<221> misc_feature
<222> 90..125
<223> homology
      id :N93603
      est
<221> misc_feature
<222> 125..363
<223> homology
      id :HSPD04938
      est
<221> misc_feature
```

```

<222> 353..517
<223> homology
      id :HSPD04938
      est
<221> misc_feature
<222> 28..227
<223> homology
      id :AA074804
      est
<221> misc_feature
<222> 265..310
<223> homology
      id :AA074804
      est
<221> misc_feature
<222> 227..263
<223> homology
      id :AA074804
      est
<221> misc_feature
<222> 352..385
<223> homology
      id :AA074804
      est
<300>
<400> 66
aaaaggaaag aggtysggag cgctcgcgag atctcggacc acccaacctg aaagggtgctt      60
aggaagttga aaggcccaga ggagggcctcc gggcaaatgg ccggagctgg accgaccatg      120
ctgctacgag aagagaatgg ctgttgcagt cggcgtcaga gcagctccag tgccggggat      180
tcggacggag agcgcgagga ctcgggcggt gagcgcgccc gacagcagct agagggcgctg      240
ctcaacaaga ctatgcgcat tcgcatgaca g atg gac gga cac tgg tcg gct      292
                               Met Asp Gly His Trp Ser Ala
                               -40
gct ttc tct gca ctg acc gtg act gca atg tca tcc tgg gct cgg cgc      340
Ala Phe Ser Ala Leu Thr Val Thr Ala Met Ser Ser Trp Ala Arg Arg
-35                               -30                               -25                               -20
agg agt tcc tca agc cgt cgg att cct tct ctg ccg ggg agc ccc gtg      388
Arg Ser Ser Ser Ser Arg Arg Ile Pro Ser Leu Pro Gly Ser Pro Val
                               -15                               -10                               -5
tgc tgg gcc tgg cca tgg tac ccg gac acc aca tcg ttt cca ttg agg      436
Cys Trp Ala Trp Pro Trp Tyr Pro Asp Thr Thr Ser Phe Pro Leu Arg
      1                               5                               10
tgc aga ggg aga gtc tgaccggggc tccgtatctc tgaccacgat ggcgcttacc      491
Cys Arg Gly Arg Val
      15
tttcagactt cattaaactt atgaccaaaa aaaaaaaaaa      531
<210> 67
<211> 783
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 381..629
<223> Von Heijne matrix
      score 8.60000038146973
      seq LELLTSCSPASA/SQ
<221> polyA_signal
<222> 736..741
<221> polyA_site
<222> 770..783
<221> misc_feature
<222> 207..263
<223> homology

```

```

id :AA357230
est
<300>
<400> 67
agggaacttcc ggcctcgctg gcgtggacgt ttgtgggtggg gcgtgttggg ccgcgctctc      60
agaactgtgc tgggaaggat ggtagggcga ctggggctca cctccgcacc gttgtaggac      120
ccggggtagg gttttgagcc cgtgggagct gccccacgcg gcctcgctct gccaacggtc      180
ggatggcgga gacgaaggac gcagcgacga tgttgggtgac cttcaaggat gtggctgtga      240
cctttaccgg ggaggagtgg agacagctgg acctggccca gaggaccctg taccgagagg      300
tgatcggggt cccaaaccag agttgggtcca cctgctagag catgggcagg agctgtggat      360
agtgaagaga ggcctctcac atg cta cct gtg cag agt ttc act ctt gtt gcc      413
Met Leu Pro Val Gln Ser Phe Thr Leu Val Ala
-80 -75
cag gct gga gtg cag tgg cgc cat ctc agc tca ctg caa ctt ctg cct      461
Gln Ala Gly Val Gln Trp Arg His Leu Ser Ser Leu Gln Leu Leu Pro
-70 -65 -60
ccc gag ttc aag gga ttc tcc tgc ctc agc ctc ccg agt agc tgg gat      509
Pro Glu Phe Lys Gly Phe Ser Cys Leu Ser Leu Pro Ser Ser Trp Asp
-55 -50 -45
tac agg cgc cca cca cca tgc ccg gct ggt ttt ttt gta ttt tta gta      557
Tyr Arg Arg Pro Pro Pro Cys Pro Ala Gly Phe Phe Val Phe Leu Val
-40 -35 -30 -25
gag acg ggg ctt cac cat gtt ggc cag gct ggt ctt gaa ctc ttg acc      605
Glu Thr Gly Leu His His Val Gly Gln Ala Gly Leu Glu Leu Leu Thr
-20 -15 -10
tca tgt agt cca ccc gcc tct gcc tcc caa agt gct gcg att aca ggc      653
Ser Cys Ser Pro Pro Ala Ser Ala Ser Gln Ser Ala Ala Ile Thr Gly
-5 1 5
gtg agc cac gtg ccc ggc aaa aaa aaa ctg ctt aag gtt gaa aag aaa      701
Val Ser His Val Pro Gly Lys Lys Lys Leu Leu Lys Val Glu Lys Lys
10 15 20
aat tta aga aaw ttg ctg acg gra ata aaa acy taataaaaact accacccgaa      754
Asn Leu Arg Xaa Leu Thr Xaa Ile Lys Thr
25 30 35
ggaatgaaaa aacccaaaaa aaaaaaaaaa      783
<210> 68
<211> 996
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 140..205
<223> Von Heijne matrix
score 5.90000009536743
seq IILGCLALFLLLQ/RK
<221> polyA_signal
<222> 965..970
<221> polyA_site
<222> 984..996
<221> misc_feature
<222> 676..959
<223> homology
id :AA399103
est
<221> misc_feature
<222> 609..679
<223> homology
id :AA399103
est
<221> misc_feature
<222> 225..433
<223> homology
id :AA398040

```



```

      est
<221> misc_feature
<222> 433..563
<223> homology
      id :AA398040
      est
<300>
<400> 68
aacagttacg aaggagagct gcaaaagttg cagcagaaaag gttgggagtc cgcacaggtt      60
ccgtagccca cagaaaaagaa gcaagggacg gcaggactgt ttcacacttt tctgcttctg      120
gaagggtgctg gacaaaaaac atg gaa cta att tcc cca aca gtg att ata atc      172
      Met Glu Leu Ile Ser Pro Thr Val Ile Ile Ile
      -20
ctg ggt tgc ctt gct ctg ttc tta ctc ctt cag cgg aag aat ttg cgc      220
Leu Gly Cys Leu Ala Leu Phe Leu Leu Leu Gln Arg Lys Asn Leu Arg
      -10      -5      1      5
aga ccc ccg tgc atc aag ggc tgg att cct tgg att gga gtt gga ttt      268
Arg Pro Pro Cys Ile Lys Gly Trp Ile Pro Trp Ile Gly Val Gly Phe
      10      15      20
gak ttt ggg aaa gcc cct cta gaa ttt ata gag aaa gca aga atc aag      316
Xaa Phe Gly Lys Ala Pro Leu Glu Phe Ile Glu Lys Ala Arg Ile Lys
      25      30      35
gta tgt ggt cgt ggc ava cgg ggt ctc cag agg aga caa tgc ttt ctt      364
Val Cys Gly Arg Gly Xaa Arg Gly Leu Gln Arg Arg Gln Cys Phe Leu
      40      45      50
ttt taaactttct ttcattgact ctttaagtga gggctagaac acggggaaca      417
Phe
tacctgcttg cctcaaaacta aaggatctag tcmtytctga aktcctctac tsacrtrtra      477
caacaatatc ctgtgcaaaa ttttgcaaaa gaaatgaaat acaattgcmg cgtgcatcga      537
catttttggg agtagagatt aacyyttcgt atttttactt cmtcgaagtt aagttccaaa      597
tgtgtatgtg ttaagtaaat gtttttcagta aytgggaaaag ataaagtgtg atccaattta      657
agtttgtgaa aatgagtaat tccgtatcca aaytggagtt aacaccaaag tattgtacaa      717
attgcttgca cagttgggtcc gtacacaata gacaggctyt gtatttttag ctgacgttgt      777
tatttgatga tgatgtactc cattttcamt acggcccgaa gagamtagta atcctccttg      837
tagtagatgt ttttgccttg aaagtatctt ttaaagtgtt gagcacttta aggaacagac      897
ccttattaat gtyttttaag ttttattcaa tttccagtca caaatatttt atggtatttg      957
attgtytaat aaatttgtat gatattaaaa aaaaaaaaaa      996
<210> 69
<211> 657
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 183..338
<223> Von Heijne matrix
      score 3.79999995231628
      seq VMLETCGLLVSLG/QS
<221> polyA_signal
<222> 620..625
<221> polyA_site
<222> 644..657
<221> misc_feature
<222> 207..263
<223> homology
      id :AA357230
      est
<300>
<400> 69
agggacttcc ggcctcgctg gcgtggacgt ttgtgggtggg gcgtggttggg ccgcgctctc      60
agaactgtgc tgggaaggat ggtagggcga ctgggggtca cctccgcacc gttgtaggac      120
ccggggtagg gttttgagcc cgtgggagct gccccacgcg gcctcgtcct gccaacggtc      180
gg atg gcg gag acg aag gac gca gcg cag atg ttg gtg acc ttc aag      227
      Met Ala Glu Thr Lys Asp Ala Ala Gln Met Leu Val Thr Phe Lys
```

72

-50	-45	-40	
gat gtg gct gtg acc ttt acc cgg gag gag tgg aga cag ctg gac ctg			275
Asp Val Ala Val Thr Phe Thr Arg Glu Glu Trp Arg Gln Leu Asp Leu			
-35	-30	-25	
gcc cag agg acc ctg tac cga gag gtg atg ctg gag acc tgt ggg ctt			323
Ala Gln Arg Thr Leu Tyr Arg Glu Val Met Leu Glu Thr Cys Gly Leu			
-20	-15	-10	
ctg gtt tca cta ggg caa agc att tgg ctg cat ata aca gaa aac cag			371
Leu Val Ser Leu Gly Gln Ser Ile Trp Leu His Ile Thr Glu Asn Gln			
-5	1	5	10
atc aaa ctg gct tca cct gga agg aaa ttc act aac tcg cct gat gag			419
Ile Lys Leu Ala Ser Pro Gly Arg Lys Phe Thr Asn Ser Pro Asp Glu			
15	20	25	
aag cct gag gtg tgg ttg gct cca ggc ctg ttc ggt gcc gca gcc cag			467
Lys Pro Glu Val Trp Leu Ala Pro Gly Leu Phe Gly Ala Ala Ala Gln			
30	35	40	
tgacgccatc aaggatgtct tggttctctg ttccttcttc ttgggttcagg cttctggatt			527
gtcctcaggc tggctcctca tagggatgct ggggtgctgca gccttgactg gggcagcagg			587
cccccatggt tcaatccatc ctcccacctt ggaataaatg ctttcttttc acaatgagaa			647
aaaaaaaaaa			657
<210> 70			
<211> 416			
<212> DNA			
<213> Homo sapiens			
<220>			
<221> sig_peptide			
<222> 140..205			
<223> Von Heijne matrix			
score 5.90000009536743			
seq IILGCLALFLLLQ/RK			
<221> polyA_signal			
<222> 383..388			
<221> polyA_site			
<222> 405..416			
<221> misc_feature			
<222> 225..316			
<223> homology			
id :AA398040			
est			
<300>			
<400> 70			
aacagttacg aaggagagct gcaaaagtgt cagcagaaag gttgggagtc cgcacaggtt			60
ccgtagccca cagaaaagaa gcaagggacg gcaggactgt ttcacacttt tctgcttctg			120
gaagggtgctg gacaaaaac atg gaa cta att tcc cca aca gtg att ata atc			172
Met Glu Leu Ile Ser Pro Thr Val Ile Ile Ile			
-20	-15		
ctg ggt tgc ctt gct ctg ttc tta ctc ctt cag cgg aag aat ttg cgc			220
Leu Gly Cys Leu Ala Leu Phe Leu Leu Leu Gln Arg Lys Asn Leu Arg			
-10	-5	1	5
aga ccc ccg tgc atc aag ggc tgg att cct tgg att gga gtt gga ttt			268
Arg Pro Pro Cys Ile Lys Gly Trp Ile Pro Trp Ile Gly Val Gly Phe			
10	15	20	
gag ttt ggg aaa gcc cct cta gaa ttt ata gag aaa gca aga atc aag			316
Glu Phe Gly Lys Ala Pro Leu Glu Phe Ile Glu Lys Ala Arg Ile Lys			
25	30	35	
cat gga cca ata ttt aca gtc ttt gct atg gga aac cga atg acc ttt			364
Tyr Gly Pro Ile Phe Thr Val Phe Ala Met Gly Asn Arg Met Thr Phe			
40	45	50	
gtt act gaa gaa gga agg aat taatgtgttt ctaaaatcca aaaaaaaaaa a			416
Val Thr Glu Glu Gly Arg Asn			
55	60		
<210> 71			
<211> 543			

```

<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 129..176
<223> Von Heijne matrix
      score 4.80000019073486
      seq SLFIYIFLTCSNT/SP
<221> polyA_signal
<222> 513..518
<221> polyA_site
<222> 530..543
<221> misc_feature
<222> 264..500
<223> homology
      id :AA534039
      est
<221> misc_feature
<222> 205..315
<223> homology
      id :T82645
      est
<221> misc_feature
<222> 295..382
<223> homology
      id :T82645
      est
<221> misc_feature
<222> 375..405
<223> homology
      id :T82645
      est
<300>
<400> 71
actgtcccat tcctccccct acaacacaca cacctttcag gcagggasgn gatgagcttc      60
cagccccaag agtggaggct gccacatcct aacatasgta tctattgaaa aggaagcagt      120
gtgtatct atg att ata tct ctg ttc atc tat ata ttt ttg aca tgt agc      170
      Met Ile Ile Ser Leu Phe Ile Tyr Ile Phe Leu Thr Cys Ser
      -15 -10 -5
aac acc tct cca tct tat caa gga act caa ctc ggt ctg ggt ctc ccc      218
Asn Thr Ser Pro Ser Tyr Gln Gly Thr Gln Leu Gly Leu Gly Leu Pro
      1 5 10
agt gcc cag tgg tgg cct ttg aca ggt agg agg atg cag tgc tgc agg      266
Ser Ala Gln Trp Trp Pro Leu Thr Gly Arg Arg Met Gln Cys Cys Arg
      15 20 25 30
cta ttt tgt ttt ttg tta caa aac tgt ctt ttc cct ttt ccc ctc cac      314
Leu Phe Cys Phe Leu Leu Gln Asn Cys Leu Phe Pro Phe Pro Leu His
      35 40 45
ctg att cag cat gat ccc tgt gag ctg gtt ctc aca atc tcc tgg gac      362
Leu Ile Gln His Asp Pro Cys Glu Leu Val Leu Thr Ile Ser Trp Asp
      50 55 60
tgg gct gag gca ggg gct tcg ctc tat tct ccc taaccatact gtcttccttt      415
Trp Ala Glu Ala Gly Ala Ser Leu Tyr Ser Pro
      65 70
cccccttgcc acttagcagt tatccccca gctatgcctt ctcctccct cccttgccct      475
ggcatatatt gtgccttatt tatgtgcaa atataacatt aaactatcaa gtgaaaaaaa      535
aaaaaaaa
<210> 72
<211> 605
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide

```

<222> 285..341  
<223> Von Heijne matrix  
score 5.599999990463257  
seq PTLCVSSSPALWA/AS  
<221> polyA\_signal  
<222> 575..580  
<221> polyA\_site  
<222> 592..605  
<221> misc\_feature  
<222> 53..296  
<223> homology  
id :W07033  
est  
<221> misc\_feature  
<222> 348..432  
<223> homology  
id :W07033  
est  
<221> misc\_feature  
<222> 435..497  
<223> homology  
id :W07033  
est  
<221> misc\_feature  
<222> 293..337  
<223> homology  
id :W07033  
est  
<221> misc\_feature  
<222> 521..560  
<223> homology  
id :W07033  
est  
<221> misc\_feature  
<222> 489..520  
<223> homology  
id :W07033  
est  
<221> misc\_feature  
<222> 15..337  
<223> homology  
id :AA151004  
est  
<221> misc\_feature  
<222> 348..412  
<223> homology  
id :AA151004  
est  
<221> misc\_feature  
<222> 434..485  
<223> homology  
id :AA151004  
est  
<221> misc\_feature  
<222> 83..324  
<223> homology  
id :AA476506  
est  
<221> misc\_feature  
<222> 347..560  
<223> homology  
id :AA476506  
est

```

<221> misc_feature
<222> 16..347
<223> homology
      id :W56567
      est
<221> misc_feature
<222> 350..405
<223> homology
      id :W56567
      est
<221> misc_feature
<222> 433..470
<223> homology
      id :W56567
      est
<221> misc_feature
<222> 15..296
<223> homology
      id :AA147584
      est
<221> misc_feature
<222> 348..421
<223> homology
      id :AA147584
      est
<221> misc_feature
<222> 293..337
<223> homology
      id :AA147584
      est
<221> misc_feature
<222> 419..453
<223> homology
      id :AA147584
      est
<221> misc_feature
<222> 2..338
<223> homology
      id :AA281959
      est
<221> misc_feature
<222> 350..432
<223> homology
      id :AA281959
      est
<300>
<400> 72
aacgcctwta agacagcgga actaagaaaa gaagaggcct gtggacagaa caatcatgtc      60
tgactccctg gtggtgtgcg aggtagaccc agagctaaca gaaaagctga kgaaattccg      120
cttccgaaaa gagacagaca atgcagccat cataatgaag gtggacaaag accggcagat      180
ggtggtgctg gaggaagaat ttcagaacat ttccccagag gagctcaaaa tggagttgcc      240
ggagagacag cccagggttcg tggtttacag ctacaagtac gtgc atg acg atg gcc      296
                                         Met Thr Met Ala
gag tgt cct acc ctt tgt gtt tca tct tct cca gcc ctg tgg gct gca      344
Glu Cys Pro Thr Leu Cys Val Ser Ser Ser Pro Ala Leu Trp Ala Ala
-15                               -10                               -5                               1
agc gaa aca aca gat gat gta tgc agg gag taaaaacagg ctggtgcaga      394
Ser Glu Thr Thr Asp Asp Val Cys Arg Glu
      5                               10
cagcagagct cacaaagggtg ttcgaaatcc gcaccactga tgacctcact gaggcctggc      454
tccaagaaaa gttgtctttc ttctcgttgat ccttgggctg gggactgaat tcctgatgtc      514
tgagtcttca aggtgactgg ggacttggaa cccctaggac ctgaacaacc aaggacttta      574
aataaat tttt aaaatgcaaa aaaaaaaaaa a
                                         605

```

<210> 73  
<211> 864  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> sig\_peptide  
<222> 136..444  
<223> Von Heijne matrix  
score 4.90000009536743  
seq VYAFLGLTAPSGS/KE  
<221> polyA\_signal  
<222> 835..840  
<221> polyA\_site  
<222> 851..864  
<221> misc\_feature  
<222> 222..456  
<223> homology  
id :AA136758  
est  
<221> misc\_feature  
<222> 557..648  
<223> homology  
id :AA136758  
est  
<221> misc\_feature  
<222> 501..571  
<223> homology  
id :AA136758  
est  
<221> misc\_feature  
<222> 130..456  
<223> homology  
id :AA393612  
est  
<221> misc\_feature  
<222> 88..130  
<223> homology  
id :AA393612  
est  
<221> misc\_feature  
<222> 501..538  
<223> homology  
id :AA393612  
est  
<221> misc\_feature  
<222> 130..458  
<223> homology  
id :R59039  
est  
<221> misc\_feature  
<222> 71..130  
<223> homology  
id :R59039  
est  
<221> misc\_feature  
<222> 557..716  
<223> homology  
id :W48624  
est  
<221> misc\_feature  
<222> 365..456  
<223> homology  
id :W48624

```

      est
<221> misc_feature
<222> 501..571
<223> homology
      id :W48624
      est
<221> misc_feature
<222> 716..751
<223> homology
      id :W48624
      est
<221> misc_feature
<222> 222..458
<223> homology
      id :AA136810
      est
<221> misc_feature
<222> 501..581
<223> homology
      id :AA136810
      est
<221> misc_feature
<222> 587..668
<223> homology
      id :AA136810
      est
<221> misc_feature
<222> 130..419
<223> homology
      id :T35647
      est
<221> misc_feature
<222> 59..130
<223> homology
      id :T35647
      est
<221> misc_feature
<222> 557..852
<223> homology
      id :HUM093F06A
      est
<221> misc_feature
<222> 501..571
<223> homology
      id :HUM093F06A
      est
<221> misc_feature
<222> 130..384
<223> homology
      id :T35666
      est
<300>
<400> 73
aaagttctcc ttccaccttc ccccaccctt ctctgccaac cgctgtttca gcccctagct      60
ggattccagc cattgctgca gctgctccac agcccttttc aggaccctaaa caaccgcagc      120
cgctgttccc caggr atg gtg atc cgt gta tat att gca tct tcc tct ggc      171
          Met Val Ile Arg Val Tyr Ile Ala Ser Ser Ser Gly
          -100                                -95
tct aca gcg att aag aag aaa caa caa gat gtg ctt ggt ttc cta gaa      219
Ser Thr Ala Ile Lys Lys Lys Gln Gln Asp Val Leu Gly Phe Leu Glu
-90                                -85                                -80
gcc aac aaa ata gga ttt gaa gaa aaa gat att gca gcc aat gaa gag      267
Ala Asn Lys Ile Gly Phe Glu Glu Lys Asp Ile Ala Ala Asn Glu Glu

```

78

-75	-70	-65	-60	
aat cgg aag tgg atg aga gaa aat gta cct gaa aat agt cga cca gcc				315
Asn Arg Lys Trp Met Arg Glu Asn Val Pro Glu Asn Ser Arg Pro Ala				
	-55	-50	-45	
aca ggt aac ccc ctg cca cct cag att ttc aat gaa agc cag tat cgc				363
Thr Gly Asn Pro Leu Pro Pro Gln Ile Phe Asn Glu Ser Gln Tyr Arg				
	-40	-35	-30	
ggg gac tat gat gcc ttc ttt gaa gcc aga gaa aat aat gca gtg tat				411
Gly Asp Tyr Asp Ala Phe Phe Glu Ala Arg Glu Asn Asn Ala Val Tyr				
	-25	-20	-15	
gcc ttc tta ggc ttg aca gcc cca tct ggt tca aag gaa gca gga agg				459
Ala Phe Leu Gly Leu Thr Ala Pro Ser Gly Ser Lys Glu Ala Gly Arg				
	-10	-5	1	5
tgc aag caa agc agc aag cca tgaaccttga gcaactgtgct ttttaagcatc				510
Cys Lys Gln Ser Ser Lys Pro				
	10			
ctgaaaaatg agtctccatt gcttttataa aatagcagaa ttagctttgc sttcaaaaga				570
aataggstta atgttgaaat aatagattag ttgggttttc acatgcaaac amtcaaaatg				630
aatacaaaat taaaatttga acattatggt gattatgggt aggagaatgg gatattaaca				690
taaaattata ttaataagta gatatygtag aaatagtgtt gttacctgcc aagccatcct				750
gtatacacca atgatttttac aaagaaaaca cccttccctc cttytgccat tamtatggca				810
acctaagtgt atytgcagct ttacattaaa aaggagaaag agaaaaaaaaaaaa				864

<210> 74

<211> 1033

<212> DNA

<213> Homo sapiens

<220>

<221> sig\_peptide

<222> 200..427

<223> Von Heijne matrix  
score 4.69999980926514  
seq LIVYLLWVVSFIAS/SS

<221> polyA\_signal

<222> 1001..1006

<221> polyA\_site

<222> 1022..1033

<221> misc\_feature

<222> 55..406

<223> homology  
id :AA056667  
est

<221> misc\_feature

<222> 397..487

<223> homology  
id :AA056667  
est

<221> misc\_feature

<222> 527..584

<223> homology  
id :AA056667  
est

<221> misc\_feature

<222> 581..634

<223> homology  
id :AA056667  
est

<221> misc\_feature

<222> 397..700



<223> homology  
id :AA044187  
est  
<221> misc\_feature  
<222> 222..406  
<223> homology  
id :AA044187  
est  
<221> misc\_feature  
<222> 693..748  
<223> homology  
id :AA044187  
est  
<221> misc\_feature  
<222> 68..406  
<223> homology  
id :AA131958  
est  
<221> misc\_feature  
<222> 397..517  
<223> homology  
id :AA131958  
est  
<221> misc\_feature  
<222> 510..558  
<223> homology  
id :AA131958  
est  
<221> misc\_feature  
<222> 77..531  
<223> homology  
id :W95957  
est  
<221> misc\_feature  
<222> 527..558  
<223> homology  
id :W95957  
est  
<221> misc\_feature  
<222> 397..586  
<223> homology  
id :AA041216  
est  
<221> misc\_feature  
<222> 286..406  
<223> homology  
id :AA041216  
est  
<221> misc\_feature  
<222> 582..700  
<223> homology  
id :AA041216  
est  
<221> misc\_feature  
<222> 77..406  
<223> homology  
id :W95790  
est  
<221> misc\_feature  
<222> 397..539  
<223> homology  
id :W95790  
est

```

<221> misc_feature
<222> 474..760
<223> homology
      id :AA461134
      est
<221> misc_feature
<222> 788..940
<223> homology
      id :AA461134
      est
<300>
<400> 74
aagacgaggt catgaatcat gtgacggtgg cttgaggagg aacctgtctt taaagctgtc   60
cctgaagtga cagcggagag aaccaggcag cccagaaacc ccaggcgtgg agattgatcc   120
tgcgagagaa gggggttcat catggcggat gacctaaagc gattcttgta taaaaagtta   180
ccaagtgttg aagggtccc atg cca ttg ttg tgt cag ata gag atg gag tac   232
                Met Pro Leu Leu Cys Gln Ile Glu Met Glu Tyr
                -75                               -70
ctg tta tta aag tgg caa atg aca atg ctc cag agc atg ctt tgc gac   280
Leu Leu Leu Lys Trp Gln Met Thr Met Leu Gln Ser Met Leu Cys Asp
-65                               -60                               -55                               -50
ctg gtt tct tat cca ctt ttg ccc ttg caa cag acc aag gaa gca aac   328
Leu Val Ser Tyr Pro Leu Leu Pro Leu Gln Gln Thr Lys Glu Ala Asn
                -45                               -40                               -35
ttg gac ttt cca aaa ata aaa gta tca tct gtt act ata aca cct acc   376
Leu Asp Phe Pro Lys Ile Lys Val Ser Ser Val Thr Ile Thr Pro Thr
                -30                               -25                               -20
agg tgg ttc aat tta atc gtt tac ctt tgg gtg gtg agt ttc ata gcc   424
Arg Trp Phe Asn Leu Ile Val Tyr Leu Trp Val Val Ser Phe Ile Ala
                -15                               -10                               -5
agc agc agt gcc aat aca gga cta att gtc agc cta gaa aag gaa ctt   472
Ser Ser Ser Ala Asn Thr Gly Leu Ile Val Ser Leu Glu Lys Glu Leu
      1                               5                               10                               15
gct cca ttg ttt gaa gaa ctg aga caa gtt gtg gaa gtt tct   514
Ala Pro Leu Phe Glu Glu Leu Arg Gln Val Val Glu Val Ser
                20                               25
taatctgaca gtggtttcag tgtgtacctt atcttcatta taacaacaca atatcaatcc   574
agcaatcttt agactacaat aatactttta tccatgtgct caagaaaggg cccctttttc   634
caacttatac taaagagcta gcatatagat gtaatttata gatagatcag ttgctatatt   694
ttctgggtga gggctcttct tatttagtga gatctaggga taccacagaa atgggttcagt   754
ctatcaacag ctcccatgga gttagtctgg tcacagatat ggatgagaga ttytattcag   814
tggatcagaa tcaaactggt acattgatcc acttgagccg ttaagtgtg ccaattgtac   874
aatatgcca ggcttgca gaataaagccaa ctttttattg tgaataataa taaggacata   934
tttttyttca gattatgtt tatttytttg cattgagtga ggaacataaa atggcttggt   994
aaaagtaata aatcagttac aatcactaaa aaaaaaaaaa
<210> 75
<211> 499
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 68..133
<223> Von Heijne matrix
      score 9.80000019073486
      seq LVVFCLALQLVPG/SP
<221> polyA_signal
<222> 472..477
<221> polyA_site
<222> 490..499
<300>
<400> 75
aaacagcagt gcctgggtcaa acccagcaac ccttggccag aacttactca cccatcccac   60
tgacacc atg aag cct gtg ctg cct ctc cag ttc ctg gtg gtg ttc tgc   109

```

81

Met	Lys	Pro	Val	Leu	Pro	Leu	Gln	Phe	Leu	Val	Val	Phe	Cys			
-20														-15	-10	
cta	gca	ctg	cag	ctg	gtg	cct	ggg	agt	ccc	aag	cag	cgt	gtt	ctg	aag	157
Leu	Ala	Leu	Gln	Leu	Val	Pro	Gly	Ser	Pro	Lys	Gln	Arg	Val	Leu	Lys	
-5														1	5	
tat	atc	ttg	gaa	cct	cca	ccc	tgc	ata	tca	gca	cct	gaa	aac	tgt	act	205
Tyr	Ile	Leu	Glu	Pro	Pro	Pro	Cys	Ile	Ser	Ala	Pro	Glu	Asn	Cys	Thr	
10														15	20	
cac	ctg	tgt	aca	atg	cag	gaa	gat	tgc	gag	aaa	gga	ttt	cag	tgc	tgt	253
His	Leu	Cys	Thr	Met	Gln	Glu	Asp	Cys	Glu	Lys	Gly	Phe	Gln	Cys	Cys	
25														30	35	40
tcc	tcc	ttc	tgt	ggg	ata	gtc	tgt	tca	tca	gaa	aca	ttt	caa	aag	cgc	301
Ser	Ser	Phe	Cys	Gly	Ile	Val	Cys	Ser	Ser	Glu	Thr	Phe	Gln	Lys	Arg	
45														50	55	
aac	aga	atc	aaa	cac	aag	ggc	tca	gaa	gtc	atc	atg	cct	gcc	aac		346
Asn	Arg	Ile	Lys	His	Lys	Gly	Ser	Glu	Val	Ile	Met	Pro	Ala	Asn		
60														65	70	
tgaggcatat	ttcctagatc	atcttgcctc	tacgatgttt	tttcttggtc	caccttttagg										406	
aaggattatga	gaagcaagaa	actggaggcc	caatatctaa	cctgcaaate	gttttttgagt										466	
ttggcaataa	aggctaattc	acaaaaaaaa	aaa												499	
<210> 76																
<211> 978																
<212> DNA																
<213> Homo sapiens																
<220>																
<221> sig_peptide																
<222> 274..399																
<223> Von Heijne matrix																
score 5.19999980926514																
seq LLFDLVCHEFCQS/DD																
<221> polyA_signal																
<222> 943..948																
<221> polyA_site																
<222> 966..978																
<221> misc_feature																
<222> 335..518																
<223> homology																
id :AA206225																
est																
<221> misc_feature																
<222> 225..274																
<223> homology																
id :AA206225																
est																
<221> misc_feature																
<222> 812..861																
<223> homology																
id :AA206225																
est																
<221> misc_feature																
<222> 186..224																
<223> homology																
id :AA206225																
est																
<221> misc_feature																
<222> 708..748																
<223> homology																
id :AA206225																
est																
<221> misc_feature																
<222> 276..314																
<223> homology																
id :AA206225																

```
      est
<221> misc_feature
<222> 146..176
<223> homology
      id :AA206225
      est
<221> misc_feature
<222> 879..909
<223> homology
      id :AA206225
      est
<221> misc_feature
<222> 182..518
<223> homology
      id :C15003
      est
<221> misc_feature
<222> 708..748
<223> homology
      id :C15003
      est
<221> misc_feature
<222> 182..517
<223> homology
      id :HUM407E11B
      est
<221> misc_feature
<222> 170..202
<223> homology
      id :AA544037
      est
<221> misc_feature
<222> 517..595
<223> homology
      id :HUM00TW170
      est
<221> misc_feature
<222> 596..665
<223> homology
      id :HUM00TW170
      est
<221> misc_feature
<222> 697..748
<223> homology
      id :HUM00TW170
      est
<221> misc_feature
<222> 805..861
<223> homology
      id :HUM00TW170
      est
<221> misc_feature
<222> 212..369
<223> homology
      id :HUM169E08B
      est
<221> misc_feature
<222> 406..493
<223> homology
      id :HUM169E08B
      est
<221> misc_feature
<222> 542..595
```

```

<223> homology
      id :HUM00TW112
      est
<221> misc_feature
<222> 697..748
<223> homology
      id :HUM00TW112
      est
<300>
<400> 76
accaggaaca tccagctatt tatgatagca tttgcttcat tatgtcaagt tcaacaaatg      60
ttgacttgct ggtgaagggtg ggggaggttg tggacaagct ctttgatttg gatgagaaac      120
taatgttaag aatgggtcag aaatggggct gctcagcctc tggaccaacc ccaggaagag      180
tctgaagagc agccagtgtt tgggcttgtg ccctgtatac ttgaagctgc caaacaagta      240
cgttctgaaa atccagaatg gcttgatgtt tac atg cac att tta caa ctg ctt      294
                               Met His Ile Leu Gln Leu Leu
                               -40
act aca gtg gat gat gga att caa gca att gta cat tgt cct gac act      342
Thr Thr Val Asp Asp Gly Ile Gln Ala Ile Val His Cys Pro Asp Thr
-35                               -30                               -25                               -20
gga aaa gac att tgg aat tta ctt ttt gac ctg gtc tgc cat gaa ttc      390
Gly Lys Asp Ile Trp Asn Leu Leu Phe Asp Leu Val Cys His Glu Phe
                               -15                               -10                               -5
tgc cag tct gat gat cca gcc atc att ctt caa gaa cag aaa aca gtg      438
Cys Gln Ser Asp Asp Pro Ala Ile Ile Leu Gln Glu Gln Lys Thr Val
                               1                               5                               10
cta gcc tct gtt ttt tca gtg ttg tct gcc atc tat gcc tca cag act      486
Leu Ala Ser Val Phe Ser Val Leu Ser Ala Ile Tyr Ala Ser Gln Thr
                               15                               20                               25
gag caa gag tat cta aag ata gaa aaa gta gat ctt cct cta att gac      534
Glu Gln Glu Tyr Leu Lys Ile Glu Lys Val Asp Leu Pro Leu Ile Asp
30                               35                               40                               45
agc ctc att cgg gtc tta caa aat atg gaa cag tgt cag aaa aaa cca      582
Ser Leu Ile Arg Val Leu Gln Asn Met Glu Gln Cys Gln Lys Lys Pro
                               50                               55                               60
gag aac tcg gca gga gtc taacacagag gaaactaaaa ggactgattt      630
Glu Asn Ser Ala Gly Val
                               65
aacc caagat gatttccact tgaaaatctt aaaaggatat tgttatgggtg aagtttctgt      690
ctaataatctt ttcaggcatt aacaaaggag acggtggctc agggagtaaa ggaaggccgt      750
tgagcaaaca gaagtgttcc tctgcaattt caaaarcctt cttctttcta tagccctgt      810
gggtggaaga ttttattaaa atcctacgtg aagttgataa ggcgcttgct kgatgacttg      870
gaaaaaaamc ttccaagtt tgaaggttca gaastaaaaa rscktgaatg ggaattactt      930
sstgtbcaag aaaataaact ttatttttct cactgaaaaa aaaaaaaaa      978
<210> 77
<211> 587
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 421..465
<223> Von Heijne matrix
      score 3.90000009536743
      seq LVPLGQSFLSEP/RC
<221> polyA_signal
<222> 553..558
<221> polyA_site
<222> 575..587
<221> misc_feature
<222> 182..322
<223> homology
      id :T35951
      est

```

<221> misc\_feature  
<222> 32..132  
<223> homology  
    id :T35951  
    est  
<221> misc\_feature  
<222> 136..193  
<223> homology  
    id :T35951  
    est  
<221> misc\_feature  
<222> 182..322  
<223> homology  
    id :T35949  
    est  
<221> misc\_feature  
<222> 32..132  
<223> homology  
    id :T35949  
    est  
<221> misc\_feature  
<222> 136..193  
<223> homology  
    id :T35949  
    est  
<221> misc\_feature  
<222> 136..299  
<223> homology  
    id :AA381111  
    est  
<221> misc\_feature  
<222> 32..132  
<223> homology  
    id :AA381111  
    est  
<221> misc\_feature  
<222> 136..322  
<223> homology  
    id :AA381001  
    est  
<221> misc\_feature  
<222> 85..132  
<223> homology  
    id :AA381001  
    est  
<221> misc\_feature  
<222> 182..322  
<223> homology  
    id :HSCZQE041  
    est  
<221> misc\_feature  
<222> 136..193  
<223> homology  
    id :HSCZQE041  
    est  
<221> misc\_feature  
<222> 82..132  
<223> homology  
    id :HSCZQE041  
    est  
<221> misc\_feature  
<222> 316..428  
<223> homology

```

        id :AA477628
        est
<221> misc_feature
<222> 475..554
<223> homology
        id :AA477628
        est
<221> misc_feature
<222> 182..322
<223> homology
        id :HSC34G011
        est
<221> misc_feature
<222> 136..192
<223> homology
        id :HSC34G011
        est
<221> misc_feature
<222> 41..119
<223> homology
        id :AA090647
        est
<221> misc_feature
<222> 136..184
<223> homology
        id :AA090647
        est
<221> misc_feature
<222> 316..426
<223> homology
        id :AA505962
        est
<300>
<400> 77
aattcatttt tcactcctcc ctccctagggtc acactttttca gaaaaagaat ctgcatcctg      60
gaaaccagaa gaaaaaatatg agacggggaa tcatcgtgtg atgtgtgtgc tgcctttggc      120
tkwgtgtgk gaagtycckg ctccaggtgtt aggtacagtg tgtttgatcg tgggtggcttg      180
aggggaaccc gctgttcaga gctgtgactg cggctgcact cagagaagct gcccttggct      240
gctcgtagcg ccgggccttc tctcctcgtc atcatccaga gcagccagtg tccgggagggc      300
agaagatgcc ccactccagc ctctggactg ggggctctct tcagtggctg aatgtccagc      360
agagctattt ccttccacag ggggccttgc agggaaaggg ccaggacttg acatcttaag      420
atg cgt ctt gtc ccc ttg ggc cag tca ttt ccc ctc tct gag cct cgg      468
Met Arg Leu Val Pro Leu Gly Gln Ser Phe Pro Leu Ser Glu Pro Arg
-15 -10 -5 1
tgt ctt caa cct gtg aaa tgg gat cat aat cac tgc ctt acc tcc ctc      516
Cys Leu Gln Pro Val Lys Trp Asp His Asn His Cys Leu Thr Ser Leu
5 10 15
acg gtt gtt gtg agg act gag tgt gtg gaa gtt ttt cat aaa ctt tgg      564
Thr Val Val Val Arg Thr Glu Cys Val Glu Val Phe His Lys Leu Trp
20 25 30
atg cta gtg taaaaaaaaa aaaa
Met Leu Val
35
<210> 78
<211> 400
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 198..278
<223> Von Heijne matrix
score 4.90000009536743
seq CLLSYIALGAIHA/KI

```

```

<221> polyA_signal
<222> 364..369
<221> polyA_site
<222> 387..400
<300>
<400> 78
aactttgcct ggggtgtcttg cgttctgcac attccggagg accagcttcc ccatacagaag      60
tctgactcca tggaaaccag atggggcaac ggggtgggttc tagtgcagac tgtagctgca      120
gctcctctcc acctctagcc tgctcatttc cagctcagaa attctactaa tggcggtttt      180
tcttctctgaa aaaggaa atg aac agg gtc cct gct gat tct cca aat atg      230
                Met Asn Arg Val Pro Ala Asp Ser Pro Asn Met
                -25                               -20

tgt cta atc tgt tta ctg agt tac ata gca ctt gga gcc atc cat gca      278
Cys Leu Ile Cys Leu Leu Ser Tyr Ile Ala Leu Gly Ala Ile His Ala
-15                               -10                               -5

aaa atc tgt aga aga gca ttc cag gaa gag gga aga gca aat gca aag      326
Lys Ile Cys Arg Arg Ala Phe Gln Glu Glu Gly Arg Ala Asn Ala Lys
1           5           10           15

acg ggc gtg aga gct tgg tgc ata cag cca tgg gcc aaa taaagtttcc      375
Thr Gly Val Arg Ala Trp Cys Ile Gln Pro Trp Ala Lys
20           25

ttggaatagc caaaaaaaaa aaaaaa      400
<210> 79
<211> 1166
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 167..229
<223> Von Heijne matrix
      score 5.59999990463257
      seq LVLSLQFLLSYD/LF
<221> polyA_signal
<222> 1133..1138
<221> polyA_site
<222> 1154..1166
<221> misc_feature
<222> 22..377
<223> homology
      id :AA306911
      est
<221> misc_feature
<222> 424..540
<223> homology
      id :AA306911
      est
<221> misc_feature
<222> 376..424
<223> homology
      id :AA306911
      est
<221> misc_feature
<222> 4..458
<223> homology
      id :AA417777
      est
<221> misc_feature
<222> 10..447
<223> homology
      id :AA236327
      est
<221> misc_feature
<222> 279..714

```



```
<223> homology
      id :AA410332
      est
<221> misc_feature
<222> 680..893
<223> homology
      id :N32991
      est
<221> misc_feature
<222> 881..1023
<223> homology
      id :N32991
      est
<221> misc_feature
<222> 1056..1109
<223> homology
      id :N32991
      est
<221> misc_feature
<222> 1122..1153
<223> homology
      id :N32991
      est
<221> misc_feature
<222> 1024..1054
<223> homology
      id :N32991
      est
<221> misc_feature
<222> 703..893
<223> homology
      id :N24951
      est
<221> misc_feature
<222> 881..1023
<223> homology
      id :N24951
      est
<221> misc_feature
<222> 1056..1109
<223> homology
      id :N24951
      est
<221> misc_feature
<222> 1122..1153
<223> homology
      id :N24951
      est
<221> misc_feature
<222> 1024..1054
<223> homology
      id :N24951
      est
<221> misc_feature
<222> 225..563
<223> homology
      id :AA455215
      est
<221> misc_feature
<222> 544..631
<223> homology
      id :AA455215
      est
```

<221> misc\_feature  
 <222> 629..660  
 <223> homology  
     id :AA455215  
     est  
 <221> misc\_feature  
 <222> 680..793  
 <223> homology  
     id :N66437  
     est

<300>

<400> 79

```

aatgacaacc gacgttggag tttggagggtg cttgccttag agcaagggaa acagctctca    60
ttcaaaggaa ctagaagcct ctccctcagt ggtagggaga cagccaggag cggttttctg    120
ggaactgtgg gatgtgccct tggggggccc agaaaacaga aggaag atg ctc cag    175
                                   Met Leu Gln
                                   -20
acc agt aac tac agc ctg gtg ctc tct ctg cag ttc ctg ctg ctg tcc    223
Thr Ser Asn Tyr Ser Leu Val Leu Ser Leu Gln Phe Leu Leu Leu Ser
                                   -15                                   -10                                   -5
tat gac ctc ttt gtc aat tcc ttc tca gaa ctg ctc caa aag act cct    271
Tyr Asp Leu Phe Val Asn Ser Phe Ser Glu Leu Leu Gln Lys Thr Pro
                                   1                                   5                                   10
gtc atc cag ctt gtg ctc ttc atc atc cag gat att gca gtc ctc ttc    319
Val Ile Gln Leu Val Leu Phe Ile Ile Gln Asp Ile Ala Val Leu Phe
15                                   20                                   25                                   30
aac atc atc atc att ttc ctc atg ttc ttc aac acc tcc gtc ttc cag    367
Asn Ile Ile Ile Ile Phe Leu Met Phe Phe Asn Thr Ser Val Phe Gln
                                   35                                   40                                   45
gct ggc ctg gtc aac ctc cta ttc cat aag ttc aaa ggg acc atc atc    415
Ala Gly Leu Val Asn Leu Leu Phe His Lys Phe Lys Gly Thr Ile Ile
                                   50                                   55                                   60
ctg aca gct gtg tac ttt gcc ctc agc atc tcc ctt cat gtc tgg gtc    463
Leu Thr Ala Val Tyr Phe Ala Leu Ser Ile Ser Leu His Val Trp Val
                                   65                                   70                                   75
atg aac tta cgc tgg aaa aac tcc aac agc ttc ata tgg aca gat gga    511
Met Asn Leu Arg Trp Lys Asn Ser Asn Ser Phe Ile Trp Thr Asp Gly
                                   80                                   85                                   90
ctt caa atg ctg ttt gta ttc cag aga cta gca gca gtg ttg tac tgc    559
Leu Gln Met Leu Phe Val Phe Gln Arg Leu Ala Ala Val Leu Tyr Cys
95                                   100                                   105                                   110
tac ttc tat aaa cgg aca gcc gta aga cta ggc gat cct cac ttc tac    607
Tyr Phe Tyr Lys Arg Thr Ala Val Arg Leu Gly Asp Pro His Phe Tyr
                                   115                                   120                                   125
cag gac tct ttg tgg ctg cgc aag gag ttc atg caa gtt cga agg    652
Gln Asp Ser Leu Trp Leu Arg Lys Glu Phe Met Gln Val Arg Arg
                                   130                                   135                                   140
tgacctcttg tcacactgat ggatactttt ccttcctgat agaagccaca tttgctgctt    712
tgcagggaga gttggcccta tgcattgggca aacagctgga ctttccaagg aagggttcaga    772
ctagctgtgt tcagcattca agaaggaaga tccccctct tgcacaatta gagtgtcccc    832
atcggtctcc agtgccgcat cccttccttg ccttctacct ctgtccacc cccttccttc    892
ctctcctctc tgtaccattc attctccctg accggccttt cttgccgagg gttctgtggc    952
tcttaccctt gtgaagcttt tccttttagcc tgggacagaa ggacctcccg gccccaaaag    1012
gatctcccaag wtgaccaaaag gatgcgaaga gtgatagtta cgntgctcct gactgatcac    1072
accgcagaca ttttagatatt tatacccaag gcactttaaa aaaatgtttt ataaatagag    1132
aataaattga attyttgttc caaaaaaaaa aaaa
                                   1166
<210> 80
<211> 754
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 180..383

```

```
<223> Von Heijne matrix
      score 4.599999990463257
      seq LPFSLVSMMLVTQG/LV
<221> polyA_signal
<222> 722..727
<221> polyA_site
<222> 743..754
<221> misc_feature
<222> 116..450
<223> homology
      id :W68799
      est
<221> misc_feature
<222> 593..710
<223> homology
      id :W68799
      est
<221> misc_feature
<222> 18..117
<223> homology
      id :W68799
      est
<221> misc_feature
<222> 561..598
<223> homology
      id :W68799
      est
<221> misc_feature
<222> 48..511
<223> homology
      id :AA149518
      est
<221> misc_feature
<222> 593..673
<223> homology
      id :AA149518
      est
<221> misc_feature
<222> 535..710
<223> homology
      id :W80356
      est
<221> misc_feature
<222> 256..405
<223> homology
      id :W80356
      est
<221> misc_feature
<222> 432..511
<223> homology
      id :W80356
      est
<221> misc_feature
<222> 392..437
<223> homology
      id :W80356
      est
<221> misc_feature
<222> 535..710
<223> homology
      id :W80631
      est
<221> misc_feature
```

```

<222> 289..437
<223> homology
      id :W80631
      est
<221> misc_feature
<222> 432..511
<223> homology
      id :W80631
      est
<221> misc_feature
<222> 343..511
<223> homology
      id :AA142865
      est
<221> misc_feature
<222> 535..710
<223> homology
      id :AA142865
      est
<221> misc_feature
<222> 256..341
<223> homology
      id :AA142865
      est
<221> misc_feature
<222> 248..511
<223> homology
      id :AA405876
      est
<221> misc_feature
<222> 21..271
<223> homology
      id :AA405876
      est
<221> misc_feature
<222> 121..450
<223> homology
      id :W68728
      est
<221> misc_feature
<222> 592..710
<223> homology
      id :W68728
      est
<300>
<400> 80
aagacagggtg ggggtactcgg gaagctggag cgggccggcg gtgcagtcac gggggagcga      60
ggcctgctgg gcttggaac gagggactcg gcctcggagg cgaccagac cacacagaca      120
ctgggtcaag gagtaagcag aggataaaca actggaagga gagcaagcac aaagtcac      179
atg gct tca gcg tct gct cgt gga aac caa gat aaa gat gcc cat ttt      227
Met Ala Ser Ala Ser Ala Arg Gly Asn Gln Asp Lys Asp Ala His Phe
      -65      -60      -55
cca cca cca agc aag cag agc ctg ttg ttt tgt cca aaa tca aaa ctg      275
Pro Pro Pro Ser Lys Gln Ser Leu Phe Cys Pro Lys Ser Lys Leu
      -50      -45      -40
cac atc cac aga gca gag atc tca aag att atg cga gaa tgt cag gaa      323
His Ile His Arg Ala Glu Ile Ser Lys Ile Met Arg Glu Cys Gln Glu
      -35      -30      -25
gaa agt ttc tgg aag aga gct ctg cct ttt tct ctt gta agc atg ctt      371
Glu Ser Phe Trp Lys Arg Ala Leu Pro Phe Ser Leu Val Ser Met Leu
      -20      -15      -10      -5
gtc acc cag gga cta gtc tac caa ggt tat ttg gca gct aat tct aga      419
Val Thr Gln Gly Leu Val Tyr Gln Gly Tyr Leu Ala Ala Asn Ser Arg

```

91

1	5	10	
ttt gga tca ttg ccc aaa gtt gca ctt gct ggt ctc ttg gga ttt ggc			467
Phe Gly Ser Leu Pro Lys Val Ala Leu Ala Gly Leu Leu Gly Phe Gly			
15	20	25	
ctt gga aag gta tca tac ata gga gta tgc cag agt aaa ttc cat ttt			515
Leu Gly Lys Val Ser Tyr Ile Gly Val Cys Gln Ser Lys Phe His Phe			
30	35	40	
ttt gaa gat cag ctc cgt ggg gct ggt ttt ggt ccw aca gca			557
Phe Glu Asp Gln Leu Arg Gly Ala Gly Phe Gly Pro Thr Ala			
45	50	55	
taacaggcac tgcctcctta cctgtgagga atgcaaaata aagcatggat taagtgaagaa			617
gggagactct cagccttcag cttcctaaat tctgtgtctg tgactttcga agtttttttaa			677
acctctgaat ttgtacacat ttaaaatttc aaggtgtact ttaaaatnaa aatacttcta			737
atgtvaaaaa aaaaaaa			754

<210> 81

<211> 709

<212> DNA

<213> Homo sapiens

<220>

<221> sig\_peptide

<222> 179..298

<223> Von Heijne matrix

score 4.30000019073486

seq ITLVSAAPGKVIC/EM

<221> polyA\_signal

<222> 680..685

<221> polyA\_site

<222> 697..708

<221> misc\_feature

<222> 137..291

<223> homology

id :AA121372

est

<221> misc\_feature

<222> 6..91

<223> homology

id :AA121372

est

<221> misc\_feature

<222> 318..397

<223> homology

id :AA121372

est

<221> misc\_feature

<222> 95..132

<223> homology

id :AA121372

est

<221> misc\_feature

<222> 460..501

<223> homology

id :AA121372

est

<221> misc\_feature

<222> 432..465

<223> homology

id :AA121372

est

<221> misc\_feature

<222> 284..313

<223> homology

id :AA121372

est

<221> misc\_feature  
<222> 254..670  
<223> homology  
    id :AA614605  
    est  
<221> misc\_feature  
<222> 392..658  
<223> homology  
    id :T55234  
    est  
<221> misc\_feature  
<222> 271..327  
<223> homology  
    id :T55234  
    est  
<221> misc\_feature  
<222> 358..670  
<223> homology  
    id :AA121362  
    est  
<221> misc\_feature  
<222> 312..344  
<223> homology  
    id :AA121362  
    est  
<221> misc\_feature  
<222> 2..102  
<223> homology  
    id :T53974  
    est  
<221> misc\_feature  
<222> 150..258  
<223> homology  
    id :T53974  
    est  
<221> misc\_feature  
<222> 95..171  
<223> homology  
    id :T53974  
    est  
<221> misc\_feature  
<222> 322..628  
<223> homology  
    id :HSPD02295  
    est  
<221> misc\_feature  
<222> 445..670  
<223> homology  
    id :AA454502  
    est  
<221> misc\_feature  
<222> 2..102  
<223> homology  
    id :R09314  
    est  
<221> misc\_feature  
<222> 95..171  
<223> homology  
    id :R09314  
    est  
<221> misc\_feature  
<222> 150..222  
<223> homology

```

id :R09314
est
<300>
<400> 81
aaaatcgcg accaccggg ctgccaketc gcctgactcc cggcctcttg cgctcctagg      60
ggcggagaag ggtgcgggct cttcgccctt tgtgtccttc tttcactaac ttctggactt      120
tccagctctt ccgaagttcg ttcttgcgca aagcccaaag gctggaaaac cgtccacg      178
atg acc agc atg act cag tct ctg cgg gag gtg ata aag gcc atg acc      226
Met Thr Ser Met Thr Gln Ser Leu Arg Glu Val Ile Lys Ala Met Thr
-40          -35          -30          -25
aag gct cgc aat ttt gag aga gtt ttg gga aag att act ctt gtc tct      274
Lys Ala Arg Asn Phe Glu Arg Val Leu Gly Lys Ile Thr Leu Val Ser
-20          -15          -10
gct gct cct ggg aaa gtg att tgt gaa atg aaa gta gaa gaa gag cat      322
Ala Ala Pro Gly Lys Val Ile Cys Glu Met Lys Val Glu Glu Glu His
-5          1          5
acc aat gca ata ggc act ctc cac ggc ggt ttg aca gcc acg tta gta      370
Thr Asn Ala Ile Gly Thr Leu His Gly Gly Leu Thr Ala Thr Leu Val
10          15          20
gat aac ata tca aca atg gct ctg cta tgc acg gaa agg gga gca ccc      418
Asp Asn Ile Ser Thr Met Ala Leu Leu Cys Thr Glu Arg Gly Ala Pro
25          30          35          40
gga gtc agt gtc gat atg aac ata acg tac atg tca cct gca aaa tta      466
Gly Val Ser Val Asp Met Asn Ile Thr Tyr Met Ser Pro Ala Lys Leu
45          50          55
gga gag gat ata gtg att aca gca cat gtt ctg aag caa gga aaa aca      514
Gly Glu Asp Ile Val Ile Thr Ala His Val Leu Lys Gln Gly Lys Thr
60          65          70
ctt gca ttt acc tct gtg ggt ctg acc aac aag gcc aca gga aaa tta      562
Leu Ala Phe Thr Ser Val Gly Leu Thr Asn Lys Ala Thr Gly Lys Leu
75          80          85
ata gca caa gga aga cac aca aaa cac ctg gga aac tgagagaaca      608
Ile Ala Gln Gly Arg His Thr Lys His Leu Gly Asn
90          95          100
gcagaatgac ctaaagaaac ccaacaatga atatcaagta tagatttgac tcaaacaatt      668
gtaatttttg aaataaacta gcaaaaccaa aaaaaaaaaa g      709
<210> 82
<211> 243
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 100..171
<223> Von Heijne matrix
score 3.70000004768372
seq ILFNLLIFLCGFT/NY
<221> polyA_signal
<222> 211..216
<221> polyA_site
<222> 230..243
<221> misc_feature
<222> 2..164
<223> homology
id :H64488
est
<221> misc_feature
<222> 2..164
<223> homology
id :AA131065
est
<221> misc_feature
<222> 5..164
<223> homology

```

```
      id :AA224847
      est
<221> misc_feature
<222> 10..164
<223> homology
      id :AA161042
      est
<221> misc_feature
<222> 2..84
<223> homology
      id :AA088770
      est
<221> misc_feature
<222> 104..164
<223> homology
      id :AA088770
      est
<221> misc_feature
<222> 10..164
<223> homology
      id :AA100852
      est
<221> misc_feature
<222> 79..164
<223> homology
      id :AA146774
      est
<221> misc_feature
<222> 79..164
<223> homology
      id :AA146605
      est
<221> misc_feature
<222> 109..164
<223> homology
      id :AA299239
      est
<221> misc_feature
<222> 158..207
<223> homology
      id :AA037885
      est
<221> misc_feature
<222> 160..207
<223> homology
      id :AA480512
      est
<221> misc_feature
<222> 160..207
<223> homology
      id :AA468030
      est
<221> misc_feature
<222> 160..207
<223> homology
      id :AA420727
      est
<221> misc_feature
<222> 160..207
<223> homology
      id :AA574382
      est
<221> misc_feature
```



```

<222> 160..207
<223> homology
      id :AA133048
      est
<221> misc_feature
<222> 200..229
<223> homology
      id :AA469266
      est
<221> misc_feature
<222> 200..229
<223> homology
      id :AA550735
      est
<221> misc_feature
<222> 200..229
<223> homology
      id :AA601071
      est
<221> misc_feature
<222> 200..229
<223> homology
      id :AA225190
      est
<300>
<400> 82
aactcagtg caacacccgg gagctgtttt gtcctttgtg gagcctcagc agttccctct      60
ttcagaactc actgccaaga gccctgaaca ggagccacc atg cag tgc ttc agc      114
                                   Met Gln Cys Phe Ser
                                   -20
ttc att aag acc atg atg atc ctc ttc aat ttg ctc atc ttt ctg tgt      162
Phe Ile Lys Thr Met Met Ile Leu Phe Asn Leu Leu Ile Phe Leu Cys
      -15      -10      -5
ggc ttc acc aac tat acg gat ttt gag gac tca ccc tac ttc aaa atg      210
Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp Ser Pro Tyr Phe Lys Met
      1      5      10
cat aaa cct gtt aca atg taaaaaaaaa aaaaaa      243
His Lys Pro Val Thr Met
      15
<210> 83
<211> 829
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 346..408
<223> Von Heijne matrix
      score 5.5
      seq SFLPSALVIWTS/AF
<221> polyA_signal
<222> 792..797
<221> polyA_site
<222> 817..829
<221> misc_feature
<222> 260..464
<223> homology
      id :H57434
      est
<221> misc_feature
<222> 118..184
<223> homology
      id :H57434
      est

```

```
<221> misc_feature
<222> 56..113
<223> homology
      id :H57434
      est
<221> misc_feature
<222> 454..485
<223> homology
      id :H57434
      est
<221> misc_feature
<222> 118..545
<223> homology
      id :N27248
      est
<221> misc_feature
<222> 65..369
<223> homology
      id :H94779
      est
<221> misc_feature
<222> 471..519
<223> homology
      id :H94779
      est
<221> misc_feature
<222> 61..399
<223> homology
      id :H09880
      est
<221> misc_feature
<222> 408..452
<223> homology
      id :H09880
      est
<221> misc_feature
<222> 60..399
<223> homology
      id :H29351
      est
<221> misc_feature
<222> 393..432
<223> homology
      id :H29351
      est
<221> misc_feature
<222> 260..444
<223> homology
      id :AA459511
      est
<221> misc_feature
<222> 449..545
<223> homology
      id :AA459511
      est
<221> misc_feature
<222> 117..184
<223> homology
      id :AA459511
      est
<221> misc_feature
<222> 122..399
<223> homology
```

```

      id :T74091
      est
<221> misc_feature
<222> 393..434
<223> homology
      id :T74091
      est
<221> misc_feature
<222> 61..378
<223> homology
      id :HSC3CB081
      est
<221> misc_feature
<222> 118..399
<223> homology
      id :T82010
      est
<221> misc_feature
<222> 268..545
<223> homology
      id :W02860
      est
<221> misc_feature
<222> 268..545
<223> homology
      id :N44490
      est
<300>
<400> 83
actcctttta gcataggggc ttcggcgcca gcgccagcg ctagtcgggc tggtaagtgc      60
ctgatgccga gttccgtctc tcgcgtcttt tcctggtccc aggcaaagcg gasgnagatc      120
ctcaaacggc ctagtgcttc gcgcttccgg agaaaatcag cggctctaatt aattcctctg      180
gtttgttgaa gcagttacca agaattctca accctttccc acaaaagcta attgagtaca      240
cgttcctgtt gagtacacgt tcctgttgat ttacaaaagg tgcaggtatg agcaggtctg      300
aagactaaca ttttgtgaag ttgtaaaaca gaaaacctgt tagaa atg tgg tgg ttt      357
                                     Met Trp Trp Phe
                                     -20
cag caa ggc ctc agt ttc ctt cct tca gcc ctt gta att tgg aca tct      405
Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val Ile Trp Thr Ser
      -15      -10      -5
gct gct ttc ata ttt tca tac att act gca gta aca ctc cac cat ata      453
Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr Leu His His Ile
      1      5      10      15
gac ccg gct tta cct tat atc agt gac act ggt aca gta gct cca gaa      501
Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr Val Ala Pro Glu
      20      25      30
aaa tgc tta ttt ggg gca atg cta aat att gcg gca gtc tta tgt caa      549
Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala Val Leu Cys Gln
      35      40      45
aaa tagaaatcag gaagataatt caacttaaag aagttcattt catgaccaa      602
Lys
ctcttcagaa acatgtcttt acaagcatat ctcttgattt gctttctaca ctgttgaaatt      662
gtctggcaat atttctgcag tggaaaattt gatttagcta gttcttgact tggataaata      722
tggtaagggtg ggcttttccc cctgtgtaat tggctacsac gtcttacttg agccaagttg      782
gtaagttgaa ataaaatgat watgagagtg acacavaaaa aaaaaaa      829
<210> 84
<211> 674
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 177..233
<223> Von Heijne matrix

```

```
score 6.09999990463257
seq LALLWSLPASDLG/RS
<221> polyA_signal
<222> 644..649
<221> polyA_site
<222> 663..674
<221> misc_feature
<222> 194..592
<223> homology
      id :AA496246
      est
<221> misc_feature
<222> 1..100
<223> homology
      id :AA496246
      est
<221> misc_feature
<222> 99..202
<223> homology
      id :AA496246
      est
<221> misc_feature
<222> 187..592
<223> homology
      id :AA476481
      est
<221> misc_feature
<222> 594..661
<223> homology
      id :AA476481
      est
<221> misc_feature
<222> 188..592
<223> homology
      id :AA496245
      est
<221> misc_feature
<222> 594..661
<223> homology
      id :AA496245
      est
<221> misc_feature
<222> 194..444
<223> homology
      id :AA476480
      est
<221> misc_feature
<222> 1..102
<223> homology
      id :AA476480
      est
<221> misc_feature
<222> 99..187
<223> homology
      id :AA476480
      est
<221> misc_feature
<222> 437..592
<223> homology
      id :AA505488
      est
<221> misc_feature
<222> 594..661
```

```

<223> homology
      id :AA505488
      est
<221> misc_feature
<222> 441..592
<223> homology
      id :AA554685
      est
<221> misc_feature
<222> 594..661
<223> homology
      id :AA554685
      est
<221> misc_feature
<222> 414..503
<223> homology
      id :AA215595
      est
<221> misc_feature
<222> 510..539
<223> homology
      id :AA215595
      est
<300>
<400> 84
ataagtgaac cagaccaccc tgatggcatc cacagtgatg tcaagggttg ggctggccag      60
gggtgggttg actagaagca tttgggagta gtggccaggg gccctggacg ctagccacgg      120
agctgctgca cagagcctgg tgtccacaag cttccaggtt ggggttgag cctggg atg      179
                                         Met
agc ccc ggc agc gcc ttg gcc ctt ctg tgg tcc ctg cca gcc tct gac      227
Ser Pro Gly Ser Ala Leu Ala Leu Leu Trp Ser Leu Pro Ala Ser Asp
      -15      -10      -5
ctg ggc cgg tca gtc att gct gga ctc tgg cca cac act ggc gtt ctc      275
Leu Gly Arg Ser Val Ile Ala Gly Leu Trp Pro His Thr Gly Val Leu
      1      5      10
atc cac ttg gaa aca agc cag tct ttt ctg caa ggt cag ttg acc aag      323
Ile His Leu Glu Thr Ser Gln Ser Phe Leu Gln Gly Gln Leu Thr Lys
      15      20      25      30
agc ata ttt ccc ctc tgt tgt aca tcg ttg ttt tgt gtt tgt gtt gta      371
Ser Ile Phe Pro Leu Cys Cys Thr Ser Leu Phe Cys Val Cys Val Val
      35      40      45
aca gtg ggt gga ggg agg gtg ggg tct aca ttt gtt gca tgagtcgatg      420
Thr Val Gly Gly Gly Arg Val Gly Ser Thr Phe Val Ala
      50      55
ggtcagaact ttagtatacg catgcgtcct ctgagtgaca gggcattttg tcgaaaataa      480
gcaccttggt aactaaaccc ctctaatagc tataaaggct ttagttctgt attgattaag      540
ttactgtaaa agcttgggtt tatttttgta ggacttaatg gctaagaatt agggaacata      600
gcaagggggc tcctctgttg gagtaatgta aattgtaatt ataaataaac atgcaaacct      660
ttaaaaaaaaa aaaa
<210> 85
<211> 478
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 179..319
<223> Von Heijne matrix
      score 5.5
      seq SALLFFARPCVFC/FK
<221> polyA_signal
<222> 461..466
<221> polyA_site
<222> 465..478

```

<221> misc\_feature  
<222> 2..464  
<223> homology  
    id :AA310996  
    est  
<221> misc\_feature  
<222> 8..464  
<223> homology  
    id :AA312901  
    est  
<221> misc\_feature  
<222> 2..416  
<223> homology  
    id :AA401411  
    est  
<221> misc\_feature  
<222> 2..349  
<223> homology  
    id :R64030  
    est  
<221> misc\_feature  
<222> 56..464  
<223> homology  
    id :AA400108  
    est  
<221> misc\_feature  
<222> 126..273  
<223> homology  
    id :AA010825  
    est  
<221> misc\_feature  
<222> 2..147  
<223> homology  
    id :AA010825  
    est  
<221> misc\_feature  
<222> 358..435  
<223> homology  
    id :AA010825  
    est  
<221> misc\_feature  
<222> 78..464  
<223> homology  
    id :AA504732  
    est  
<221> misc\_feature  
<222> 90..441  
<223> homology  
    id :H60506  
    est  
<221> misc\_feature  
<222> 59..349  
<223> homology  
    id :AA346780  
    est  
<221> misc\_feature  
<222> 2..331  
<223> homology  
    id :AA281167  
    est  
<221> misc\_feature  
<222> 6..236  
<223> homology

```

      id :R35805
      est
<221> misc_feature
<222> 232..284
<223> homology
      id :R35805
      est
<221> misc_feature
<222> 41..307
<223> homology
      id :H13784
      est
<221> misc_feature
<222> 2..40
<223> homology
      id :H13784
      est
<221> misc_feature
<222> 64..280
<223> homology
      id :AA128122
      est
<221> misc_feature
<222> 293..349
<223> homology
      id :AA128122
      est
<221> misc_feature
<222> 332..385
<223> homology
      id :AA128122
      est
<221> misc_feature
<222> 163..420
<223> homology
      id :AA555127
      est
<300>
<400> 85
aagtccttcg cgccctcctc gccctcccca cgcacatcat gctccagttc ctgcttggat      60
ttacactggg caacgtgggt ggaatgtatc tggctcagaa ctatgatata ccaaacctgg      120
ctaaaaaact tgaagaaatt aaaaaggact tggatgccaa gaagaaaccc cctagtgc      178
atg aga ctg cct cca gca ctg cct tca gga tat act gat tct act gct      226
Met Arg Leu Pro Pro Ala Leu Pro Ser Gly Tyr Thr Asp Ser Thr Ala
      -45      -40      -35
ctt gag ggc ctc gtt tac tat ctg aac caa aag ctt ttg ttt tcg tct      274
Leu Glu Gly Leu Val Tyr Tyr Leu Asn Gln Lys Leu Leu Phe Ser Ser
      -30      -25      -20
cca gcc tca gca ctt ctc ttc ttt gct aga ccc tgt gtt ttt tgc ttt      322
Pro Ala Ser Ala Leu Leu Phe Phe Ala Arg Pro Cys Val Phe Cys Phe
      -15      -10      -5      1
aaa gca agc aaa atg ggg ccc caa ttt gag aac tac cca aca ttt cca      370
Lys Ala Ser Lys Met Gly Pro Gln Phe Glu Asn Tyr Pro Thr Phe Pro
      5      10      15
aca tac tca cct ctt ccc ata atc cct ttc caa ctg cat ggg agg ttc      418
Thr Tyr Ser Pro Leu Pro Ile Ile Pro Phe Gln Leu His Gly Arg Phe
      20      25      30
taagactgga attatggtgc tagattagta aacatgactt ttaatgaaaa aaaaacaaaa      478
<210> 86
<211> 952
<212> DNA
<213> Homo sapiens
<220>

```

102

```

<221> sig_peptide
<222> 112..237
<223> Von Heijne matrix
      score 7.19999980926514
      seq ILFSLSFLLVIIT/FP
<221> polyA_signal
<222> 910..915
<221> polyA_site
<222> 940..952
<300>
<400> 86
aatactttct cctctccctt ctcccaagca catctgagtt gctgcctgtt cttcacactt      60
agctccaaac ccatgaaaaa ttgccaagta taaaagcttc tcaagaatga g atg gat      117
                                     Met Asp
tct agg gtg tct tca cct gag aag caa gat aaa gag aat ttc gtg ggt      165
Ser Arg Val Ser Ser Pro Glu Lys Gln Asp Lys Glu Asn Phe Val Gly
-40                               -35          -30          -25
gtc aac aat aaa cgg ctt ggt gta tgt ggc tgg atc ctg ttt tcc ctc      213
Val Asn Asn Lys Arg Leu Gly Val Cys Gly Trp Ile Leu Phe Ser Leu
                               -20          -15          -10
tct ttc ctg ttg gtg atc att acc ttc ccc atc tcc ata tgg atg tgc      261
Ser Phe Leu Leu Val Ile Ile Thr Phe Pro Ile Ser Ile Trp Met Cys
                               -5              1              5
ttg aag att tgatcctggt cctgccatgc ataratgtgt ttgtcaaagt      310
Leu Lys Ile
10
tgacctccga acagttactt gcaacattcc tccacaagag atcctcacca rgagactccg      370
taactactca ggtagatgga gttgtctatt acagaatcta tagtgctgtc tcagcagtgg      430
ctaakgtcaa cgatgtccat caagcaacat ttctgctggc tcaaaccact ctgagaaatg      490
tcktagggac acaggacctt gtccccagat cttaggctgg acgagaagag atcgcccata      550
agcatccaga ctktacttga tgatgccacc gaactgggtg gggatccggg tggcccgagt      610
ggaaatcaaa gatgttcgga ttcccgtgca gttgcagaga tccatggcag ccgaggstga      670
ggccaccggg gaagsgagag ccaaggtcct tgcagctgaa ggagaaatga atgsttccaa      730
atccctgaag tcagcctcca tgggtgstggs tgagtytccc atagctytcc agstgsgsta      790
cctgcagacc ttgagcacgg tagccaccga gaagaatttt acgatttgtt ttcctbtgcc      850
catgaatata ctagagggca ttggtggcgt cagstatgat aaccacaaga agsttbscaa      910
ataaagcctg aggtcybctt gcggtagtca aaaaaaaaaa aa      952
<210> 87
<211> 131
<212> PRT
<213> Homo sapiens
<220>
<221> SIGNAL
<222> -13..-1
<300>
<400> 87
Met Leu Ala Val Ser Leu Thr Val Pro Leu Leu Gly Ala Met Met Leu
      -10                               -5              1
Leu Glu Ser Pro Ile Asp Pro Gln Pro Leu Ser Phe Lys Glu Pro Pro
      5              10              15
Leu Leu Leu Gly Val Leu His Pro Asn Thr Lys Leu Arg Gln Ala Glu
      20              25              30              35
Arg Leu Phe Glu Asn Gln Leu Val Gly Pro Glu Ser Ile Ala His Ile
      40              45              50
Gly Asp Val Met Phe Thr Gly Thr Ala Asp Gly Arg Val Val Lys Leu
      55              60              65
Glu Asn Gly Glu Ile Glu Thr Ile Ala Arg Phe Gly Ser Gly Pro Cys
      70              75              80
Lys Thr Arg Gly Asp Glu Pro Val Cys Gly Arg Pro Leu Gly Ile Arg
      85              90              95
Gly Arg Ala Gln Trp Asp Ser Leu Cys Gly Arg Cys Ile Gln Arg Asp
      100              105              110              115
Tyr Leu Lys

```



<210> 88  
 <211> 63  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -35...-1  
 <300>  
 <400> 88  
 Met Leu Thr Val Asn Asp Val Arg Phe Tyr Arg Asn Val Arg Ser Asn  
 -35 -30 -25 -20  
 His Phe Pro Phe Val Arg Leu Cys Gly Leu Leu His Leu Trp Leu Lys  
 -15 -10 -5  
 Val Phe Ser Leu Lys Gln Leu Lys Lys Lys Ser Trp Ser Lys Tyr Leu  
 1 5 10  
 Phe Glu Ser Cys Cys Tyr Arg Ser Leu Tyr Val Cys Val Phe Ile  
 15 20 25  
 <210> 89  
 <211> 163  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -31...-1  
 <300>  
 <400> 89  
 Met Ser Pro Ala Phe Arg Ala Met Asp Val Glu Pro Arg Ala Lys Gly  
 -30 -25 -20  
 Ser Phe Trp Ser Pro Leu Ser Thr Arg Ser Gly Gly Thr His Ala Cys  
 -15 -10 -5 1  
 Ser Ala Ser Met Arg Gln Pro Trp Ala Ser Pro Trp Ser Gln Gly Asn  
 5 10 15  
 Ile Ser Ser Thr Arg Pro Ser Leu Leu Arg Cys Ala Asn Ser Leu Pro  
 20 25 30  
 Ser Thr Lys Asp Lys Ala Lys Gly Pro Leu Leu Ala Gly His Pro Cys  
 35 40 45  
 Pro Ile Phe Ser Pro Gly Pro Phe Pro Cys Gly His Arg Glu Val Trp  
 50 55 60 65  
 Pro Glu Tyr Pro Thr Pro Ala Pro Leu His Pro Glu Leu Gly Ala Thr  
 70 75 80  
 Ser Glu Val Ser Ser Leu Ser Glu His Xaa Phe Pro Cys Ser Ser Arg  
 85 90 95  
 Gly Leu Ser Arg Leu Ser Asp Ala Gly Ala Xaa Xaa Pro Glu Xaa Lys  
 100 105 110  
 Gly Val Gln Pro Val Val Cys Lys Ala Leu Xaa Gly Thr Ala Glu Thr  
 115 120 125  
 Pro Pro Pro  
 130  
 <210> 90  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -32...-1  
 <300>  
 <400> 90  
 Met Leu Gly Thr Thr Gly Leu Gly Thr Gln Gly Pro Ser Gln Gln Ala  
 -30 -25 -20  
 Leu Gly Phe Phe Ser Phe Met Leu Leu Gly Met Gly Gly Cys Leu Pro  
 -15 -10 -5  
 Gly Phe Leu Leu Gln Pro Pro Asn Arg Ser Pro Thr Leu Pro Ala Ser  
 1 5 10 15

Thr Phe Ala His  
20

<210> 91

<211> 124

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> -97...-1

<300>

<400> 91

Met Ala Asp Asp Leu Lys Arg Phe Leu Tyr Lys Lys Leu Pro Ser Val  
-95 -90 -85  
Glu Gly Leu His Ala Ile Val Val Ser Asp Arg Asp Gly Val Pro Val  
-80 -75 -70  
Ile Lys Val Ala Asn Asp Asn Ala Pro Glu His Ala Leu Arg Pro Gly  
-65 -60 -55 -50  
Phe Leu Ser Thr Phe Ala Leu Ala Thr Asp Gln Gly Ser Lys Leu Gly  
-45 -40 -35  
Leu Ser Lys Asn Lys Ser Ile Ile Cys Tyr Tyr Asn Thr Tyr Gln Val  
-30 -25 -20  
Val Gln Phe Asn Arg Leu Pro Leu Val Val Ser Phe Ile Ala Ser Ser  
-15 -10 -5  
Ser Ala Asn Thr Gly Leu Ile Val Ser Leu Glu Lys Glu Leu Ala Pro  
1 5 10 15  
Leu Phe Glu Glu Leu Arg Gln Val Val Glu Ile Ser  
20 25

<210> 92

<211> 230

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> -24...-1

<300>

<400> 92

Met Ala Ser Leu Gly Leu Gln Leu Val Gly Tyr Ile Leu Gly Leu Leu  
-20 -15 -10  
Gly Leu Leu Gly Thr Leu Val Ala Met Leu Leu Pro Ser Trp Lys Thr  
-5 1 5  
Ser Ser Tyr Val Gly Ala Ser Ile Val Thr Ala Val Gly Phe Ser Lys  
10 15 20  
Gly Leu Trp Met Glu Cys Ala Thr His Ser Thr Gly Ile Thr Gln Cys  
25 30 35 40  
Asp Ile Tyr Ser Thr Leu Leu Gly Leu Pro Ala Asp Ile Xaa Ala Ala  
45 50 55  
Gln Ala Met Met Val Thr Ser Ser Ala Ile Ser Ser Leu Ala Cys Ile  
60 65 70  
Ile Ser Val Val Gly Met Xaa Cys Thr Val Phe Cys Gln Glu Ser Arg  
75 80 85  
Ala Lys Asp Arg Val Ala Val Ala Gly Gly Val Phe Phe Ile Leu Gly  
90 95 100  
Gly Leu Leu Gly Phe Ile Pro Val Ala Trp Asn Leu His Gly Ile Leu  
105 110 115 120  
Arg Asp Phe Tyr Ser Pro Leu Val Pro Asp Ser Met Lys Phe Glu Ile  
125 130 135  
Gly Glu Ala Leu Tyr Leu Gly Ile Ile Ser Ser Leu Phe Ser Leu Ile  
140 145 150  
Ala Gly Ile Ile Leu Cys Phe Ser Cys Ser Ser Gln Arg Asn Arg Ser  
155 160 165  
Asn Tyr Tyr Asp Ala Tyr Gln Ala Gln Pro Leu Ala Thr Arg Ser Ser  
170 175 180  
Pro Arg Pro Gly Gln Pro Pro Lys Val Lys Ser Glu Phe Asn Ser Tyr

185 190 105 195 200  
 Ser Leu Thr Gly Tyr Val  
 205

<210> 93  
 <211> 72  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -32...-1  
 <300>  
 <400> 93

Met Phe Ala Pro Ala Val Met Arg Ala Phe Arg Lys Asn Lys Thr Leu  
 -30 -25 -20  
 Gly Tyr Gly Val Pro Met Leu Leu Leu Ile Val Gly Gly Ser Phe Gly  
 -15 -10 -5  
 Leu Arg Glu Phe Ser Gln Ile Arg Tyr Asp Ala Val Lys Ser Lys Met  
 1 5 10 15  
 Asp Pro Glu Leu Glu Lys Lys Pro Lys Glu Asn Lys Ile Ser Leu Glu  
 20 25 30  
 Ser Glu Tyr Glu Gly Ser Ile Cys  
 35 40

<210> 94  
 <211> 91  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -36...-1  
 <300>  
 <400> 94

Met Asn Thr Phe Glu Pro Asp Ser Leu Ala Val Ile Ala Phe Phe Leu  
 -35 -30 -25  
 Pro Ile Trp Thr Phe Ser Ala Leu Thr Phe Leu Phe Leu His Leu Pro  
 -20 -15 -10 -5  
 Pro Ser Thr Ser Leu Phe Ile Asn Leu Ala Arg Gly Gln Ile Lys Gly  
 1 5 10  
 Pro Leu Gly Leu Ile Leu Leu Leu Ser Phe Cys Gly Gly Tyr Thr Lys  
 15 20 25  
 Cys Asp Phe Ala Leu Ser Tyr Leu Glu Ile Pro Asn Arg Ile Glu Phe  
 30 35 40  
 Ser Ile Met Asp Pro Lys Arg Lys Thr Lys Cys  
 45 50 55

<210> 95  
 <211> 106  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -32...-1  
 <300>  
 <400> 95

Met Phe Ala Pro Ala Val Met Arg Ala Phe Arg Lys Asn Lys Thr Leu  
 -30 -25 -20  
 Gly Tyr Gly Val Pro Met Leu Leu Leu Ile Val Gly Gly Ser Phe Gly  
 -15 -10 -5  
 Leu Arg Glu Phe Ser Gln Ile Arg Tyr Asp Ala Val Lys Gly Lys Met  
 1 5 10 15  
 Asp Pro Glu Leu Glu Lys Lys Leu Lys Glu Asn Lys Ile Ser Leu Glu  
 20 25 30  
 Ser Glu Tyr Glu Lys Ile Lys Asp Ser Lys Phe Asp Asp Trp Lys Asn  
 35 40 45  
 Ile Arg Gly Pro Arg Pro Trp Glu Asp Pro Asp Leu Leu Gln Gly Arg

50 55 106  
 60  
 Asn Pro Glu Ser Leu Lys Thr Lys Thr Thr  
 65 70  
 <210> 96  
 <211> 172  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -21...-1  
 <300>  
 <400> 96  
 Met Trp Trp Phe Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val  
 -20 -15 -10  
 Ile Trp Thr Ser Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr  
 -5 1 5 10  
 Leu His His Ile Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr  
 15 20 25  
 Val Ala Pro Glu Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala  
 30 35 40  
 Val Leu Cys Ile Ala Thr Ile Tyr Val Arg Tyr Lys Gln Val His Ala  
 45 50 55  
 Leu Ser Pro Glu Glu Asn Val Ile Ile Lys Leu Asn Lys Ala Gly Leu  
 60 65 70 75  
 Val Leu Gly Ile Leu Ser Cys Leu Gly Leu Ser Ile Val Ala Asn Phe  
 80 85 90  
 Gln Glu Asn Asn Pro Phe Cys Cys Thr Cys Lys Trp Ser Cys Ala Tyr  
 95 100 105  
 Leu Trp Tyr Gly Leu Ile Ile Tyr Val Cys Ser Asp His Pro Phe Leu  
 110 115 120  
 Pro Lys Cys Ser Pro Lys Ser Asn Gly Lys Thr Ser Leu Leu Asp Gln  
 125 130 135  
 Thr Val Val Gly Tyr Leu Val Trp Ser Lys Cys Thr  
 140 145 150  
 <210> 97  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -42...-1  
 <300>  
 <400> 97  
 Met Cys Phe Pro Glu His Arg Arg Gln Met Tyr Ile Gln Asp Arg Leu  
 -40 -35 -30  
 Asp Ser Val Thr Arg Arg Ala Arg Gln Gly Arg Ile Cys Ala Ile Leu  
 -25 -20 -15  
 Leu Leu Gln Ser Gln Cys Ala Tyr Trp Ala Leu Pro Glu Pro Arg Thr  
 -10 -5 1 5  
 Leu Asp Gly Gly His Leu Met Gln  
 10  
 <210> 98  
 <211> 46  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -22...-1  
 <300>  
 <400> 98  
 Met Gln Asn His Leu Gln Thr Arg Pro Leu Phe Leu Thr Cys Leu Phe  
 -20 -15 -10  
 Trp Pro Leu Ala Ala Leu Asn Val Asn Ser Thr Phe Glu Cys Leu Ile

-5                          1                          107  
Leu Gln Cys Ser Val Phe Ser Phe Ala Phe Phe Ala Leu Trp      10

<210> 99  
<211> 251  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SIGNAL  
<222> -28...-1  
<300>  
<400> 99

Met Trp Arg Leu Leu Ala Arg Ala Ser Ala Pro Leu Leu Arg Val Pro  
      -25                          -20                          -15  
Leu Ser Asp Ser Trp Ala Leu Leu Pro Ala Ser Ala Gly Val Lys Thr  
      -10                          -5                          1  
Leu Leu Pro Val Pro Ser Phe Glu Asp Val Ser Ile Pro Glu Lys Pro  
5                          10                          15                          20  
Lys Leu Arg Phe Ile Glu Arg Ala Pro Leu Val Pro Lys Val Arg Arg  
                        25                          30                          35  
Glu Pro Lys Asn Leu Ser Asp Ile Arg Gly Pro Ser Thr Glu Ala Thr  
                        40                          45                          50  
Glu Xaa Thr Glu Gly Asn Phe Ala Ile Leu Ala Leu Gly Gly Tyr  
                        55                          60                          65  
Leu His Trp Gly His Phe Glu Met Met Arg Leu Thr Ile Asn Arg Ser  
      70                          75                          80  
Met Asp Pro Lys Asn Met Phe Ala Ile Trp Arg Val Pro Ala Pro Phe  
85                          90                          95                          100  
Lys Pro Ile Thr Arg Lys Ser Val Gly His Arg Met Gly Gly Gly Lys  
                        105                          110                          115  
Gly Ala Ile Asp His Tyr Val Thr Pro Val Lys Ala Gly Arg Xaa Xaa  
                        120                          125                          130  
Val Glu Met Gly Gly Arg Cys Xaa Phe Glu Glu Val Gln Gly Phe Leu  
                        135                          140                          145  
Asp Gln Val Ala His Lys Leu Pro Phe Ala Ala Lys Ala Val Ser Arg  
      150                          155                          160  
Gly Thr Leu Glu Lys Met Arg Lys Asp Gln Glu Arg Glu Xaa Asn  
165                          170                          175                          180  
Asn Gln Asn Pro Trp Thr Phe Glu Arg Ile Ala Thr Ala Xaa Met Leu  
                        185                          190                          195  
Gly Ile Arg Lys Val Leu Ser Pro Tyr Asp Leu Thr His Lys Gly Lys  
                        200                          205                          210  
Xaa Trp Gly Lys Phe Tyr Met Pro Xaa Arg Val  
      215                          220

<210> 100  
<211> 77  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SIGNAL  
<222> -30...-1  
<300>  
<400> 100

Met Leu Arg Leu Asp Ile Ile Asn Ser Leu Val Thr Thr Val Phe Met  
-30                          -25                          -20                          -15  
Leu Ile Val Ser Val Leu Ala Leu Ile Pro Glu Thr Thr Thr Leu Thr  
                        -10                          -5                          1  
Val Gly Gly Gly Val Phe Ala Leu Val Thr Ala Val Cys Cys Leu Ala  
      5                          10                          15  
Asp Gly Ala Leu Ile Tyr Arg Lys Leu Leu Phe Asn Pro Ser Gly Pro  
      20                          25                          30  
Tyr Gln Lys Lys Pro Val His Glu Lys Lys Glu Val Leu  
35                          40                          45

108

<210> 101  
 <211> 81  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -31...-1  
 <300>  
 <400> 101  
 Met Ser Asn Thr His Thr Val Leu Val Ser Leu Pro His Pro His Pro  
 -30 -25 -20  
 Ala Leu Thr Cys Cys His Leu Gly Leu Pro His Pro Val Arg Ala Pro  
 -15 -10 -5 1  
 Arg Pro Leu Pro Arg Val Glu Pro Trp Asp Pro Arg Trp Gln Asp Ser  
 5 10 15  
 Glu Leu Arg Tyr Pro Gln Ala Met Asn Ser Phe Leu Asn Glu Arg Ser  
 20 25 30  
 Ser Pro Cys Arg Thr Leu Arg Gln Glu Ala Ser Ala Asp Arg Cys Asp  
 35 40 45  
 Leu  
 50  
 <210> 102  
 <211> 126  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -20...-1  
 <300>  
 <400> 102  
 Met Lys Val His Met His Thr Lys Phe Cys Leu Ile Cys Leu Leu Thr  
 -20 -15 -10 -5  
 Phe Ile Phe His His Cys Asn His Cys His Glu Glu His Asp His Gly  
 1 5 10  
 Pro Glu Ala Leu His Arg Gln His Arg Gly Met Thr Glu Leu Glu Pro  
 15 20 25  
 Ser Lys Phe Ser Lys Gln Ala Glu Asn Glu Lys Lys Tyr Tyr Ile  
 30 35 40  
 Glu Lys Leu Phe Glu Arg Tyr Gly Glu Asn Gly Arg Leu Ser Phe Phe  
 45 50 55 60  
 Gly Leu Glu Lys Leu Leu Thr Asn Leu Gly Leu Gly Glu Arg Lys Val  
 65 70 75  
 Val Glu Ile Asn His Glu Asp Leu Gly His Asp His Val Ser His Leu  
 80 85 90  
 Arg Tyr Phe Gly Ser Ser Arg Gly Lys Ala Phe Ser Leu Thr  
 95 100 105  
 <210> 103  
 <211> 273  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -45...-1  
 <300>  
 <400> 103  
 Met Asn Trp Ser Ile Phe Glu Gly Leu Leu Ser Gly Val Asn Lys Tyr  
 -45 -40 -35 -30  
 Ser Thr Ala Phe Gly Arg Ile Trp Leu Ser Leu Val Phe Ile Phe Arg  
 -25 -20 -15  
 Val Leu Val Tyr Leu Val Thr Ala Glu Arg Val Trp Ser Asp Asp His  
 -10 -5 1  
 Lys Asp Phe Asp Cys Asn Thr Arg Gln Pro Gly Cys Ser Asn Val Cys  
 5 10 15

109

Phe Asp Glu Phe Phe Pro Val Ser His Val Arg Leu Trp Ala Leu Gln  
 20 25 30 35  
 Leu Ile Leu Val Thr Cys Pro Ser Leu Leu Val Val Met His Val Ala  
 40 45 50  
 Tyr Arg Glu Val Gln Glu Lys Arg His Arg Glu Ala His Gly Glu Asn  
 55 60 65  
 Ser Gly Arg Leu Tyr Leu Asn Pro Gly Lys Lys Arg Gly Glu Leu Trp  
 70 75 80  
 Trp Thr Tyr Val Cys Ser Leu Val Phe Lys Ala Ser Val Asp Ile Ala  
 85 90 95  
 Phe Leu Tyr Val Phe His Ser Phe Tyr Pro Lys Tyr Ile Leu Pro Pro  
 100 105 110 115  
 Val Val Lys Cys His Ala Asp Pro Cys Pro Asn Ile Val Asp Cys Phe  
 120 125 130  
 Ile Ser Lys Pro Ser Glu Lys Asn Ile Phe Thr Leu Phe Met Val Ala  
 135 140 145  
 Thr Ala Ala Ile Cys Ile Leu Leu Asn Leu Val Glu Leu Ile Tyr Leu  
 150 155 160  
 Val Ser Lys Arg Cys His Glu Cys Leu Ala Ala Arg Lys Ala Gln Ala  
 165 170 175  
 Met Xaa Thr Gly His His Pro Xaa Asp Thr Thr Phe Ser Xaa Lys Gln  
 180 185 190 195  
 Xaa Asp Xaa Xaa Ser Gly Asp Xaa Ile Phe Leu Gly Ser Asp Ser His  
 200 205 210  
 Xaa Pro Xaa Leu Pro Asp Arg Pro Arg Asp His Val Lys Lys Thr Ile  
 215 220 225  
 Leu

<210> 104  
 <211> 158  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -37...-1  
 <300>  
 <400> 104

Met Ala Ser Lys Ile Leu Leu Asn Val Gln Glu Glu Val Thr Cys Pro  
 -35 -30 -25  
 Ile Cys Leu Glu Leu Leu Thr Glu Pro Leu Ser Leu Asp Cys Gly His  
 -20 -15 -10  
 Ser Leu Cys Arg Ala Cys Ile Thr Val Ser Asn Lys Glu Ala Val Thr  
 -5 1 5 10  
 Ser Met Gly Gly Lys Ser Ser Cys Pro Val Cys Gly Ile Ser Tyr Ser  
 15 20 25  
 Phe Glu His Leu Gln Ala Asn Gln His Arg Ala Asn Ile Val Glu Arg  
 30 35 40  
 Leu Lys Glu Val Lys Leu Ser Pro Asp Asn Gly Lys Lys Arg Asp Leu  
 45 50 55  
 Cys Asp His His Gly Glu Lys Leu Leu Leu Phe Cys Lys Glu Asp Arg  
 60 65 70 75  
 Lys Val Ile Cys Trp Leu Cys Glu Arg Ser Gln Glu His Arg Gly His  
 80 85 90  
 His Thr Gly Pro His Gly Gly Ser Ile Gln Gly Met Ser Gly Glu Thr  
 95 100 105  
 Pro Gly Ser Pro Gln Glu Ala Glu Gly Arg Gly Gly Ser  
 110 115 120

<210> 105  
 <211> 51  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -19...-1

&lt;300&gt;

&lt;400&gt; 105

Met Arg Thr Leu Phe Asn Leu Leu Trp Leu Ala Leu Ala Cys Ser Pro  
 -15 -10 -5

Val His Thr Thr Leu Ser Lys Ser Asp Ala Xaa Lys Pro Pro Gln Arg  
 1 5 10

Arg Cys Trp Arg Arg Val Ser Phe Gln Ile Ser Arg Cys Lys Thr Gly  
 15 20 25

Val Trp Trp

30

&lt;210&gt; 106

&lt;211&gt; 359

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -34..-1

&lt;300&gt;

&lt;400&gt; 106

Met Leu Leu Ser Ile Gly Met Leu Met Leu Ser Ala Thr Gln Val Tyr  
 -30 -25 -20

Thr Ile Leu Thr Val Gln Leu Phe Ala Phe Leu Asn Leu Leu Pro Val  
 -15 -10 -5

Glu Ala Asp Ile Leu Ala Tyr Asn Phe Glu Asn Ala Ser Gln Thr Phe  
 1 5 10

Asp Asp Leu Pro Ala Xaa Phe Gly Tyr Arg Leu Pro Ala Glu Gly Leu  
 15 20 25 30

Lys Gly Phe Leu Ile Asn Ser Lys Pro Glu Asn Ala Cys Glu Pro Ile  
 35 40 45

Val Pro Pro Pro Val Lys Asp Asn Ser Ser Gly Thr Phe Ile Val Leu  
 50 55 60

Ile Xaa Xaa Leu Asp Cys Asn Phe Asp Ile Lys Val Leu Asn Ala Gln  
 65 70 75

Arg Ala Gly Tyr Lys Ala Ala Ile Val His Asn Val Asp Ser Asp Asp  
 80 85 90

Leu Ile Ser Met Gly Ser Asn Asp Ile Glu Val Leu Lys Lys Ile Asp  
 95 100 105 110

Ile Pro Ser Val Phe Ile Gly Glu Ser Ser Ala Ser Ser Leu Lys Asp  
 115 120 125

Glu Phe Thr Xaa Glu Lys Gly Gly His Leu Ile Leu Val Pro Glu Phe  
 130 135 140

Ser Leu Pro Leu Glu Tyr Tyr Leu Ile Pro Phe Leu Ile Xaa Val Gly  
 145 150 155

Ile Cys Leu Ile Leu Ile Val Ile Phe Met Ile Thr Lys Leu Ser Arg  
 160 165 170

Asp Arg His Arg Ala Arg Arg Asn Arg Leu Arg Lys Asp Gln Leu Lys  
 175 180 185 190

Lys Leu Pro Val His Lys Phe Lys Lys Gly Asp Glu Tyr Asp Val Cys  
 195 200 205

Ala Ile Cys Leu Asp Glu Tyr Glu Asp Gly Asp Lys Leu Arg Ile Leu  
 210 215 220

Pro Cys Ser His Ala Tyr His Cys Lys Cys Val Asp Pro Trp Leu Thr  
 225 230 235

Lys Thr Lys Lys Thr Cys Pro Val Cys Arg Gln Lys Val Val Pro Ser  
 240 245 250

Gln Gly Asp Ser Asp Ser Asp Thr Asp Ser Ser Gln Glu Glu Asn Glu  
 255 260 265 270

Val Thr Glu His Thr Pro Leu Leu Arg Pro Leu Xaa Phe Cys Gln Cys  
 275 280 285

Pro Xaa Xaa Phe Gly Ala Leu Xaa Gly Xaa Pro Ala His Xaa Gln Xaa  
 290 295 300

His Asp Arg Ile Ile Gln Thr Xaa Glu Asp Asp Asn Glu Asp Thr  
 305 310 315



111

Asp Ser Ser Asp Ala Glu Glu  
 320 325  
 <210> 107  
 <211> 291  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -42...-1  
 <300>  
 <400> 107  
 Met Asp Ser Arg Val Ser Ser Pro Glu Lys Gln Asp Lys Glu Asn Phe  
 -40 -35 -30  
 Val Gly Val Asn Asn Lys Arg Leu Gly Val Cys Gly Trp Ile Leu Phe  
 -25 -20 -15  
 Ser Leu Ser Phe Leu Leu Val Ile Ile Thr Phe Pro Ile Ser Ile Trp  
 -10 -5 1 5  
 Met Cys Leu Lys Ile Ile Lys Glu Tyr Glu Arg Ala Val Val Phe Arg  
 10 15 20  
 Leu Gly Arg Ile Gln Ala Asp Lys Ala Lys Gly Pro Gly Leu Ile Leu  
 25 30 35  
 Val Leu Pro Cys Ile Asp Val Phe Val Lys Val Asp Leu Arg Thr Val  
 40 45 50  
 Thr Cys Asn Ile Pro Pro Gln Glu Ile Leu Thr Arg Asp Ser Val Thr  
 55 60 65 70  
 Thr Gln Val Asp Gly Val Val Tyr Tyr Arg Ile Tyr Ser Ala Val Ser  
 75 80 85  
 Ala Val Ala Asn Val Asn Asp Val His Gln Ala Thr Phe Leu Leu Ala  
 90 95 100  
 Gln Thr Thr Leu Arg Asn Val Leu Gly Thr Gln Thr Leu Ser Gln Ile  
 105 110 115  
 Leu Ala Gly Arg Glu Glu Ile Ala His Ser Ile Gln Thr Leu Leu Asp  
 120 125 130  
 Asp Ala Thr Glu Leu Trp Gly Ile Arg Val Ala Arg Val Glu Ile Lys  
 135 140 145 150  
 Asp Val Arg Ile Pro Val Gln Leu Gln Arg Ser Met Ala Ala Glu Ala  
 155 160 165  
 Glu Ala Thr Arg Glu Ala Arg Ala Lys Val Leu Ala Ala Glu Gly Glu  
 170 175 180  
 Met Ser Ala Ser Lys Ser Leu Lys Ser Ala Ser Met Val Leu Ala Glu  
 185 190 195  
 Ser Pro Ile Ala Leu Gln Leu Arg Tyr Leu Gln Thr Leu Ser Thr Val  
 200 205 210  
 Ala Thr Glu Lys Asn Ser Thr Ile Val Phe Pro Leu Pro Met Asn Ile  
 215 220 225 230  
 Leu Glu Gly Ile Gly Gly Val Ser Tyr Asp Asn His Lys Lys Leu Pro  
 235 240 245  
 Asn Lys Ala  
 <210> 108  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -26...-1  
 <300>  
 <400> 108  
 Met Ser Thr Trp Leu Leu Leu Ile Ala Leu Lys Thr Leu Ile Thr Trp  
 -25 -20 -15  
 Val Ser Leu Phe Ile Asp Cys Val Met Thr Arg Lys Leu Thr Asn Cys  
 -10 -5 1 5  
 Asn Ala Arg Glu Thr Ile Lys Gly Ile Gln Lys Arg Glu Ala Ser Asn  
 10 15 20

112

Cys Phe Ala Ile Arg His Phe Glu Asn Lys Phe Ala Val Glu Thr Leu  
 25 30 35  
 Ile Cys Ser  
 40  
 <210> 109  
 <211> 127  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -63...-1  
 <300>  
 <400> 109  
 Met Ser Ala Ala Gly Ala Arg Gly Leu Arg Ala Thr Tyr His Arg Leu  
 -60 -55 -50  
 Leu Asp Lys Val Glu Leu Met Leu Pro Glu Lys Leu Arg Pro Leu Tyr  
 -45 -40 -35  
 Asn His Pro Ala Gly Pro Arg Thr Val Phe Phe Trp Ala Pro Ile Met  
 -30 -25 -20  
 Lys Trp Gly Leu Val Cys Ala Gly Leu Ala Asp Met Ala Arg Pro Ala  
 -15 -10 -5 1  
 Glu Lys Leu Ser Thr Ala Gln Ser Ala Val Leu Met Ala Thr Gly Phe  
 5 10 15  
 Ile Trp Ser Arg Tyr Ser Leu Val Ile Ile Pro Lys Asn Trp Ser Leu  
 20 25 30  
 Phe Ala Val Asn Phe Phe Val Gly Ala Ala Gly Ala Ser Gln Leu Phe  
 35 40 45  
 Arg Ile Trp Arg Tyr Asn Gln Glu Leu Lys Ala Lys Ala His Lys  
 50 55 60  
 <210> 110  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -20...-1  
 <300>  
 <400> 110  
 Met Lys Gly Trp Gly Trp Leu Ala Leu Leu Leu Gly Ala Leu Leu Gly  
 -20 -15 -10 -5  
 Thr Ala Trp Ala Arg Arg Ser Arg Asp Leu His Cys Gly Ala Cys Arg  
 1 5 10  
 Ala Leu Val Asp Glu Leu Glu Trp Glu Ile Ala Gln Val Asp Pro Lys  
 15 20 25  
 Lys Thr Ile Gln Met Gly Ser Phe Arg Ile Asn Pro Asp Gly Ser Gln  
 30 35 40  
 Ser Val Val Glu Val Thr Val Thr Xaa Ser Pro Lys Thr Lys Val Ala  
 45 50 55 60  
 His Ser Gly Phe Trp Met Lys Ile Arg Leu Leu Lys Lys Gly Pro Trp  
 65 70 75  
 Ser  
 <210> 111  
 <211> 86  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -20...-1  
 <300>  
 <400> 111  
 Met Lys Gly Trp Gly Trp Leu Ala Leu Leu Leu Gly Ala Leu Leu Gly  
 -20 -15 -10 -5  
 Thr Ala Trp Ala Arg Arg Ser Gln Asp Leu His Cys Gly Ala Cys Arg

113  
 1 5 10  
 Ala Leu Val Asp Glu Thr Arg Met Gly Asn Cys Pro Gly Gly Pro Gln  
 15 20 25  
 Glu Asp His Ser Asp Gly Ile Phe Pro Asp Gln Ser Arg Trp Gln Pro  
 30 35 40  
 Val Ser Gly Gly Gly Ala Leu Cys Pro Leu Arg Gly Pro Pro His Arg  
 45 50 55 60  
 Ala Ala Gly Gly Asp Met  
 65  
 <210> 112  
 <211> 71  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -25...-1  
 <300>  
 <400> 112  
 Met Pro Ala Gly Val Pro Met Ser Thr Tyr Leu Lys Met Phe Ala Ala  
 -25 -20 -15 -10  
 Ser Leu Leu Ala Met Cys Ala Gly Ala Glu Val Val His Arg Tyr Tyr  
 -5 1 5  
 Arg Pro Asp Leu Thr Ile Pro Glu Ile Pro Pro Lys Arg Gly Glu Leu  
 10 15 20  
 Lys Thr Glu Leu Leu Gly Leu Lys Glu Arg Lys His Lys Pro Gln Val  
 25 30 35  
 Ser Gln Gln Glu Glu Leu Lys  
 40 45  
 <210> 113  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -42...-1  
 <300>  
 <400> 113  
 Met Asp Gly His Trp Ser Ala Ala Phe Ser Ala Leu Thr Val Thr Ala  
 -40 -35 -30  
 Met Ser Ser Trp Ala Arg Arg Ser Ser Ser Ser Arg Arg Ile Pro  
 -25 -20 -15  
 Ser Leu Pro Gly Ser Pro Val Cys Trp Ala Trp Pro Trp Tyr Pro Asp  
 -10 -5 1 5  
 Thr Thr Ser Phe Pro Leu Arg Cys Arg Gly Arg Val  
 10 15  
 <210> 114  
 <211> 118  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -83...-1  
 <300>  
 <400> 114  
 Met Leu Pro Val Gln Ser Phe Thr Leu Val Ala Gln Ala Gly Val Gln  
 -80 -75 -70  
 Trp Arg His Leu Ser Ser Leu Gln Leu Leu Pro Pro Glu Phe Lys Gly  
 -65 -60 -55  
 Phe Ser Cys Leu Ser Leu Pro Ser Ser Trp Asp Tyr Arg Arg Pro Pro  
 -50 -45 -40  
 Pro Cys Pro Ala Gly Phe Phe Val Phe Leu Val Glu Thr Gly Leu His  
 -35 -30 -25 -20  
 His Val Gly Gln Ala Gly Leu Glu Leu Leu Thr Ser Cys Ser Pro Pro

114

-15                      -        10                      -5  
Ala Ser Ala Ser Gln Ser Ala Ala Ile Thr Gly Val Ser His Val Pro  
                        1                      5                      10  
Gly Lys Lys Lys Leu Leu Lys Val Glu Lys Lys Asn Leu Arg Xaa Leu  
                        15                      20                      25  
Leu Thr Xaa Ile Lys Thr  
30                      35  
<210> 115  
<211> 76  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SIGNAL  
<222> -22...-1  
<300>  
<400> 115  
Met Glu Leu Ile Ser Pro Thr Val Ile Ile Ile Leu Gly Cys Leu Ala  
                        -20                      -15                      -10  
Leu Phe Leu Leu Leu Gln Arg Lys Asn Leu Arg Arg Pro Pro Cys Ile  
                        -5                      1                      5                      10  
Lys Gly Trp Ile Pro Trp Ile Gly Val Gly Phe Xaa Phe Gly Lys Ala  
                        15                      20                      25  
Pro Leu Glu Phe Ile Glu Lys Ala Arg Ile Lys Val Cys Gly Arg Gly  
                        30                      35                      40  
Xaa Arg Gly Leu Gln Arg Arg Gln Cys Phe Leu Phe  
                        45                      50  
<210> 116  
<211> 95  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SIGNAL  
<222> -52...-1  
<300>  
<400> 116  
Met Ala Glu Thr Lys Asp Ala Ala Gln Met Leu Val Thr Phe Lys Asp  
                        -50                      -45                      -40  
Val Ala Val Thr Phe Thr Arg Glu Glu Trp Arg Gln Leu Asp Leu Ala  
                        -35                      -30                      -25  
Gln Arg Thr Leu Tyr Arg Glu Val Met Leu Glu Thr Cys Gly Leu Leu  
                        -20                      -15                      -10                      -5  
Val Ser Leu Gly Gln Ser Ile Trp Leu His Ile Thr Glu Asn Gln Ile  
                        1                      5                      10  
Lys Leu Ala Ser Pro Gly Arg Lys Phe Thr Asn Ser Pro Asp Glu Lys  
                        15                      20                      25  
Pro Glu Val Trp Leu Ala Pro Gly Leu Phe Gly Ala Ala Ala Gln  
                        30                      35                      40  
<210> 117  
<211> 82  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SIGNAL  
<222> -22...-1  
<300>  
<400> 117  
Met Glu Leu Ile Ser Pro Thr Val Ile Ile Ile Leu Gly Cys Leu Ala  
                        -20                      -15                      -10  
Leu Phe Leu Leu Leu Gln Arg Lys Asn Leu Arg Arg Pro Pro Cys Ile  
                        -5                      1                      5                      10  
Lys Gly Trp Ile Pro Trp Ile Gly Val Gly Phe Glu Phe Gly Lys Ala  
                        15                      20                      25  
Pro Leu Glu Phe Ile Glu Lys Ala Arg Ile Lys Tyr Gly Pro Ile Phe

30 115 40  
 Thr Val Phe Ala Met Gly Asn Arg Met Thr Phe Val Thr Glu Glu Gly  
 45 50 55  
 Arg Asn  
 60  
 <210> 118  
 <211> 89  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -16...-1  
 <300>  
 <400> 118  
 Met Ile Ile Ser Leu Phe Ile Tyr Ile Phe Leu Thr Cys Ser Asn Thr  
 -15 -10 -5  
 Ser Pro Ser Tyr Gln Gly Thr Gln Leu Gly Leu Gly Leu Pro Ser Ala  
 1 5 10 15  
 Gln Trp Trp Pro Leu Thr Gly Arg Arg Met Gln Cys Cys Arg Leu Phe  
 20 25 30  
 Cys Phe Leu Leu Gln Asn Cys Leu Phe Pro Phe Pro Leu His Leu Ile  
 35 40 45  
 Gln His Asp Pro Cys Glu Leu Val Leu Thr Ile Ser Trp Asp Trp Ala  
 50 55 60  
 Glu Ala Gly Ala Ser Leu Tyr Ser Pro  
 65 70  
 <210> 119  
 <211> 30  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -19...-1  
 <300>  
 <400> 119  
 Met Thr Met Ala Glu Cys Pro Thr Leu Cys Val Ser Ser Ser Pro Ala  
 -15 -10 -5  
 Leu Trp Ala Ala Ser Glu Thr Thr Asp Asp Val Cys Arg Glu  
 1 5 10  
 <210> 120  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -103...-1  
 <300>  
 <400> 120  
 Met Val Ile Arg Val Tyr Ile Ala Ser Ser Ser Gly Ser Thr Ala Ile  
 -100 -95 -90  
 Lys Lys Lys Gln Gln Asp Val Leu Gly Phe Leu Glu Ala Asn Lys Ile  
 -85 -80 -75  
 Gly Phe Glu Glu Lys Asp Ile Ala Ala Asn Glu Glu Asn Arg Lys Trp  
 -70 -65 -60  
 Met Arg Glu Asn Val Pro Glu Asn Ser Arg Pro Ala Thr Gly Asn Pro  
 -55 -50 -45 -40  
 Leu Pro Pro Gln Ile Phe Asn Glu Ser Gln Tyr Arg Gly Asp Tyr Asp  
 -35 -30 -25  
 Ala Phe Phe Glu Ala Arg Glu Asn Asn Ala Val Tyr Ala Phe Leu Gly  
 -20 -15 -10  
 Leu Thr Ala Pro Ser Gly Ser Lys Glu Ala Gly Arg Cys Lys Gln Ser  
 -5 1 5  
 Ser Lys Pro

10  
 <210> 121  
 <211> 105  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -76...-1  
 <300>  
 <400> 121  
 Met Pro Leu Leu Cys Gln Ile Glu Met Glu Tyr Leu Leu Leu Lys Trp  
       -75                      -70                      -65  
 Gln Met Thr Met Leu Gln Ser Met Leu Cys Asp Leu Val Ser Tyr Pro  
   -60                      -55                      -50                      -45  
 Leu Leu Pro Leu Gln Gln Thr Lys Glu Ala Asn Leu Asp Phe Pro Lys  
                       -40                      -35                      -30  
 Ile Lys Val Ser Ser Val Thr Ile Thr Pro Thr Arg Trp Phe Asn Leu  
                       -25                      -20                      -15  
 Ile Val Tyr Leu Trp Val Val Ser Phe Ile Ala Ser Ser Ser Ala Asn  
                       -10                      -5                      1  
 Thr Gly Leu Ile Val Ser Leu Glu Lys Glu Leu Ala Pro Leu Phe Glu  
   5                      10                      15                      20  
 Glu Leu Arg Gln Val Val Glu Val Ser  
                       25  
 <210> 122  
 <211> 93  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -22...-1  
 <300>  
 <400> 122  
 Met Lys Pro Val Leu Pro Leu Gln Phe Leu Val Val Phe Cys Leu Ala  
       -20                      -15                      -10  
 Leu Gln Leu Val Pro Gly Ser Pro Lys Gln Arg Val Leu Lys Tyr Ile  
   -5                      1                      5                      10  
 Leu Glu Pro Pro Pro Cys Ile Ser Ala Pro Glu Asn Cys Thr His Leu  
                       15                      20                      25  
 Cys Thr Met Gln Glu Asp Cys Glu Lys Gly Phe Gln Cys Cys Ser Ser  
                       30                      35                      40  
 Phe Cys Gly Ile Val Cys Ser Ser Glu Thr Phe Gln Lys Arg Asn Arg  
                       45                      50                      55  
 Ile Lys His Lys Gly Ser Glu Val Ile Met Pro Ala Asn  
   60                      65                      70  
 <210> 123  
 <211> 109  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -42...-1  
 <300>  
 <400> 123  
 Met His Ile Leu Gln Leu Leu Thr Thr Val Asp Asp Gly Ile Gln Ala  
       -40                      -35                      -30  
 Ile Val His Cys Pro Asp Thr Gly Lys Asp Ile Trp Asn Leu Leu Phe  
   -25                      -20                      -15  
 Asp Leu Val Cys His Glu Phe Cys Gln Ser Asp Asp Pro Ala Ile Ile  
   -10                      -5                      1                      5  
 Leu Gln Glu Gln Lys Thr Val Leu Ala Ser Val Phe Ser Val Leu Ser  
                       10                      15                      20  
 Ala Ile Tyr Ala Ser Gln Thr Glu Gln Glu Tyr Leu Lys Ile Glu Lys

25 30 117 35  
 Val Asp Leu Pro Leu Ile Asp Ser Leu Ile Arg Val Leu Gln Asn Met  
 40 45 50  
 Glu Gln Cys Gln Lys Lys Pro Glu Asn Ser Ala Gly Val  
 55 60 65  
 <210> 124  
 <211> 51  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -15...-1  
 <300>  
 <400> 124  
 Met Arg Leu Val Pro Leu Gly Gln Ser Phe Pro Leu Ser Glu Pro Arg  
 -15 -10 -5 1  
 Cys Leu Gln Pro Val Lys Trp Asp His Asn His Cys Leu Thr Ser Leu  
 5 10 15  
 Thr Val Val Val Arg Thr Glu Cys Val Glu Val Phe His Lys Leu Trp  
 20 25 30  
 Met Leu Val  
 35  
 <210> 125  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -27...-1  
 <300>  
 <400> 125  
 Met Asn Arg Val Pro Ala Asp Ser Pro Asn Met Cys Leu Ile Cys Leu  
 -25 -20 -15  
 Leu Ser Tyr Ile Ala Leu Gly Ala Ile His Ala Lys Ile Cys Arg Arg  
 -10 -5 1 5  
 Ala Phe Gln Glu Glu Gly Arg Ala Asn Ala Lys Thr Gly Val Arg Ala  
 10 15 20  
 Trp Cys Ile Gln Pro Trp Ala Lys  
 25  
 <210> 126  
 <211> 162  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -21...-1  
 <300>  
 <400> 126  
 Met Leu Gln Thr Ser Asn Tyr Ser Leu Val Leu Ser Leu Gln Phe Leu  
 -20 -15 -10  
 Leu Leu Ser Tyr Asp Leu Phe Val Asn Ser Phe Ser Glu Leu Leu Gln  
 -5 1 5 10  
 Lys Thr Pro Val Ile Gln Leu Val Leu Phe Ile Ile Gln Asp Ile Ala  
 15 20 25  
 Val Leu Phe Asn Ile Ile Ile Ile Phe Leu Met Phe Phe Asn Thr Ser  
 30 35 40  
 Val Phe Gln Ala Gly Leu Val Asn Leu Leu Phe His Lys Phe Lys Gly  
 45 50 55  
 Thr Ile Ile Leu Thr Ala Val Tyr Phe Ala Leu Ser Ile Ser Leu His  
 60 65 70 75  
 Val Trp Val Met Asn Leu Arg Trp Lys Asn Ser Asn Ser Phe Ile Trp  
 80 85 90  
 Thr Asp Gly Leu Gln Met Leu Phe Val Phe Gln Arg Leu Ala Ala Val

```

118
95      100      105
Leu Tyr Cys Tyr Phe Tyr Lys Arg Thr Ala Val Arg Leu Gly Asp Pro
      110      115      120
His Phe Tyr Gln Asp Ser Leu Trp Leu Arg Lys Glu Phe Met Gln Val
      125      130      135
Arg Arg
140
<210> 127
<211> 126
<212> PRT
<213> Homo sapiens
<220>
<221> SIGNAL
<222> -68...-1
<300>
<400> 127
Met Ala Ser Ala Ser Ala Arg Gly Asn Gln Asp Lys Asp Ala His Phe
      -65      -60      -55
Pro Pro Pro Ser Lys Gln Ser Leu Leu Phe Cys Pro Lys Ser Lys Leu
      -50      -45      -40
His Ile His Arg Ala Glu Ile Ser Lys Ile Met Arg Glu Cys Gln Glu
      -35      -30      -25
Glu Ser Phe Trp Lys Arg Ala Leu Pro Phe Ser Leu Val Ser Met Leu
      -20      -15      -10
Val Thr Gln Gly Leu Val Tyr Gln Gly Tyr Leu Ala Ala Asn Ser Arg
      1      5      10
Phe Gly Ser Leu Pro Lys Val Ala Leu Ala Gly Leu Leu Gly Phe Gly
      15      20      25
Leu Gly Lys Val Ser Tyr Ile Gly Val Cys Gln Ser Lys Phe His Phe
      30      35      40
Phe Glu Asp Gln Leu Arg Gly Ala Gly Phe Gly Pro Thr Ala
      45      50      55
<210> 128
<211> 140
<212> PRT
<213> Homo sapiens
<220>
<221> SIGNAL
<222> -40...-1
<300>
<400> 128
Met Thr Ser Met Thr Gln Ser Leu Arg Glu Val Ile Lys Ala Met Thr
      -40      -35      -30      -25
Lys Ala Arg Asn Phe Glu Arg Val Leu Gly Lys Ile Thr Leu Val Ser
      -20      -15      -10
Ala Ala Pro Gly Lys Val Ile Cys Glu Met Lys Val Glu Glu Glu His
      -5      1      5
Thr Asn Ala Ile Gly Thr Leu His Gly Gly Leu Thr Ala Thr Leu Val
      10      15      20
Asp Asn Ile Ser Thr Met Ala Leu Leu Cys Thr Glu Arg Gly Ala Pro
      25      30      35      40
Gly Val Ser Val Asp Met Asn Ile Thr Tyr Met Ser Pro Ala Lys Leu
      45      50      55
Gly Glu Asp Ile Val Ile Thr Ala His Val Leu Lys Gln Gly Lys Thr
      60      65      70      75
Leu Ala Phe Thr Ser Val Gly Leu Thr Asn Lys Ala Thr Gly Lys Leu
      75      80      85
Ile Ala Gln Gly Arg His Thr Lys His Leu Gly Asn
      90      95      100
<210> 129
<211> 43
<212> PRT
<213> Homo sapiens

```



<220>  
 <221> SIGNAL  
 <222> -24...-1  
 <300>  
 <400> 129  
 Met Gln Cys Phe Ser Phe Ile Lys Thr Met Met Ile Leu Phe Asn Leu  
                                   -20                                  -15                                  -10  
 Leu Ile Phe Leu Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp Ser  
                                   -5                                  1                                  5  
 Pro Tyr Phe Lys Met His Lys Pro Val Thr Met  
                                   10                                  15  
 <210> 130  
 <211> 69  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -21...-1  
 <300>  
 <400> 130  
 Met Trp Trp Phe Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val  
                                   -20                                  -15                                  -10  
 Ile Trp Thr Ser Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr  
                                   -5                                  1                                  5                                  10  
 Leu His His Ile Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr  
                                   15                                  20                                  25  
 Val Ala Pro Glu Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala  
                                   30                                  35                                  40  
 Val Leu Cys Gln Lys  
                                   45  
 <210> 131  
 <211> 78  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -19...-1  
 <300>  
 <400> 131  
 Met Ser Pro Gly Ser Ala Leu Ala Leu Leu Trp Ser Leu Pro Ala Ser  
                                   -15                                  -10                                  -5  
 Asp Leu Gly Arg Ser Val Ile Ala Gly Leu Trp Pro His Thr Gly Val  
                                   1                                  5                                  10  
 Leu Ile His Leu Glu Thr Ser Gln Ser Phe Leu Gln Gly Gln Leu Thr  
                                   15                                  20                                  25  
 Lys Ser Ile Phe Pro Leu Cys Cys Thr Ser Leu Phe Cys Val Cys Val  
                                   30                                  35                                  40                                  45  
 Val Thr Val Gly Gly Gly Arg Val Gly Ser Thr Phe Val Ala  
                                   50                                  55  
 <210> 132  
 <211> 80  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -47...-1  
 <300>  
 <400> 132  
 Met Arg Leu Pro Pro Ala Leu Pro Ser Gly Tyr Thr Asp Ser Thr Ala  
                                   -45                                  -40                                  -35  
 Leu Glu Gly Leu Val Tyr Tyr Leu Asn Gln Lys Leu Phe Ser Ser  
                                   -30                                  -25                                  -20  
 Pro Ala Ser Ala Leu Leu Phe Phe Ala Arg Pro Cys Val Phe Cys Phe

[illegible]

121																						
Lys	Gly	Leu	Phe	Glu	Val	Asn	Pro	Trp							Lys	Arg	Glu	Val	Lys	Leu	Leu	
		115					120											125				
ctg	tcc	tcc	gag	aca	ccc	att	gag	ggg	aag	aac	atg	tcc	ttt	gtg	aat	601						
Leu	Ser	Ser	Glu	Thr	Pro	Ile	Glu	Gly	Lys	Asn	Met	Ser	Phe	Val	Asn							
		130					135											140				
gat	ctt	aca	gtc	act	cag	gat	ggg	agg	aag	att	tat	ttc	acc	gat	tct	649						
Asp	Leu	Thr	Val	Thr	Gln	Asp	Gly	Arg	Lys	Ile	Tyr	Phe	Thr	Asp	Ser							
		145					150											155				
agc	agc	aaa	tgg	caa	aga	cga	gac	tac	ctg	ctt	ctg	gtg	atg	gag	ggc	697						
Ser	Ser	Lys	Trp	Gln	Arg	Arg	Asp	Tyr	Leu	Leu	Leu	Val	Met	Glu	Gly							
				165													175					
aca	gat	gac	ggg	cgc	ctg	ctg	gag	tat	gat	act	gtg	acc	agg	gaa	gta	745						
Thr	Asp	Asp	Gly	Arg	Leu	Leu	Glu	Tyr	Asp	Thr	Val	Thr	Arg	Glu	Val							
		180					185											190				
aaa	gtt	tta	ttg	gac	cag	ctg	cgg	ttc	ccg	aat	gga	gtc	cag	ctg	tct	793						
Lys	Val	Leu	Leu	Asp	Gln	Leu	Arg	Phe	Pro	Asn	Gly	Val	Gln	Leu	Ser							
		195					200											205				
cct	gca	gaa	gac	ttt	gtc	ctg	gtg	gca	gaa	aca	acc	atg	gcc	agg	ata	841						
Pro	Ala	Glu	Asp	Phe	Val	Leu	Val	Ala	Glu	Thr	Thr	Met	Ala	Arg	Ile							
		210					215											220				
cga	aga	gtc	tac	gtt	tct	ggc	ctg	atg	aag	ggc	ggg	gct	gat	ctg	ttt	889						
Arg	Arg	Val	Tyr	Val	Ser	Gly	Leu	Met	Lys	Gly	Gly	Ala	Asp	Leu	Phe							
		225					230											235				
gtg	gag	aac	atg	cct	gga	ttt	cca	gac	aac	atc	cgg	ccc	agc	agc	tct	937						
Val	Glu	Asn	Met	Pro	Gly	Phe	Pro	Asp	Asn	Ile	Arg	Pro	Ser	Ser	Ser							
				245													250					
ggg	ggg	tac	tgg	gtg	ggc	atg	tcg	acc	atc	cgc	cct	aac	cct	ggg	ttt	985						
Gly	Gly	Tyr	Trp	Val	Gly	Met	Ser	Thr	Ile	Arg	Pro	Asn	Pro	Gly	Phe							
		260					265											270				
tcc	atg	ctg	gat	ttc	tta	tct	gag	aga	ccc	tgg	att	aaa	agg	atg	att	1033						
Ser	Met	Leu	Asp	Phe	Leu	Ser	Glu	Arg	Pro	Trp	Ile	Lys	Arg	Met	Ile							
		275					280											285				
ttt	aag	gta	aaaaaaaaa	a												1053						
Phe	Lys	Val																				
290																						
<210> 135																						
<211> 675																						
<212> DNA																						
<213> Homo sapiens																						
<220>																						
<221> polyA_signal																						
<222> 638..643																						
<221> polyA_site																						
<222> 662..675																						
<300>																						
<400> 135																						

122

tatttttcaa taatatgaga agaaaatggg ccgtaaattg ttaaccattt tatgttcaga  
426  
tattttctcta gtttttacct agtttgcttt aacatagaga ccagcaagtg aatatatatg 486  
cataacctta tatgttgaca caataattca gaataatttg ttaaagataa actaattttt 546  
cagagaagaa catttaaagg gtttaatttt ttgaaacgtt ttcagataat atctatttga 606  
ttattgtggc ttctatttga aatgtgtcta aaataaatgc tgtttattta aaatgaaaaa 666  
aaaaaaa 675  
<210> 136  
<211> 1112  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> sig\_peptide  
<222> 111..194  
<223> Von Heijne matrix  
score 4.80000019073486  
seq GVLEPFVHQVGG/HS  
<221> polyA\_signal  
<222> 1080..1085  
<221> polyA\_site  
<222> 1101..1112  
<300>  
<400> 136  
ccgagagaga ctacacggta ctgggacaca cggacaaaca acagacagaa gacgtactgg 60  
ccgctggact ccgctgctc ccccatctcc ccgccatctg cgcccgagg atg agc 116  
Met Ser  
cca gcc ttc agg gcc atg gat gtg gag ccc cgc gcc aaa ggc gtc ctt 164  
Pro Ala Phe Arg Ala Met Asp Val Glu Pro Arg Ala Lys Gly Val Leu  
-25 -20 -15  
ctg gag ccc ttt gtc cac cag gtc ggg ggg cac tca tgc gtg ctc cgc 212  
Leu Glu Pro Phe Val His Gln Val Gly Gly His Ser Cys Val Leu Arg  
-10 -5 1 5  
ttc aat gag aca acc ctg tgc aag ccc ctg gtc cca agg gaa cat cag 260  
Phe Asn Glu Thr Thr Leu Cys Lys Pro Leu Val Pro Arg Glu His Gln  
10 15 20  
ttc tac gag acc ctc cct gct gag atg cgc aaa ttc tct ccc cag tac 308  
Phe Tyr Glu Thr Leu Pro Ala Glu Met Arg Lys Phe Ser Pro Gln Tyr  
25 30 35  
aaa gga caa agc caa agg ccc ctt gtt agc tgg cca tcc ctg ccc cat 356  
Lys Gly Gln Ser Gln Arg Pro Leu Val Ser Trp Pro Ser Leu Pro His  
40 45 50  
ttt ttc ccc tgg tcc ttt ccc ctg tgg cca cag gga agt gtg gcc 401  
Phe Phe Pro Trp Ser Phe Pro Leu Trp Pro Gln Gly Ser Val Ala  
55 60 65  
tgaatacccc accccggctc ctctgcaccc agagctgggg gccacctcag aagtgtcatc 461  
tctctctgag cagcattcc cctgcagcag tgcaggactg agcagattga gtgatgctgg 521  
ggcagagagg cctgagagga aagggtgttca gccagtcgtt tgtaaggcgc tcgtcggcac 581  
ctgctgaaac gccccaccc gacagcccca tcttcaaaga ctgtcttaat tactcatggc 641  
aggttctaga gacttaaggg gaaaagctgc tttcaaggcc accacatgac tgtgctcccc 701  
aaccagctct atctgccttg tgttcatttt gttattttgt gacgtgagac agcaaagacc 761  
aataaaaaaca tattttataa gaacaaaagg cctgggtgcc taccctgtgt ggggcactgt 821  
gggaagcctt tgctaggggtg tcttgtgctg tgtggtttgt tttgtttgcc cttttatttt 881  
gctttgctta cccagctctc ccttactctt ggatgcttct taaccctcag gcaaacctgt 941  
gttccccctg tattcaggct ctgctttaa gcaagcatg aggctgttgg agtttctgtt 1001  
tagggcatta aaaattccc caaactataa agagcaatgt tttcagctct ttaggattag 1061  
agaattaca taaaaattaa taaacatttt caatgatgga aaaaaaaaa a 1112  
<210> 137  
<211> 547  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> sig\_peptide  
<222> 359..454

```

<223> Von Heijne matrix
      score 4
      seq FSFMLLGMGGLP/GF
<221> polyA_site
<222> 536..547
<300>
<400> 137
ctggggagcc ctgcctaaga ctcatgctac aagaagttaa ataagtttcc cgaagtcaca      60
cagctagcct ctcatccctt ttctactgag aggaagtgga atgcactccg acaaggataa      120
ggttttattg tgagctggcc ttggaattaa accaccacca acacactttt ggattatcag      180
aagggtggaag gagtgcacaaa atgtcattcc catgcttgtc tgccaggcaa cctgggtgtcc      240
attcttttatg acgcctttcc tgaatcacag gtgcattggg gtgcttcctc ctccccagga      300
ctccccacca accttctgaa cacaaccacac ttagaggagt tatctcagca cattatga      358
atg ttg ggg acc acg ggc ctc ggg aca cag ggt cct tcc cag cag gct      406
Met Leu Gly Thr Thr Gly Leu Gly Thr Gln Gly Pro Ser Gln Gln Ala
      -30      -25      -20
ctg ggc ttt ttc tcc ttt atg tta ctt gga atg ggc ggg tgc ctg cct      454
Leu Gly Phe Phe Ser Phe Met Leu Leu Gly Met Gly Gly Cys Leu Pro
      -15      -10      -5
gga ttc ctg cta cag cct ccc aat cga tct cct act ttg cct gca tcc      502
Gly Phe Leu Leu Gln Pro Pro Asn Arg Ser Pro Thr Leu Pro Ala Ser
1          5          10          15
acc ttt gcc cat taaagtcaat tctccacca taaaaaaaaa aaa      547
Thr Phe Ala His
      20

<210> 138
<211> 1198
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 26..316
<223> Von Heijne matrix
      score 4
      seq RLPLVVSFIASSS/AN
<221> polyA_signal
<222> 1164..1169
<221> polyA_site
<222> 1187..1198
<300>
<400> 138
atcctgcgaa agaaggggggt tcatc atg gcg gat gac cta aag cga ttc ttg      52
Met Ala Asp Asp Leu Lys Arg Phe Leu
      -95      -90
tat aaa aag tta cca agt gtt gaa ggg ctc cat gcc att gtt gtg tca      100
Tyr Lys Lys Leu Pro Ser Val Glu Gly Leu His Ala Ile Val Val Ser
      -85      -80      -75
gat aga gat gga gta cct gtt gtt aaa gtg gca aat gac aat gct cca      148
Asp Arg Asp Gly Val Pro Val Val Lys Val Ala Asn Asp Asn Ala Pro
      -70      -65      -60
gag cat gct ttg cga cct ggt ttc tta tcc act ttt gcc ctt gca aca      196
Glu His Ala Leu Arg Pro Gly Phe Leu Ser Thr Phe Ala Leu Ala Thr
      -55      -50      -45
gac caa gga agc aaa ctt gga ctt tcc aaa aat aaa agt atc atc tgt      244
Asp Gln Gly Ser Lys Leu Gly Leu Ser Lys Asn Lys Ser Ile Ile Cys
      -40      -35      -30      -25
tac tat aac acc tac cag gtg gtt caa ttt aat cgt tta cct ttg gtg      292
Tyr Tyr Asn Thr Tyr Gln Val Val Gln Phe Asn Arg Leu Pro Leu Val
      -20      -15      -10
gtg agt ttc ata gcc agc agc agt gcc aat aca gga cta att gtc agc      340
Val Ser Phe Ile Ala Ser Ser Ser Ala Asn Thr Gly Leu Ile Val Ser
      -5      1      5
cta gaa aag gag ctt gct cca ttg ttt gaa gaa ctg aga caa gtt gtg      388

```

	124																
Leu Glu Lys Glu Leu Ala Pro Leu Phe									Glu Glu Leu Arg Gln Val Val								
10                15                20																	
gaa gtt tct taatctgaca gtgggttccag tgtgtacatt atcttcatta									437								
Glu Val Ser																	
25																	
taacaacaca atatcaatcc agcaatcttt agactacaat aatgcttttta tccatgtgct	497																
caagaaaggg cccctttttc caacttatac taaagagcta gcatatagat gtaatttata	557																
gatagatcag ttgctatatatt ttctgggtgta gggtcttttct tatttagtgga gatctaggga	617																
taccacagaaa atgggttcagt ctatcacagc tcccattggag ttagtctgggt caccagatat	677																
ggatgagaga ttctatttcag tggattagaa tcaaacttgtt acattgatcc acttgagccg	737																
ttaagtgtcg ccaattgttac aatatgccca ggcttgcaga ataaagccaa cttttttattg	797																
tgaataataaa taaggacata tttttcttcca gattatgttt tatttctttg cattgagtga	857																
ggtacataaaa atggccttggt aaaagtaata aaatcagtagc aatcactaac ttccctttgt	917																
acataattatt ttgcagtata gatgaatatt actaatcagt ttgattattc tcagagggtg	977																
ctgctctttta atgaaaaatga aaattatagc taatgttttt tcctcaaaact ctgctttctg	1037																
taaccaatca gtgtttttaat gtttgtgtgt tcttcataaaa atttaaatac aattcgttat	1097																
tctgttttcca atgttagtat gtatgtaaac atgatagtac agccattttt ttcatatgtg	1157																
agtaaaaaata aaatagtatt tttaaaagta aaaaaaaaaa a	1198																
<210> 139																	
<211> 1400																	
<212> DNA																	
<213> Homo sapiens																	
<220>																	
<221> sig_peptide																	
<222> 36..107																	
<223> Von Heijne matrix																	
score 5.69999980926514																	
seq ILGLLGLLGLTVA/ML																	
<221> polyA_signal																	
<222> 1302..1307																	
<221> polyA_site																	
<222> 1389..1400																	
<300>																	
<400> 139																	
cagtcacctga agacgcttct actgagaggt ctgcc atg gcc tct ctt ggc ctc									53								
Met Ala Ser Leu Gly Leu																	
-20																	
caa ctt gtg ggc tac atc cta ggc ctt ctg ggg ctt ttg ggc aca ctg	101																
Gln Leu Val Gly Tyr Ile Leu Gly Leu Leu Gly Thr Leu																	
-15                -10                -5																	
gtt gcc atg ctg ctc ccc agc tgg aaa aca agt tct tat gtc ggt gcc	149																
Val Ala Met Leu Leu Pro Ser Trp Lys Thr Ser Ser Tyr Val Gly Ala																	
1                5                10																	
agc att gtg aca gca gtt ggc ttc tcc aag ggc ctc tgg atg gaa tgt	197																
Ser Ile Val Thr Ala Val Gly Phe Ser Lys Gly Leu Trp Met Glu Cys																	
15                20                25                30																	
gcc aca cac agc aca ggc atc acc cag tgt gac atc tat agc acc ctt	245																
Ala Thr His Ser Thr Gly Ile Thr Gln Cys Asp Ile Tyr Ser Thr Leu																	
35                40                45																	
ctg ggc ctg ccc gct gac atc cag gct gcc cag gcc atg atg gtg aca	293																
Leu Gly Leu Pro Ala Asp Ile Gln Ala Ala Gln Ala Met Met Val Thr																	
50                55                60																	
tcc agt gca atc tcc tcc ctg gcc tgc att atc tct gtg gtg ggc atg	341																
Ser Ser Ala Ile Ser Ser Leu Ala Cys Ile Ile Ser Val Val Gly Met																	
65                70                75																	
aga tgc aca gtc ttc tgc cag gaa tcc cga gcc aaa gac aga gtg gcg	389																
Arg Cys Thr Val Phe Cys Gln Glu Ser Arg Ala Lys Asp Arg Val Ala																	
80                85                90																	
gta gca ggt gga gtc ttt ttc atc ctt gga ggc ctc ctg gga ttc att	437																
Val Ala Gly Gly Val Phe Phe Ile Leu Gly Gly Leu Leu Gly Phe Ile																	
95                100                105                110																	
cct gtt gcc tgg aat ctt cat ggg atc cta cgg gac ttc tac tca cca	485																
Pro Val Ala Trp Asn Leu His Gly Ile Leu Arg Asp Phe Tyr Ser Pro																	

```

115      125
ctg gtg cct gac agc atg aaa ttt gag att gga gag gct ctt tac ttg      533
Leu Val Pro Asp Ser Met Lys Phe Glu Ile Gly Glu Ala Leu Tyr Leu
130      135      140
ggc att att tct tcc ctg ttc tcc ctg ata gct gga atc atc ctc tgc      581
Gly Ile Ile Ser Ser Leu Phe Ser Leu Ile Ala Gly Ile Ile Leu Cys
145      150      155
ttt tcc tgc tca tcc cag aga aat cgc tcc aac tac tac gat gcc tac      629
Phe Ser Cys Ser Ser Gln Arg Asn Arg Ser Asn Tyr Tyr Asp Ala Tyr
160      165      170
caa gcc caa cct ctt gcc aca agg agc tct cca agg cct ggt caa cct      677
Gln Ala Gln Pro Leu Ala Thr Arg Ser Ser Pro Arg Pro Gly Gln Pro
175      180      185      190
ccc aaa gtc aag agt gag ttc aat tcc tac agc ctg aca ggg tat gtg      725
Pro Lys Val Lys Ser Glu Phe Asn Ser Tyr Ser Leu Thr Gly Tyr Val
195      200      205
tgaagaacca ggggccagag ctggggggtg gctgggtctg tgaaaaacag tggacagcac      785
cccgaggggcc acaggtgagg gacactacca ctggatcgtg tcagaagggtg ctgctgaggg      845
tagactgact ttggccattg gattgagcaa aggcagaaat gggggctagt gtaacagcat      905
gcaggttgaa ttgccaaagg tgctcgccat gccagccttt ctgttttctt caccttgctg      965
ctcccctgcc ctaagtcccc aaccctcaac ttgaaacccc attcccttaa gccaggactc      1025
agaggatccc tttgccctct ggtttacctg ggactccatc cccaaaccca ctaatcacat      1085
cccactgact gaccctctgt gatcaaagac cctccctctg gctgagggtg gctcttagct      1145
cattgctggg gatgggaagg agaagcagtg gcttttgtgg gcattgctct aacctacttc      1205
tcaagcttcc ctccaaagaa actgattggc cctggaacct ccatccact cttgttatga      1265
ctccacagtg tccagactaa tttgtgcatg aactgaaata aaaccatcct acggtatcca      1325
gggaacagaa agcaggatgc aggatgggag gacaggaagg cagcctggga catttaaaaa      1385
aataaaaaaa aaaaaa
<210> 140
<211> 538
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 35..130
<223> Von Heijne matrix
score 8
seq VPMLLLIAGGSFG/LR
<221> polyA_signal
<222> 505..510
<221> polyA_site
<222> 526..538
<300>
<400> 140
gcttggagtt ctgagccgat ggaggagttc actc atg ttt gca ctc gcg gtg atg      55
Met Phe Ala Leu Ala Val Met
-30
cgt gct ttt cgc aag aac aag act ctc ggc tat gga gtc ccc atg ttg      103
Arg Ala Phe Arg Lys Asn Lys Thr Leu Gly Tyr Gly Val Pro Met Leu
-25      -20      -15      -10
ttg ctg att gct gga ggt tct ttt ggt ctt cgt gag ttt tct caa atc      151
Leu Leu Ile Ala Gly Ser Phe Gly Leu Arg Glu Phe Ser Gln Ile
-5      1      5
cga tat gat gct gtg aag agt aaa atg gat cct gag ctt gaa aaa aaa      199
Arg Tyr Asp Ala Val Lys Ser Lys Met Asp Pro Glu Leu Glu Lys Lys
10      15      20
ccg aaa gag aat aaa ata tct tta gag tcg gaa tat gag gga agt atc      247
Pro Lys Glu Asn Lys Ile Ser Leu Glu Ser Glu Tyr Glu Gly Ser Ile
25      30      35
tgt tgaagggcta ctatctttcc ttggcccttc tcccttggtg ggactcaatc      300
Cys
40
tccagactat ctcccagag aatcttgtca aggccttggt ttaagcttg ttgggaaat      360

```

126

```

caaagactcc aagtttgatg actggaagaa          tatcagagga cccaggcctt gggaagatcc
420
tgacctcctc caaggaagaa atccagaaag ccttaagact aagacaactt gactctgctg      480
attctttttt cctttttttt tttaaataaa aatactatta actggaaaaa aaaaaaaa      538
<210> 141
<211> 1167
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 169..267
<223> Von Heijne matrix
      score 7.80000019073486
      seq LTFLFLHLPSTS/LF
<221> polyA_signal
<222> 1132..1137
<221> polyA_site
<222> 1155..1167
<300>
<400> 141
gtaggaacta ctgtcccaga gctgaggcaa ggggatttct caggtcattt ggagaacaag      60
tgcttttagta gtagtttaaa gtagtaactg ctactgtatt tagtgggggtg gaattcagaa      120
gaaatttgaa gaccagatca tgggtgggtct gcatgtgaat gaacagga atg agc cag      177
                                   Met Ser Gln
aca gcc tgg ctg tca ttg ctt tct tcc tcc cca ttt gga ccc ttc tct      225
Thr Ala Trp Leu Ser Leu Ser Ser Ser Pro Phe Gly Pro Phe Ser
-30          -25          -20          -15
gcc ctt aca ttt ttg ttt ctc cat cta cca cca tcc acc agt cta ttt      273
Ala Leu Thr Phe Leu Phe Leu His Leu Pro Pro Ser Thr Ser Leu Phe
          -10          -5          1
att aac tta gca aga gga caa ata aag ggc cct ctt ggc ttg att ttg      321
Ile Asn Leu Ala Arg Gly Gln Ile Lys Gly Pro Leu Gly Leu Ile Leu
          5          10          15
ctt ctt tct ttc tgt gga gga tat act aag tgc gac ttt gcc cta tcc      369
Leu Leu Ser Phe Cys Gly Gly Tyr Thr Lys Cys Asp Phe Ala Leu Ser
          20          25          30
tat ttg gaa atc cct aac aga att gag ttt tct att atg gat cca aaa      417
Tyr Leu Glu Ile Pro Asn Arg Ile Glu Phe Ser Ile Met Asp Pro Lys
          35          40          45          50
aga aaa aca aaa tgc taatgaagcc atcagtcaag ggtcacatgc caataaacia      472
Arg Lys Thr Lys Cys
          55
taaattttcc agaagaaatg aaatccaact agacaaataa agtagagctt atgaaatggt      532
tcagtaagga tgagcttggt gtttttttgtt ttgttttgtt ttgttttttt aaagacggag      592
tctcgctctg tcaactcaggc tggagtgcag tgggtatgatc ttggctcact gtaacctccg      652
cctcccgggt tcaagccatt ctccctgcctc agtctcctga gtagctggga ttgcaggtgc      712
gtgccaccat gcctgggctaa ttttttgtgtt tttggtagag acagggtttc accacgttgg      772
tcgggctggg ctcgggctcc tgacctcttg atccgcctgc cttggcctcc caaagtgatg      832
ggattacaga tgtgagccac cgtgcctagc caaggatgag atttttaaag tatgttccag      892
ttctgtgtca tgggttggag acagagtagg aaggatatgg aaaaggatcat ggggaagcag      952
aggtgattca tggctctgtg aatttgaggt gaatgggtcc ttattgtcta ggccacttgt      1012
gaagaatatg agtcagttat tgccagcctt ggaatttact tctctagctt acaatggacc      1072
ttttgaactg ggaaacacct tgtctgcatt cactttaaaa tgtcaaaaact aatttttata      1132
ataaatgttt attttcacat cgaaaaaaaa aaaaaa      1167
<210> 142
<211> 730
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 143..238
<223> Von Heijne matrix
      score 8.80000019073486

```



```

      seq VPMLLLIVGGSFG/LR
<221> polyA_signal
<222> 697..702
<221> polyA_site
<222> 721..730
<300>
<400> 142
nctttgcctt tctntccaca ggtgtccnct cccaggtcca actgcagact tngaattcgt      60
cttggtgaga gcgtgagctg ctgagatttg ggagtcctgcg ctaggcccg cttggagtctt      120
gagccgatgg aagagttcac tc atg ttt gca ccc gcg gtg acg cgt gct ttt      172
              Met Phe Ala Pro Ala Val Thr Arg Ala Phe
              -30                                -25
cgc aag aac aag act ctc ggc tat gga gtc ccc atg ttg ttg ctg att      220
Arg Lys Asn Lys Thr Leu Gly Tyr Gly Val Pro Met Leu Leu Leu Ile
              -20                                -15                                -10
gtt gga ggt tct ttt ggt ctt cgt gag ttt tct caa atc cga tat gat      268
Val Gly Gly Ser Phe Gly Leu Arg Glu Phe Ser Gln Ile Arg Tyr Asp
              -5                                1                                5                                10
gct gtg aag agt aaa atg gat cct gag ctt gaa aaa aaa ctg aaa gag      316
Ala Val Lys Ser Lys Met Asp Pro Glu Leu Glu Lys Lys Leu Lys Glu
              15                                20                                25
aat aaa ata tct tta gag tcg gaa tat gag aaa atc aaa gac tcc aag      364
Asn Lys Ile Ser Leu Glu Ser Glu Tyr Glu Lys Ile Lys Asp Ser Lys
              30                                35                                40
ttt gat gac tgg aag aat att cga gga ccc agg cct tgg gaa gat cct      412
Phe Asp Asp Trp Lys Asn Ile Arg Gly Pro Arg Pro Trp Glu Asp Pro
              45                                50                                55
gac ctc ctc caa gga aga aat cca gaa agc ctt aag act aag aca act      460
Asp Leu Leu Gln Gly Arg Asn Pro Glu Ser Leu Lys Thr Lys Thr Thr
              60                                65                                70
tgactctgct gattctcttt tctttttttt ttttaaataa aaatactatt aactggactt      520
cctaataatat acttctatca agtggaaagg aaattccagg cccatggaaa cttggatatg      580
ggtaatttga tgacaaataa tcttcactaa aggtcatgta cagggttttta tacttcccag      640
ctattccatc tgtggatgaa agtaacaatg ttggccacgt atattttaca cctcgaaata      700
aaaaatgtga atactgctcc aaaaaaaaaa
<210> 143
<211> 1174
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 108..170
<223> Von Heijne matrix
      score 5.5
      seq SFLPSALVIWTS/AF
<221> polyA_signal
<222> 1141..1146
<221> polyA_site
<222> 1161..1174
<300>
<400> 143
cacgttcctg ttgagtacac gttcctgttg atttacaaaa ggtgcaggta tgagcaggtc      60
tgaagactaa cattttgtga agttgtaaaa cagaaaacct gttagaa atg tgg tgg      116
              Met Trp Trp
              -20
ttt cag caa ggc ctc agt ttc ctt cct tca gcc ctt gta att tgg aca      164
Phe Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val Ile Trp Thr
              -15                                -10                                -5
tct gct gct ttc ata ttt tca tac att act gca gta aca ctc cac cat      212
Ser Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr Leu His His
              1                                5                                10
ata gac ccg gct tta cct tat atc agt gac act ggt aca gta gct cca      260
Ile Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr Val Ala Pro

```

128

15	20	25	30	
gaa aaa tgc tta ttt ggg gca atg cta aat att gcg gca gtt tta tgc				308
Glu Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala Val Leu Cys				
	35	40	45	
att gct acc att tat gtt cgt tat aag caa gtt cat gct ctg agt cct				356
Ile Ala Thr Ile Tyr Val Arg Tyr Lys Gln Val His Ala Leu Ser Pro				
	50	55	60	
gaa gag aac gtt atc atc aaa tta aac aag gct ggc ctt gta ctt gga				404
Glu Glu Asn Val Ile Ile Lys Leu Asn Lys Ala Gly Leu Val Leu Gly				
	65	70	75	
ata ctg agt tgt tta gga ctt tct att gtg gca aac ttc cag aaa aca				452
Ile Leu Ser Cys Leu Gly Leu Ser Ile Val Ala Asn Phe Gln Lys Thr				
	80	85	90	
acc ctt ttt gct gca cat gta agt gga gct gtg ctt acc ttt ggt atg				500
Thr Leu Phe Ala Ala His Val Ser Gly Ala Val Leu Thr Phe Gly Met				
	95	100	105	110
ggc tca tta tat atg ttt gtt cag acc atc ctt tcc tac caa atg cag				548
Gly Ser Leu Tyr Met Phe Val Gln Thr Ile Leu Ser Tyr Gln Met Gln				
	115	120	125	
ccc aaa atc cat ggc aaa caa gtc ttc tgg atc aga ctg ttg ttg gtt				596
Pro Lys Ile His Gly Lys Gln Val Phe Trp Ile Arg Leu Leu Leu Val				
	130	135	140	
atc tgg tgt gga gta agt gca ctt agc atg ctg act tgc tca tca gtt				644
Ile Trp Cys Gly Val Ser Ala Leu Ser Met Leu Thr Cys Ser Ser Val				
	145	150	155	
ttg cac agt ggc aat ttt ggg act gat tta gaa cag aaa ctc cat tgg				692
Leu His Ser Gly Asn Phe Gly Thr Asp Leu Glu Gln Lys Leu His Trp				
	160	165	170	
aac ccc gag gac aaa ggt tat gcg ctt cac atg atc act act gca gca				740
Asn Pro Glu Asp Lys Gly Tyr Ala Leu His Met Ile Thr Thr Ala Ala				
	175	180	185	190
gaa tgg tct atg tca ttt tcc ttc ttt ggt ttt ttc ctg act tac att				788
Glu Trp Ser Met Ser Phe Ser Phe Phe Phe Leu Thr Tyr Ile				
	195	200	205	
cgt gat ttt cag aaa att tcc tta cgg gtg gaa gcc aac tta cat gga				836
Arg Asp Phe Gln Lys Ile Ser Leu Arg Val Glu Ala Asn Leu His Gly				
	210	215	220	
tta acc ctc tat gac act gca cct tgc cct att aac aat gaa cga aca				884
Leu Thr Leu Tyr Asp Thr Ala Pro Cys Pro Ile Asn Asn Glu Arg Thr				
	225	230	235	
cgg cta ctt tcc aga gat att aga tgaaaggata aaatatttct gtaatgatta				938
Arg Leu Leu Ser Arg Asp Ile Arg				
	240	245		
tgattctcag ggattgggga aagggttcaca gaagttgctt attcttctct gaaattttca				998
accacttaat caaggctgac agtaacactg atgaatgctg ataatcagga aacatgaaag				1058
aagccatttg atagattatt ctaaaggata tcatcaagaa gactattaaa aacacctatg				1118
cctatacttt tttatctcag aaaataaagt caaaagacta tgaaaaaaaa aaaaaa				1174
<210> 144				
<211> 1158				
<212> DNA				
<213> Homo sapiens				
<220>				
<221> polyA_signal				
<222> 1133..1138				
<221> polyA_site				
<222> 1146..1158				
<300>				
<400> 144				
aarttgagct tggggactgc agctgtgggg agatttcagt gcattgcctc ccctgggtgc				60
tcttcatctt ggatttgaaa gttgagagca gcatgttttg cccactgaaa ctcatcctgs				120
tgrsagtga mtggattatt ccttgggcct gaatgacttg aatgtttccc cgctgagct				180
aacagtcctat gtgggtgatt cagctctg atg gga tgt gtt ttc cag agc aca				232
Met Gly Cys Val Phe Gln Ser Thr				

[illegible]

130

gtcttttgagg tcacgagaag agaatgcctt ctagatgcaa aatcacctct aaaccagacc  
 301

acttttcttg acttgccctgt tttggccatt agctgcctta aacgttaaca gcacatttga 361  
 atgccttatt ctacaatgca gcgtgttttc ctttgccttt tttgcacttt ggtgaattac 421  
 gtgcctccat aacctgaact gtgccgactc cacaaaacga ttatgtactc ttctgagata 481  
 gaagatgctg ttcttctgag agatacgtta ctctctcctt ggaatctgtg gatttgaaga 541  
 tggctcctgc cttctcacgt ggggaatcagt gaagtgttta gaaactgctg caagacaaac 601  
 aagactccag tgggggtggtc agtaggagag cacgttcaga gggaagagcc atctcaacag 661  
 aatcgcacca aactatactt tcaggatgaa tttcttcttt ctgccatctt ttggaataaa 721  
 tattttcttc ctttctatgt aaaaaaaaaa aaa 754

<210> 146  
 <211> 1073  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 98..181  
 <223> Von Heijne matrix  
 score 3.59999990463257  
 seq PLSDSWALLPASA/GV  
 <221> polyA\_signal  
 <222> 1035..1040  
 <221> polyA\_site  
 <222> 1060..1073  
 <300>  
 <400> 146

ccgattacag ctaggtagtg gagcgccgct gcttacctgg gtgcaggaga cagccggagt 60  
 cgctggggga gctccgcgcc gccggacgcc cgtgacc atg tgg agg ctg ctg gct 115  
 Met Trp Arg Leu Leu Ala  
 -25

cgc gct agt gcg ccg ctc ctg cgg gtg ccc ttg tca gat tcc tgg gca 163  
 Arg Ala Ser Ala Pro Leu Leu Arg Val Pro Leu Ser Asp Ser Trp Ala  
 -20 -15 -10

ctc ctc ccc gcc agt gct ggc gta aag aca ctg ctc cca gta cca agt 211  
 Leu Leu Pro Ala Ser Ala Gly Val Lys Thr Leu Leu Pro Val Pro Ser  
 -5 1 5 10

ttt gaa gat gtt tcc att cct gaa aaa ccc aag ctt aga ttt att gaa 259  
 Phe Glu Asp Val Ser Ile Pro Glu Lys Pro Lys Leu Arg Phe Ile Glu  
 15 20 25

agg gca cca ctt gtg cca aaa gta aga aga gaa cct aaa aat tta agt 307  
 Arg Ala Pro Leu Val Pro Lys Val Arg Glu Pro Lys Asn Leu Ser  
 30 35 40

gac ata cgg gga cct tcc act gaa gct acg gag ttt aca gaa ggc aat 355  
 Asp Ile Arg Gly Pro Ser Thr Glu Ala Thr Glu Phe Thr Glu Gly Asn  
 45 50 55

ttt gca atc ttg gca ttg ggt ggc tac ctg cat tgg ggc cac ttt 403  
 Phe Ala Ile Leu Ala Leu Gly Gly Tyr Leu His Trp Gly His Phe  
 60 65 70

gaa atg atg cgc ctg aca atc aac cgc tct atg gac ccc aag aac atg 451  
 Glu Met Met Arg Leu Thr Ile Asn Arg Ser Met Asp Pro Lys Asn Met  
 75 80 85 90

ttt gcc ata tgg cga gta cca gcc cct ttc aag ccc atc act cgc aaa 499  
 Phe Ala Ile Trp Arg Val Pro Ala Pro Phe Lys Pro Ile Thr Arg Lys  
 95 100 105

agt gtt ggg cat cgc atg ggg gga ggc aaa ggt gct att gac cac tac 547  
 Ser Val Gly His Arg Met Gly Gly Gly Lys Gly Ala Ile Asp His Tyr  
 110 115 120

gtg aca cct gtg aag gct ggc cgc ctt gtt gta gag atg ggt ggg cgt 595  
 Val Thr Pro Val Lys Ala Gly Arg Leu Val Val Glu Met Gly Gly Arg  
 125 130 135

tgt gaa ttt gaa gaa gtg caa ggt ttc ctt gac cag gtt gcc cac aag 643  
 Cys Glu Phe Glu Glu Val Gln Gly Phe Leu Asp Gln Val Ala His Lys  
 140 145 150

131

```

ttg ccc ttc gca gca aag gct gtg agc      cgc ggg act cta gag aag atg      691
Leu Pro Phe Ala Ala Lys Ala Val Ser Arg Gly Thr Leu Glu Lys Met
155                               160                               165                               170
cga aaa gat caa gag gaa aga gaa cgt aac aac cag aac ccc tgg aca      739
Arg Lys Asp Gln Glu Arg Glu Arg Asn Asn Gln Asn Pro Trp Thr
                               175                               180                               185
ttt gag cga ata gcc act gcc aac atg ctg ggc ata cgg aaa gta ctg      787
Phe Glu Arg Ile Ala Thr Ala Asn Met Leu Gly Ile Arg Lys Val Leu
                               190                               195                               200
agc cca tat gac ttg acc cac aag ggg aaa tac tgg ggc aag ttc tac      835
Ser Pro Tyr Asp Leu Thr His Lys Gly Lys Tyr Trp Gly Lys Phe Tyr
                               205                               210                               215
atg ccc aaa cgt gtg tagtgagtgt aggagataac tgtatatagg ctactgaaag      890
Met Pro Lys Arg Val
220
aaggattctg catttctatt cccctcagcc taccactga agtctttggg tagctcttaa      950
gccataacta aggagcagca tttgagtaga tttctgaaaa acgatgttat ttgttgattt      1010
aaaaagaaaa ctgtattttt attaaataaa atttaaacat cacttcagga aaaaaaaaaa      1070
aaa
<210> 147
<211> 413
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 46..189
<223> Von Heijne matrix
      score 4.09999990463257
      seq VFMLIVSVLALIP/ET
<221> polyA_signal
<222> 377..382
<221> polyA_site
<222> 402..413
<300>
<400> 147
tgagaagagt tgagggaaag tgctgctgct gggctctgcag acgcg atg gat aac gtg      57
                               Met Asp Asn Val
                               -45
cag ccg aaa ata aaa cat cgc ccc ttc tgc ttc agt gtg aaa ggc cac      105
Gln Pro Lys Ile Lys His Arg Pro Phe Cys Phe Ser Val Lys Gly His
                               -40                               -35                               -30
gtg aag atg ctg cgg ctg gat att atc aac tca ctg gta aca aca gta      153
Val Lys Met Leu Arg Leu Asp Ile Ile Asn Ser Leu Val Thr Thr Val
                               -25                               -20                               -15
ttc atg ctc atc gta tct gtg ttg gca ctg ata cca gaa acc aca aca      201
Phe Met Leu Ile Val Ser Val Leu Ala Leu Ile Pro Glu Thr Thr Thr
                               -10                               -5                               1
ttg aca gtt ggt gga ggg gtg ttt gca ctt gtg aca gca gta tgc tgc      249
Leu Thr Val Gly Gly Gly Val Phe Ala Leu Val Thr Ala Val Cys Cys
5                               10                               15                               20
ctt gcc gac ggg gcc ctt att tac cgg aag ctt ctg ttc aat ccc agc      297
Leu Ala Asp Gly Ala Leu Ile Tyr Arg Lys Leu Leu Phe Asn Pro Ser
                               25                               30                               35
ggc cct tac cag aaa aag cct gtg cat gaa aaa aaa gaa gtt ttg      342
Gly Pro Tyr Gln Lys Lys Pro Val His Glu Lys Lys Glu Val Leu
                               40                               45                               50
taattttata ttacttttta gtttgatact aagratataa catatttctg tattcttcca      402
aaaaaaaaaa a
<210> 148
<211> 609
<212> DNA
<213> Homo sapiens
<220>

```

<221> sig\_peptide  
 <222> 139..231  
 <223> Von Heijne matrix  
     score 4.40000009536743  
     seq TCCHLGLPHPVRA/PR  
 <221> polyA\_signal  
 <222> 579..584  
 <221> polyA\_site  
 <222> 598..609  
 <300>  
 <400> 148  
 tgtcggagtt ggaaagggac gcctggtttc cccccaagcg aaccgggatg ggaagtgact 60  
 tcaatgagat tgaacttcag ctggattgaa agagaggcta gaagttccgc ttgccagcag 120  
 cctccttagt agagcgga atg agt aat acc cac acg gtg ctt gtc tca ctt 171  
                     Met Ser Asn Thr His Thr Val Leu Val Ser Leu  
                     -30                    -25  
 ccc cat ccg cac ccg gcc ctc acc tgc tgt cac ctc ggc ctc cca cac 219  
 Pro His Pro His Pro Ala Leu Thr Cys Cys His Leu Gly Leu Pro His  
 -20                    -15                    -10                    -5  
 ccg gtc cgc gct ccc cgc cct ctt cct cgc gta gaa ccg tgg gat cct 267  
 Pro Val Arg Ala Pro Arg Pro Leu Pro Arg Val Glu Pro Trp Asp Pro  
                     1                    5                    10  
 agg tgg cag gac tca gag cta agg tat cca cag gcc atg aat tcc ttc 315  
 Arg Trp Gln Asp Ser Glu Leu Arg Tyr Pro Gln Ala Met Asn Ser Phe  
                     15                    20                    25  
 cta aat gag cgg tca tgc ccg tgc agg acc tta agg caa gaa gca tgc 363  
 Leu Asn Glu Arg Ser Ser Pro Cys Arg Thr Leu Arg Gln Glu Ala Ser  
                     30                    35                    40  
 gct gac aga tgt gat ctc tgaacctgat agattgctga ttttatctta 411  
 Ala Asp Arg Cys Asp Leu  
                     45                    50  
 ttttatcctt gacttggtag aagttttggg atttctgaaa agaccatata gataaccaca 471  
 aatatcaaga aagtcgtctt cagtattaag tagaatttag atttaggttt ctttctgtct 531  
 tcccacctcc ttctgaataag gaaacgtctt tgggaccaac tttatggaat aaataagctg 591  
 agctgcaaaa aaaaaaaaaa 609  
 <210> 149  
 <211> 522  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> polyA\_site  
 <222> 512..522  
 <300>  
 <400> 149  
 ccaactgcag nttcgaattt accgagcgga gaggagatgc acacggcact cgagtgtgag 60  
 gaaaaataga a atg aag gta cat atg cac aca aaa ttt tgc ctc att tgt 110  
                     Met Lys Val His Met His Thr Lys Phe Cys Leu Ile Cys  
                     1                    5                    10  
 ttg ctg aca ttt att ttt cat cat tgc aac cat tgc cat gaa gaa cat 158  
 Leu Leu Thr Phe Ile Phe His His Cys Asn His Cys His Glu Glu His  
                     15                    20                    25  
 gac cat ggc cct gaa gcg ctt cac aga cag cat cgt gga atg aca gaa 206  
 Asp His Gly Pro Glu Ala Leu His Arg Gln His Arg Gly Met Thr Glu  
                     30                    35                    40                    45  
 ttg gag cca agc aaa ttt tca aag caa gct gct gaa aat gaa aaa aaa 254  
 Leu Glu Pro Ser Lys Phe Ser Lys Gln Ala Ala Glu Asn Glu Lys Lys  
                     50                    55                    60  
 tac tat att gaa aaa ctt ttt gag cgt tat ggt gaa aat gga aga tta 302  
 Tyr Tyr Ile Glu Lys Leu Phe Glu Arg Tyr Gly Glu Asn Gly Arg Leu  
                     65                    70                    75  
 tcc ttt ttt ggt ttg gag aaa ctt tta aca aac ttg ggc ctt gga gag 350  
 Ser Phe Phe Gly Leu Glu Lys Leu Leu Thr Asn Leu Gly Leu Gly Glu  
                     80                    85                    90

133

```

aga aaa gta gtt gag att aat cat gag      gat ctt ggc cac gat cat gtt      398
Arg Lys Val Val Glu Ile Asn His Glu Asp Leu Gly His Asp His Val
   95                               100                               105
tct cat tta ggt att ttg gca gtt caa gag gga aag cat ttt cac tca      446
Ser His Leu Gly Ile Leu Ala Val Gln Glu Gly Lys His Phe His Ser
110                               115                               120                               125
cat aac cac cag cat tcc cat aat cat tta aat tca gaa aat caa act      494
His Asn His Gln His Ser His Asn His Leu Asn Ser Glu Asn Gln Thr
                               130                               135                               140
gtg acc agt gta tcc aca aaaaaaaaaa      522
Val Thr Ser Val Ser Thr
                               145
<210> 150
<211> 1322
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 126..260
<223> Von Heijne matrix
      score 4.59999990463257
      seq VLVYLVTAERVWS/DD
<221> polyA_signal
<222> 1283..1288
<221> polyA_site
<222> 1309..1322
<300>
<400> 150
ccgaaaacct tccccgcttc tggatatgaa attcaagctg cttgctgagt cctattgccg      60
gctgctggga gccaggagag ccctgaggag tagtcactca gtagcagctg acgcgtgggt      120
ccacc atg aac tgg agt atc ttt gag gga ctc ctg agt ggg gtc aac aag      170
Met Asn Trp Ser Ile Phe Glu Gly Leu Leu Ser Gly Val Asn Lys
   -45                               -40                               -35
tac tcc aca gcc ttt ggg cgc atc tgg ctg tct ctg gtc ttc atc ttc      218
Tyr Ser Thr Ala Phe Gly Arg Ile Trp Leu Ser Leu Val Phe Ile Phe
-30                               -25                               -20                               -15
cgc gtg ctg gtg tac ctg gtg acg gcc gag cgt gtg tgg agt gat gac      266
Arg Val Leu Val Tyr Leu Val Thr Ala Glu Arg Val Trp Ser Asp Asp
                               -10                               -5                               1
cac aag gac ttc gac tgc aat act cgc cag ccc ggc tgc tcc aac gtc      314
His Lys Asp Phe Asp Cys Asn Thr Arg Gln Pro Gly Cys Ser Asn Val
   5                               10                               15
tgc ttt gat gag ttc ttc cct gtg tcc cat gtg cgc ctc tgg gcc ctg      362
Cys Phe Asp Glu Phe Phe Pro Val Ser His Val Arg Leu Trp Ala Leu
20                               25                               30
cag ctt atc ctg gtg aca tgc ccc tca ctg ctc gtg gtc atg cac gtg      410
Gln Leu Ile Leu Val Thr Cys Pro Ser Leu Leu Val Val Met His Val
35                               40                               45                               50
gcc tac cgg gag gtt cag gag aag agg cac cga gaa gcc cat ggg gag      458
Ala Tyr Arg Glu Val Gln Glu Lys Arg His Arg Glu Ala His Gly Glu
                               55                               60                               65
aac agt ggg cgc ctc tac ctg aac ccc ggc aag aag cgg ggt ggg ctc      506
Asn Ser Gly Arg Leu Tyr Leu Asn Pro Gly Lys Lys Arg Gly Gly Leu
70                               75                               80
tgg tgg aca tat gtc tgc agc cta gtg ttc aag gcg agc gtg gac atc      554
Trp Trp Thr Tyr Val Cys Ser Leu Val Phe Lys Ala Ser Val Asp Ile
85                               90                               95
gcc ttt ctc tat gtg ttc cac tca ttc tac ccc aaa tat atc ctc cct      602
Ala Phe Leu Tyr Val Phe His Ser Phe Tyr Pro Lys Tyr Ile Leu Pro
100                               105                               110
cct gtg gtc aag tgc cac gca gat cca tgt ccc aat ata gtg gac tgc      650
Pro Val Val Lys Cys His Ala Asp Pro Cys Pro Asn Ile Val Asp Cys
115                               120                               125                               130

```

134

```

ttc atc tcc aag ccc tca gag aag aac      att ttc acc ctc ttc atg gtg      698
Phe Ile Ser Lys Pro Ser Glu Lys Asn Ile Phe Thr Leu Phe Met Val
      135      140      145
gcc aca gct gcc atc tgc atc ctg ctc aac ctc gtg gag ctc atc tac      746
Ala Thr Ala Ala Ile Cys Ile Leu Leu Asn Leu Val Glu Leu Ile Tyr
      150      155      160
ctg gtg agc aag aga tgc cac gag tgc ctg gca gca agg aaa gct caa      794
Leu Val Ser Lys Arg Cys His Glu Cys Leu Ala Ala Arg Lys Ala Gln
      165      170      175
gcc atg tgc aca ggt cat cac ccc cac gat acc acc tct tcc tgc aaa      842
Ala Met Cys Thr Gly His His Pro His Asp Thr Thr Ser Ser Cys Lys
      180      185      190
caa gac gac ctc ctt tgc ggt gac ctc atc ttt ctg ggc tca gac agt      890
Gln Asp Asp Leu Leu Ser Gly Asp Leu Ile Phe Leu Gly Ser Asp Ser
      195      200      205      210
cat cct cct ctc tta cca gac cgc ccc cga gac cat gtg aag aaa acc      938
His Pro Pro Leu Leu Pro Asp Arg Pro Arg Asp His Val Lys Lys Thr
      215      220      225
atc ttg tgaggggctg cctggactgg tctggcaggt tgggcctgga tggggaggct      994
Ile Leu
ctagcatctc tcataggtgc aacctgagag tgggggagct aagccatgag gtaggggcag      1054
gcaagagaga ggattcagac gctctgggag ccagttccta gtcctcaact ccagccacct      1114
gccccagctc gacggcactg ggccagtccc ccctctgctc tgcagctcgg ttctcttttc      1174
tagaatggaa atagtggagg ccaatgcccc ggggttgagg gaggagggcg ttcatagaag      1234
aacacacatg cgggcacctt catcgtgtgt ggcccactgt cagaacttaa taaaagtcaa      1294
ctcatttgct ggtaaaaaa aaaaaaaaaa      1322
<210> 151
<211> 1290
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 50..160
<223> Von Heijne matrix
      score 4
      seq PLSLDCGHS LCRA/CI
<221> polyA_site
<222> 1280..1290
<300>
<400> 151
gaggagagcc tcaggagtta ggaccagaag aagccaggga agcagtgca atg gct tca      58
                        Met Ala Ser
                        -35
aaa atc ttg ctt aac gta caa gag gag gtg acc tgt ccc atc tgc ctg      106
Lys Ile Leu Leu Asn Val Gln Glu Glu Val Thr Cys Pro Ile Cys Leu
      -30      -25      -20
gag ctg ttg aca gaa ccc ttg agt cta gac tgt ggc cac agc ctc tgc      154
Glu Leu Leu Thr Glu Pro Leu Ser Leu Asp Cys Gly His Ser Leu Cys
      -15      -10      -5
cga gcc tgc atc act gtg agc aac aag gag gca gtg acc agc atg gga      202
Arg Ala Cys Ile Thr Val Ser Asn Lys Glu Ala Val Thr Ser Met Gly
      1      5      10
gga aaa agc agc tgt cct gtg tgt ggt atc agt tac tca ttt gaa cat      250
Gly Lys Ser Ser Cys Pro Val Cys Gly Ile Ser Tyr Ser Phe Glu His
      15      20      25      30
cta cag gct aat cag cat ctg gcc aac ata gtg gag aga ctc aag gag      298
Leu Gln Ala Asn Gln His Leu Ala Asn Ile Val Glu Arg Leu Lys Glu
      35      40      45
gtc aag ttg agc cca gac aat ggg aag aga gat ctc tgt gat cat      346
Val Lys Leu Ser Pro Asp Asn Gly Lys Lys Arg Asp Leu Cys Asp His
      50      55      60
cat gga gag aaa ctc cta ctc ttc tgt aag gag gat agg aaa gtc att      394
His Gly Glu Lys Leu Leu Leu Phe Cys Lys Glu Asp Arg Lys Val Ile

```



135

65	70	75	
tgc tgg ctt tgt gag cgg tct cag gag cac cgt ggt cac cac aca gtc			442
Cys Trp Leu Cys Glu Arg Ser Gln Glu His Arg Gly His His Thr Val			
80	85	90	
ctc acg gag gaa gta ttc aag gaa tgt cag gag aaa ctc cag gca gtc			490
Leu Thr Glu Glu Val Phe Lys Glu Cys Gln Glu Lys Leu Gln Ala Val			
95	100	105	110
ctc aag agg ctg aag aag gaa gag gag gaa gct gag aag ctg gaa gct			538
Leu Lys Arg Leu Lys Lys Glu Glu Glu Glu Ala Glu Lys Leu Glu Ala			
115	120	125	
gac atc aga gaa gag aaa act tcc tgg aag tat cag gta caa act gag			586
Asp Ile Arg Glu Glu Lys Thr Ser Trp Lys Tyr Gln Val Gln Thr Glu			
130	135	140	
aga caa agg ata caa aca gaa ttt gat cag ctt aga agc atc cta aat			634
Arg Gln Arg Ile Gln Thr Glu Phe Asp Gln Leu Arg Ser Ile Leu Asn			
145	150	155	
aat gag gag cag aga gag ctg caa aga ttg gaa gaa gaa gaa aag aag			682
Asn Glu Glu Gln Arg Glu Leu Gln Arg Leu Glu Glu Glu Lys Lys			
160	165	170	
acg ctg gat aag ttt gca gag gct gag gat gag cta gtt cag cag aag			730
Thr Leu Asp Lys Phe Ala Glu Ala Glu Asp Glu Leu Val Gln Gln Lys			
175	180	185	190
cag ttg gtg aga gag ctg atc tca gat gtg gag tgt cgg agt cag tgg			778
Gln Leu Val Arg Glu Leu Ile Ser Asp Val Glu Cys Arg Ser Gln Trp			
195	200	205	
tca aca atg gag ctg ctg cag gac atg agt gga atc atg aaa tgg agt			826
Ser Thr Met Glu Leu Leu Gln Asp Met Ser Gly Ile Met Lys Trp Ser			
210	215	220	
gag atc tgg agg ctg aaa aag cca aaa atg gtt tcc aag aaa ctg aag			874
Glu Ile Trp Arg Leu Lys Lys Pro Lys Met Val Ser Lys Lys Leu Lys			
225	230	235	
act gta ttc cat gct cca gat ctg agt agg atg ctg caa atg ttt aga			922
Thr Val Phe His Ala Pro Asp Leu Ser Arg Met Leu Gln Met Phe Arg			
240	245	250	
gaa ctg aca gct gtc cgg tgc tac tgg gtg gat gtc aca ctg aat tca			970
Glu Leu Thr Ala Val Arg Cys Tyr Trp Val Asp Val Thr Leu Asn Ser			
255	260	265	270
gtc aac cta aat ttg aat ctt gtc ctt tca gaa gat cag aga caa gtg			1018
Val Asn Leu Asn Leu Asn Leu Val Leu Ser Glu Asp Gln Arg Gln Val			
275	280	285	
ata tct gtg cca att tgg cct ttt cag tgt tat aat tat ggt gtc ttg			1066
Ile Ser Val Pro Ile Trp Pro Phe Gln Cys Tyr Asn Tyr Gly Val Leu			
290	295	300	
gga tcc caa tat ttc tcc tct ggg aaa cat tac tgg gaa gtg gac gtg			1114
Gly Ser Gln Tyr Phe Ser Ser Gly Lys His Tyr Trp Glu Val Asp Val			
305	310	315	
tcc aag aaa act gcc tgg atc ctg ggg gta tac tgt aga aca tat tcc			1162
Ser Lys Lys Thr Ala Trp Ile Leu Gly Val Tyr Cys Arg Thr Tyr Ser			
320	325	330	
cgc cat atg aag tat gtt gtt aga aga tgt gca aat cgt caa aat ctt			1210
Arg His Met Lys Tyr Val Val Arg Arg Cys Ala Asn Arg Gln Asn Leu			
335	340	345	350
tac acc aaa tac aga cct cta ttt ggc tac tgg gtt ata ggg tta cag			1258
Tyr Thr Lys Tyr Arg Pro Leu Phe Gly Tyr Trp Val Ile Gly Leu Gln			
355	360	365	
aat aaa tgt aag tat ggt gcc aaaaaaaaa a			1290
Asn Lys Cys Lys Tyr Gly Ala			

370

&lt;210&gt; 152

&lt;211&gt; 1364

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

```

<221> sig_peptide
<222> 83..139
<223> Von Heijne matrix
      score 8.60000038146973
      seq LLWLALACSPVHT/TL
<221> polyA_site
<222> 1356..1354
<300>
<400> 152
gcctggggagc tgaggcagcc accgtctcag cctggccagc cctctggacc ccgaggttgg      60
accctactgtgacacaccta cc atg cgg aca ctc ttc aac ctc ctc tgg ctt      112
                               Met Arg Thr Leu Phe Asn Leu Leu Trp Leu
                               -15                               -10
gcc ctg gcc tgc agc cct gtt cac act acc ctg tca aag tca gat gcc      160
Ala Leu Ala Cys Ser Pro Val His Thr Thr Leu Ser Lys Ser Asp Ala
                               -5                               1                               5
aaa aaa gcc gcc tca aag acg ctg ctg gag aag agt cag ttt tca gat      208
Lys Lys Ala Ala Ser Lys Thr Leu Leu Glu Lys Ser Gln Phe Ser Asp
                               10                               15                               20
aag ccg gtg caa gac cgg ggt ttg gtg gtg acg gac ctc aaa gct gag      256
Lys Pro Val Gln Asp Arg Gly Leu Val Val Thr Asp Leu Lys Ala Glu
                               25                               30                               35
agt gtg gtt ctt gag cat cgc agc tac tgc tgc gca aag gcc cgg gac      304
Ser Val Val Leu Glu His Arg Ser Tyr Cys Ser Ala Lys Ala Arg Asp
                               40                               45                               50                               55
aga cac ttt gct ggg gat gta ctg ggc tat gtc act cca tgg aac agc      352
Arg His Phe Ala Gly Asp Val Leu Gly Tyr Val Thr Pro Trp Asn Ser
                               60                               65                               70
cat ggc tac gat gtc acc aag gtc ttt ggg agc aag ttc aca cag atc      400
His Gly Tyr Asp Val Thr Lys Val Phe Gly Ser Lys Phe Thr Gln Ile
                               75                               80                               85
tca ccc gtc tgg ctg cag ttg aag aga cgt ggc cgt gag atg ttt gag      448
Ser Pro Val Trp Leu Gln Leu Lys Arg Arg Gly Arg Glu Met Phe Glu
                               90                               95                               100
gtc acg ggc ctc cac gac gtg gac caa ggg tgg atg cga gct gtc agg      496
Val Thr Gly Leu His Asp Val Asp Gln Gly Trp Met Arg Ala Val Arg
                               105                               110                               115
aag cat gcc aag ggc ctg cac ata gtg cct cgg ctc ctg ttt gag gac      544
Lys His Ala Lys Gly Leu His Ile Val Pro Arg Leu Leu Phe Glu Asp
                               120                               125                               130                               135
tgg act tac gat gat ttc cgg aac gtc tta gac agt gag gat gag ata      592
Trp Thr Tyr Asp Asp Phe Arg Asn Val Leu Asp Ser Glu Asp Glu Ile
                               140                               145                               150
gag gag ctg agc aag acc gtg gtc cag gtg gca aag aac cag cat ttc      640
Glu Glu Leu Ser Lys Thr Val Val Gln Val Ala Lys Asn Gln His Phe
                               155                               160                               165
gat ggc ttc gtg gtg gag gtc tgg aac cag ctg cta agc cag aag cgc      688
Asp Gly Phe Val Val Glu Val Trp Asn Gln Leu Leu Ser Gln Lys Arg
                               170                               175                               180
gtg ggc ctc atc cac atg ctc acc cac ttg gcc gag gcc ctg cac cag      736
Val Gly Leu Ile His Met Leu Thr His Leu Ala Glu Ala Leu His Gln
                               185                               190                               195
gcc cgg ctg ctg gcc ctc ctg gtc atc ccg cct gcc atc acc ccc ggg      784
Ala Arg Leu Leu Ala Leu Leu Val Ile Pro Pro Ala Ile Thr Pro Gly
                               200                               205                               210                               215
acc gac cag ctg ggc atg ttc acg cac aag gag ttt gag cag ctg gcc      832
Thr Asp Gln Leu Gly Met Phe Thr His Lys Glu Phe Glu Gln Leu Ala
                               220                               225                               230
ccc gtg ctg gat ggt ttc agc ctc atg acc tac gac tac tct aca gcg      880
Pro Val Leu Asp Gly Phe Ser Leu Met Thr Tyr Asp Tyr Ser Thr Ala
                               235                               240                               245
cat cag cct ggc cct aat gca ccc ctg tcc tgg gtt cga gcc tgc gtc      928
His Gln Pro Gly Pro Asn Ala Pro Leu Ser Trp Val Arg Ala Cys Val

```

137

<p>250</p> <p>cag gtc ctg gac ccg aag tcc aag tgg cga agc aaa atc ctc ctg ggg</p> <p>Gln Val Leu Asp Pro Lys Ser Lys Trp Arg Ser Lys Ile Leu Leu Gly</p> <p>265</p> <p>ctc aac ttc tat ggt atg gac tac gcg acc tcc aag gat gcc cgt gag</p> <p>Leu Asn Phe Tyr Gly Met Asp Tyr Ala Thr Ser Lys Asp Ala Arg Glu</p> <p>280</p> <p>cct gtt gtc ggg gcc agg tac atc cag aca ctg aag gac cac agg ccc</p> <p>Pro Val Val Gly Ala Arg Tyr Ile Gln Thr Leu Lys Asp His Arg Pro</p> <p>300</p> <p>cgg atg gtg tgg gac agc cag gcc tca gag cac ttc ttc gag tac aag</p> <p>Arg Met Val Trp Asp Ser Gln Ala Ser Glu His Phe Phe Glu Tyr Lys</p> <p>315</p> <p>aag agc cgc agt ggg agg cac gtc gtc ttc tac cca acc ctg aag tcc</p> <p>Lys Ser Arg Ser Gly Arg His Val Val Phe Tyr Pro Thr Leu Lys Ser</p> <p>330</p> <p>ctg cag gtg cgg ctg gag ctg gcc cgg gag ctg ggc gtt ggg gtc tct</p> <p>Leu Gln Val Arg Leu Glu Leu Ala Arg Glu Leu Gly Val Gly Val Ser</p> <p>345</p> <p>atc tgg gag ctg ggc cag ggc ctg gac tac ttc tac gac ctg ctc</p> <p>Ile Trp Glu Leu Gly Gln Gly Leu Asp Tyr Phe Tyr Asp Leu Leu</p> <p>360</p> <p>taggtgggca ttgcggcctc cgcgggtggac gtgttctttt ctaagccatg gaggtagtga</p> <p>gcagggtgtga aatacaggcc tccactccgt ttgcaaaaaa aaa</p>	<p>976</p> <p>1024</p> <p>1072</p> <p>1120</p> <p>1168</p> <p>1216</p> <p>1261</p> <p>1321</p> <p>1364</p>
<p>&lt;210&gt; 153</p> <p>&lt;211&gt; 1470</p> <p>&lt;212&gt; DNA</p> <p>&lt;213&gt; Homo sapiens</p> <p>&lt;220&gt;</p> <p>&lt;221&gt; sig_peptide</p> <p>&lt;222&gt; 57..95</p> <p>&lt;223&gt; Von Heijne matrix</p> <p>score 3.90000009536743</p> <p>seq MLSIGMLMLSAT/QV</p> <p>&lt;221&gt; polyA_signal</p> <p>&lt;222&gt; 1438..1443</p> <p>&lt;221&gt; polyA_site</p> <p>&lt;222&gt; 1458..1470</p> <p>&lt;300&gt;</p> <p>&lt;400&gt; 153</p>	
<p>gctggcaaga ctgtttgtgt tgcggggggcc ggacttcaag gtgattttac aacgag atg</p> <p>Met</p> <p>ctg ctc tcc ata ggg atg ctc atg ctg tca gcc aca caa gtc tac acc</p> <p>Leu Leu Ser Ile Gly Met Leu Met Leu Ser Ala Thr Gln Val Tyr Thr</p> <p>-10 -5 1</p> <p>gtc ttg act gtc cag ctc ttt gca ttc tta aac cca ctg cct gta gaa</p> <p>Val Leu Thr Val Gln Leu Phe Ala Phe Leu Asn Pro Leu Pro Val Glu</p> <p>5 10 15 20</p> <p>gca gac att tta gca tat aac ttt gaa aat gca tct cag aca ttt gat</p> <p>Ala Asp Ile Leu Ala Tyr Asn Phe Glu Asn Ala Ser Gln Thr Phe Asp</p> <p>25 30 35</p> <p>gac ctc cct gca aga ttt ggt tat aga ctt cca gct gaa ggt tta aag</p> <p>Asp Leu Pro Ala Arg Phe Gly Tyr Arg Leu Pro Ala Glu Gly Leu Lys</p> <p>40 45 50</p> <p>ggt ttt tta att aac tca aaa cca gag aat gcc tgt gaa ccc ata gtg</p> <p>Gly Phe Leu Ile Asn Ser Lys Pro Glu Asn Ala Cys Glu Pro Ile Val</p> <p>55 60 65</p> <p>cct cca cca gta aaa gac aat tca tct ggc act ttc atc gtg tta att</p> <p>Pro Pro Pro Val Lys Asp Asn Ser Ser Gly Thr Phe Ile Val Leu Ile</p> <p>70 75 80</p> <p>aga aga ctt gat tgt aat ttt gat ata aag gtt tta aat gca cag aga</p> <p>Arg Arg Leu Asp Cys Asn Phe Asp Ile Lys Val Leu Asn Ala Gln Arg</p> <p>85 90 95 100</p>	<p>59</p> <p>107</p> <p>155</p> <p>203</p> <p>251</p> <p>299</p> <p>347</p> <p>395</p>

138  
gca gga tac aag gca gcc ata gtt cac aat gtt gat tct gat gac ctc 443  
Ala Gly Tyr Lys Ala Ala Ile Val His Asn Val Asp Ser Asp Asp Leu  
105 110 115  
att agc atg gga tcc aac gac att gag gta cta aag aaa att gac att 491  
Ile Ser Met Gly Ser Asn Asp Ile Glu Val Leu Lys Lys Ile Asp Ile  
120 125 130  
cca tct gtc ttt att ggt gaa tca tca gct agt tct ctg aaa gat gaa 539  
Pro Ser Val Phe Ile Gly Glu Ser Ser Ala Ser Ser Leu Lys Asp Glu  
135 140 145  
ttc aca tat gaa aaa ggg ggc cac ctt atc tta gtt cca gaa ttt agt 587  
Phe Thr Tyr Glu Lys Gly Glu His Leu Ile Leu Val Pro Glu Phe Ser  
150 155 160  
ctt cct ttg gaa tac tac cta att ccc ttc ctt atc ata gtg ggc atc 635  
Leu Pro Leu Glu Tyr Tyr Leu Ile Pro Phe Leu Ile Ile Val Gly Ile  
165 170 175 180  
tgt ctc atc ttg ata gtc att ttc atg atc aca aaa ttt gtc cag gat 683  
Cys Leu Ile Leu Ile Val Ile Phe Met Ile Thr Lys Phe Val Gln Asp  
185 190 195  
aga cat aga gct aga aga aac aga ctt cgt aaa gat caa ctt aag aaa 731  
Arg His Arg Ala Arg Arg Asn Arg Leu Arg Lys Asp Gln Leu Lys Lys  
200 205 210  
ctt cct gta cat aaa ttc aag aaa gga gat gag tat gat gta tgt gcc 779  
Leu Pro Val His Lys Phe Lys Lys Gly Asp Glu Tyr Asp Val Cys Ala  
215 220 225  
att tgt ttg gat gag tat gaa gat gga gac aaa ctc aga atc ctt ccc 827  
Ile Cys Leu Asp Glu Tyr Glu Asp Gly Asp Lys Leu Arg Ile Leu Pro  
230 235 240  
tgt tcc cat gct tat cat tgc aag tgt gta gac cct tgg cta act aaa 875  
Cys Ser His Ala Tyr His Cys Lys Cys Val Asp Pro Trp Leu Thr Lys  
245 250 255 260  
acc aaa aaa acc tgt cca gtg tgc agg caa aaa gtt gtt cct tct caa 923  
Thr Lys Lys Thr Cys Pro Val Cys Arg Gln Lys Val Val Pro Ser Gln  
265 270 275  
ggc gat tca gac tct gac aca gac agt agt caa gaa gaa aat gaa gtg 971  
Gly Asp Ser Asp Ser Asp Thr Asp Ser Ser Gln Glu Glu Asn Glu Val  
280 285 290  
aca gaa cat acc cct tta ctg aga cct tta gct tct gtc agt gcc cag 1019  
Thr Glu His Thr Pro Leu Leu Arg Pro Leu Ala Ser Val Ser Ala Gln  
295 300 305  
tca ttt ggg gct tta tgc gaa tcc cgc tca cat cag aac atg aca gaa 1067  
Ser Phe Gly Ala Leu Ser Glu Ser Arg Ser His Gln Asn Met Thr Glu  
310 315 320  
tct tca gac tat gag gaa gac gac aat gaa gat act gac agt agt gat 1115  
Ser Ser Asp Tyr Glu Glu Asp Asp Asn Glu Asp Thr Asp Ser Ser Asp  
325 330 335 340  
gca gaa aat gaa att aat gaa cat gat gtc gtg gtc cag ttg cag cct 1163  
Ala Glu Asn Glu Ile Asn Glu His Asp Val Val Val Gln Leu Gln Pro  
345 350 355  
aat ggt gaa cgg gat tac aac ata gca aat act gtt tgactttcag 1209  
Asn Gly Glu Arg Asp Tyr Asn Ile Ala Asn Thr Val  
360 365  
aagatgattg gttttatttcc ctttaaaatg attaggtata tactgtaatt tgattttttg 1269  
ctcccttaaa agattttctgt agaaataact tatttttttag tactctacag tttaatacaaa 1329  
ttactgaaac aggacttttg atctgggtatt tatctgcca gaataactt cattcactaa 1389  
taatagactg gtgctgtaac tcaagcatca attcagctct tcttttggaa tgaaagtata 1449  
gccaaaacaa aaaaaaaaaa a 1470  
<210> 154  
<211> 982  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> sig\_peptide  
<222> 72..197

<223> Von Heijne matrix  
 score 7.19999980926514  
 seq ILFSLSFLLVIIT/FP

<221> polyA\_site

<222> 970..982

<300>

<400> 154

gctgcctgtt cttcacactt agctccaaac ccatgaaaaa ttgccaagta taaaagcttc 60  
 tcaagaatga g atg gat tct agg gtg tct tca cct gag aag caa gat aaa 110  
 Met Asp Ser Arg Val Ser Ser Pro Glu Lys Gln Asp Lys  
 -40 -35 -30

gag aat ttc gtg ggt gtc aac aat aaa cgg ctt ggt gta tgt ggc tgg 158  
 Glu Asn Phe Val Gly Val Asn Asn Lys Arg Leu Gly Val Cys Gly Trp  
 -25 -20 -15

atc ctg ttt tcc ctc tct ttc ctg ttg gtg atc att acc ttc ccc atc 206  
 Ile Leu Phe Ser Leu Ser Phe Leu Leu Val Ile Ile Thr Phe Pro Ile  
 -10 -5 1

tcc ata tgg atg tgc ttg aag atc att agg gag tat gaa cgt gct gtt 254  
 Ser Ile Trp Met Cys Leu Lys Ile Ile Arg Glu Tyr Glu Arg Ala Val  
 5 10 15

gta ttc cgt ctg gga cgc atc caa gct gac aaa gcc aag ggg cca ggt 302  
 Val Phe Arg Leu Gly Arg Ile Gln Ala Asp Lys Ala Lys Gly Pro Gly  
 20 25 30 35

ttg atc ctg gtc ctg cca tgc ata gat gtg ttt gtc aag gtt gac ctc 350  
 Leu Ile Leu Val Leu Pro Cys Ile Asp Val Phe Val Lys Val Asp Leu  
 40 45 50

cga aca gtt act tgc aac att cct cca caa gag atc ctc acc aga gac 398  
 Arg Thr Val Thr Cys Asn Ile Pro Pro Gln Glu Ile Leu Thr Arg Asp  
 55 60 65

tcc gta act act cag gta gat gga gtt gtc tat tac aga atc tat agt 446  
 Ser Val Thr Thr Gln Val Asp Gly Val Val Tyr Tyr Arg Ile Tyr Ser  
 70 75 80

gct gtc tca gca gtg gct aat gtc aac gat gtc cat caa gca aca ttt 494  
 Ala Val Ser Ala Val Ala Asn Val Asn Asp Val His Gln Ala Thr Phe  
 85 90 95

ctg ctg gct caa acc act ctg aga aat gtc tta ggg aca cag acc ttg 542  
 Leu Leu Ala Gln Thr Thr Leu Arg Asn Val Leu Gly Thr Gln Thr Leu  
 100 105 110 115

tcc cag atc tta gct gga cga gaa gag atc gcc cat agc atc cag act 590  
 Ser Gln Ile Leu Ala Gly Arg Glu Glu Ile Ala His Ser Ile Gln Thr  
 120 125 130

tta ctt gat gat gcc acc gaa ctg tgg ggg atc cgg gtg gcc cga gtg 638  
 Leu Leu Asp Asp Ala Thr Glu Leu Trp Gly Ile Arg Val Ala Arg Val  
 135 140 145

gaa atc aaa gat gtt cgg att ccc gtg cag ttg cag aga tcc atg gca 686  
 Glu Ile Lys Asp Val Arg Ile Pro Val Gln Leu Gln Arg Ser Met Ala  
 150 155 160

gcc gag gct gag gcc acc cgg gaa gcg aga gcc aag gtc ctt gca gct 734  
 Ala Glu Ala Glu Ala Thr Arg Glu Ala Arg Ala Lys Val Leu Ala Ala  
 165 170 175

gaa gga gaa atg agt gct tcc aaa tcc ctg aag tca gcc tcc atg gtg 782  
 Glu Gly Glu Met Ser Ala Ser Lys Ser Leu Lys Ser Ala Ser Met Val  
 180 185 190 195

ctg gct gag tct ccc ata gct ctc cag ctg cgc tac ctg cag acc ttg 830  
 Leu Ala Glu Ser Pro Ile Ala Leu Gln Leu Arg Tyr Leu Gln Thr Leu  
 200 205 210

agc acg gta gcc acc gag aag aat tct acg att gtg ttt cct ctg ccc 878  
 Ser Thr Val Ala Thr Glu Lys Asn Ser Thr Ile Val Phe Pro Leu Pro  
 215 220 225

atg aat ata cta gag ggc att ggt ggc gtc agc tat gat aac cac aag 926  
 Met Asn Ile Leu Glu Gly Ile Gly Gly Val Ser Tyr Asp Asn His Lys  
 230 235 240

aag ctt cca aat aaa gcc tgaggtcctc ttgcggtagt cagctaaaaa aaaaaaaaa 982

140

Lys Leu Pro Asn Lys Ala  
 245  
 <210> 155  
 <211> 455  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> polyA\_signal  
 <222> 425..430  
 <221> polyA\_site  
 <222> 443..455  
 <300>  
 <400> 155  
 gtt atg cca ccc aga aac cta ctg gag tta ctt att aac atc aag gct 48  
 Met Pro Pro Arg Asn Leu Leu Glu Leu Leu Ile Asn Ile Lys Ala  
 1 5 10 15  
 gga acc tat ttg cct cag tcc tat ctg att cat gag cac atg gtt att 96  
 Gly Thr Tyr Leu Pro Gln Ser Tyr Leu Ile His Glu His Met Val Ile  
 20 25 30  
 act gat cgc atc gaa aac att gat cac ctg ggt ttc ttt att tat cga 144  
 Thr Asp Arg Ile Glu Asn Ile Asp His Leu Gly Phe Phe Ile Tyr Arg  
 35 40 45  
 ctg tgt cat gac aag gaa act tac aaa ctg caa cgc aga gaa act att 192  
 Leu Cys His Asp Lys Glu Thr Tyr Lys Leu Gln Arg Arg Glu Thr Ile  
 50 55 60  
 aaa ggt att cag aaa cgt gaa gcc agc aat tgt ttc gca att cgg cat 240  
 Lys Gly Ile Gln Lys Arg Glu Ala Ser Asn Cys Phe Ala Ile Arg His  
 65 70 75  
 ttt gaa aac aaa ttt gcc gtg gaa act tta att tgt tct tgaacagtca 289  
 Phe Glu Asn Lys Phe Ala Val Glu Thr Leu Ile Cys Ser  
 80 85 90  
 agaaaaacat tattgaggaa aattaatatc acagcataac cccacccttt acattttgtg 349  
 cagtgtattat tttttaaaagt cttctttcat gtaagtagca aacagggctt tactatcttt 409  
 tcatctcatt aattcaatta aaaccattac cccaaaaaaa aaaaaa 455  
 <210> 156  
 <211> 738  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 90..278  
 <223> Von Heijne matrix  
 score 3.5  
 seq GLVCAGLADMARF/AE  
 <221> polyA\_signal  
 <222> 704..709  
 <221> polyA\_site  
 <222> 724..738  
 <300>  
 <400> 156  
 gggaaaaagtg actagctccc cttegtttgtc agccagggac gagaacacag ccacgctccc 60  
 acccggtctg caacgatccc tcggcggcg atg tcg gcc gcc ggt gcc cga ggc 113  
 Met Ser Ala Ala Gly Ala Arg Gly  
 -60  
 ctg cgg gcc acc tac cac cgg ctc ccc gat aaa gtg gag ctg atg ctg 161  
 Leu Arg Ala Thr Tyr His Arg Leu Pro Asp Lys Val Glu Leu Met Leu  
 -55 -50 -45 -40  
 ccc gag aaa ttg agg ccg ttg tac aac cat cca gca ggt ccc aga aca 209  
 Pro Glu Lys Leu Arg Pro Leu Tyr Asn His Pro Ala Gly Pro Arg Thr  
 -35 -30 -25  
 gtt ttc ttc tgg gct cca att atg aaa tgg ggg ttg gtg tgt gct gga 257  
 Val Phe Phe Trp Ala Pro Ile Met Lys Trp Gly Leu Val Cys Ala Gly  
 -20 -15 -10

141

```

ttg gct gat atg gcc aga cct gca gaa      aaa ctt agc aca gct caa tct      305
Leu Ala Asp Met Ala Arg Pro Ala Glu Lys Leu Ser Thr Ala Gln Ser
      -5              1              5
gct gtt ttg atg gct aca ggg ttt att tgg tca aga tac tca ctt gta      353
Ala Val Leu Met Ala Thr Gly Phe Ile Trp Ser Arg Tyr Ser Leu Val
10              15              20              25
att att ccg aaa aat tgg agt ctg ttt gct gtt aat ttc ttt gtg ggg      401
Ile Ile Pro Lys Asn Trp Ser Leu Phe Ala Val Asn Phe Phe Val Gly
      30              35              40
gca gca gga gcc tct cag ctt ttt cgt att tgg aga tat aac caa gaa      449
Ala Ala Gly Ala Ser Gln Leu Phe Arg Ile Trp Arg Tyr Asn Gln Glu
      45              50              55
cta aaa gct aaa gca cac aaa taaaagagtt cctgatcacc tgaacaatct      500
Leu Lys Ala Lys Ala His Lys
      60
agatgtggac aaaaccattg ggacctagtt tattatttgg ttattgataa agcaaagcta      560
actgtgtgtt tagaaggcac tgtaactggt agctagttct tgattcaata gaaaaatgca      620
gcaaactttt aataacagtc tctctacatg accttaaggaa cttatctatg gatattagta      680
acatttttct accatttgtc cgtaataaac catacttgct cgtaaaaaaa aaaaaaaa      738
<210> 157
<211> 649
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 88..147
<223> Von Heijne matrix
      score 12.3999996185303
      seq ALLLGALLGTAWA/RR
<221> polyA_signal
<222> 619..624
<221> polyA_site
<222> 637..649
<300>
<400> 157
ccaaagtgag agtccagcgg tcttccagcg cttggggccac ggcgggcgcc ctgggagcag      60
aggaggagcg accccattac gctaaag atg aaa ggc tgg ggt tgg ctg gcc ctg      114
      Met Lys Gly Trp Gly Trp Leu Ala Leu
      -20              -15
ctt ctg ggg gcc ctg ctg gga acc gcc tgg gct cgg agg agc cag gat      162
Leu Leu Gly Ala Leu Leu Gly Thr Ala Trp Ala Arg Ser Gln Asp
      -10              -5              1              5
ctc cac tgt gga gca tgc agg gct ctg gtg gat gaa cta gaa tgg gaa      210
Leu His Cys Gly Ala Cys Arg Ala Leu Val Asp Glu Leu Glu Trp Glu
      10              15              20
att gcc cag gtg gac ccc aag aag acc att cag atg gga tcc ttc cgg      258
Ile Ala Gln Val Asp Pro Lys Lys Thr Ile Gln Met Gly Ser Phe Arg
      25              30              35
atc aat cca gat ggc agc cag tca gtg gtg gag gta act gtt act gtt      306
Ile Asn Pro Asp Gly Ser Gln Ser Val Val Glu Val Thr Val Thr Val
      40              45              50
ccc cca aac aaa gta gct cac tct ggc ttt gga tgaaattcga ctgcttaaaa      359
Pro Pro Asn Lys Val Ala His Ser Gly Phe Gly
      55              60
aggaccttgg tctaatagaa atgaagaaaa cagactcaga aaaaagattt ggctctgtct      419
catttgggaag aagctgcagg cttattcccc atgcacttgc ttcttggtg caaaccttaa      479
tactttgttt ctgctgtaga atttgttagc aaacaggagag tcctgatcag cacccttctc      539
cacatccaca tgactggttt ttaatgtagc actgtggtat acatgcaaac atccgttcaa      599
aatctgagtc ggagctaaaa ataaaaaatg aaaaaacaaa aaaaaaaaaa      649
<210> 158
<211> 714
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> sig_peptide
<222> 33..92
<223> Von Heijne matrix
      score 12.3999996185303
      seq ALLLGALLGTAWA/RR
<221> polyA_site
<222> 703..714
<300>
<400> 158
agcagagggtg gagcgacccc attacgctaa ag atg aaa ggc tgg ggt tgg ctg      53
                                   Met Lys Gly Trp Gly Trp Leu
                                   -20
gcc ctg ctt ctg ggg gcc ctg ctg gga acc gcc tgg gct cgg agg agc      101
Ala Leu Leu Leu Gly Ala Leu Leu Gly Thr Ala Trp Ala Arg Arg Ser
                                   -10
cag gat ctc cac tgt gga gca tgc agg gct ctg gtg gat gaa cta gaa      149
Gln Asp Leu His Cys Gly Ala Cys Arg Ala Leu Val Asp Glu Leu Glu
                                   5
tgg gaa att gcc cag gtg gac ccc aag aag acc att cag atg gga tct      197
Trp Glu Ile Ala Gln Val Asp Pro Lys Lys Thr Ile Gln Met Gly Ser
20                                   25
ttc cgg atc aat cca gat ggc agc cag tca gtg gtg gag gtg cct tat      245
Phe Arg Ile Asn Pro Asp Gly Ser Gln Ser Val Val Glu Val Pro Tyr
                                   40
gcc cgc tca gag gcc cac ctc aca gag ctg ctg gag gag ata tgt gac      293
Ala Arg Ser Glu Ala His Leu Thr Glu Leu Leu Glu Glu Ile Cys Asp
                                   55
cgg atg aag gag tat ggg gaa cag att gat cct tcc acc cat cgc aag      341
Arg Met Lys Glu Tyr Gly Glu Gln Ile Asp Pro Ser Thr His Arg Lys
70                                   75
aac tac gta cgt gta gtg ggc cgg aat gga gaa tcc agt gaa ctg gac      389
Asn Tyr Val Arg Val Val Gly Arg Asn Gly Glu Ser Ser Glu Leu Asp
85                                   90
cta caa ggc atc cga atc gac tca gat att agc ggc acc ctc aag ttt      437
Leu Gln Gly Ile Arg Ile Asp Ser Asp Ile Ser Gly Thr Leu Lys Phe
100                                   105
gcg tgt ggg agc att gtg gag gaa tac gag gat gaa ctc att gaa ttc      485
Ala Cys Gly Ser Ile Val Glu Glu Tyr Glu Asp Glu Leu Ile Glu Phe
120                                   125
ttt tcc cga gag gct gac aat gtt aaa gac aaa ctt tgc agt aag cga      533
Phe Ser Arg Glu Ala Asp Asn Val Lys Asp Lys Leu Cys Ser Lys Arg
135                                   140
aca gat ctt tgt gac cat gcc ctg cac ata tcg cat gat gag cta      578
Thr Asp Leu Cys Asp His Ala Leu His Ile Ser His Asp Glu Leu
150                                   155
tgaaccactg gagcagccca cactggcttg atggatcacc cccaggaggg gaaaatgggtg      638
gcaatgcctt ttatatatta tgtttttact gaaattaact gaaaaaatat gaaacaaaaa      698
gtacaaaaaa aaaaaa
<210> 159
<211> 596
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 33..107
<223> Von Heijne matrix
      score 5
      seq MFAASLLAMCAGA/EV
<221> polyA_signal
<222> 546..551
<221> polyA_site
<222> 584..596

```



143	
<300>	
<400> 159	
cacagttcct ctcctcctag agcctgccga cc atg ccc gcg ggc gtg ccc atg	53
	Met Pro Ala Gly Val Pro Met
	-25
tcc acc tac ctg aaa atg ttc gca gcc agt ctc ctg gcc atg tgc gca	101
Ser Thr Tyr Leu Lys Met Phe Ala Ala Ser Leu Leu Ala Met Cys Ala	
	-15
	-10
	-5
ggg gca gaa gtg gtg cac agg tac tac cga ccg gac ctg aca ata cct	149
Gly Ala Glu Val Val His Arg Tyr Tyr Arg Pro Asp Leu Thr Ile Pro	
	10
gaa att cca cca aag cgt gga gaa ctc aaa acg gag ctt ttg gga ctg	197
Glu Ile Pro Pro Lys Arg Gly Glu Leu Lys Thr Glu Leu Leu Gly Leu	
	15
	20
	25
	30
aaa gaa aga aaa cac aaa cct caa gtt tct caa cag gag gaa ctt aaa	245
Lys Glu Arg Lys His Lys Pro Gln Val Ser Gln Gln Glu Glu Leu Lys	
	35
	40
	45
taactatgcc aagaattctg tgaataatat aagtcttaaa tatgtatttc ttaatttatt	305
gcatcaaact acttgctcctt aagcacttag tctaattgcta actgcaagag gaggtgctca	365
gtggatgttt agccgatacgt ttgaaattta attacggttt gattgatatt tcttgaaaac	425
tgccaaagca catatcatca aaccatttca tgaatatggg ttggaagatg tttagtcttg	485
aatataacgc gaaatagaat atttgtaagt ctactatatg gggtgtcttt atttcatata	545
aattaagaaa ttatttaaaa ctatgaacta gtttcattaa aaaaaaaga a	596
<210> 160	
<211> 403	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> polyA_signal	
<222> 375..380	
<221> polyA_site	
<222> 390..403	
<300>	
<400> 160	
tgaagagaat ggctgttgca gtcggcgctca gagcagctcc agtgccggggg attcggacgg	60
agagcgcgag gactcggcgg ctgagcgcgc ccgacagcag ctagaggcgc tgctcaacaa	120
gact atg cgc att cgc atg aca gat gga cgg aca ctg gtc gcc tgc ttt	169
Met Arg Ile Arg Met Thr Asp Gly Arg Thr Leu Val Gly Cys Phe	
	1
	5
	10
	15
ctc tgc act gac cgt gac tgc aat gtc atc ctg gcc tcg gcg cag gag	217
Leu Cys Thr Asp Arg Asp Cys Asn Val Ile Leu Gly Ser Ala Gln Glu	
	20
	25
	30
ttc ctc aag ccg tcg gat tcc ttc tct gcc ggg gag ccc cgt gtg ctg	265
Phe Leu Lys Pro Ser Asp Ser Phe Ser Ala Gly Glu Pro Arg Val Leu	
	35
	40
	45
ggc ctg gcc atg gta ccc gga cac cac atc gtt tcc att gag gtg cag	313
Gly Leu Ala Met Val Pro Gly His His Ile Val Ser Ile Glu Val Gln	
	50
	55
	60
agg gag agt ctg acc ggg cct ccg tat ctc tgaccacgat ggcgcttacc	363
Arg Glu Ser Leu Thr Gly Pro Pro Tyr Leu	
	65
	70
tttcagactt cattaacttt atgaccaaaa aaaaaaaaaa	403
<210> 161	
<211> 727	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> sig_peptide	
<222> 126..575	
<223> Von Heijne matrix	
score 8.60000038146973	
seq LELLTSCSPPASASQ	
<221> polyA_signal	

<222> 670..675  
 <221> polyA\_site  
 <222> 721..727  
 <300>  
 <400> 161  
 ctcagaactg tgctgggaag gatggtaggg cgactggggc tcacctccgc accgtttgtag 60  
 gaccgggggt aggggttttga gcccgtggga gctgccccac gcggcctcgt cctgccaacg 120  
 gtcgg atg gcg gag acg aag gac aca gcg cag atg ttg gtg acc ttc aag 170  
 Met Ala Glu Thr Lys Asp Thr Ala Gln Met Leu Val Thr Phe Lys  
 -150 -145 -140  
 gat gtg gct gtg acc ttt acc cgg gag gag tgg aga cag ctg gac ctg 218  
 Asp Val Ala Val Thr Phe Thr Arg Glu Glu Trp Arg Gln Leu Asp Leu  
 -135 -130 -125  
 gcc cag agg acc ctg tac cga gag ggc atc ggg ttc ccn aaa cca gag 266  
 Ala Gln Arg Thr Leu Tyr Arg Glu Gly Ile Gly Phe Pro Lys Pro Glu  
 -115 -110 -105  
 ttg gtc cac ctg cta gag cat ggg cag gag ctg tgg ata gtg aag aga 314  
 Leu Val His Leu Leu Glu His Gly Gln Glu Leu Trp Ile Val Lys Arg  
 -100 -95 -90  
 ggc ctc tca cat gct acc tgt gca gag ttt cac tct tgt tgc cca ggc 362  
 Gly Leu Ser His Ala Thr Cys Ala Glu Phe His Ser Cys Cys Pro Gly  
 -85 -80 -75  
 tgg agt gca gtg gnn cgc cat ctc agc tca ctg caa ctt ctg cct ccc 410  
 Trp Ser Ala Val Xaa Arg His Leu Ser Ser Leu Gln Leu Leu Pro Pro  
 -70 -65 -60  
 gag ttc aag gga ttc tcc tgc ctc agc ctc ccg agt agc tgg gat tac 458  
 Glu Phe Lys Gly Phe Ser Cys Leu Ser Leu Pro Ser Ser Trp Asp Tyr  
 -55 -50 -45  
 agg cgc cca cca cca tgc ccg gct ggt ttt ttt gta ttt tta gta gag 506  
 Arg Arg Pro Pro Pro Cys Pro Ala Gly Phe Phe Val Phe Leu Val Glu  
 -35 -30 -25  
 acg ggg ctt cac cat gtt ggc cag gct ggt ctt gaa ctc ttg acc tca 554  
 Thr Gly Leu His Val Gly Gln Ala Gly Leu Glu Leu Leu Thr Ser  
 -20 -15 -10  
 tgt agt cca ccc gcc tct gcc tcc caa agt gct gcg att aca ggc gtg 602  
 Cys Ser Pro Pro Ala Ser Ala Ser Gln Ser Ala Ala Ile Thr Gly Val  
 -5 1 5  
 agc cac cgt gcc cgg cag aga aaa act gct taagggttgaa aagagaaatt 652  
 Ser His Arg Ala Arg Gln Arg Lys Thr Ala  
 10 15  
 taagaaattg ctgacggaat aaaaacataa tagaactaca acaccgaagg aaatgaaaga 712  
 agcaaaaaaa aaaaa 727  
 <210> 162  
 <211> 944  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 90..155  
 <223> Von Heijne matrix  
 score 5.90000009536743  
 seq IILGCLALFLLQ/RK  
 <221> polyA\_signal  
 <222> 913..918  
 <221> polyA\_site  
 <222> 932..944  
 <300>  
 <400> 162  
 gaatcagggt ccgtagccca cagaaaagaa gcaagggacg gcaggactgt ttcacacttt 60  
 tctgcttctg gaaggtgctg gacaaaaac atg gaa cta att tcc cca aca gtg 113  
 Met Glu Leu Ile Ser Pro Thr Val  
 -20 -15  
 att ata atc ctg ggt tgc ctt gct ctg ttc tta ctc ctt cag cgg aag 161

Ile Ile Ile Leu Gly Cys Leu Ala Leu Phe Leu Leu Leu Gln Arg Lys  
 -10 -5 1  
 aat ttg cgt aga ccc ccg tgc atc aag ggc tgg att cct tgg att gga 209  
 Asn Leu Arg Arg Pro Pro Cys Ile Lys Gly Trp Ile Pro Trp Ile Gly  
 5 10 15  
 gtt gga ttt gag ttt ggg aaa gcc cct cta gaa ttt ata gag aaa gca 257  
 Val Gly Phe Glu Phe Gly Lys Ala Pro Leu Glu Phe Ile Glu Lys Ala  
 20 25 30  
 aga atc aag gta tgt ggt cgt ggc aga cgg ggt ctc cag agg aga caa 305  
 Arg Ile Lys Val Cys Gly Arg Gly Arg Arg Gly Leu Gln Arg Arg Gln  
 35 40 45 50  
 tgc ttt ctt ttt taaactttct ttcattgact ctttaagtga gggctagaac 357  
 Cys Phe Leu Phe  
 acggggaaca tacctgcttg cctcaactaa aggatctagt cttttctgaa ttcctctact 417  
 aacaattaac aacaatatcc tgtgcaaaat tttgcaaaag aaatgaaata caattgcagc 477  
 gtgcacgcac attttttgaa gtagagatta acttttcgta tttttacttc atcgaagtta 537  
 agttccaaat gtgtatgtgt taagtaaatg ttttcagtaa ttgggaaaga taaagtgtaa 597  
 tccaatttaa gtttgtgaaa atgagtaatt cgtatccaaa ttggagttaa caccaaagta 657  
 ttgtacaaat tgcttgcaca gttgggtcgt acacaataga caggctctgt attttttagct 717  
 gacgttgta tttgatgatg atgtactcca ttttactac ggcccgaaga gactagtaat 777  
 cctccttgta gtagatgttt ttgtcttgaa agtatctttt aaatgtctga gcactttaag 837  
 gaacagacc ttattaatgt cttttaagtt ttattcaatt tccagtcaca aatattttat 897  
 ggtatttgat tgtctaataa atttgtatga tattaaaaaa aaaaaaa 944  
 <210> 163  
 <211> 598  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 126..287  
 <223> Von Heijne matrix  
 score 3.90000009536743  
 seq LETCGLLVSLVES/IW  
 <221> polyA\_signal  
 <222> 561..566  
 <221> polyA\_site  
 <222> 587..598  
 <300>  
 <400> 163  
 ctcagaactg tgctgggaag gatggtaggg cgactggggc tcacctccgc accgtttag 60  
 gaccgggggt aggggttttga gcccgtagga gctgccccac ggggctcgt cctgccaacg 120  
 gtccg atg gcg gag acg aag gac gca gcg cag atg ttg gtg acc ttc aag 170  
 Met Ala Glu Thr Lys Asp Ala Ala Gln Met Leu Val Thr Phe Lys  
 -50 -45 -40  
 gat gtg gct gtg acc ttt acc cgg gag gag tgg aga cag ctg gac ctg 218  
 Asp Val Ala Val Thr Phe Thr Arg Glu Glu Trp Arg Gln Leu Asp Leu  
 -35 -30 -25  
 gcc cag agg acc ctg tac cga gag gtg atg ctg gag acc tgt ggg ctt 266  
 Ala Gln Arg Thr Leu Tyr Arg Glu Val Met Leu Glu Thr Cys Gly Leu  
 -20 -15 -10  
 ctg gtt tca cta gtg gaa agc att tgg ctg cat ata aca gaa aac cag 314  
 Leu Val Ser Leu Val Glu Ser Ile Trp Leu His Ile Thr Glu Asn Gln  
 -5 1 5  
 atc aaa ctg gct tca cct gga agg aaa ttc act aac tcg cct gat gag 362  
 Ile Lys Leu Ala Ser Pro Gly Arg Lys Phe Thr Asn Ser Pro Asp Glu  
 10 15 20 25  
 aag cct gag gtg tgg ttg gct cca ggc ctg ttc ggt gcc gca gcc cag 410  
 Lys Pro Glu Val Trp Leu Ala Pro Gly Leu Phe Gly Ala Ala Ala Gln  
 30 35 40  
 tgacgccatc aaggatgtct tgggttctctg ttccttcttc ttgggttcagg cttctgattg 470  
 tcttcaggct ggctcctcat agggatgctg ggtgctgcag ccttgactgg ggcagcaggc 530  
 ccccatgttc aatccatcct cccaccttg aataaatgct ttcttttcac aatgagaaaa 590  
 aaaaaaa 598



		147	
ctc cac ctg att cag cat gat ccc tgt		gag ctg gtt ctc aca atc tcc	304
Leu His Leu Ile Gln His Asp Pro Cys Glu Leu Val Leu Thr Ile Ser			
45	50	55	60
tgg gac tgg gct gag gca ggg gct tcg ctc tat tct ccc taaccatact			353
Trp Asp Trp Ala Glu Ala Gly Ala Ser Leu Tyr Ser Pro			
65	70		
gtcttcctttt ccccttgcc acttagcagt tatcccccca gctatgcctt ctcctccct			413
cccttgccct ggcatatatt gtgccttatt tatgctgcaa atataacatt aaactatcaa			473
gtgaaaaaaaa aaaaaaa			490
<210> 166			
<211> 488			
<212> DNA			
<213> Homo sapiens			
<220>			
<221> polyA_signal			
<222> 458..463			
<221> polyA_site			
<222> 475..488			
<300>			
<400> 166			
ccgcttccga aaagagacag acaatgcagc catcata atg aag gtg gac aaa gac			55
	Met Lys Val Asp Lys Asp		
	1	5	
cgg cag atg gtg gtg ctg gag gaa gaa ttt cgg aac att tcc cca gag			103
Arg Gln Met Val Val Leu Glu Glu Glu Phe Arg Asn Ile Ser Pro Glu			
10	15	20	
gag ctc aaa atg gag ttg ccg gag aga cag ccc agg ttc gtg gtt tac			151
Glu Leu Lys Met Glu Leu Pro Glu Arg Gln Pro Arg Phe Val Val Tyr			
25	30	35	
agc tac aag tac gtg cgt gac gat ggc cga gtg tcc tac cct ttg tgt			199
Ser Tyr Lys Tyr Val Arg Asp Asp Gly Arg Val Ser Tyr Pro Leu Cys			
40	45	50	
ttc atc ttc tcc agc cct gtg ggc tgc aag ccg gaa caa cag atg atg			247
Phe Ile Phe Ser Ser Pro Val Gly Cys Lys Pro Glu Gln Gln Met Met			
55	60	65	70
tat gca ggg agt aaa aac agg ctg gtg cag aca gca gag ctc aca aag			295
Tyr Ala Gly Ser Lys Asn Arg Leu Val Gln Thr Ala Glu Leu Thr Lys			
75	80	85	
gtg ttc gaa atc cgc acc act gat gac ctc act gag gcc tgg ctc caa			343
Val Phe Glu Ile Arg Thr Thr Asp Asp Leu Thr Glu Ala Trp Leu Gln			
90	95	100	
gaa aag ttg tct ttc ttt cgt tgatctctgg gctggggact gaattcctga			394
Glu Lys Leu Ser Phe Phe Arg			
105			
tgctctgagtc ctcaagggtga ctgggggactt ggaaccccta ggacctgaac aaccaagact			454
ttaaataaat tttaaaatgc aaaaaaaaaa aaaa			488
<210> 167			
<211> 771			
<212> DNA			
<213> Homo sapiens			
<220>			
<221> sig_peptide			
<222> 48..356			
<223> Von Heijne matrix			
score 4.90000009536743			
seq VYAFGLTAPSGS/KE			
<221> polyA_signal			
<222> 742..747			
<221> polyA_site			
<222> 760..771			
<300>			
<400> 167			
ccacagccct ttccaggacc caaacaaccg cagccgctgt tcccagg atg gtg atc			56

148

Met Val Ile  
 cgt gta tat att gca tct tcc tct ggc tct aca gcg att aag aag aaa 104  
 Arg Val Tyr Ile Ala Ser Ser Ser Gly Ser Thr Ala Ile Lys Lys Lys  
 -100 -95 -90 -85  
 caa caa gat gtg ctt ggt ttc cta gaa gcc aac aaa ata gga ttt gaa 152  
 Gln Gln Asp Val Leu Gly Phe Leu Glu Ala Asn Lys Ile Gly Phe Glu  
 -80 -75 -70  
 gaa aaa gat att gca gcc aat gaa gag aat cgg aag tgg atg aga gaa 200  
 Glu Lys Asp Ile Ala Ala Asn Glu Glu Asn Arg Lys Trp Met Arg Glu  
 -65 -60 -55  
 aat gta cct gag aat agt cga cca gcc aca ggt aac ccc ctg cca cct 248  
 Asn Val Pro Glu Asn Ser Arg Pro Ala Thr Gly Asn Pro Leu Pro Pro  
 -50 -45 -40  
 cag att ttc aat gaa agc cag tat cgc ggg gac tat gat gcc ttc ttt 296  
 Gln Ile Phe Asn Glu Ser Gln Tyr Arg Gly Asp Tyr Asp Ala Phe Phe  
 -35 -30 -25  
 gaa gcc aga gaa aat aat gca gtg tat gcc ttc tta ggc ttg aca gcc 344  
 Glu Ala Arg Glu Asn Asn Ala Val Tyr Ala Phe Leu Gly Leu Thr Ala  
 -20 -15 -10 -5  
 cca tct ggt tca aag gaa gca gaa gtg caa gca aag cag caa gca 389  
 Pro Ser Gly Ser Lys Glu Ala Glu Val Gln Ala Lys Gln Gln Ala  
 1 5 10  
 tgaaccttga gcactgtgct ttaagcatcc tgaaaaatga gtctccattg cttttataaa 449  
 atagcagaat tagctttgct tcaaaagaaa taggcttaat gttgaaataa tagattagtt 509  
 gggttttcac atgcaaacac tcaaaatgaa tacaaaatta aaatttgaac attatggtga 569  
 ttatggtgag gagaatggga tattaacata aaattatatt aataagtaga tatcgtagaa 629  
 atagtgtgtg tacctgcca gccatcctgt atacaccaat gattttacaa agaaaacacc 689  
 cttccctcct tctgccatta ctatggcaac ctaagtgtat ctgcagctct acattaaaaa 749  
 ggagaaagag aaaaaaaaaa aa 771  
 <210> 168  
 <211> 959  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 69..359  
 <223> Von Heijne matrix  
 score 4  
 seq RLPLVVSFIASSS/AN  
 <221> polyA\_signal  
 <222> 927..932  
 <221> polyA\_site  
 <222> 947..959  
 <300>  
 <400> 168  
 cggagagaac caggcagccc agaaacccca ggcgtggaga ttgatcctgc gagagaaggg 60  
 gggttcac atg gcg gat gac cta aag cga ttc ttg tat aaa aag tta cca 110  
 Met Ala Asp Asp Leu Lys Arg Phe Leu Tyr Lys Lys Leu Pro  
 -95 -90 -85  
 agt gtt gaa ggg ctc cat gcc att gtt gtg tca gat aga gat gga gta 158  
 Ser Val Glu Gly Leu His Ala Ile Val Val Ser Asp Arg Asp Gly Val  
 -80 -75 -70  
 cct gtt att aaa gtg gca aat gac aat gct cca gag cat gct ttg cga 206  
 Pro Val Ile Lys Val Ala Asn Asp Asn Ala Pro Glu His Ala Leu Arg  
 -65 -60 -55  
 cct ggt ttc tta tcc act ttt gcc ctt gca aca gac caa gga agc aaa 254  
 Pro Gly Phe Leu Ser Thr Phe Ala Leu Ala Thr Asp Gln Gly Ser Lys  
 -50 -45 -40  
 ctt gga ctt tcc aaa aat aaa agt atc atc tgt tac tat aac acc tac 302  
 Leu Gly Leu Ser Lys Asn Lys Ser Ile Ile Cys Tyr Tyr Asn Thr Tyr  
 -35 -30 -25 -20  
 cag gtg gtt caa ttt aat cgt tta cct ttg gtg gtg agt ttc ata gcc 350  
 Gln Val Val Gln Phe Asn Arg Leu Pro Leu Val Val Ser Phe Ile Ala



150

```

<223> Von Heijne matrix
      score 5.19999980926514
      seq LLFDLVCHEFCQS/DD
<221> polyA_signal
<222> 764..769
<221> polyA_site
<222> 787..799
<300>
<400> 170
ccaaccccag gaagagtctg aagagcagcc agtgtttcgg cttgtgccct gtataacttga      60
agctgccaaa caagtacgtt ctgaaaatcc agaatggctt gatgtttac atg cac att      118
                                         Met His Ile
                                         -40
tta caa ctg ctt act aca gtg gat gat gga att caa gca att gta cat      166
Leu Gln Leu Leu Thr Thr Val Asp Asp Gly Ile Gln Ala Ile Val His
                        -35                        -30                        -25
tgt cct gac act gga aaa gac att tgg aat cta ctt ttt gac ctg gtc      214
Cys Pro Asp Thr Gly Lys Asp Ile Trp Asn Leu Leu Phe Asp Leu Val
                        -20                        -15                        -10
tgc cat gaa ttc tgc cag tct gat gat cca ccc atc att ctt caa gaa      262
Cys His Glu Phe Cys Gln Ser Asp Asp Pro Pro Ile Ile Leu Gln Glu
                        -5                        1                        5
cag aaa aca gtg cta gcc tct gtt ttt tca gtg ttg tct gcc atc tat      310
Gln Lys Thr Val Leu Ala Ser Val Phe Ser Val Leu Ser Ala Ile Tyr
10                        15                        20                        25
gcc tca cag act gag caa gag tat cta aag ata gaa aaa gta gat ctt      358
Ala Ser Gln Thr Glu Gln Glu Tyr Leu Lys Ile Glu Lys Val Asp Leu
                        30                        35                        40
cct cta att gac agc ctc att cgg gtc tta caa aat atg gaa cag tgt      406
Pro Leu Ile Asp Ser Leu Ile Arg Val Leu Gln Asn Met Glu Gln Cys
                        45                        50                        55
cag aaa aaa cca gag aac tcg gca gag tct aac aca gag gaa act aaa      454
Gln Lys Lys Pro Glu Asn Ser Ala Glu Ser Asn Thr Glu Glu Thr Lys
60                        65                        70
agg act gat tta acc caa gat gat ttc cac ttg aaa atc tta aag gat      502
Arg Thr Asp Leu Thr Gln Asp Asp Phe His Leu Lys Ile Leu Lys Asp
75                        80                        85
att tta tgt gaa ttt ctt tct aat att ttt cag gca tta aca aag gag      550
Ile Leu Cys Glu Phe Leu Ser Asn Ile Phe Gln Ala Leu Thr Lys Glu
90                        95                        100                        105
acg gtg gct cag gga gta aag gaa ggc cag ttg agc aaa cag aag tgt      598
Thr Val Ala Gln Gly Val Lys Glu Gly Gln Leu Ser Lys Gln Lys Cys
110                        115                        120
tcc tct gca ttt caa aac ctt ctt cct ttc tat agc cct gtg gtg gaa      646
Ser Ser Ala Phe Gln Asn Leu Leu Pro Phe Tyr Ser Pro Val Val Glu
125                        130                        135
gat ttt att aaa atc cta cgt gaa gtt gat aag gcg ctt gct gat gac      694
Asp Phe Ile Lys Ile Leu Arg Glu Val Asp Lys Ala Leu Ala Asp Asp
140                        145                        150
ttg gaa aaa aac ttc cca agt ttg aag gtt cag act taaaacctga      740
Leu Glu Lys Asn Phe Pro Ser Leu Lys Val Gln Thr
155                        160                        165
attggaatta cttctgtaca agaaataaac tttatttttc tcactgaaaa aaaaaaaaaa      799
<210> 171
<211> 320
<212> DNA
<213> Homo sapiens
<220>
<221> polyA_site
<222> 308..320
<300>
<400> 171
tcatcatcca gagcagccag tgtccgggag gcagaag atg ccc cac tcc aag cct      55

```



151

Met Pro His Ser Lys Pro  
1 5  
ctg gac tgg ggg ctc tct tca gtg gct gaa tgt cca gca gag cta ttt 103  
Leu Asp Trp Gly Leu Ser Ser Val Ala Glu Cys Pro Ala Glu Leu Phe  
10 15 20  
cct tcc aca ggg ggc ctt gca ggg aag ggt cca gga ctt gac atc tta 151  
Pro Ser Thr Gly Gly Leu Ala Gly Lys Gly Pro Gly Leu Asp Ile Leu  
25 30 35  
aga tgc gtc ttg tcc cct tgg gcc agt cat ttc ccc tct ctg agc ctc 199  
Arg Cys Val Leu Ser Pro Trp Ala Ser His Phe Pro Ser Leu Ser Leu  
40 45 50  
ggc gtc ttc aac ctg tgaatggga tcataatcac tgccttacct ccctcacggt 254  
Gly Val Phe Asn Leu  
55  
tgttgtgagg actgagtgtg tggaaagtttt tcataaactt tggatgctag tgtaaaaaaa 314  
aaaaaa 320  
<210> 172  
<211> 331  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> sig\_peptide  
<222> 129..209  
<223> Von Heijne matrix  
score 4.90000009536743  
seq CLLSYIALGAIHA/KI  
<221> polyA\_site  
<222> 318..331  
<300>  
<400> 172  
atggaaacca gatggggcaa cgggggtggtt ctagtgcaga ctgtagctgc agctcctctc 60  
cacctctagc ctgctcatTT ccagctcaga aattctacta atggcgTTTT ttcttctga 120  
aaaaggaa atg aac agg gtc cct gct gat tct cca aat atg tgt cta atc 170  
Met Asn Arg Val Pro Ala Asp Ser Pro Asn Met Cys Leu Ile  
-25 -20 -15  
tgt tta ctg agt tac ata gca ctt gga gcc atc cat gca aaa atc tgt 218  
Cys Leu Leu Ser Tyr Ile Ala Leu Gly Ala Ile His Ala Lys Ile Cys  
-10 -5 1  
agg aga gca ttc cag gaa gag gga aga gca aat gca aag acg ggc gtg 266  
Arg Arg Ala Phe Gln Glu Glu Gly Arg Ala Asn Ala Lys Thr Gly Val  
5 10 15  
aga gct tgg tgc ata cag cca tgg gcc aaa taaagtttcc ttggaatagc 316  
Arg Ala Trp Cys Ile Gln Pro Trp Ala Lys  
20 25  
caaaaaaaaa aaaaa  
<210> 173 331  
<211> 1075  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> sig\_peptide  
<222> 78..359  
<223> Von Heijne matrix  
score 4.19999980926514  
seq IILTAVYFALSIS/LH  
<221> polyA\_signal  
<222> 1042..1047  
<221> polyA\_site  
<222> 1063..1075  
<300>  
<400> 173  
gtggtaggga gcagccagga gcgggttttct gggaactgtg ggatgtgccc ttggggggccc 60  
gagaaaacag aaggaag atg ctc cag acc agt aac tac agc ctg gtg ctc 110

152

Met Leu Gln Thr      Ser Asn Tyr Ser Leu Val Leu

-90      -85

tct ctg cag ttc ctg ctg ctg tcc tat gac ctc ttt gtc aat tcc ttc 158  
 Ser Leu Gln Phe Leu Leu Leu Ser Tyr Asp Leu Phe Val Asn Ser Phe  
 -80      -75      -70

tca gaa ctg ctc caa aag act cct gtc atc cag ctt gtg ctc ttc atc 206  
 Ser Glu Leu Leu Gln Lys Thr Pro Val Ile Gln Leu Val Leu Phe Ile  
 -65      -60      -55

atc cag gat att gca gtc ctc ttc aac atc atc atc att ttc ctc atg 254  
 Ile Gln Asp Ile Ala Val Leu Phe Asn Ile Ile Ile Ile Phe Leu Met  
 -50      -45      -40

ttc ttc aac acc ttc gtc ttc cag gct ggc ctg gtc aac ctc cta ttc 302  
 Phe Phe Asn Thr Phe Val Phe Gln Ala Gly Leu Val Asn Leu Leu Phe  
 -35      -30      -25      -20

cat aag ttc aaa ggg acc atc atc ctg aca gct gtg tac ttt gcc ctc 350  
 His Lys Phe Lys Gly Thr Ile Ile Leu Thr Ala Val Tyr Phe Ala Leu  
 -15      -10      -5

agc atc tcc ctt cat gtc tgg gtc atg aac tta cgc tgg aaa aac tcc 398  
 Ser Ile Ser Leu His Val Trp Val Met Asn Leu Arg Trp Lys Asn Ser  
 1      5      10

aac agc ttc ata tgg aca gat gga ctt caa atg ctg ttt gta ttc cag 446  
 Asn Ser Phe Ile Trp Thr Asp Gly Leu Gln Met Leu Phe Val Phe Gln  
 15      20      25

aga cta gca gca gtg ttg tac tgc tac ttc tat aaa cgg aca gcc gta 494  
 Arg Leu Ala Ala Val Leu Tyr Cys Tyr Phe Tyr Lys Arg Thr Ala Val  
 30      35      40      45

aga cta ggc gat cct cac ttc tac cag gac tct ttg tgg ctg cgc aag 542  
 Arg Leu Gly Asp Pro His Phe Tyr Gln Asp Ser Leu Trp Leu Arg Lys  
 50      55      60

gag ttc atg caa gtt cga agg tgacctcttg tcacactgat ggatactttt 593  
 Glu Phe Met Gln Val Arg Arg  
 65

ccttcctgat agaagccaca tttgctgctt tgcagggaga gttggcccta tgcattgggca 653  
 aacagctgga ctttccaagg aagggttcaga ctactgtgtg tcagcattca agaaggaaga 713  
 tccccctct tgcacaatta gagggtcccc atcgggtctcc agtgccgcat cccttccttg 773  
 cctttacatt ctgttccacc cccttccttc ctctcctctc tgtaccattc attctccctg 833  
 accggccttt ctgtccgagg gttctgtggc tcttaccctt gtgaagcttt tccttttagcc 893  
 tgggacagaa ggacctcccg gcccccaaag gatctccag tgaccaaaagg atgcgaagag 953  
 tgatagttac gtgctcctga ctgatcacac cgcagacatt tagattttta taccceaaggc 1013  
 actttaaaaa aatgttttat aaatagagaa taaattgaat tcttggtcca aaaaaaaaaa 1073  
 aa 1075

<210> 174  
 <211> 632  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> sig\_peptide  
 <222> 62..265  
 <223> Von Heijne matrix  
 score 4.59999990463257  
 seq LPFSLVSMMLVTQG/LV  
 <221> polyA\_signal  
 <222> 602..607  
 <221> polyA\_site  
 <222> 621..632  
 <300>  
 <400> 174

cactgggtca aggagtaagc agaggataaa caactggaag gagagcaagc acaaagtcac 60  
 c atg gct tca gcg tct gct cgt gga aac caa gat aaa gat gcc cat ttt 109  
 Met Ala Ser Ala Ser Ala Arg Gly Asn Gln Asp Lys Asp Ala His Phe  
 -65      -60      -55

cca cca cca agc aag cag agc ctg ttg ttt tgt cca aaa tca aaa ctg 157  
 Pro Pro Pro Ser Lys Gln Ser Leu Leu Phe Cys Pro Lys Ser Lys Leu

153

-50                      -45                      -40

cac atc cac aga gca gag atc tca aag att atg cga gaa tgt cag gaa                      205  
 His Ile His Arg Ala Glu Ile Ser Lys Ile Met Arg Glu Cys Gln Glu

-35                      -30                      -25

gaa agt ttc tgg aag aga gct ctg cct ttt tct ctt gta agc atg ctt                      253  
 Glu Ser Phe Trp Lys Arg Ala Leu Pro Phe Ser Leu Val Ser Met Leu

-20                      -15                      -10                      -5

gtc acc cag gga cta gtc tac caa ggt tat ttg gca gct aat tct aga                      301  
 Val Thr Gln Gly Leu Val Tyr Gln Gly Tyr Leu Ala Ala Asn Ser Arg

1                      5                      10

ttt gga tca ttg ccc aaa gtt gca ctt gct ggt ctc ttg gga ttt ggc                      349  
 Phe Gly Ser Leu Pro Lys Val Ala Leu Ala Gly Leu Leu Gly Phe Gly

15                      20                      25

ctt gga aag gta tca tac ata gga gta tgc cag agt aaa ttc cat ttt                      397  
 Leu Gly Lys Val Ser Tyr Ile Gly Val Cys Gln Ser Lys Phe His Phe

30                      35                      40

ttt gaa gat cag ctc cgt ggg gct ggt ttt ggt cca cag cat aac agg                      445  
 Phe Glu Asp Gln Leu Arg Gly Ala Gly Phe Gly Pro Gln His Asn Arg

45                      50                      55                      60

cac tgc ctc ctt acc tgt gag gaa tgc aaa ata aag cat gga tta agt                      493  
 His Cys Leu Leu Thr Cys Glu Glu Cys Lys Ile Lys His Gly Leu Ser

65                      70                      75

gag aag gga gac tct cag cct tca gct tcc taaattctgt gtctgtgact                      543  
 Glu Lys Gly Asp Ser Gln Pro Ser Ala Ser

80                      85

ttcgaagttt ttttaacctc tgaatttgta cacattttaa atttcaagtg tactttaaaa                      603  
 taaaatactt ctaatgtaaa aaaaaaaaaa                      632

<210> 175  
 <211> 430  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> polyA\_signal  
 <222> 402..407  
 <221> polyA\_site  
 <222> 419..430  
 <300>  
 <400> 175

gtattgggaa agtgatttgt gaa atg aaa gta gaa gaa gag cat acc aat gca                      53  
 Met Lys Val Glu Glu Glu His Thr Asn Ala

1                      5                      10

ata ggc act ctc cac ggc ggt ttg aca gcc acg tta gta gat aac ata                      101  
 Ile Gly Thr Leu His Gly Gly Leu Thr Ala Thr Leu Val Asp Asn Ile

15                      20                      25

tca aca atg gct ctg cta tgc acg gaa agg gga gca ccc gga gtc agt                      149  
 Ser Thr Met Ala Leu Leu Cys Thr Glu Arg Gly Ala Pro Gly Val Ser

30                      35                      40

gtc gat atg aac ata acg tac atg tca cct gca aaa tta gga gag gat                      197  
 Val Asp Met Asn Ile Thr Tyr Met Ser Pro Ala Lys Leu Gly Glu Asp

45                      50                      55

ata gtg att aca gca cat gtt ctg aag caa gga aaa aca ctt gca ttt                      245  
 Ile Val Ile Thr Ala His Val Leu Lys Gln Gly Lys Thr Leu Ala Phe

60                      65                      70

acc tct gtg ggt ctg acc aac aag gcc aca gga aaa tta ata gca caa                      293  
 Thr Ser Val Gly Leu Thr Asn Lys Ala Thr Gly Lys Leu Ile Ala Gln

75                      80                      85                      90

gga aga cac aca aaa cac ctg gga aac tgagagaaca gcagaatgac                      340  
 Gly Arg His Thr Lys His Leu Gly Asn

95

ctaaagaaac ccaacaatga atatcaagta tagatttgac tcaaacatt gtaatttttg                      400  
 aaataaacta gcaaaaacaa aaaaaaaaaa                      430

<210> 176  
 <211> 185

154

```

<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 42..113
<223> Von Heijne matrix
      score 3.70000004768372
      seq ILFNLLIFLCGFT/NY
<221> polyA_site
<222> 172..185
<300>
<400> 176
ctttcagaac tcactgccaa gagccctgaa caggagccac c atg cag tgc ttc agc      56
                                         Met Gln Cys Phe Ser
                                         -20

ttc att aag acc atg atg atc ctc ttc aat ttg ctc atc ttt ctg tgt      104
Phe Ile Lys Thr Met Met Ile Leu Phe Asn Leu Leu Ile Phe Leu Cys
      -15      -10      -5

ggc ttc acc aac tat acg gat ttt gag gac tca ccc tac ttc aaa atg      152
Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp Ser Pro Tyr Phe Lys Met
      1      5      10

cat aaa cct gtt aca atg taaaaaaaa aaaaa      185
His Lys Pro Val Thr Met
      15

<210> 177
<211> 585
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 108..170
<223> Von Heijne matrix
      score 5.5
      seq SFLPSALVIWTS/AF
<221> polyA_signal
<222> 550..555
<221> polyA_site
<222> 574..585
<300>
<400> 177
cacgttcctg ttgagtacac gttcctgttg atttacaaaa ggtgcaggta tgagcaggtc      60
tgaagactaa cattttgtga agttgtaaaa cagaaaaacct gttagaa atg tgg tgg      116
                                         Met Trp Trp
                                         -20

ttt cag caa ggc ctc agt ttc ctt cct tca gcc ctt gta att tgg aca      164
Phe Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val Ile Trp Thr
      -15      -10      -5

tct gct gct ttc ata ttt tca tac att act gca gta aca ctc cac cat      212
Ser Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr Leu His His
      1      5      10

ata gac ccg gct tta cct tat atc agt gac act ggt aca gta gct cca      260
Ile Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr Val Ala Pro
      15      20      25      30

gaa aaa tgc tta ttt ggg gca atg cta aat att gcg gca gtc tta tgt      308
Glu Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala Val Leu Cys
      35      40      45

caa aaa tagaaatcag gaagataatt caacttaaag aagttcattt catgaccaaa      364
Gln Lys
ctcttcagaa acatgtctttt acaagcatat ctcttgattt gctttctaca ctgttgaatt      424
gtctggcaat atttctgcag tggaaaaattt gatttagcta gttcttgact gataaatatg      484
gtaaggtggg cttttccccc tgtgtaattg gctactatgt cttactgagc caagttgtaa      544
tttgaataaa aatgatatga gagtgcacaa aaaaaaaaa a      585

<210> 178

```

```

<211> 613
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 118..171
<223> Von Heijne matrix
      score 5.90000009536743
      seq ALALLWSLPASDL/GR
<221> polyA_signal
<222> 583..588
<221> polyA_site
<222> 602..613
<300>
<400> 178
ggggtgggtg gactagaagc atttgggagt agtggccagg ggccctggac gctagccacg      60
gagctgccgc acagagcctg gtgtccacaa gcttccaggt tggggttgga gcctggg      117
atg agc ccc ggc agc gcc ttg gcc ctt ctg tgg tcc ctg cca gcc tct      165
Met Ser Pro Gly Ser Ala Leu Ala Leu Leu Trp Ser Leu Pro Ala Ser
      -15                      -10                      -5
gac ctg ggc cgg tca gtc att gct gga ctc tgg cca cac act ggc gtt      213
Asp Leu Gly Arg Ser Val Ile Ala Gly Leu Trp Pro His Thr Gly Val
      1                      5                      10
ctc atc cac ttg gaa aca agc cag tct ttt ctg caa ggt cag ttg acc      261
Leu Ile His Leu Glu Thr Ser Gln Ser Phe Leu Gln Gly Gln Leu Thr
      15                      20                      25                      30
aag agc ata ttt ccc ctc tgt tgt aca tcg ttg ttt tgt gtt tgt gtt      309
Lys Ser Ile Phe Pro Leu Cys Cys Thr Ser Leu Phe Cys Val Cys Val
      35                      40                      45
gta aca gtg ggt gga ggg agg gtg ggg tct aca ttt gtt gca      351
Val Thr Val Gly Gly Gly Arg Val Gly Ser Thr Phe Val Ala
      50                      55                      60
tgagtcgatg ggtcagaact ttagtatacg catgcgtcct ctgagtgaca gggcattttg      411
tcgaaaataa gcaccttggg aactaaaccc ctctaatagc tataaaggct ttagttctgt      471
attgattaag ttactgtaaa agcttgggtt tatttttcta ggacttaatg gctaagaatt      531
agaacatagc aagggggctc ctctgttga gtaatgtaaa ttgtaattat aaataaacat      591
gcaaaccttt aaaaaaaaaa aa      613
<210> 179
<211> 427
<212> DNA
<213> Homo sapiens
<220>
<221> sig_peptide
<222> 128..268
<223> Von Heijne matrix
      score 5.5
      seq SALLFFARPCVFC/FK
<221> polyA_signal
<222> 410..415
<221> polyA_site
<222> 424..427
<300>
<400> 179
agcttggatt tacactgggc aacgtggttg gaatgtatct ggctcagaac tatgatatac      60
caaacctggc taaaaaactt gaagaaatta aaaaggactt ggatgccaaag aagaaacccc      120
ctagtgc atg aga ctg cct cca gca ctg cct tca gga tat act gat tct      169
      Met Arg Leu Pro Pro Ala Leu Pro Ser Gly Tyr Thr Asp Ser
      -45                      -40                      -35
act gct ctt gag ggc ctc gtt tac tat ctg aac caa aag ctt ttg ttt      217
Thr Ala Leu Glu Gly Leu Val Tyr Tyr Leu Asn Gln Lys Leu Leu Phe
      -30                      -25                      -20
tcg tct cca gcc tca gca ctt ctc ttc ttt gct aga ccc tgt gtt ttt      265
Ser Ser Pro Ala Ser Ala Leu Leu Phe Phe Ala Arg Pro Cys Val Phe

```

	-15	-10	156	-5		
tgc ttt aaa gca agc aaa atg ggg ccc caa ttt gag aac tac cca aca						313
Cys Phe Lys Ala Ser Lys Met Gly Pro Gln Phe Glu Asn Tyr Pro Thr						
1 5 10 15						
ttt cca aca tac tca cct ctt ccc ata atc cct ttc caa ctg cat ggg						361
Phe Pro Thr Tyr Ser Pro Leu Pro Ile Ile Pro Phe Gln Leu His Gly						
20 25 30						
agg ttc taagactgga attatgggtgc tagattagta aacatgacctt ttaatgaaaa						417
Arg Phe						
aaaaaaaaaa						427
<210> 180						
<211> 905						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> sig_peptide						
<222> 149..457						
<223> Von Heijne matrix						
score 4.90000009536743						
seq FLAQTTLRNVLG/TQ						
<221> polyA_site						
<222> 893..912						
<300>						
<400> 180						
gctgcctggt cttcacactt agctccaaac ccataaaaaa ttgccaaagta taaaagcttc						60
tcaagaatga gatggattct aggggtgctt cacctgagaa gcaagataaa gagaatttccg						120
tgggtgtcaa caataaacgg cttgggtgt atg tgg ctg gat cct gtt ttc cct						172
Met Trp Leu Asp Pro Val Phe Pro						
-100						
ctc ttt cct gtt ggt gat cat tac ctt ccc cat ctc cat atg gat gtg						220
Leu Phe Pro Val Gly Asp His Tyr Leu Pro His Leu His Met Asp Val						
-95 -90 -85 -80						
ctt gaa ggt ttg atc ctg gtc ctg cca tgc ata gat gtg ttt gtc aaa						268
Leu Glu Gly Leu Ile Leu Val Leu Pro Cys Ile Asp Val Phe Val Lys						
-75 -70 -65						
gtt gac ctc cga aca gtt act tgc aac att cct cca caa gag atc ctc						316
Val Asp Leu Arg Thr Val Thr Cys Asn Ile Pro Pro Gln Glu Ile Leu						
-60 -55 -50						
acc aga gac tcc gta act act cag gta gat gga gtt gtc tat tac aga						364
Thr Arg Asp Ser Val Thr Thr Gln Val Asp Gly Val Val Tyr Tyr Arg						
-45 -40 -35						
atc tat agt gct gtc tca gca gtg gct aat gtc aac gat gtc cat caa						412
Ile Tyr Ser Ala Val Ser Ala Val Ala Asn Val Asn Asp Val His Gln						
-30 -25 -20						
gca aca ttt ctg ctg gct caa acc act ctg aga aat gtc tta ggg aca						460
Ala Thr Phe Leu Leu Ala Gln Thr Thr Leu Arg Asn Val Leu Gly Thr						
-15 -10 -5 1						
cag acc ttg tcc cag atc tta gct gga cga gaa gag atc gcc cat agc						508
Gln Thr Leu Ser Gln Ile Leu Ala Gly Arg Glu Glu Ile Ala His Ser						
5 10 15						
atc cag act tta ctt gat gat gcc acc gaa ctg tgg ggg atc cgg gtg						556
Ile Gln Thr Leu Leu Asp Asp Ala Thr Glu Leu Trp Gly Ile Arg Val						
20 25 30						
gcc cga gtg gaa atc aaa gat gtt cgg att ccc gtg cag ttg cag aga						604
Ala Arg Val Glu Ile Lys Asp Val Arg Ile Pro Val Gln Leu Gln Arg						
35 40 45						
tcc atg gca gcc gag gct gag gcc acc cgg gaa gcg aga gcc aag gtc						652
Ser Met Ala Ala Glu Ala Glu Ala Thr Arg Glu Ala Arg Ala Lys Val						
50 55 60 65						
ctt gca gct gaa gga atg aat gct tcc aaa tcc ctg aag tca gcc						700
Leu Ala Ala Glu Gly Glu Met Asn Ala Ser Lys Ser Leu Lys Ser Ala						
70 75 80						
tcc atg gtg ctg gct gag tct ccc ata gct ctc cag ctg cgc tac ctg						748

157

Ser Met Val Leu Ala Glu Ser Pro Ile Ala Leu Gln Leu Arg Tyr Leu  
85 90 95  
cag acc ttg agc acg gta gcc acc gag aag aat tct acg att gtg ttt 796  
Gln Thr Leu Ser Thr Val Ala Thr Glu Lys Asn Ser Thr Ile Val Phe  
100 105 110  
cct ctg ccc atg aat ata cta gag ggc att ggt ggc gtc agc tat gat 844  
Pro Leu Pro Met Asn Ile Leu Glu Gly Ile Gly Gly Val Ser Tyr Asp  
115 120 125  
aac cac aag aag ctt cca aat aaa gcc tgaggctctc ttgcggtagt 891  
Asn His Lys Lys Leu Pro Asn Lys Ala  
130 135  
caaaaaaaaaaaaa  
<210> 181 905  
<211> 307  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SIGNAL  
<222> -13...-1  
<300>  
<400> 181

Met Leu Ala Val Ser Leu Thr Val Pro Leu Leu Gly Ala Met Met Leu  
-10 -5 1  
Leu Glu Ser Pro Ile Asp Pro Gln Pro Leu Ser Phe Lys Glu Pro Pro  
5 10 15  
Leu Leu Leu Gly Val Leu His Pro Asn Thr Lys Leu Arg Gln Ala Glu  
20 25 30 35  
Arg Leu Phe Glu Asn Gln Leu Val Gly Pro Glu Ser Ile Ala His Ile  
40 45 50  
Gly Asp Val Met Phe Thr Gly Thr Ala Asp Gly Arg Val Val Lys Leu  
55 60 65  
Glu Asn Gly Glu Ile Glu Thr Ile Ala Arg Phe Gly Ser Gly Pro Cys  
70 75 80  
Lys Thr Arg Gly Asp Glu Pro Val Cys Gly Arg Pro Leu Gly Ile Arg  
85 90 95  
Ala Gly Pro Asn Gly Thr Leu Phe Val Ala Asp Ala Tyr Lys Gly Leu  
100 105 110 115  
Phe Glu Val Asn Pro Trp Lys Arg Glu Val Lys Leu Leu Leu Ser Ser  
120 125 130  
Glu Thr Pro Ile Glu Gly Lys Asn Met Ser Phe Val Asn Asp Leu Thr  
135 140 145  
Val Thr Gln Asp Gly Arg Lys Ile Tyr Phe Thr Asp Ser Ser Ser Lys  
150 155 160  
Trp Gln Arg Arg Asp Tyr Leu Leu Leu Val Met Glu Gly Thr Asp Asp  
165 170 175  
Gly Arg Leu Leu Glu Tyr Asp Thr Val Thr Arg Glu Val Lys Val Leu  
180 185 190 195  
Leu Asp Gln Leu Arg Phe Pro Asn Gly Val Gln Leu Ser Pro Ala Glu  
200 205 210  
Asp Phe Val Leu Val Ala Glu Thr Thr Met Ala Arg Ile Arg Arg Val  
215 220 225  
Tyr Val Ser Gly Leu Met Lys Gly Gly Ala Asp Leu Phe Val Glu Asn  
230 235 240  
Met Pro Gly Phe Pro Asp Asn Ile Arg Pro Ser Ser Ser Gly Gly Tyr  
245 250 255  
Trp Val Gly Met Ser Thr Ile Arg Pro Asn Pro Gly Phe Ser Met Leu  
260 265 270 275  
Asp Phe Leu Ser Glu Arg Pro Trp Ile Lys Arg Met Ile Phe Lys Val  
280 285 290  
Lys Lys Lys  
<210> 182  
<211> 59  
<212> PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;300&gt;

&lt;400&gt; 182

```

Met Met Tyr Val Ser Ile Glu Met Ser Gly Pro Thr Ile Ser His Leu
1           5           10           15
Phe Asp Tyr Val Val Cys Tyr Ile Tyr Gly Leu Lys Ser Phe Ser Leu
           20           25           30
Lys Gln Leu Lys Lys Lys Ser Trp Ser Lys Tyr Leu Phe Glu Ser Cys
           35           40           45
Cys Tyr Arg Ser Leu Tyr Val Cys Val Phe Ile
           50           55

```

&lt;210&gt; 183

&lt;211&gt; 97

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -28...-1

&lt;300&gt;

&lt;400&gt; 183

```

Met Ser Pro Ala Phe Arg Ala Met Asp Val Glu Pro Arg Ala Lys Gly
           -25           -20           -15
Val Leu Leu Glu Pro Phe Val His Gln Val Gly Gly His Ser Cys Val
           -10           -5           1
Leu Arg Phe Asn Glu Thr Thr Leu Cys Lys Pro Leu Val Pro Arg Glu
5           10           15           20
His Gln Phe Tyr Glu Thr Leu Pro Ala Glu Met Arg Lys Phe Ser Pro
           25           30           35
Gln Tyr Lys Gly Gln Ser Gln Arg Pro Leu Val Ser Trp Pro Ser Leu
           40           45           50
Pro His Phe Phe Pro Trp Ser Phe Pro Leu Trp Pro Gln Gly Ser Val
           55           60           65
Ala

```

&lt;210&gt; 184

&lt;211&gt; 52

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -32...-1

&lt;300&gt;

&lt;400&gt; 184

```

Met Leu Gly Thr Thr Gly Leu Gly Thr Gln Gly Pro Ser Gln Gln Ala
           -30           -25           -20
Leu Gly Phe Phe Ser Phe Met Leu Leu Gly Met Gly Gly Cys Leu Pro
           -15           -10           -5
Gly Phe Leu Leu Gln Pro Pro Asn Arg Ser Pro Thr Leu Pro Ala Ser
1           5           10           15
Thr Phe Ala His
           20

```

&lt;210&gt; 185

&lt;211&gt; 124

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -97...-1

&lt;300&gt;

&lt;400&gt; 185

```

Met Ala Asp Asp Leu Lys Arg Phe Leu Tyr Lys Lys Leu Pro Ser Val
           -95           -90           -85
Glu Gly Leu His Ala Ile Val Val Ser Asp Arg Asp Gly Val Pro Val

```



159

-80	-75	-70	
Val Lys Val Ala Asn Asp Asn Ala Pro Glu His Ala Leu Arg Pro Gly			
-65	-60	-55	-50
Phe Leu Ser Thr Phe Ala Leu Ala Thr Asp Gln Gly Ser Lys Leu Gly			
	-45	-40	-35
Leu Ser Lys Asn Lys Ser Ile Ile Cys Tyr Tyr Asn Thr Tyr Gln Val			
	-30	-25	-20
Val Gln Phe Asn Arg Leu Pro Leu Val Val Ser Phe Ile Ala Ser Ser			
	-15	-10	-5
Ser Ala Asn Thr Gly Leu Ile Val Ser Leu Glu Lys Glu Leu Ala Pro			
1	5	10	15
Leu Phe Glu Glu Leu Arg Gln Val Val Glu Val Ser			
	20	25	

&lt;210&gt; 186

&lt;211&gt; 230

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -24...-1

&lt;300&gt;

&lt;400&gt; 186

Met Ala Ser Leu Gly Leu Gln Leu Val Gly Tyr Ile Leu Gly Leu Leu		
	-20	-15
Gly Leu Leu Gly Thr Leu Val Ala Met Leu Leu Pro Ser Trp Lys Thr		-10
	-5	1
Ser Ser Tyr Val Gly Ala Ser Ile Val Thr Ala Val Gly Phe Ser Lys		5
	10	15
Gly Leu Trp Met Glu Cys Ala Thr His Ser Thr Gly Ile Thr Gln Cys		20
25	30	35
Asp Ile Tyr Ser Thr Leu Leu Gly Leu Pro Ala Asp Ile Gln Ala Ala		40
	45	50
Gln Ala Met Met Val Thr Ser Ser Ala Ile Ser Ser Leu Ala Cys Ile		55
	60	65
Ile Ser Val Val Gly Met Arg Cys Thr Val Phe Cys Gln Glu Ser Arg		70
	75	80
Ala Lys Asp Arg Val Ala Val Ala Gly Gly Val Phe Phe Ile Leu Gly		85
	90	95
Gly Leu Leu Gly Phe Ile Pro Val Ala Trp Asn Leu His Gly Ile Leu		100
105	110	115
Arg Asp Phe Tyr Ser Pro Leu Val Pro Asp Ser Met Lys Phe Glu Ile		120
	125	130
Gly Glu Ala Leu Tyr Leu Gly Ile Ile Ser Ser Leu Phe Ser Leu Ile		135
	140	145
Ala Gly Ile Ile Leu Cys Phe Ser Cys Ser Ser Gln Arg Asn Arg Ser		150
	155	160
Asn Tyr Tyr Asp Ala Tyr Gln Ala Gln Pro Leu Ala Thr Arg Ser Ser		165
	170	175
Pro Arg Pro Gly Gln Pro Pro Lys Val Lys Ser Glu Phe Asn Ser Tyr		180
185	190	195
Ser Leu Thr Gly Tyr Val		200
	205	

&lt;210&gt; 187

&lt;211&gt; 72

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -32...-1

&lt;300&gt;

&lt;400&gt; 187

Met Phe Ala Leu Ala Val Met Arg Ala Phe Arg Lys Asn Lys Thr Leu		
	-30	-25
		-20

160

Gly Tyr Gly Val Pro Met Leu Leu Leu Ile Ala Gly Gly Ser Phe Gly  
 -15 -10 -5  
 Leu Arg Glu Phe Ser Gln Ile Arg Tyr Asp Ala Val Lys Ser Lys Met  
 1 5 10 15  
 Asp Pro Glu Leu Glu Lys Lys Pro Lys Glu Asn Lys Ile Ser Leu Glu  
 20 25 30  
 Ser Glu Tyr Glu Gly Ser Ile Cys  
 35 40

&lt;210&gt; 188

&lt;211&gt; 88

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -33...-1

&lt;300&gt;

&lt;400&gt; 188

Met Ser Gln Thr Ala Trp Leu Ser Leu Leu Ser Ser Ser Pro Phe Gly  
 -30 -25 -20  
 Pro Phe Ser Ala Leu Thr Phe Leu Phe Leu His Leu Pro Pro Ser Thr  
 -15 -10 -5  
 Ser Leu Phe Ile Asn Leu Ala Arg Gly Gln Ile Lys Gly Pro Leu Gly  
 1 5 10 15  
 Leu Ile Leu Leu Leu Ser Phe Cys Gly Gly Tyr Thr Lys Cys Asp Phe  
 20 25 30  
 Ala Leu Ser Tyr Leu Glu Ile Pro Asn Arg Ile Glu Phe Ser Ile Met  
 35 40 45  
 Asp Pro Lys Arg Lys Thr Lys Cys  
 50 55

&lt;210&gt; 189

&lt;211&gt; 106

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -32...-1

&lt;300&gt;

&lt;400&gt; 189

Met Phe Ala Pro Ala Val Thr Arg Ala Phe Arg Lys Asn Lys Thr Leu  
 -30 -25 -20  
 Gly Tyr Gly Val Pro Met Leu Leu Ile Val Gly Gly Ser Phe Gly  
 -15 -10 -5  
 Leu Arg Glu Phe Ser Gln Ile Arg Tyr Asp Ala Val Lys Ser Lys Met  
 1 5 10 15  
 Asp Pro Glu Leu Glu Lys Lys Leu Lys Glu Asn Lys Ile Ser Leu Glu  
 20 25 30  
 Ser Glu Tyr Glu Lys Ile Lys Asp Ser Lys Phe Asp Asp Trp Lys Asn  
 35 40 45  
 Ile Arg Gly Pro Arg Pro Trp Glu Asp Pro Asp Leu Leu Gln Gly Arg  
 50 55 60  
 Asn Pro Glu Ser Leu Lys Thr Lys Thr Thr  
 65 70

&lt;210&gt; 190

&lt;211&gt; 267

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -21...-1

&lt;300&gt;

&lt;400&gt; 190

Met Trp Trp Phe Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val  
 -20 -15 -10

161  
 Ile Trp Thr Ser Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr  
 -5 1 5 10  
 Leu His His Ile Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr  
 15 20 25  
 Val Ala Pro Glu Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala  
 30 35 40  
 Val Leu Cys Ile Ala Thr Ile Tyr Val Arg Tyr Lys Gln Val His Ala  
 45 50 55  
 Leu Ser Pro Glu Glu Asn Val Ile Ile Lys Leu Asn Lys Ala Gly Leu  
 60 65 70 75  
 Val Leu Gly Ile Leu Ser Cys Leu Gly Leu Ser Ile Val Ala Asn Phe  
 80 85 90  
 Gln Lys Thr Thr Leu Phe Ala Ala His Val Ser Gly Ala Val Leu Thr  
 95 100 105  
 Phe Gly Met Gly Ser Leu Tyr Met Phe Val Gln Thr Ile Leu Ser Tyr  
 110 115 120  
 Gln Met Gln Pro Lys Ile His Gly Lys Gln Val Phe Trp Ile Arg Leu  
 125 130 135  
 Leu Leu Val Ile Trp Cys Gly Val Ser Ala Leu Ser Met Leu Thr Cys  
 140 145 150 155  
 Ser Ser Val Leu His Ser Gly Asn Phe Gly Thr Asp Leu Glu Gln Lys  
 160 165 170  
 Leu His Trp Asn Pro Glu Asp Lys Gly Tyr Ala Leu His Met Ile Thr  
 175 180 185  
 Thr Ala Ala Glu Trp Ser Met Ser Phe Ser Phe Phe Gly Phe Phe Leu  
 190 195 200  
 Thr Tyr Ile Arg Asp Phe Gln Lys Ile Ser Leu Arg Val Glu Ala Asn  
 205 210 215  
 Leu His Gly Leu Thr Leu Tyr Asp Thr Ala Pro Cys Pro Ile Asn Asn  
 220 225 230 235  
 Glu Arg Thr Arg Leu Leu Ser Arg Asp Ile Arg  
 240 245

&lt;210&gt; 191

&lt;211&gt; 108

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;300&gt;

&lt;400&gt; 191

Met Gly Cys Val Phe Gln Ser Thr Glu Asp Lys Cys Ile Phe Lys Ile  
 1 5 10 15  
 Asp Trp Thr Leu Ser Pro Gly Glu His Ala Lys Asp Glu Tyr Val Leu  
 20 25 30  
 Tyr Tyr Tyr Ser Asn Leu Ser Val Pro Ile Gly Arg Phe Gln Asn Arg  
 35 40 45  
 Val His Leu Met Gly Asp Ile Leu Cys Asn Asp Gly Ser Leu Leu Leu  
 50 55 60  
 Gln Asp Val Gln Glu Ala Asp Gln Gly Thr Tyr Ile Cys Glu Ile Arg  
 65 70 75 80  
 Leu Lys Gly Glu Ser Gln Val Phe Lys Lys Ala Val Val Leu His Val  
 85 90 95  
 Leu Pro Glu Glu Pro Lys Gly Thr Gln Met Leu Thr  
 100 105

&lt;210&gt; 192

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -46...-1

&lt;300&gt;

&lt;400&gt; 192

Met Ser Val Phe Trp Gly Phe Val Gly Phe Leu Val Pro Trp Phe Ile

162

-45                      -40                      -35

Pro Lys Gly Pro Asn Arg Gly Val Ile Ile Thr Met Leu Val Thr Cys

-30                      -25                      -20                      -15

Ser Val Cys Cys Tyr Leu Phe Trp Leu Ile Ala Ile Leu Ala Gln Leu

                    -10                      -5                      1

Asn Pro Leu Phe Gly Pro Gln Leu Lys Asn Glu Thr Ile Trp Tyr Leu

                    5                      10                      15

Lys Tyr His Trp Pro

                    20

<210> 193

<211> 251

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> -28...-1

<300>

<400> 193

Met Trp Arg Leu Leu Ala Arg Ala Ser Ala Pro Leu Leu Arg Val Pro

                    -25                      -20                      -15

Leu Ser Asp Ser Trp Ala Leu Leu Pro Ala Ser Ala Gly Val Lys Thr

                    -10                      -5                      1

Leu Leu Pro Val Pro Ser Phe Glu Asp Val Ser Ile Pro Glu Lys Pro

5                      10                      15                      20

Lys Leu Arg Phe Ile Glu Arg Ala Pro Leu Val Pro Lys Val Arg Arg

                    25                      30                      35

Glu Pro Lys Asn Leu Ser Asp Ile Arg Gly Pro Ser Thr Glu Ala Thr

                    40                      45                      50

Glu Phe Thr Glu Gly Asn Phe Ala Ile Leu Ala Leu Gly Gly Gly Tyr

                    55                      60                      65

Leu His Trp Gly His Phe Glu Met Met Arg Leu Thr Ile Asn Arg Ser

70                      75                      80

Met Asp Pro Lys Asn Met Phe Ala Ile Trp Arg Val Pro Ala Pro Phe

85                      90                      95                      100

Lys Pro Ile Thr Arg Lys Ser Val Gly His Arg Met Gly Gly Gly Lys

                    105                      110                      115

Gly Ala Ile Asp His Tyr Val Thr Pro Val Lys Ala Gly Arg Leu Val

                    120                      125                      130

Val Glu Met Gly Gly Arg Cys Glu Phe Glu Glu Val Gln Gly Phe Leu

                    135                      140                      145

Asp Gln Val Ala His Lys Leu Pro Phe Ala Ala Lys Ala Val Ser Arg

150                      155                      160

Gly Thr Leu Glu Lys Met Arg Lys Asp Gln Glu Arg Glu Arg Asn

165                      170                      175                      180

Asn Gln Asn Pro Trp Thr Phe Glu Arg Ile Ala Thr Ala Asn Met Leu

                    185                      190                      195

Gly Ile Arg Lys Val Leu Ser Pro Tyr Asp Leu Thr His Lys Gly Lys

                    200                      205                      210

Tyr Trp Gly Lys Phe Tyr Met Pro Lys Arg Val

                    215                      220

<210> 194

<211> 99

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> -48...-1

<300>

<400> 194

Met Asp Asn Val Gln Pro Lys Ile Lys His Arg Pro Phe Cys Phe Ser

                    -45                      -40                      -35

Val Lys Gly His Val Lys Met Leu Arg Leu Asp Ile Ile Asn Ser Leu

                    -30                      -25                      -20

163

Val Thr Thr Val Phe Met Leu Ile Val Ser Val Leu Ala Leu Ile Pro  
-15 -10 -5  
Glu Thr Thr Thr Leu Thr Val Gly Gly Gly Val Phe Ala Leu Val Thr  
1 5 10 15  
Ala Val Cys Cys Leu Ala Asp Gly Ala Leu Ile Tyr Arg Lys Leu Leu  
20 25 30  
Phe Asn Pro Ser Gly Pro Tyr Gln Lys Lys Pro Val His Glu Lys Lys  
35 40 45  
Glu Val Leu  
50  
<210> 195  
<211> 81  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SIGNAL  
<222> -31...-1  
<300>  
<400> 195  
Met Ser Asn Thr His Thr Val Leu Val Ser Leu Pro His Pro His Pro  
-30 -25 -20  
Ala Leu Thr Cys Cys His Leu Gly Leu Pro His Pro Val Arg Ala Pro  
-15 -10 -5  
Arg Pro Leu Pro Arg Val Glu Pro Trp Asp Pro Arg Trp Gln Asp Ser  
5 10 15  
Glu Leu Arg Tyr Pro Gln Ala Met Asn Ser Phe Leu Asn Glu Arg Ser  
20 25 30  
Ser Pro Cys Arg Thr Leu Arg Gln Glu Ala Ser Ala Asp Arg Cys Asp  
35 40 45  
Leu  
50  
<210> 196  
<211> 150  
<212> PRT  
<213> Homo sapiens  
<220>  
<300>  
<400> 196  
Met Lys Val His Met His Thr Lys Phe Cys Leu Ile Cys Leu Leu Thr  
1 5 10 15  
Phe Ile Phe His His Cys Asn His Cys His Glu Glu His Asp His Gly  
20 25 30  
Pro Glu Ala Leu His Arg Gln His Arg Gly Met Thr Glu Leu Glu Pro  
35 40 45  
Ser Lys Phe Ser Lys Gln Ala Ala Glu Asn Glu Lys Lys Tyr Tyr Ile  
50 55 60  
Glu Lys Leu Phe Glu Arg Tyr Gly Glu Asn Gly Arg Leu Ser Phe Phe  
65 70 75 80  
Gly Leu Glu Lys Leu Leu Thr Asn Leu Gly Leu Gly Glu Arg Lys Val  
85 90 95  
Val Glu Ile Asn His Glu Asp Leu Gly His Asp His Val Ser His Leu  
100 105 110  
Gly Ile Leu Ala Val Gln Glu Gly Lys His Phe His Ser His Asn His  
115 120 125  
Gln His Ser His Asn His Leu Asn Ser Glu Asn Gln Thr Val Thr Ser  
130 135 140  
Val Ser Thr Lys Lys Lys  
145 150  
<210> 197  
<211> 273  
<212> PRT  
<213> Homo sapiens  
<220>

&lt;221&gt; SIGNAL

&lt;222&gt; -45...-1

&lt;300&gt;

&lt;400&gt; 197

Met Asn Trp Ser Ile Phe Glu Gly Leu Leu Ser Gly Val Asn Lys Tyr  
 -45 -40 -35 -30  
 Ser Thr Ala Phe Gly Arg Ile Trp Leu Ser Leu Val Phe Ile Phe Arg  
 -25 -20 -15  
 Val Leu Val Tyr Leu Val Thr Ala Glu Arg Val Trp Ser Asp Asp His  
 -10 -5 1  
 Lys Asp Phe Asp Cys Asn Thr Arg Gln Pro Gly Cys Ser Asn Val Cys  
 5 10 15  
 Phe Asp Glu Phe Phe Pro Val Ser His Val Arg Leu Trp Ala Leu Gln  
 20 25 30 35  
 Leu Ile Leu Val Thr Cys Pro Ser Leu Leu Val Val Met His Val Ala  
 40 45 50  
 Tyr Arg Glu Val Gln Glu Lys Arg His Arg Glu Ala His Gly Glu Asn  
 55 60 65  
 Ser Gly Arg Leu Tyr Leu Asn Pro Gly Lys Lys Arg Gly Gly Leu Trp  
 70 75 80  
 Trp Thr Tyr Val Cys Ser Leu Val Phe Lys Ala Ser Val Asp Ile Ala  
 85 90 95  
 Phe Leu Tyr Val Phe His Ser Phe Tyr Pro Lys Tyr Ile Leu Pro Pro  
 100 105 110 115  
 Val Val Lys Cys His Ala Asp Pro Cys Pro Asn Ile Val Asp Cys Phe  
 120 125 130  
 Ile Ser Lys Pro Ser Glu Lys Asn Ile Phe Thr Leu Phe Met Val Ala  
 135 140 145  
 Thr Ala Ala Ile Cys Ile Leu Leu Asn Leu Val Glu Leu Ile Tyr Leu  
 150 155 160  
 Val Ser Lys Arg Cys His Glu Cys Leu Ala Ala Arg Lys Ala Gln Ala  
 165 170 175  
 Met Cys Thr Gly His His Pro His Asp Thr Thr Ser Ser Cys Lys Gln  
 180 185 190 195  
 Asp Asp Leu Leu Ser Gly Asp Leu Ile Phe Leu Gly Ser Asp Ser His  
 200 205 210  
 Pro Pro Leu Leu Pro Asp Arg Pro Arg Asp His Val Lys Lys Thr Ile  
 215 220 225

Leu

&lt;210&gt; 198

&lt;211&gt; 413

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -37...-1

&lt;300&gt;

&lt;400&gt; 198

Met Ala Ser Lys Ile Leu Leu Asn Val Gln Glu Glu Val Thr Cys Pro  
 -35 -30 -25  
 Ile Cys Leu Glu Leu Leu Thr Glu Pro Leu Ser Leu Asp Cys Gly His  
 -20 -15 -10  
 Ser Leu Cys Arg Ala Cys Ile Thr Val Ser Asn Lys Glu Ala Val Thr  
 -5 1 5 10  
 Ser Met Gly Gly Lys Ser Ser Cys Pro Val Cys Gly Ile Ser Tyr Ser  
 15 20 25  
 Phe Glu His Leu Gln Ala Asn Gln His Leu Ala Asn Ile Val Glu Arg  
 30 35 40  
 Leu Lys Glu Val Lys Leu Ser Pro Asp Asn Gly Lys Lys Arg Asp Leu  
 45 50 55  
 Cys Asp His His Gly Glu Lys Leu Leu Leu Phe Cys Lys Glu Asp Arg  
 60 65 70 75  
 Lys Val Ile Cys Trp Leu Cys Glu Arg Ser Gln Glu His Arg Gly His

80 165 85 90  
 His Thr Val Leu Thr Glu Glu Val Phe Lys Glu Cys Gln Glu Lys Leu  
 95 100 105  
 Gln Ala Val Leu Lys Arg Leu Lys Lys Glu Glu Glu Glu Ala Glu Lys  
 110 115 120  
 Leu Glu Ala Asp Ile Arg Glu Glu Lys Thr Ser Trp Lys Tyr Gln Val  
 125 130 135  
 Gln Thr Glu Arg Gln Arg Ile Gln Thr Glu Phe Asp Gln Leu Arg Ser  
 140 145 150 155  
 Ile Leu Asn Asn Glu Glu Gln Arg Glu Leu Gln Arg Leu Glu Glu Glu  
 160 165 170  
 Glu Lys Lys Thr Leu Asp Lys Phe Ala Glu Ala Glu Asp Glu Leu Val  
 175 180 185  
 Gln Gln Lys Gln Leu Val Arg Glu Leu Ile Ser Asp Val Glu Cys Arg  
 190 195 200  
 Ser Gln Trp Ser Thr Met Glu Leu Leu Gln Asp Met Ser Gly Ile Met  
 205 210 215  
 Lys Trp Ser Glu Ile Trp Arg Leu Lys Lys Pro Lys Met Val Ser Lys  
 220 225 230 235  
 Lys Leu Lys Thr Val Phe His Ala Pro Asp Leu Ser Arg Met Leu Gln  
 240 245 250  
 Met Phe Arg Glu Leu Thr Ala Val Arg Cys Tyr Trp Val Asp Val Thr  
 255 260 265  
 Leu Asn Ser Val Asn Leu Asn Leu Asn Leu Val Leu Ser Glu Asp Gln  
 270 275 280  
 Arg Gln Val Ile Ser Val Pro Ile Trp Pro Phe Gln Cys Tyr Asn Tyr  
 285 290 295  
 Gly Val Leu Gly Ser Gln Tyr Phe Ser Ser Gly Lys His Tyr Trp Glu  
 300 305 310 315  
 Val Asp Val Ser Lys Lys Thr Ala Trp Ile Leu Gly Val Tyr Cys Arg  
 320 325 330  
 Thr Tyr Ser Arg His Met Lys Tyr Val Val Arg Arg Cys Ala Asn Arg  
 335 340 345  
 Gln Asn Leu Tyr Thr Lys Tyr Arg Pro Leu Phe Gly Tyr Trp Val Ile  
 350 355 360  
 Gly Leu Gln Asn Lys Cys Lys Tyr Gly Ala Lys Lys Lys  
 365 370 375

&lt;210&gt; 199

&lt;211&gt; 393

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -19...-1

&lt;300&gt;

&lt;400&gt; 199

Met Arg Thr Leu Phe Asn Leu Leu Trp Leu Ala Leu Ala Cys Ser Pro  
 -15 -10 -5  
 Val His Thr Thr Leu Ser Lys Ser Asp Ala Lys Lys Ala Ala Ser Lys  
 1 5 10  
 Thr Leu Leu Glu Lys Ser Gln Phe Ser Asp Lys Pro Val Gln Asp Arg  
 15 20 25  
 Gly Leu Val Val Thr Asp Leu Lys Ala Glu Ser Val Val Leu Glu His  
 30 35 40 45  
 Arg Ser Tyr Cys Ser Ala Lys Ala Arg Asp Arg His Phe Ala Gly Asp  
 50 55 60  
 Val Leu Gly Tyr Val Thr Pro Trp Asn Ser His Gly Tyr Asp Val Thr  
 65 70 75  
 Lys Val Phe Gly Ser Lys Phe Thr Gln Ile Ser Pro Val Trp Leu Gln  
 80 85 90  
 Leu Lys Arg Arg Gly Arg Glu Met Phe Glu Val Thr Gly Leu His Asp  
 95 100 105  
 Val Asp Gln Gly Trp Met Arg Ala Val Arg Lys His Ala Lys Gly Leu

110 115 166 120 125  
 His Ile Val Pro Arg Leu Leu Phe Glu Asp Trp Thr Tyr Asp Asp Phe  
 130 135 140  
 Arg Asn Val Leu Asp Ser Glu Asp Glu Ile Glu Glu Leu Ser Lys Thr  
 145 150 155  
 Val Val Gln Val Ala Lys Asn Gln His Phe Asp Gly Phe Val Val Glu  
 160 165 170  
 Val Trp Asn Gln Leu Leu Ser Gln Lys Arg Val Gly Leu Ile His Met  
 175 180 185  
 Leu Thr His Leu Ala Glu Ala Leu His Gln Ala Arg Leu Leu Ala Leu  
 190 195 200 205  
 Leu Val Ile Pro Pro Ala Ile Thr Pro Gly Thr Asp Gln Leu Gly Met  
 210 215 220  
 Phe Thr His Lys Glu Phe Glu Gln Leu Ala Pro Val Leu Asp Gly Phe  
 225 230 235  
 Ser Leu Met Thr Tyr Asp Tyr Ser Thr Ala His Gln Pro Gly Pro Asn  
 240 245 250  
 Ala Pro Leu Ser Trp Val Arg Ala Cys Val Gln Val Leu Asp Pro Lys  
 255 260 265  
 Ser Lys Trp Arg Ser Lys Ile Leu Leu Gly Leu Asn Phe Tyr Gly Met  
 270 275 280 285  
 Asp Tyr Ala Thr Ser Lys Asp Ala Arg Glu Pro Val Val Gly Ala Arg  
 290 295 300  
 Tyr Ile Gln Thr Leu Lys Asp His Arg Pro Arg Met Val Trp Asp Ser  
 305 310 315  
 Gln Ala Ser Glu His Phe Phe Glu Tyr Lys Lys Ser Arg Ser Gly Arg  
 320 325 330  
 His Val Val Phe Tyr Pro Thr Leu Lys Ser Leu Gln Val Arg Leu Glu  
 335 340 345  
 Leu Ala Arg Glu Leu Gly Val Gly Val Ser Ile Trp Glu Leu Gly Gln  
 350 355 360 365  
 Gly Leu Asp Tyr Phe Tyr Asp Leu Leu  
 370

&lt;210&gt; 200

&lt;211&gt; 381

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -13...-1

&lt;300&gt;

&lt;400&gt; 200

Met Leu Leu Ser Ile Gly Met Leu Met Leu Ser Ala Thr Gln Val Tyr  
 -10 -5 1  
 Thr Val Leu Thr Val Gln Leu Phe Ala Phe Leu Asn Pro Leu Pro Val  
 5 10 15  
 Glu Ala Asp Ile Leu Ala Tyr Asn Phe Glu Asn Ala Ser Gln Thr Phe  
 20 25 30 35  
 Asp Asp Leu Pro Ala Arg Phe Gly Tyr Arg Leu Pro Ala Glu Gly Leu  
 40 45 50  
 Lys Gly Phe Leu Ile Asn Ser Lys Pro Glu Asn Ala Cys Glu Pro Ile  
 55 60 65  
 Val Pro Pro Pro Val Lys Asp Asn Ser Ser Gly Thr Phe Ile Val Leu  
 70 75 80  
 Ile Arg Arg Leu Asp Cys Asn Phe Asp Ile Lys Val Leu Asn Ala Gln  
 85 90 95  
 Arg Ala Gly Tyr Lys Ala Ala Ile Val His Asn Val Asp Ser Asp Asp  
 100 105 110 115  
 Leu Ile Ser Met Gly Ser Asn Asp Ile Glu Val Leu Lys Lys Ile Asp  
 120 125 130  
 Ile Pro Ser Val Phe Ile Gly Glu Ser Ser Ala Ser Ser Leu Lys Asp  
 135 140 145  
 Glu Phe Thr Tyr Glu Lys Gly Gly His Leu Ile Leu Val Pro Glu Phe



150 155 167 160  
 Ser Leu Pro Leu Glu Tyr Tyr Leu Ile Pro Phe Leu Ile Ile Val Gly  
 165 170 175  
 Ile Cys Leu Ile Leu Ile Val Ile Phe Met Ile Thr Lys Phe Val Gln  
 180 185 190 195  
 Asp Arg His Arg Ala Arg Arg Asn Arg Leu Arg Lys Asp Gln Leu Lys  
 200 205 210  
 Lys Leu Pro Val His Lys Phe Lys Lys Gly Asp Glu Tyr Asp Val Cys  
 215 220 225  
 Ala Ile Cys Leu Asp Glu Tyr Glu Asp Gly Asp Lys Leu Arg Ile Leu  
 230 235 240  
 Pro Cys Ser His Ala Tyr His Cys Lys Cys Val Asp Pro Trp Leu Thr  
 245 250 255  
 Lys Thr Lys Lys Thr Cys Pro Val Cys Arg Gln Lys Val Val Pro Ser  
 260 265 270 275  
 Gln Gly Asp Ser Asp Ser Asp Thr Asp Ser Ser Gln Glu Glu Asn Glu  
 280 285 290  
 Val Thr Glu His Thr Pro Leu Leu Arg Pro Leu Ala Ser Val Ser Ala  
 295 300 305  
 Gln Ser Phe Gly Ala Leu Ser Glu Ser Arg Ser His Gln Asn Met Thr  
 310 315 320  
 Glu Ser Ser Asp Tyr Glu Glu Asp Asp Asn Glu Asp Thr Asp Ser Ser  
 325 330 335  
 Asp Ala Glu Asn Glu Ile Asn Glu His Asp Val Val Val Gln Leu Gln  
 340 345 350 355  
 Pro Asn Gly Glu Arg Asp Tyr Asn Ile Ala Asn Thr Val  
 360 365  
  
 <210> 201  
 <211> 291  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -42...-1  
 <300>  
 <400> 201  
 Met Asp Ser Arg Val Ser Ser Pro Glu Lys Gln Asp Lys Glu Asn Phe  
 -40 -35 -30  
 Val Gly Val Asn Asn Lys Arg Leu Gly Val Cys Gly Trp Ile Leu Phe  
 -25 -20 -15  
 Ser Leu Ser Phe Leu Leu Val Ile Ile Thr Phe Pro Ile Ser Ile Trp  
 -10 -5 1 5  
 Met Cys Leu Lys Ile Ile Arg Glu Tyr Glu Arg Ala Val Val Phe Arg  
 10 15 20  
 Leu Gly Arg Ile Gln Ala Asp Lys Ala Lys Gly Pro Gly Leu Ile Leu  
 25 30 35  
 Val Leu Pro Cys Ile Asp Val Phe Val Lys Val Asp Leu Arg Thr Val  
 40 45 50  
 Thr Cys Asn Ile Pro Pro Gln Glu Ile Leu Thr Arg Asp Ser Val Thr  
 55 60 65 70  
 Thr Gln Val Asp Gly Val Val Tyr Tyr Arg Ile Tyr Ser Ala Val Ser  
 75 80 85  
 Ala Val Ala Asn Val Asn Asp Val His Gln Ala Thr Phe Leu Leu Ala  
 90 95 100  
 Gln Thr Thr Leu Arg Asn Val Leu Gly Thr Gln Thr Leu Ser Gln Ile  
 105 110 115  
 Leu Ala Gly Arg Glu Glu Ile Ala His Ser Ile Gln Thr Leu Leu Asp  
 120 125 130  
 Asp Ala Thr Glu Leu Trp Gly Ile Arg Val Ala Arg Val Glu Ile Lys  
 135 140 145 150  
 Asp Val Arg Ile Pro Val Gln Leu Gln Arg Ser Met Ala Ala Glu Ala  
 155 160 165  
 Glu Ala Thr Arg Glu Ala Arg Ala Lys Val Leu Ala Ala Glu Gly Glu

168  
 170 175 180  
 Met Ser Ala Ser Lys Ser Leu Lys Ser Ala Ser Met Val Leu Ala Glu  
 185 190 195  
 Ser Pro Ile Ala Leu Gln Leu Arg Tyr Leu Gln Thr Leu Ser Thr Val  
 200 205 210  
 Ala Thr Glu Lys Asn Ser Thr Ile Val Phe Pro Leu Pro Met Asn Ile  
 215 220 225 230  
 Leu Glu Gly Ile Gly Gly Val Ser Tyr Asp Asn His Lys Lys Leu Pro  
 235 240 245

Asn Lys Ala

<210> 202

<211> 92

<212> PRT

<213> Homo sapiens

<220>

<300>

<400> 202

Met Pro Pro Arg Asn Leu Leu Glu Leu Leu Ile Asn Ile Lys Ala Gly  
 1 5 10 15  
 Thr Tyr Leu Pro Gln Ser Tyr Leu Ile His Glu His Met Val Ile Thr  
 20 25 30  
 Asp Arg Ile Glu Asn Ile Asp His Leu Gly Phe Phe Ile Tyr Arg Leu  
 35 40 45  
 Cys His Asp Lys Glu Thr Tyr Lys Leu Gln Arg Arg Glu Thr Ile Lys  
 50 55 60  
 Gly Ile Gln Lys Arg Glu Ala Ser Asn Cys Phe Ala Ile Arg His Phe  
 65 70 75 80  
 Glu Asn Lys Phe Ala Val Glu Thr Leu Ile Cys Ser  
 85 90

<210> 203

<211> 127

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> -63...-1

<300>

<400> 203

Met Ser Ala Ala Gly Ala Arg Gly Leu Arg Ala Thr Tyr His Arg Leu  
 -60 -55 -50  
 Pro Asp Lys Val Glu Leu Met Leu Pro Glu Lys Leu Arg Pro Leu Tyr  
 -45 -40 -35  
 Asn His Pro Ala Gly Pro Arg Thr Val Phe Phe Trp Ala Pro Ile Met  
 -30 -25 -20  
 Lys Trp Gly Leu Val Cys Ala Gly Leu Ala Asp Met Ala Arg Pro Ala  
 -15 -10 -5 1  
 Glu Lys Leu Ser Thr Ala Gln Ser Ala Val Leu Met Ala Thr Gly Phe  
 5 10 15  
 Ile Trp Ser Arg Tyr Ser Leu Val Ile Ile Pro Lys Asn Trp Ser Leu  
 20 25 30  
 Phe Ala Val Asn Phe Phe Val Gly Ala Ala Gly Ala Ser Gln Leu Phe  
 35 40 45  
 Arg Ile Trp Arg Tyr Asn Gln Glu Leu Lys Ala Lys Ala His Lys  
 50 55 60

<210> 204

<211> 84

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> -20...-1

<300>

<400> 204

169

Met Lys Gly Trp Gly Trp Leu Ala Leu Leu Leu Gly Ala Leu Leu Gly  
 -20 -15 -10 -5  
 Thr Ala Trp Ala Arg Arg Ser Gln Asp Leu His Cys Gly Ala Cys Arg  
 1 5 10  
 Ala Leu Val Asp Glu Leu Glu Trp Glu Ile Ala Gln Val Asp Pro Lys  
 15 20 25  
 Lys Thr Ile Gln Met Gly Ser Phe Arg Ile Asn Pro Asp Gly Ser Gln  
 30 35 40  
 Ser Val Val Glu Val Thr Val Thr Val Pro Pro Asn Lys Val Ala His  
 45 50 55 60  
 Ser Gly Phe Gly

&lt;210&gt; 205

&lt;211&gt; 182

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -20...-1

&lt;300&gt;

&lt;400&gt; 205

Met Lys Gly Trp Gly Trp Leu Ala Leu Leu Leu Gly Ala Leu Leu Gly  
 -20 -15 -10 -5  
 Thr Ala Trp Ala Arg Arg Ser Gln Asp Leu His Cys Gly Ala Cys Arg  
 1 5 10  
 Ala Leu Val Asp Glu Leu Glu Trp Glu Ile Ala Gln Val Asp Pro Lys  
 15 20 25  
 Lys Thr Ile Gln Met Gly Ser Phe Arg Ile Asn Pro Asp Gly Ser Gln  
 30 35 40  
 Ser Val Val Glu Val Pro Tyr Ala Arg Ser Glu Ala His Leu Thr Glu  
 45 50 55 60  
 Leu Leu Glu Glu Ile Cys Asp Arg Met Lys Glu Tyr Gly Glu Gln Ile  
 65 70 75  
 Asp Pro Ser Thr His Arg Lys Asn Tyr Val Arg Val Val Gly Arg Asn  
 80 85 90  
 Gly Glu Ser Ser Glu Leu Asp Leu Gln Gly Ile Arg Ile Asp Ser Asp  
 95 100 105  
 Ile Ser Gly Thr Leu Lys Phe Ala Cys Gly Ser Ile Val Glu Glu Tyr  
 110 115 120  
 Glu Asp Glu Leu Ile Glu Phe Phe Ser Arg Glu Ala Asp Asn Val Lys  
 125 130 135 140  
 Asp Lys Leu Cys Ser Lys Arg Thr Asp Leu Cys Asp His Ala Leu His  
 145 150 155  
 Ile Ser His Asp Glu Leu  
 160

&lt;210&gt; 206

&lt;211&gt; 71

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -25...-1

&lt;300&gt;

&lt;400&gt; 206

Met Pro Ala Gly Val Pro Met Ser Thr Tyr Leu Lys Met Phe Ala Ala  
 -25 -20 -15 -10  
 Ser Leu Leu Ala Met Cys Ala Gly Ala Glu Val Val His Arg Tyr Tyr  
 -5 1 5  
 Arg Pro Asp Leu Thr Ile Pro Glu Ile Pro Pro Lys Arg Gly Glu Leu  
 10 15 20  
 Lys Thr Glu Leu Leu Gly Leu Lys Glu Arg Lys His Lys Pro Gln Val  
 25 30 35  
 Ser Gln Gln Glu Glu Leu Lys  
 40 45

170

<210> 207  
 <211> 73  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <300>  
 <400> 207  
 Met Arg Ile Arg Met Thr Asp Gly Arg Thr Leu Val Gly Cys Phe Leu  
 1 5 10 15  
 Cys Thr Asp Arg Asp Cys Asn Val Ile Leu Gly Ser Ala Gln Glu Phe  
 20 25 30  
 Leu Lys Pro Ser Asp Ser Phe Ser Ala Gly Glu Pro Arg Val Leu Gly  
 35 40 45  
 Leu Ala Met Val Pro Gly His His Ile Val Ser Ile Glu Val Gln Arg  
 50 55 60  
 Glu Ser Leu Thr Gly Pro Pro Tyr Leu  
 65 70  
 <210> 208  
 <211> 169  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -150...-1  
 <300>  
 <400> 208  
 Met Ala Glu Thr Lys Asp Thr Ala Gln Met Leu Val Thr Phe Lys Asp  
 -150 -145 -140 -135  
 Val Ala Val Thr Phe Thr Arg Glu Glu Trp Arg Gln Leu Asp Leu Ala  
 -130 -125 -120  
 Gln Arg Thr Leu Tyr Arg Glu Gly Ile Gly Phe Pro Lys Pro Glu Leu  
 -115 -110 -105  
 Val His Leu Leu Glu His Gly Gln Glu Leu Trp Ile Val Lys Arg Gly  
 -100 -95 -90  
 Leu Ser His Ala Thr Cys Ala Glu Phe His Ser Cys Cys Pro Gly Trp  
 -85 -80 -75  
 Ser Ala Val Xaa Arg His Leu Ser Ser Leu Gln Leu Leu Pro Pro Glu  
 -70 -65 -60 -55  
 Phe Lys Gly Phe Ser Cys Leu Ser Leu Pro Ser Ser Trp Asp Tyr Arg  
 -50 -45 -40  
 Arg Pro Pro Pro Cys Pro Ala Gly Phe Phe Val Phe Leu Val Glu Thr  
 -35 -30 -25  
 Gly Leu His His Val Gly Gln Ala Gly Leu Glu Leu Leu Thr Ser Cys  
 -20 -15 -10  
 Ser Pro Pro Ala Ser Ala Ser Gln Ser Ala Ala Ile Thr Gly Val Ser  
 -5 1 5 10  
 His Arg Ala Arg Gln Arg Lys Thr Ala  
 15  
 <210> 209  
 <211> 76  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -22...-1  
 <300>  
 <400> 209  
 Met Glu Leu Ile Ser Pro Thr Val Ile Ile Ile Leu Gly Cys Leu Ala  
 -20 -15 -10  
 Leu Phe Leu Leu Leu Gln Arg Lys Asn Leu Arg Arg Pro Pro Cys Ile  
 -5 1 5 10  
 Lys Gly Trp Ile Pro Trp Ile Gly Val Gly Phe Glu Phe Gly Lys Ala  
 15 20 25

171

Pro Leu Glu Phe Ile Glu Lys Ala Arg Ile Lys Val Cys Gly Arg Gly  
 30 35 40  
 Arg Arg Gly Leu Gln Arg Arg Gln Cys Phe Leu Phe  
 45 50

&lt;210&gt; 210

&lt;211&gt; 95

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -54...-1

&lt;300&gt;

&lt;400&gt; 210

Met Ala Glu Thr Lys Asp Ala Ala Gln Met Leu Val Thr Phe Lys Asp  
 -50 -45 -40  
 Val Ala Val Thr Phe Thr Arg Glu Glu Trp Arg Gln Leu Asp Leu Ala  
 -35 -30 -25  
 Gln Arg Thr Leu Tyr Arg Glu Val Met Leu Glu Thr Cys Gly Leu Leu  
 -20 -15 -10  
 Val Ser Leu Val Glu Ser Ile Trp Leu His Ile Thr Glu Asn Gln Ile  
 -5 1 5 10  
 Lys Leu Ala Ser Pro Gly Arg Lys Phe Thr Asn Ser Pro Asp Glu Lys  
 15 20 25  
 Pro Glu Val Trp Leu Ala Pro Gly Leu Phe Gly Ala Ala Ala Gln  
 30 35 40

&lt;210&gt; 211

&lt;211&gt; 92

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -22...-1

&lt;300&gt;

&lt;400&gt; 211

Met Glu Leu Ile Ser Pro Thr Val Ile Ile Ile Leu Gly Cys Leu Ala  
 -20 -15 -10  
 Leu Phe Leu Leu Leu Gln Arg Lys Asn Leu Arg Arg Pro Pro Cys Ile  
 -5 1 5 10  
 Lys Gly Trp Ile Pro Trp Ile Gly Val Gly Phe Glu Phe Gly Lys Ala  
 15 20 25  
 Pro Leu Glu Phe Ile Glu Lys Ala Arg Ile Lys Tyr Gly Pro Ile Phe  
 30 35 40  
 Thr Val Phe Ala Met Gly Asn Arg Met Thr Phe Val Thr Glu Glu Glu  
 45 50 55  
 Gly Ile Asn Val Phe Leu Lys Ser Lys Lys Lys Lys  
 60 65 70

&lt;210&gt; 212

&lt;211&gt; 89

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -16...-1

&lt;300&gt;

&lt;400&gt; 212

Met Ile Ile Ser Leu Phe Ile Tyr Ile Phe Leu Thr Cys Ser Asn Thr  
 -15 -10 -5  
 Ser Pro Ser Tyr Gln Gly Thr Gln Leu Gly Leu Gly Leu Pro Ser Ala  
 1 5 10 15  
 Gln Trp Trp Pro Leu Thr Gly Arg Arg Met Gln Cys Cys Arg Leu Phe  
 20 25 30  
 Cys Phe Leu Leu Gln Asn Cys Leu Phe Pro Phe Pro Leu His Leu Ile  
 35 40 45

172

Gln His Asp Pro Cys Glu Leu Val Leu Thr Ile Ser Trp Asp Trp Ala  
 50 55 60  
 Glu Ala Gly Ala Ser Leu Tyr Ser Pro  
 65 70  
 <210> 213  
 <211> 109  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <300>  
 <400> 213  
 Met Lys Val Asp Lys Asp Arg Gln Met Val Val Leu Glu Glu Glu Phe  
 1 5 10 15  
 Arg Asn Ile Ser Pro Glu Glu Leu Lys Met Glu Leu Pro Glu Arg Gln  
 20 25 30  
 Pro Arg Phe Val Val Tyr Ser Tyr Lys Tyr Val Arg Asp Asp Gly Arg  
 35 40 45  
 Val Ser Tyr Pro Leu Cys Phe Ile Phe Ser Ser Pro Val Gly Cys Lys  
 50 55 60  
 Pro Glu Gln Gln Met Met Tyr Ala Gly Ser Lys Asn Arg Leu Val Gln  
 65 70 75 80  
 Thr Ala Glu Leu Thr Lys Val Phe Glu Ile Arg Thr Thr Asp Asp Leu  
 85 90 95  
 Thr Glu Ala Trp Leu Gln Glu Lys Leu Ser Phe Phe Arg  
 100 105  
 <210> 214  
 <211> 114  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -103...-1  
 <300>  
 <400> 214  
 Met Val Ile Arg Val Tyr Ile Ala Ser Ser Ser Gly Ser Thr Ala Ile  
 -100 -95 -90  
 Lys Lys Lys Gln Gln Asp Val Leu Gly Phe Leu Glu Ala Asn Lys Ile  
 -85 -80 -75  
 Gly Phe Glu Glu Lys Asp Ile Ala Ala Asn Glu Glu Asn Arg Lys Trp  
 -70 -65 -60  
 Met Arg Glu Asn Val Pro Glu Asn Ser Arg Pro Ala Thr Gly Asn Pro  
 -55 -50 -45 -40  
 Leu Pro Pro Gln Ile Phe Asn Glu Ser Gln Tyr Arg Gly Asp Tyr Asp  
 -35 -30 -25  
 Ala Phe Phe Glu Ala Arg Glu Asn Asn Ala Val Tyr Ala Phe Leu Gly  
 -20 -15 -10  
 Leu Thr Ala Pro Ser Gly Ser Lys Glu Ala Glu Val Gln Ala Lys Gln  
 -5 1 5  
 Gln Ala  
 10  
 <210> 215  
 <211> 124  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -97...-1  
 <300>  
 <400> 215  
 Met Ala Asp Asp Leu Lys Arg Phe Leu Tyr Lys Lys Leu Pro Ser Val  
 -95 -90 -85  
 Glu Gly Leu His Ala Ile Val Val Ser Asp Arg Asp Gly Val Pro Val  
 -80 -75 -70

173

Ile	Lys	Val	Ala	Asn	Asp	Asn	Ala	Pro		Glu	His	Ala	Leu	Arg	Pro	Gly
-65					-60					-55					-50	
Phe	Leu	Ser	Thr	Phe	Ala	Leu	Ala	Thr	Asp	Gln	Gly	Ser	Lys	Leu	Gly	
				-45					-40					-35		
Leu	Ser	Lys	Asn	Lys	Ser	Ile	Ile	Cys	Tyr	Tyr	Asn	Thr	Tyr	Gln	Val	
			-30					-25					-20			
Val	Gln	Phe	Asn	Arg	Leu	Pro	Leu	Val	Val	Ser	Phe	Ile	Ala	Ser	Ser	
		-15					-10					-5				
Ser	Ala	Asn	Thr	Gly	Leu	Ile	Val	Ser	Leu	Glu	Lys	Glu	Leu	Ala	Pro	
1					5					10					15	
Leu	Phe	Glu	Glu	Leu	Arg	Gln	Val	Val	Glu	Val	Ser					
				20					25							

&lt;210&gt; 216

&lt;211&gt; 93

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -22...-1

&lt;300&gt;

&lt;400&gt; 216

Met	Lys	Pro	Val	Leu	Pro	Leu	Gln	Phe	Leu	Val	Val	Phe	Cys	Leu	Ala	
		-20					-15					-10				
Leu	Gln	Leu	Val	Pro	Gly	Ser	Pro	Lys	Gln	Arg	Val	Leu	Lys	Tyr	Ile	
	-5					1				5					10	
Leu	Glu	Pro	Pro	Pro	Cys	Ile	Ser	Ala	Pro	Glu	Asn	Cys	Thr	His	Leu	
				15					20					25		
Cys	Thr	Met	Gln	Glu	Asp	Cys	Glu	Lys	Gly	Phe	Gln	Cys	Cys	Ser	Ser	
			30				35						40			
Phe	Cys	Gly	Ile	Val	Cys	Ser	Ser	Glu	Thr	Phe	Gln	Lys	Arg	Asn	Arg	
	45					50						55				
Ile	Lys	His	Lys	Gly	Ser	Glu	Val	Ile	Met	Pro	Ala	Asn				
60						65					70					

&lt;210&gt; 217

&lt;211&gt; 207

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SIGNAL

&lt;222&gt; -42...-1

&lt;300&gt;

&lt;400&gt; 217

Met	His	Ile	Leu	Gln	Leu	Leu	Thr	Thr	Val	Asp	Asp	Gly	Ile	Gln	Ala	
		-40					-35					-30				
Ile	Val	His	Cys	Pro	Asp	Thr	Gly	Lys	Asp	Ile	Trp	Asn	Leu	Leu	Phe	
	-25					-20					-15					
Asp	Leu	Val	Cys	His	Glu	Phe	Cys	Gln	Ser	Asp	Asp	Pro	Pro	Ile	Ile	
	-10				-5					1				5		
Leu	Gln	Glu	Gln	Lys	Thr	Val	Leu	Ala	Ser	Val	Phe	Ser	Val	Leu	Ser	
			10					15					20			
Ala	Ile	Tyr	Ala	Ser	Gln	Thr	Glu	Gln	Glu	Tyr	Leu	Lys	Ile	Glu	Lys	
	25					30					35					
Val	Asp	Leu	Pro	Leu	Ile	Asp	Ser	Leu	Ile	Arg	Val	Leu	Gln	Asn	Met	
	40					45				50						
Glu	Gln	Cys	Gln	Lys	Lys	Pro	Glu	Asn	Ser	Ala	Glu	Ser	Asn	Thr	Glu	
	55				60					65				70		
Glu	Thr	Lys	Arg	Thr	Asp	Leu	Thr	Gln	Asp	Asp	Phe	His	Leu	Lys	Ile	
			75					80					85			
Leu	Lys	Asp	Ile	Leu	Cys	Glu	Phe	Leu	Ser	Asn	Ile	Phe	Gln	Ala	Leu	
		90					95						100			
Thr	Lys	Glu	Thr	Val	Ala	Gln	Gly	Val	Lys	Glu	Gly	Gln	Leu	Ser	Lys	
	105					110						115				
Gln	Lys	Cys	Ser	Ser	Ala	Phe	Gln	Asn	Leu	Leu	Pro	Phe	Tyr	Ser	Pro	

120 125 174 130  
 Val Val Glu Asp Phe Ile Lys Ile Leu Arg Glu Val Asp Lys Ala Leu  
 135 140 145 150  
 Ala Asp Asp Leu Glu Lys Asn Phe Pro Ser Leu Lys Val Gln Thr  
 155 160 165  
 <210> 218  
 <211> 59  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <300>  
 <400> 218  
 Met Pro His Ser Lys Pro Leu Asp Trp Gly Leu Ser Ser Val Ala Glu  
 1 5 10 15  
 Cys Pro Ala Glu Leu Phe Pro Ser Thr Gly Gly Leu Ala Gly Lys Gly  
 20 25 30  
 Pro Gly Leu Asp Ile Leu Arg Cys Val Leu Ser Pro Trp Ala Ser His  
 35 40 45  
 Phe Pro Ser Leu Ser Leu Gly Val Phe Asn Leu  
 50 55  
 <210> 219  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -27...-1  
 <300>  
 <400> 219  
 Met Asn Arg Val Pro Ala Asp Ser Pro Asn Met Cys Leu Ile Cys Leu  
 -25 -20 -15  
 Leu Ser Tyr Ile Ala Leu Gly Ala Ile His Ala Lys Ile Cys Arg Arg  
 -10 -5 1 5  
 Ala Phe Gln Glu Glu Gly Arg Ala Asn Ala Lys Thr Gly Val Arg Ala  
 10 15 20  
 Trp Cys Ile Gln Pro Trp Ala Lys  
 25  
 <210> 220  
 <211> 162  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SIGNAL  
 <222> -94...-1  
 <300>  
 <400> 220  
 Met Leu Gln Thr Ser Asn Tyr Ser Leu Val Leu Ser Leu Gln Phe Leu  
 -90 -85 -80  
 Leu Leu Ser Tyr Asp Leu Phe Val Asn Ser Phe Ser Glu Leu Leu Gln  
 -75 -70 -65  
 Lys Thr Pro Val Ile Gln Leu Val Leu Phe Ile Ile Gln Asp Ile Ala  
 -60 -55 -50  
 Val Leu Phe Asn Ile Ile Ile Ile Phe Leu Met Phe Phe Asn Thr Phe  
 -45 -40 -35  
 Val Phe Gln Ala Gly Leu Val Asn Leu Leu Phe His Lys Phe Lys Gly  
 -30 -25 -20 -15  
 Thr Ile Ile Leu Thr Ala Val Tyr Phe Ala Leu Ser Ile Ser Leu His  
 -10 -5 1  
 Val Trp Val Met Asn Leu Arg Trp Lys Asn Ser Asn Ser Phe Ile Trp  
 5 10 15  
 Thr Asp Gly Leu Gln Met Leu Phe Val Phe Gln Arg Leu Ala Ala Val  
 20 25 30  
 Leu Tyr Cys Tyr Phe Tyr Lys Arg Thr Ala Val Arg Leu Gly Asp Pro



35					40					175								50
His	Phe	Tyr	Gln	Asp	Ser	Leu	Trp	Leu	Arg	Lys	Glu	Phe	Met	Gln	Val			
				55					60					65				
Arg	Arg																	
<210>	221																	
<211>	154																	
<212>	PRT																	
<213>	Homo sapiens																	
<220>																		
<221>	SIGNAL																	
<222>	-68...-1																	
<300>																		
<400>	221																	
Met	Ala	Ser	Ala	Ser	Ala	Arg	Gly	Asn	Gln	Asp	Lys	Asp	Ala	His	Phe			
			-65					-60					-55					
Pro	Pro	Pro	Ser	Lys	Gln	Ser	Leu	Leu	Phe	Cys	Pro	Lys	Ser	Lys	Leu			
		-50					-45					-40						
His	Ile	His	Arg	Ala	Glu	Ile	Ser	Lys	Ile	Met	Arg	Glu	Cys	Gln	Glu			
	-35					-30					-25							
Glu	Ser	Phe	Trp	Lys	Arg	Ala	Leu	Pro	Phe	Ser	Leu	Val	Ser	Met	Leu			
-20					-15					-10					-5			
Val	Thr	Gln	Gly	Leu	Val	Tyr	Gln	Gly	Tyr	Leu	Ala	Ala	Asn	Ser	Arg			
			1					5					10					
Phe	Gly	Ser	Leu	Pro	Lys	Val	Ala	Leu	Ala	Gly	Leu	Leu	Gly	Phe	Gly			
	15					20						25						
Leu	Gly	Lys	Val	Ser	Tyr	Ile	Gly	Val	Cys	Gln	Ser	Lys	Phe	His	Phe			
	30					35				40								
Phe	Glu	Asp	Gln	Leu	Arg	Gly	Ala	Gly	Phe	Gly	Pro	Gln	His	Asn	Arg			
45					50					55					60			
His	Cys	Leu	Leu	Thr	Cys	Glu	Glu	Cys	Lys	Ile	Lys	His	Gly	Leu	Ser			
				65					70					75				
Glu	Lys	Gly	Asp	Ser	Gln	Pro	Ser	Ala	Ser									
			80					85										
<210>	222																	
<211>	99																	
<212>	PRT																	
<213>	Homo sapiens																	
<220>																		
<300>																		
<400>	222																	
Met	Lys	Val	Glu	Glu	Glu	His	Thr	Asn	Ala	Ile	Gly	Thr	Leu	His	Gly			
1				5					10					15				
Gly	Leu	Thr	Al															

[illegible]





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, C07K 14/47, 16/18, C12Q 1/68</b>		<b>A3</b>	(11) International Publication Number: <b>WO 99/25825</b>
			(43) International Publication Date: 27 May 1999 (27.05.99)
(21) International Application Number: <b>PCT/IB98/01862</b> (22) International Filing Date: 13 November 1998 (13.11.98) (30) Priority Data: 60/066,677      13 November 1997 (13.11.97)      US 60/069,957      17 December 1997 (17.12.97)      US 60/074,121      9 February 1998 (09.02.98)      US 60/081,563      13 April 1998 (13.04.98)      US 60/096,116      10 August 1998 (10.08.98)      US 60/099,273      4 September 1998 (04.09.98)      US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): <b>GENSET [FR/FR]; 24, rue Royale, F-75008 Paris (FR).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>BOUGUELERET, Lydie [FR/FR]; 108, avenue Victor Hugo, F-92170 Vanves (FR). DUCLERT, Aymeric [FR/FR]; 6 Ter, rue Victorine, F-94100 Saint-Maur (FR). DUMAS MILNE EDWARDS, Jean-Baptiste [FR/FR]; 8, rue Grégoire de Tours, F-75006 Paris (FR).</b> (74) Agents: <b>MARTIN, Jean-Jacques et al.; Cabinet Regimbeau, 26, avenue Kléber, F-75116 Paris (FR).</b>		(88) Date of publication of the international search report: 29 July 1999 (29.07.99)	
(54) Title: <b>EXTENDED cDNAs FOR SECRETED PROTEINS</b>			
(57) Abstract  The sequences of extended cDNAs encoding secreted proteins are disclosed. The extended cDNAs can be used to express secreted proteins or portions thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The extended cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The extended cDNAs may also be used to design expression vectors and secretion vectors.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/01862

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C07K16/18 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E, L	<p>WO 99 06548 A (GENSET (FR); DUMAS MILNE EDWARDS J.-B.; DUCLERT A.; LACROIX B.) 11 February 1999 L: priority see abstract see page 144 - page 148; claims Seq.ID:112 is 98% identical to Seq.ID:134 nt.1-344. see page 110 - page 112 Seq.ID:366 is 97% identical to Seq.ID:181 nt.1-71. see page 540 - page 541 ---</p> <p style="text-align: center;">-/-</p>	<p>1,2,5,6, 8-11, 13-18</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 March 1999

Date of mailing of the international search report

03.06.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/01862

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 98 45436 A (GENETICS INSTITUTE INC (US) JACOBS,MCCOY,LAVALLE,RACIE,MERBERG ET AL.) 15 October 1998 see page 55 - page 61 Seq.ID:407 see page 221	1,2,5,6, 8-11, 13-18
X	Database EMBL, Entry HST03538 Accession number T03538 24 August 1993 97% identity with Seq.ID:134 nt.48-499 XP002096272	2,5
Y	see the whole document	1,6,8,9, 11,13-18
X	Database EMBL, Entry HSA57573 Accession number AA057573 19 September 1996 98% identity with Seq.ID:134 nt.102-746 XP002096273	2,10
Y	see the whole document	1,6,8,9, 11,13-18
X	Database EMBL, Entry HS409287 Accession number N57409 29 February 1996 100% identity with Seq.ID:134 nt.581-1041 reverse orientation XP002096274	2,10
Y	see the whole document	1,6,8,9, 13-18
A	WO 96 34981 A (GENSET (FR); NICOLAEVNA MERENKOVA I.; DUMAS MILNE EDWARDS J.-B.G.) 7 November 1996 cited in the application see abstract	
A	EP 0 625 572 A (KANAGAWA ACAD OF SCIENCE AND TECHNOL FOUNDATION (JP); KATO S; SEKINE S) 23 November 1994 cited in the application see abstract	
A	CARNINCI P. ET AL.: "High-efficiency full-length cDNA cloning by biotinylated CAP trapper" GENOMICS, vol. 37, no. 3, 1 November 1996, pages 327-336, XP002081729 cited in the application see abstract	
	---	
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/01862

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KATO S. ET AL.: "Construction of a human full-length cDNA bank" GENE, vol. 150, 1994, pages 243-250, XP002081364 cited in the application see abstract ---	
A	WO 97 07198 A (GENETICS INSTITUTE INC (US); JACOBS K; MCCOY JM; KELLEHER K; CARLIN M) 27 February 1997 ---	
A	TASHIRO K. ET AL.: "Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins" SCIENCE, vol. 261, 30 July 1993, pages 600-603, XP000673204 see abstract ---	
A	YOKOYAMA-KOBAYASHI M. ET AL.: "A signal sequence detection system using secreted protease activity as an indicator" GENE, vol. 163, 1995, pages 193-196, XP002053953 see abstract ---	
A	HEIJNE VON G.: "A new method for predicting signal sequence cleavage sites" NUCLEIC ACIDS RESEARCH, vol. 14, no. 11, 1986, pages 4683-4690, XP002053954 cited in the application see abstract ---	
A	LOCKHART D.J. ET AL.: "Expression monitoring by hybridization to high-density oligonucleotide arrays" BIO/TECHNOLOGY, no. 14, 14 December 1996, pages 1675-1680, XP002074420 see abstract -----	18



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 98/01862

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1,2,5,6,8-11,13-18 all partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

1. Claims: 1, 2, 5, 6, 8-11, 13-18, all partially

Nucleic acid comprising the sequence as in Seq.ID:134, complementary sequence or fragments, host cell containing said nucleic acid. Polypeptide as in Seq.ID:181, encoded by said polynucleotide, or fragments, method of making said polypeptide. Antibody specifically binding to said polypeptide.

2. Claims: 1, 2, 4, 6, 7, 9, 10, 12-18, all partially

As invention 1 but concerning Seq.ID:135,182.

3. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:136,183.

4. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:137,184.

5. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:138,168,185,215.

6. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:139,186.

7. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:140,187.

8. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:141,188.

9. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:142,189.

10. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:143,190.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

11. Claims: 1-18, all partially  
As invention 1 but concerning Seq.ID:144,191.
12. Claims: 1-18, all partially  
As invention 1 but concerning Seq.ID:145,192.
13. Claims: 1-18, all partially  
As invention 1 but concerning Seq.ID:146,193.
14. Claims: 1-18, all partially  
As invention 1 but concerning Seq.ID:147,194.
15. Claims: 1-18, all partially  
As invention 1 but concerning Seq.ID:148,195.
16. Claims: 1, 2, 6, 9, 10, 13-18, all partially  
As invention 1 but concerning Seq.ID:149,196.
17. Claims: 1-18, all partially  
As invention 1 but concerning Seq.ID:150,197.
18. Claims: 1, 2, 5, 6, 8-11, 13-18, all partially  
As invention 1 but concerning Seq.ID:151,198.
19. Claims: 1-18, all partially  
As invention 1 but concerning Seq.ID:152,199.
20. Claims: 1-18, all partially  
As invention 1 but concerning Seq.ID:153,200.
21. Claims: 1-18, all partially  
As invention 1 but concerning Seq.ID:154,180,201,207.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

22. Claims: 1, 2, 4, 6, 7, 9, 10, 12-18, all partially

As invention 1 but concerning Seq.ID:155,202.

23. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:156,203.

24. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:157,204.

25. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:158,205.

26. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:159,206.

27. Claims: 1, 2, 4, 6, 7, 9, 10, 12-18, all partially

As invention 1 but concerning Seq.ID:160,207.

28. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:161,208.

29. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:162,209.

30. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:163,210.

31. Claims: 1, 2, 5, 6, 8-11, 13-18, all partially

As invention 1 but concerning Seq.ID:164,211.

32. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:165,212.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

33. Claims: 1, 2, 4, 6, 7, 9, 10, 12-18, all partially

As invention 1 but concerning Seq.ID:166,213.

34. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:167,214.

35. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:169,216.

36. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:170,217.

37. Claims: 1, 2, 4, 6, 7, 9, 10, 12-18, all partially

As invention 1 but concerning Seq.ID:171,218.

38. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:172,219.

39. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:173,220.

40. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:174,221.

41. Claims: 1, 2, 4, 6, 7, 9, 10, 12-18, all partially

As invention 1 but concerning Seq.ID:175,222.

42. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:176,223.

43. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:177,224.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

44. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:178,225.

45. Claims: 1-18, all partially

As invention 1 but concerning Seq.ID:179,226.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 98/01862

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9906548 A	11-02-1999	AU 8554798 A	22-02-1999
WO 9845436 A	15-10-1998	AU 6891098 A	30-10-1998
WO 9634981 A	07-11-1996	FR 2733765 A	08-11-1996
		FR 2733762 A	08-11-1996
		AU 5982996 A	21-11-1996
		CA 2220045 A	07-11-1996
		EP 0824598 A	25-02-1996
EP 0625572 A	23-11-1994	JP 6153953 A	03-06-1994
		WO 9408001 A	14-04-1994
		US 5597713 A	28-01-1997
WO 9707198 A	27-02-1997	US 5707829 A	13-01-1998
		AU 6712396 A	18-02-1997
		AU 6768596 A	12-03-1997
		CA 2227220 A	06-02-1997
		CA 2229208 A	27-02-1997
		EP 0839196 A	06-05-1998
		EP 0851875 A	08-07-1998
		WO 9704097 A	06-02-1997